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 Foreword 
In any one year, about 85% of the Australian population makes at least one contact with a general 
practitioner (GP). Mothers, children, the elderly and those with chronic conditions, such as diabetes, 
asthma and hypertension, have many more contacts than that. As a result of these personal contacts 
everyone has a view about general practice. Ministers of Health have been known to base their views 
about general practice on their contact with their own GP. Similarly, specialists with influence on 
health policy form their views on general practice from the actions of the GPs who, directly or 
indirectly, refer patients to them. Each of these policy strategists sees a biased sample of the work of 
general practice. It is obvious that better health care data are needed to inform better health care 
policy. 
One of the pathfinders in the quest for evidence-based policy-making was Dr Kerr White  
(1917–2014). He was a North American epidemiologist and a champion of primary care medicine. In 
1961, he published an important paper on the ecology of medical care in the United States.1  
He showed how short periods of data collection could be used to produce a picture of people’s 
medical needs and their use of health care resources in satisfying them. He found that for any 1000 
adults, in any one-month period, 750 reported one or more illnesses or injuries; 250 consulted a 
primary care physician; 9 were admitted to hospital; 5 were referred to a specialist and only 1 to a 
tertiary hospital. These figures showed the need for primary medical care services and the chaos and 
expense in healthcare provision that would occur if they did not exist.  
The BEACH program is an Australian extension of Kerr White’s philosophies and epidemiological 
methods. Its genesis began in the 1980s with the work of the Foundation Professor of Community 
Medicine at Sydney University, Charles Bridges-Webb. The BEACH studies form a considerable 
extension and refinement of his philosophies and methods. 
They are a treasure trove of information for those who wish to be, or should be, better informed about 
what goes on in general practice before they initiate policies that may cause it, and Australian patients, 
harm. Those interested in how things have changed in clinical general practice over the last 10 years 
should read the accompanying publication A decade of Australian general practice activity 2005–06 to 
2014–15. It shows us that GPs now fit much more in to each consultation than they did a decade ago. 
This perhaps ties in to the growing complexity of diagnosed patient morbidity, clearly demonstrated in 
the feature chapter in this report (Chapter 14). 
The past year has seen government policy on general practice driven by the desire to reduce 
Medicare expenditure by placing a patient co-payment on a GP consultation. This was paired with the 
mantra of improving the quality of general practice by financially discouraging the ‘common six-minute 
GP consultation’. A perusal of the data in this BEACH study will show that the actual mean length of a 
GP consultation in 2015 is already 4.4 minutes over the 10 minutes consultation advocated by 
government. 
Another often repeated criticism about general practice is that most patients that are seen are referred 
on to medical specialists. The BEACH studies show that there has been a gradual rise in such 
referrals between 2005 and 2015 but currently only one in sixteen patient problems are referred. GPs 
are managing 94% of the problems that are presented to them. 
Data from the BEACH studies have many uses. I based my teaching of medical students around its 
data on the most common encounters, investigations and prescriptions. Knowledge of BEACH content 
should also be part of the education of general practice registrars as a complement to their training.  
  
 iv 
The BEACH team is to be complimented on the sophistication of the research methodology and the 
way in which it is presented. It says much about their recruiting skills, and the altruism of busy GPs, 
that nearly 1000 general practitioners each year are prepared to record all their activities at 100 
consecutive patient encounters. The BEACH study provides the only data available in Australia that 
gives a comprehensive picture of what goes on in general practice. In the era of ‘evidence-based 
policy making’ it is a source of essential data and in future needs and deserves to be better supported. 
 
 
Max Kamien MD, FRACGP, FACRRM, FRACP 
Emeritus Foundation Professor of General Practice  
University of Western Australia 
Chair, Archives Committee, Royal Australian College of General Practitioners 
 
1. White KL, Williams TF, Greenberg BG. The Ecology of Medical Care. NEJM, 1961;265:885–92. 
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 Summary 
This report describes clinical activity at, or associated with, general practitioner (GP) encounters, from 
April 2014 to March 2015, inclusive. It summarises results from the 17th year of the Bettering the 
Evaluation and Care of Health (BEACH) program, using a nationally representative sample of 99,500 
patient encounters with 995 randomly selected GPs, each of whom recorded details of 100 patient 
encounters. After post-stratification weighting, 98,728 encounters were analysed in this report (see 
Chapter 2, Methods). 
The companion report highlighting major change over the most recent 10 years of BEACH,  
A decade of Australian general practice activity 2005–06 to 2014–15,1 is available at 
<purl.library.usyd.edu.au/sup/9781743324547>. 
The general practitioners (Chapters 3 and 4) 
Of the 995 participating GPs: 
• 57% were male, 45% were aged 55 years and over; 67% had graduated in Australia 
• 64% were Fellows of the Royal Australian College of General Practitioners (RACGP), and 6% 
Fellows of the Australian College of Rural and Remote Medicine (ACRRM) 
• 71% practised in major cities 
• the average hours per week in direct patient care was 37 (median 36 hours) 
• the vast majority (84%) worked in a practice employing practice nurses, and 78% in practices 
with co-located pathology collection services 
• less than half (41%) worked in practices that supplied their own or cooperative after-hours care. 
The mean number of Medicare Benefits Schedule (MBS) GP service items claimed by participants 
over the previous year did not differ from the average for all GPs in the sample frame. The BEACH 
GP sample had slight under-representation of GPs aged less than 45 years, and slight 
over-representation of GPs aged 55 years or over. Statistical weighting was applied to correct for this. 
After weighting, the age–sex distribution of patients at BEACH encounters had an excellent fit 
(precision ratios 0.88–1.10), with that of patients at all GP services claimed through the MBS. 
The encounters (Chapter 5) 
The patient was seen by the GP (direct encounters) at 99% of all encounters at which a payment 
source was recorded: 97% of these were claimable through the MBS or the Department of Veterans’ 
Affairs (DVA), of which 79% were designated standard surgery consultations (Item 23). In a 
subsample of 33,392 MBS/DVA-claimable encounters at which start and finish times were recorded, 
the mean length of consultation was 14.7 minutes, and the median was 13.0 minutes. 
Clinical content of the GP–patient encounters (Chapter 5 and 8) 
Chapter 5 shows that at an average 100 encounters, patients gave 154 reasons for encounter 
(RFEs), and GPs managed 155 problems, including 55 chronic and 59 new problems. 
They prescribed 86 medications, supplied a further 8 and advised purchase of 10 over-the-counter 
medications. They provided 34 clinical treatments, undertook 17 procedures, made 10 referrals to 
medical specialists and 5 to allied health services, placed 47 pathology test orders and 12 imaging 
test orders. 
Chapter 8 shows that on average for every 100 problems they managed, GPs provided 55 
prescriptions and 22 clinical treatments, undertook 11 procedures, made 6 referrals to medical 
specialists and 3 to allied health services, and placed 30 pathology test orders and 7 imaging test 
orders. 
 xiii 
At least one management action occurred at 91% of encounters, for 85% of problems managed. 
When extrapolated to all MBS-claimed GP consultations: 
• at least one medication was prescribed, advised for over-the-counter purchase, or supplied at 
about 86 million GP–patient encounters 
• at least one procedure was undertaken at 21 million encounters 
• at least one referral to a specialist, allied health professional, hospital or emergency department 
was provided by GPs at 20 million encounters nationally 
• one or more pathology, imaging or other test was ordered at 35 million encounters. 
Who were the patients and why did they see the GP? (Chapter 6)  
Female patients accounted for 57% of encounters, and the greater proportion of encounters in all 
adult age groups. Patients aged less than 25 years accounted for 20% of encounters; those aged 
25–44 years for 22%; 45–64 years for 27%; and those aged 65 years and over for 31% of encounters. 
• The patient was new to the practice at 6% of encounters. 
• Nearly half the encounters were with patients who held a Commonwealth concession card (46%) 
and/or a Repatriation Health Card (2%). 
• One in ten encounters was with a patient from a non-English-speaking background. 
• At 2% of encounters the patient identified themselves as an Aboriginal and/or Torres Strait 
Islander person. 
At an average 100 encounters, patients presented 154 RFEs including 66 symptoms/complaints, 
29 diagnosed diseases, 23 procedural needs and 16 requests for treatment. At 59% of encounters 
only one RFE was recorded, at 29% two and at 12% three. The most common RFEs were requests 
for prescriptions, check-ups and test results. 
What problems do GPs manage at patient encounters? (Chapter 7) 
There were 153,133 problems managed, an average 155 problems per 100 encounters: one problem 
was managed at 61% of encounters, two at 26%, three at 10%, and four at 3%. The number of 
problems increased steadily with patient age from young adulthood. 
Two-thirds (66%) of problems were described as diagnoses or diseases, but 20% remained 
undiagnosed symptoms or complaints, and 9% were labelled procedures (for example, check-ups). 
• The most commonly managed were those of a general and unspecified nature (20 per 100 
encounters), musculoskeletal (19), respiratory (19), skin (17), and circulatory (16) problems. 
• Individual problems most often managed were hypertension (8 per 100 encounters), check-ups 
(7), upper respiratory tract infection (6), depression (5) and diabetes (4). 
• At least one chronic problem was managed at 41% of encounters. More than half of all chronic 
problems managed were accounted for by: non-gestational hypertension (14% of chronic 
conditions), depressive disorder (8%), non-gestational diabetes (7%), chronic arthritis (7%), lipid 
disorder (5%), oesophageal disease (5%), and asthma (4%). 
Extrapolation of these results suggests that nationally in 2014–15, 11 million encounters involved 
management of non-gestational hypertension, 6 million involved depression and 5 million involved 
non-gestational diabetes. 
Medications (Chapter 9) 
One or more medications were prescribed at 53% of encounters for 44% of the problems managed. 
There were 84,455 prescriptions recorded, at rates of 86 per 100 encounters or 55 per 100 problems 
managed. Extrapolated results suggest GPs prescribed at least one medication at 73 million 
encounters nationally. 
 xiv 
GPs recorded 80% of prescribed medications by brand (proprietary) name and 20% by their generic 
(non-proprietary) name. For 35% of prescriptions, no repeats were prescribed, and for 37% five 
repeats were ordered. Ordering one repeat was also quite common (15%). 
Medications most often prescribed were those acting on the nervous system (accounting for 25% of 
all prescribed medications), particularly opioids and antidepressants; and the cardiovascular system 
(18%), particularly anti-hypertensives and lipid lowering agents. However the 10 individual drugs most 
frequently prescribed (accounting for 23% of all), included three antibiotics, paracetamol and 
paracetamol/codeine, and oxycodone. 
GPs supplied 8 medications direct to the patients per 100 encounters, or 5 per 100 problems 
managed. The most frequently supplied were largely vaccines. 
Over-the-counter medication was advised at 8% of encounters, (paracetamol accounting for 26% of 
these medications), equivalent to an estimated 11 million encounters nationally in 2014–15. 
Other treatments (Chapter 10) 
The GP provided other treatments at 39% of encounters, for 29% of all problems managed. 
Clinical treatments accounted for two-thirds of all other treatments, and were provided at a rate of 
34 per 100 encounters, or 22 per 100 problems managed. General advice and education (18% of 
clinical treatments) and counselling about the problem being managed (12%) were most common. 
Preventive counselling/advice about nutrition and weight, exercise, smoking, lifestyle, prevention, 
and/or alcohol, were together given at a rate of 6 per 100 encounters. 
One in five problems was managed with a clinical treatment. Upper respiratory tract infection, 
depression, diabetes and anxiety represented the largest proportion of problems managed with a 
clinical treatment. 
Procedural treatments were recorded at a rate of 17 per 100 encounters, or 11 per 100 problems. 
Excision (18% of procedural treatments), dressing (14%) and local injection (14%) accounted for 
almost half of these. One in ten problems were managed with a procedure. Solar keratosis/sunburn 
(5%) and laceration/cut (5%) accounted for the largest proportion of problems managed with a 
procedure. 
Practice nurse/Aboriginal health worker activity at recorded GP–patient encounters 
A practice nurse (PN) or Aboriginal health worker (AHW) was involved in the management of 4.8% of 
all problems managed, or 7.2% of encounters. This suggests they were involved in about 10 million 
GP–patient consultations across Australia. A PN/AHW Medicare item was recorded at only 4% of the 
encounters in which they were involved. 
The vast majority (88%) of PN/AHW recorded activity was procedural. While clinical treatments 
accounted for 12% of PN/AHW recorded activity, they provided only 3% of all recorded clinical 
treatments. PNs/AHWs did 50% of the recorded immunisation injections. 
Referrals and admissions (Chapter 11) 
GPs made 16 referrals per 100 encounters, or 10 per 100 problems managed. The most frequent 
were to medical specialists (10 per 100 encounters, 6 per 100 problems managed), and to allied 
health services (5 per 100 encounters, 3 per 100 problems). Very few patients were referred to 
hospitals or emergency departments (0.7 per 100 encounters). 
Referrals to specialists were most often to surgeons (9% of specialist referrals), orthopaedic surgeons 
(9%), cardiologists (8%) and dermatologists (7%). Malignant skin neoplasms, osteoarthritis, diabetes 
and back complaints were the problems most often referred to medical specialists. The five problems 
most frequently referred to each of 10 medical specialties are described in Chapter 11. 
Referrals to allied health services were most often to physiotherapists (28% of allied health referrals), 
psychologists (24%), podiatrists/chiropodists (13%) and dietitians/nutritionists (7%). Problems most 
likely to be referred to allied health services were depression, diabetes and back complaint. 
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Tests and investigations (Chapter 12) 
Pathology tests ordered: GPs recorded 47 orders for pathology tests (or batteries of tests) per 
100 encounters (30 per 100 problems managed). At least one pathology test was recorded at 18% of 
encounters, or 13% of problems managed. 
• Chemistry tests accounted for 58% of pathology test orders. Lipid tests, multi-biochemical 
analysis, thyroid function tests, and electrolytes, urea and creatinine tests were the most common 
(each ordered at a rate of 2 per 100 problems managed). 
• Haematology tests accounted for 18% of pathology tests ordered and included full blood count, 
the most frequently ordered individual test (14% of all pathology). 
• Microbiology accounted for 14% of pathology orders; urine microscopy, culture and sensitivity 
was the most commonly ordered. 
• Almost 40% of all pathology tests ordered were generated in the management of 10 problems. 
The problems generating the highest volumes of testing were diabetes, hypertension, general 
check-ups, and weakness/tiredness. 
Imaging ordered: 12 imaging tests were ordered per 100 encounters, and 7 per 100 problems 
managed. At least one was ordered at 10% of encounters (for 7% of problems managed). Ultrasound 
accounted for 43% and diagnostic radiology for 40%, of all imaging orders. 
Patient risk factors (Chapter 13) 
Overweight and obesity in adults (18 years and over): Of 32,956 adults, 62% (70% of males and 
57% of females) were overweight (34%) or obese (28%). Estimated prevalence in adults who 
attended general practice at least once in 2014–15 was 34% overweight and 27% obese. 
Overweight and obesity in children (2–17 years): Of 3,112 children, 27% were overweight (18%) or 
obese (9%). Prevalence pattern by age did not differ between the sexes. 
Smoking status (adults 18 years and over): Of 33,685 adults, 14% (17% of males and 12% of 
females) were daily smokers. For the population attending one or more times, an estimated 17% were 
daily smokers, 3% occasional, 25% previous smokers and 55% had never smoked. 
Alcohol consumption in adults (18 years and over): Of 32,835 adult patients, 23% (28% of males, 
20% of females) reported at-risk alcohol consumption. Adjusted data suggested 26% of the attending 
population are consuming at-risk levels of alcohol. 
Adult risk profile (18 years and over): Of the 31,952 patients providing all risk factor data: 26% had 
none, 52% one and 22% two or three risk factors. Adjusted to the attending population, 25% had no 
risk factors, 50% had one, 21% two and 4% all three risk factors. 
Care of older people in general practice (Chapter 14) 
This feature chapter explores the care of people aged 65+ in general practice between April 2000 and 
March 2015 using data from the BEACH study and several of its substudies. We examine GP 
services provided, the content of the encounters, and the prevalence of chronic problems and 
multimorbidity. We look at selected issues which affect the health of older patients, including chronic 
pain, multiple medications/adverse drug events and patient risk factors (smoking, alcohol 
consumption and overweight). 
In light of recent suggestions that voluntary enrolment with a ‘medical home’ could enhance continuity 
of care, we also investigate the extent to which patients have a ‘regular practice’ that they usually 
visit. This chapter provides valuable information for health policymakers and service providers, to help 
structure a response to the future challenges of caring for an ageing population. 
Supplementary Analysis of Nominated Data (SAND) substudies (Chapter 15) 
Abstracts are provided for each of 12 recent SAND substudies which investigated aspects of the 
health of subsamples of patients at the encounter that are not captured in the encounter data. 
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Changes in general practice activity over the decade, 2005–06 to 2014–15  
The companion publication: A decade of Australian general practice 2005–06 to 2014–15 reports the 
results of each of 10 years of BEACH data and identifies changes in practice over the decade based 
on almost one million GP–patient encounter records, from 9,773 participating GPs. Estimates of the 
national effect of change in activity are made through extrapolation to total Medicare GP consultation 
items claimed in the first and last year of the decade. 
Over the decade, Australia’s population rose by 16% and the proportion aged 65 years and over rose 
by 35%. About 85% of the population claimed one or more GP services from Medicare in both  
2005–06 and 2014–15. However, the number of Medicare-claimed GP consultations grew by 36% 
from 101 million to 137 million. The average GP visits per head of population rose from 5.0 to 5.8 and 
for those who saw a GP at least once, from 5.9 to 6.8 visits. 
The general practice profession became more feminised, were older, less likely to be Australian 
graduates, and worked fewer hours per week. Average length of MBS-claimed consultations 
increased from 13.9 to 14.7 minutes and median length from 12 to 13 minutes. Patients aged 
65+ years accounted for an increasing proportion of GPs’ workload. Encounters with patients new to 
the practice decreased by one-third. 
In 2014–15, GPs managed 155 problems per 100 encounters, significantly more than a decade 
earlier (146). This increase and the increased visit rate has had a huge national effect on the 
complexity of GP services. When the growth in problems managed is combined with increase in 
actions per 100 problems managed, even larger national growth occurs. The management rate of 
chronic conditions did not change over the decade, but there were increases in depressive disorder, 
oesophageal disease, atrial fibrillation/flutter, chronic back pain and unspecified chronic pain. 
Extrapolation of results to all MBS-claimed GP consultations suggests that nationally GPs managed 
65 million more problems, including 23 million more chronic problems in 2014–15 than a decade 
earlier. 
The major changes that occurred from 2005–06 to 2014–15 are summarised below.  
• Prescribed medications decreased from 59 to 55 per 100 problems. However, due to the 
increased problems managed and the higher attendance rate, we estimate 31 million more 
prescriptions were given in 2014–15 than in 2005–06. 
• GP-supplied medications decreased but supplied childhood vaccines increased. 
• Clinical treatments were provided at similar rates (20 and 22 per 100 problems managed). 
However, more problems managed and higher attendance rates meant 17 million more clinical 
treatments were given nationally. 
• Procedural treatments increased significantly, from 10 to 11 per 100 problems, with a national 
extrapolated effect of about 9 million more procedures in 2014–15. 
• Referrals to both medical specialists and allied health services increased. These results suggest 
5 million more referrals were made to medical specialists and 4 million more to allied health.  
• Orders for pathology tests/batteries increased by 15%, from 26 to 30 per 100 problems, with a 
national extrapolated effect of about 26 million more tests/batteries ordered by GPs in 2014–15. 
• Orders for imaging tests increased significantly from 6 to 7 per 100 problems, suggesting 
7 million more tests were ordered nationally in 2014–15 than in 2005–06. 
Patient risk factor data are presented for each year from 2007–08 to 2014–15. Prevalence of obesity, 
smoking and alcohol consumption among the adult patient population who attended general practice 
at least once in each year showed: 
• obesity increased from 23% to 27% 
• daily smoking decreased from 19% to 17% 
• at-risk alcoholic consumption decreased from 29% to 26%. 
 
  
 1 Introduction 
This is the 17th annual report and the 38th book in the General practice series from the BEACH 
(Bettering the Evaluation and Care of Health) program, a continuous national study of general 
practice activity in Australia. It provides the annual results for the period April 2014 to March 2015 
inclusive, using details of 99,500 encounters between general practitioners (GPs) and patients from a 
random sample of 995 practising GPs across the country. 
Released in parallel with this report is a summary of results from the most recent 10 years of the 
BEACH program, A decade of Australian general practice activity 2005–06 to 2014–15,1 available at 
<purl.library.usyd.edu.au/sup/9781743324547>. The major changes that occurred over the decade 
are summarised at the end of each chapter of this annual report. 
The BEACH program began in April 1998 and was the culmination of about 20 years research and 
development work at the University of Sydney. BEACH is currently supported financially by 
government and private industry (see Acknowledgments). 
BEACH is a continuous national study in which ever-changing random samples of about 1,000 
individual general practitioners (GPs) participate each year. Each participating GP records details of 
100 consecutive GP–patient encounters with consenting patients. 
BEACH is the only study of its kind in the world, and the only national program that provides direct 
linkage of management actions (such as prescriptions, referrals, investigations) to the problem under 
management. The BEACH database now includes information for almost 1.7 million encounters from 
16,747 participating GPs representing 10,342 individual GPs. 
1.1 Background 
General practitioners (GPs) are usually the first port of call in the Australian healthcare system, 
generally receiving payment on a fee-for-service basis. There are no formal patient lists or 
registration. People are free to see multiple practitioners and visit multiple practices of their choice. A 
universal medical insurance scheme (managed by Medicare Australia) covers all, or part of a person’s 
costs for a GP visit. 
About 85% of the Australian population claimed at least one GP service from Medicare in both  
2005–06 and 2014–15 (personal communication, Australian Government Department of Health 
[DoH]). However, the number of Medicare-claimed GP consultation items (total non-referred 
attendances excluding practice nurse items) grew by 36% from 101.1 million to 137.4 million.2 This 
equates to about 620,000 more Medicare-claimable GP consultations per week being provided 
nationally than were provided a decade earlier. 
This means that the average number of GP visits per head of population was about 5.0 in 2005–06 
and rose to 5.8 in 2014–15. In 2005–06, those who visited at least once claimed an average 5.9 visits, 
but in 2014–15 this average had risen to 6.8 visits. 
Australia’s health expenditure in 2013–14 was $154.6 billion, $6,639 per head of population, and 
accounted for 9.8% of gross domestic product (GDP). Governments funded 60.8%, with the 
remainder (39.2%) being paid by the non-government sector and by individuals.3 In the 2014–15 
financial year, government expenditure on general practice services (total non-referred attendances 
including GP/vocationally recognised GP, Enhanced Primary Care, other, and practice nurse items) 
was almost $6.8 billion.4 
According to reports from the Australian Institute of Health and Welfare (AIHW), in Australia in 2012, 
there were 25,958 practising GPs (employed medical practitioners self-identifying as GPs), making up 
25,063 full-time equivalents (FTE, based on a 40-hour week), or 111.8 FTE GPs per 100,000 people.5 
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In contrast, recent general practice workforce statistics from DoH indicate that in 2013–14 there were 
32,401 GPs (defined as GPs or Other Medical Practitioners who provided at least one Medicare 
claimed GP service during that year), making up 19,365 FTE.6 
While Medicare statistics provide information about frequency and cost of visits claimed from 
Medicare for GP service items, they cannot tell us about the content of these visits. The BEACH 
program fills this gap. 
1.2 The BEACH program 
In summary, the BEACH program is a continuous national study of general practice activity in 
Australia. Each year an ever-changing random sample of about 1,000 practising GPs participate, 
each recording details of 100 patient encounters on structured paper-based recording sheets 
(Appendix 1). This provides details of about 100,000 GP–patient encounters per year. They also 
provide information about themselves and their major practice (Appendix 2). The BEACH methods 
are described in Chapter 2 of this report. 
Aims 
The three main aims of the BEACH program are to: 
• provide a reliable and valid data collection process for general practice that is responsive to the 
ever-changing needs of information users, and provides insight into the evolving character of 
GP–patient encounters in Australia 
• provide an ongoing database of GP–patient encounter information 
• assess patient risk factors and health states, and the relationship these factors have with health 
service activity. 
Current status of BEACH 
BEACH began in April 1998 and is now in its 18th year. The BEACH database includes records for 
almost 1.7 million GP–patient encounters from 16,747 participating GPs. Each year we publish an 
annual report of BEACH results collected in the previous 12 months. This publication reports results 
from April 2014 to March 2015. The companion publication A decade of Australian general practice 
activity 2005–06 to 2014–15,1 provides summaries of changes in the most frequent events over the 
decade. 
The strengths of the BEACH program 
• BEACH is the only national study of general practice activity in the world that is continuous, 
relying on a random ever-changing sample of GPs. The ever-changing nature of the sample 
(where each GP can participate only once per triennium) ensures reliable representation of what 
is happening in general practice across the country. 
• The sheer size of the GP sample (1,000 per year) and the relatively small cluster of encounters 
around each GP, provide more reliable estimates than a smaller number of GPs with large 
clusters of patients and/or encounters.7 Our access to a regular random sample of recognised 
GPs in active practice, through DoH, ensures that the GP sample is drawn from a very reliable 
sample frame of currently active GPs. 
• The sampling methods ensure that new entrants to the profession are available for selection 
because the sample frame is based on the most recent Medicare data. Where data collection 
programs use a fixed set of GPs over a long period, measuring what that group is doing at any 
one time or how that group has changed over time, there may well be a ‘training effect’ inherent 
in longer-term participation. Such measures cannot be generalised to the whole of general 
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practice. Further, where GPs in the group have a particular characteristic in common (for 
example, all belong to a professional organisation to which not all GPs belong; all use a selected 
software system which is not used by all GPs), the group is biased and cannot represent all GPs. 
• We have sufficient details about the characteristics of all GPs in the sample frame to test the 
representativeness of the final BEACH GP sample, and to apply post-stratification weighting to 
correct for any under or over-representation in the sample when compared with the sample 
frame. 
• Each GP records for a set number of encounters (100), but there is wide variance among them in 
the number of patient consultations they conduct in any one year. DoH therefore provides an 
individual count of activity level (that is, number of Medicare GP service items claimed in the 
previous period) for all randomly sampled GPs, allowing us to give a weighting to each GP’s set 
of encounters commensurate with his or her contribution to total general practice encounters. 
This ensures that the final encounters represent encounters with all GPs. 
• BEACH includes all patient encounters and management activities provided at these encounters, 
not just those encounters and activities funded by Medicare. 
• The structured paper encounter form leads the GP through each step in the encounter, 
encouraging entry of data for each element (see Appendix 1), with instructions and an example of 
a completed form. The structure itself forces linkage of actions to the problem being managed. In 
contrast, systems such as electronic health records rely on the GP to complete fields of interest 
without guidance. 
• BEACH is the only continuous national study in the world in which management actions at 
encounter are directly linked by the GP to the problems under management. This provides a 
measure of the ‘quality’ of care rather than just a count of the number of times an action has 
occurred (for example, how often a specific drug has been prescribed). 
• The medication data include all prescriptions, rather than being limited to those prescribed 
medications covered by the Pharmaceutical Benefits Scheme (PBS). BEACH is the only source 
of information on medications supplied directly to the patient by the GP, and about the 
medications GPs advised for over-the-counter (OTC) purchase, the patients to whom they 
provide such advice and the problems managed in this way. 
• The inclusion of other (non-pharmacological) treatments such as clinical counselling and 
procedural treatments, provides a broader view of the interventions used by GPs in the care of 
their patients than other data sources. 
• The use of an internationally standard well-structured classification system (ICPC-2)8 designed 
specifically for general practice, together with the use of a clinical interface terminology, facilitates 
reliable classification of the data by trained secondary coders, and removes the guesswork often 
applied in word searches of available records (in free text format) and in classification of a 
concept. 
• The use of the World Health Organization’s (WHO) Anatomical Therapeutic Chemical (ATC) 
classification for pharmaceuticals at the generic level ensures reporting of medications data is in 
accordance with the international standard. 
• The analytical techniques applied to the BEACH data ensure that the clustering inherent in the 
sampling methods is dealt with. Results are reported with 95% confidence intervals. Users are 
therefore aware of the level of reliability of any estimate. 
• Reliability of the methods is demonstrated by the consistency of results over time where change 
is not expected, and by the measurement of change when it might be expected. 
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1.3 Using BEACH data with other national data 
Users of the BEACH data might wish to integrate information from multiple national data sources to 
gain a more comprehensive picture of the health and health care of the Australian community. It is 
therefore important that readers are aware of how the BEACH data differ from those drawn from other 
sources. This section summarises differences between BEACH and other national sources of data 
about general practice in Australia. 
The Pharmaceutical Benefits Scheme  
Prescribed medications, for which a PBS subsidy has been paid when they are dispensed, are 
recorded by Medicare Australia. 
The PBS data: 
• count the prescription each time it crosses the pharmacist’s counter (so that one GP prescription 
written with five repeats in BEACH would be counted by the PBS six times if the patient filled all 
repeats) 
• count only prescribed medications that cost: 
– more than the minimum PBS subsidy for those holding a Commonwealth concession card 
and/or who have reached the safety net threshold  
– more than the PBS threshold (which is far higher) for non-concession card holders 
• will change with each change in the PBS co-payment level for non-Commonwealth concession 
cardholders – when the co-payment level increases, those medications that then fall under the 
new level will no longer be counted in the PBS for non-Commonwealth concession cardholders9 
• hold no record of the problem being managed (with the exception of authority prescriptions, which 
require an indication and account for a small proportion of PBS data). Morbidity cannot be reliably 
assumed on the basis of medication prescribed.10,11 
In BEACH: 
• total medications include those prescribed (whether covered by the PBS or not), those supplied 
to the patient directly by the GP, and those advised for OTC purchase 
• each prescription recorded reflects the GP’s intent that the patient receives the prescribed 
medication, and the specified number of repeats; the prescription, irrespective of the number of 
repeats ordered, is counted only once 
• the medication is directly linked to the problem being managed by the GP 
• there is no information on the number of patients who do not present their prescription to be filled 
(this also applies to the PBS). 
These differences have a major impact on the numbers of prescriptions counted and also affect their 
distribution. For example, the majority of broad spectrum antibiotics such as amoxycillin, fall under the 
non-concessional card holders‘ minimum subsidy level and would not be counted in the PBS data. 
The PBS data only include those filled under the PBS by a Commonwealth concession card holder or 
by people who had reached the annual safety net threshold.9 
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Medicare Benefits Schedule 
Consultations with GPs that are paid for in-part, or in-full, through the Medicare Benefits Schedule 
(MBS) are recorded by Medicare Australia. 
• Publicly available MBS claims data do not include data about patients and encounters funded 
through the Department of Veterans’ Affairs (DVA). 
• The MBS data include GP services that have been billed to Medicare. BEACH includes all 
consultations, irrespective of whether a charge was made or to whom it was charged. 
• The MBS data reflect the item number charged to Medicare and include some patient 
demographics, but hold no information about the content of the consultation. 
• BEACH participants are limited to recording three Medicare item numbers for each encounter. In 
contrast, MBS data include all Medicare item numbers claimed. In the BEACH data set, this may 
result in a lower number of ‘other’ Medicare items than would be counted in the Medicare data. 
• In activities of relatively low frequency with a skewed distribution across individual GPs, the 
relative frequency of the event in the BEACH data may not reflect that reported in the MBS data. 
Where activity is so skewed across the practising population, a national random sample will 
provide an underestimate of activity because the sample reflects the population rather than the 
minority. 
• One of the advantages of BEACH over the MBS is also the relative consistency of the data 
collection form over time. BEACH is relatively resilient to changes in MBS payment policies, such 
as the inclusion or removal of items from the MBS. 
Pathology data from the MBS 
Pathology tests undertaken by pathologists that are charged to Medicare are recorded by Medicare 
Australia. However, these Medicare data are not comparable with BEACH data. 
• MBS pathology data reflect pathology orders made by GPs and other medical specialists. About 
70% of the volume of MBS pathology claims are for pathology ordered by GPs.12 
• Each pathology company can respond differently to a specific test order label recorded by the 
GP. For example, the tests completed by a pathologist in response to a GP order for a full blood 
count may differ between companies. 
• The pathology companies can charge through the MBS only for the three most expensive items 
undertaken, even when more were actually done. This is called ‘coning’ and is part of the DoH 
pathology payment system. This means that the tests recorded in the MBS include only those 
charged for, not all those that were done. Coning applies only to GP pathology orders, not to 
those generated by other medical specialists. 
• Pathology MBS items contain pathology tests that have been grouped on the basis of cost (for 
example, ‘any two of the following … tests’). Therefore an MBS item often does not give a clear 
picture of the precise tests performed. 
• This means that the MBS data reflect those tests billed to the MBS after interpretation of the 
order by the pathologist, and after selection of the three most expensive MBS items. 
In BEACH, the pathology data: 
• include details of pathology tests ordered by the participating GPs; however, the GP is limited to 
the recording of five tests or battery of tests at each encounter, and as the number of 
tests/batteries ordered on any single occasion is increasing,13 an increasing number of additional 
tests ordered will be lost 
• reflect the terms used by GPs in their orders to pathologists, and for reporting purposes these 
have been grouped by the MBS pathology groups for comparability. 
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The distributions of the two data sets will therefore differ, reflecting on the one hand the GP order and 
on the other the MBS-billed services from the pathologist. 
Pathology ordering by GPs is described in Chapter 12 of this report. Those interested in pathology 
test ordering by GPs should also view the following publications: 
• Evaluation of pathology ordering by general practitioners in Australia (Doctoral thesis).14 
• Are rates of pathology test ordering higher in general practices co-located with pathology 
collection centres?15 This publication investigated the independent effect of general practice 
co-location with pathology collection centres on GP pathology test ordering in Sydney and 
Melbourne metropolitan areas. 
• Evidence-practice gap in GP pathology test ordering: a comparison of BEACH pathology data 
and recommended testing.16 
Imaging data from the MBS 
Some of the issues discussed regarding pathology data also apply to imaging data. Although coning 
is not an issue for imaging, radiologists can decide whether the test ordered by the GP is the most 
suitable and whether to undertake other or additional tests of their choosing. The MBS data therefore 
reflect the tests that are actually undertaken by the radiologist, whereas the BEACH data reflect those 
ordered by the GP. Those interested in GP ordering of imaging tests should also see Evaluation of 
imaging ordering by general practitioners in Australia.17 
The Australian Health Survey 
The 2011–13 Australian Health Survey, conducted by the Australian Bureau of Statistics (ABS), 
includes the National Health Survey, the National Nutrition and Physical Activity Survey and the 
National Health Measures Survey. The National Health Survey provides estimates of population 
prevalence of some diseases, and a measure of the problems taken to the GP by people in the two 
weeks before they were surveyed. The National Health Measures Survey includes biomedical 
measures related to chronic disease and nutritional biomarkers.18  
• Prevalence estimates from the National Health Survey are based on self-reported morbidity from 
a representative sample of the Australian population, using a structured interview to elicit 
health-related information from participants. Prevalence estimates from the National Health 
Measures Survey are based on biomedical measures of diagnosed and undiagnosed disease. 
• The National Health Survey has the advantage of accessing people who do not go to a GP as 
well as those who do. They can therefore provide an estimate of population prevalence of 
disease and a point estimate of incidence of disease. However, self-report has been 
demonstrated to be susceptible to misclassification because of a lack of clinical corroboration of 
diagnoses.19 
• Prevalence estimates based on biomedical measures have the advantage of measuring 
diagnosed and undiagnosed disease. 
Management rates of health problems in general practice represent GP workload for a health 
problem. BEACH can be used to estimate the period incidence of diagnosed disease presenting in 
general practice through the number of new cases of that disease. The management rates of 
individual health problems and management actions can be extrapolated to national management 
rates. 
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The general practice patient population sits between the more clinical hospital-based population and 
the general population, with about 85.8% of Australians visiting a GP at least once in 2014–15 
(personal communication, DoH, July 2015). Disease management rates are a product of both the 
prevalence of the disease/health problem in the population, and the frequency with which patients 
visit GPs for the treatment of that problem. Those who are older and/or have more chronic disease 
are therefore likely to visit more often, and have a greater chance of being sampled in the encounter 
data. 
Prevalence of selected diseases among the patient population seen at least once in general practice 
can be investigated using the Supplementary Analysis of Nominated Data method (see Section 2.6). 
Those interested in the prevalence of disease and multimorbidity should refer to the following papers: 
Estimating prevalence of common chronic morbidities in Australia,20 Prevalence and patterns of 
multimorbidity in Australia,21 Prevalence of chronic conditions in Australia,22 and Examining different 
measures of multimorbidity, using a large prospective cross-sectional study in Australian general 
practice.23  
1.4 Access to BEACH data 
Different bundles of BEACH data are available to the general public, to BEACH participating 
organisations, and to other organisations and researchers. 
Public domain 
This annual publication provides a comprehensive view of general practice activity in Australia. The 
BEACH program has generated many papers on a wide variety of topics in journals and professional 
magazines. All published material from BEACH is available at 
<sydney.edu.au/medicine/fmrc/publications>. 
Since April 1998, a section at the bottom of each encounter form has been used to investigate 
aspects of patient health or healthcare delivery not covered by general practice consultation-based 
information. These additional substudies are referred to as SAND (Supplementary Analysis of 
Nominated Data). The SAND methods are described in Section 2.6. Abstracts of results and the 
research tools used in all SAND substudies from April 1998 to March 2015 have been published. 
Those from: 
• April 1998 to March 1999 were published in Measures of health and health care delivery in 
general practice in Australia24 
• April 1999 to July 2006 were published in Patient-based substudies from BEACH: abstracts and 
research tools 1999–200625 
• August 2006 to March 2014 were published in each of the BEACH annual reports26-33 
• April 2014 to March 2015 are included in Chapter 14 of this report. 
Abstracts of results for all SAND substudies are also available on the Family Medicine Research 
Centre’s (FMRC) website <sydney.edu.au/medicine/fmrc/publications/sand-abstracts> where you can 
search by topic. 
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Participating organisations 
Organisations providing funding for the BEACH program receive summary reports of the encounter 
data quarterly, and standard reports or specifically designed analyses about their subjects of interest. 
Participating organisations also have direct access to straightforward analyses on any selected 
problem, medication, pathology or imaging test through an interactive web server. All data made 
available to participating organisations have been further ‘de-identified’. Patients are not identifiable 
even from the original encounter data forms, but are further stripped of date of birth (replaced with 
age in years and months) and postcode of residence (replaced with state and area type). GP 
characteristics data are provided only in the form of grouped output (for example, GPs aged less than 
35 years) to any organisation. 
External purchasers of reports 
Non-contributing organisations may purchase standard reports or other ad hoc analyses. Charges are 
outlined at <sydney.edu.au/medicine/fmrc/beach/data-reports/for-purchase>. The FMRC should be 
contacted for specific quotations. Contact details are provided at the front of this publication. 
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 2 Methods  
In summary: 
• each year, BEACH involves a new random sample of about 1,000 GPs 
• each GP records details of about 100 doctor–patient encounters of all types  
• the GP sample is a rolling (ever-changing) sample, with about 20 GPs participating in any one 
week, 50 weeks a year (with 2 weeks break over Christmas) 
• each GP can be selected only once per Quality Improvement & Continuing Professional 
Development (QI & CPD) Program triennium (that is, once in each 3-year period) 
• the encounter information is recorded by the GPs on structured paper encounter forms 
(Appendix 1) 
• GP participants also complete a questionnaire about themselves and their practice (Appendix 2). 
2.1 Sampling methods 
The source population includes all vocationally registered GPs and all general practice registrars who 
claimed a minimum of 375 Medicare general practice items of service in the most recently available 
3-month Medicare data period (which equates to 1,500 such claims in a year). This ensures inclusion 
of the majority of part-time GPs, while excluding those who are not in private practice but claim for a 
few consultations a year. 
The Medicare statistics section of DoH updates the sample frame from the Medicare records 
quarterly, using the Medicare claims data, then removes from the sample frame any GPs already 
randomly sampled in the current triennium, and draws a new sample from those remaining in the 
sample frame. This ensures the timely addition of new entries to the profession, and timely exclusion 
of those GPs who have stopped practising, or have already participated or been approached in the 
current triennium. 
2.2 Recruitment methods 
The randomly selected GPs are approached by letter, posted to the address provided by the 
Australian Government DoH. 
• Over the following 10 days, the telephone numbers generated from the Medicare data are 
checked using the electronic white and yellow pages. This is necessary because many of the 
telephone numbers provided from the Medicare data are incorrect. 
• The GPs are then telephoned in the order they were approached and, referring to the approach 
letter, asked whether they will participate. 
• This initial telephone contact with the practice often indicates that the selected GP has moved 
elsewhere, but is still in practice. Where a new address and/or telephone number can be 
obtained, these GPs are followed up at their new address. 
• GPs who agree to participate are set an agreed recording date several weeks ahead. 
• A research pack is sent to each participant before the planned start date. 
• Each GP receives a telephone reminder early in the agreed recording period – this also provides 
the GP with an opportunity to ask questions about the recording process. 
• GPs can use a ‘freecall’ (1800) number to ring the research team with any questions during their 
recording period. 
• Non-returns are followed up by regular telephone calls for 3 months. 
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• Participating GPs earn clinical audit points towards their QI & CPD requirements through the 
Royal Australian College of General Practitioners (RACGP) and/or the Australian College of 
Rural and Remote Medicine (ACRRM). As part of this QI process, each receives an analysis of 
his or her results compared with those of nine other de-identified GPs who recorded at about the 
same time. Comparisons with the national average are also provided. In addition, GPs receive 
some educational material related to the identification and management of patients who smoke or 
consume alcohol at hazardous levels. Additional points can be earned if the participant chooses 
to do a follow-up audit of smoking and alcohol consumption among a sample of patients about 
6 months later. 
2.3 Ethics approval and informed patient consent 
Ethics approval for this study in 2014–15 was obtained from the Human Ethics Committee of the 
University of Sydney. 
Although the data collected by the GPs is not sufficient to identify an individual patient, informed 
consent for GP recording of the encounter details is required from each patient. GPs are instructed to 
ensure that all patients presenting during their recording period are provided with a Patient 
Information Card (Appendix 3), and they ask the patient if they are happy for their data to be included 
in the study. If the patient refuses, details of the encounter are not recorded. This is in accordance 
with the ethics requirements for the BEACH program. 
2.4 Data elements 
BEACH includes three interrelated data collections: GP characteristics, encounter data and patient 
health status. An example of the form used to collect the encounter data and the data on patient 
health status is included in Appendix 1. The GP characteristics questionnaire is provided in 
Appendix 2. The GP characteristics and encounter data collected are summarised below. Patient 
health status data are described in Section 2.6. 
GP profile form (Appendix 2) 
• GP characteristics: age and sex, years in general practice, number of direct patient care hours 
worked per week, country of graduation, general practice registrar status, Fellow of the RACGP 
status, Fellow of the ACRRM status, use of computers at work for clinical purposes, work 
undertaken in other clinical settings, number of practice locations worked in a regular week. 
• Practice characteristics: postcode of major practice, number of individual and number of 
full-time equivalent GPs working in the practice, number of individual and number of full-time 
equivalent practice nurses working in the practice, usual after-hours care arrangements, other 
health services located or available at the major practice. 
Encounter recording form (Appendix 1) 
• Encounter data: date of consultation, type of consultation (direct/indirect) (tick box options), up 
to three MBS/DVA item numbers (where applicable), and other payment source (where 
applicable) (tick box options). 
• Patient data: date of birth, sex and postcode of residence. Tick boxes (yes/no options) are 
provided for Commonwealth concession cardholders, holders of a Repatriation Health Card (from 
DVA), non-English-speaking background (patient reported a language other than English is the 
primary language at home), Aboriginal person (self-identification), and Torres Strait Islander 
person (self-identification). Space is provided for up to three patient reasons for encounter 
(RFEs) (see Glossary). 
• The problems managed at encounter (at least one and up to four). Tick boxes are provided to 
denote the status of each problem as new or continuing for the patient (see Glossary). 
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• Management actions for each problem, including: 
– medications prescribed, supplied by the GP and advised for over-the-counter purchase 
including brand name, form (where required), strength, regimen, status (new or continuing 
medication for this problem), number of repeats 
– other treatments provided for each problem, including counselling, advice and education, and 
procedures undertaken, and whether the recorded other treatment was provided by practice 
nurse (tick box) 
– new referrals to medical specialists, allied health services, emergency departments, and 
hospital admissions 
– investigations, including pathology tests, imaging and other investigations ordered. 
2.5 The BEACH relational database 
The BEACH relational database is described diagrammatically in Figure 2.1. Note that:  
• all variables can be directly related to the encounter, the GP and the patient characteristics 
• all types of management are directly related to the problem being managed  
• RFEs have only an indirect relationship with problems managed, as a patient may describe  
one RFE (such as ‘repeat prescriptions’) that is related to multiple problems managed, or several 
RFEs (such as ‘runny nose’ and ‘cough’) that relate to a single problem (such as upper 
respiratory tract infection) managed (see Section 6.3). 
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The encounter 
 date 
 direct (face to face) 
— Medicare/DVA item 
number(s) claimable 
— workers compensation 
— other paid 
— no charge 
 indirect (e.g. telephone) 
Patient substudies (SAND) 
 risk factors 
— body mass 
— smoking status 
— alcohol consumption  
 other topics 
Management of each problem 
Medications (up to four per problem) 
 prescribed 
 over-the-counter advised 
 provided by GP 
— drug class 
— drug group 
— generic 
— brand name 
— strength 
— regimen 
— number of repeats  
— drug status (new/continued) 
 
Other treatments (up to two per 
problem) 
 procedural treatments 
 clinical treatments (e.g. advice, 
counselling) 
 practice nurse involvement 
 
Other management 
 referrals (up to two) 
— to specialists 
— to allied health professionals 
— to emergency departments 
— hospital admissions 
 pathology tests ordered (up to five) 
 imaging ordered (up to three) 
GP characteristics 
 age and sex 
 years in general practice 
 country of graduation 
 direct patient care hours/week 
 FRACGP status (yes/no) 
 FACRRM status (yes/no) 
 currently a registrar (yes/no) 
 clinical use of computers  
 
Practice characteristics 
 practice size (no. & FTE GPs) 
 practice nurse(s) (no. & FTE) 
 after-hours arrangements 
 postcode  
 presence of other health services 
Problems managed 
 diagnosis/problem label 
 problem status (new/old) 
 work-related problem status 
The patient 
 age and sex 
 practice status (new/old) 
 Commonwealth concession 
card status 
 Repatriation Health Card status 
 postcode of residence 
 NESB/Indigenous status 
 reasons for encounter 
Note: FRACGP – Fellow of the Royal Australian College of General 
Practitioners; FACRRM – Fellow of the Australian College of 
Rural and Remote Medicine; FTE – full-time equivalent;  
DVA – Department of Veterans’ Affairs; NESB – non-English-
speaking background; SAND – Supplementary Analysis of 
Nominated Data. 
Figure 2.1: The BEACH relational database 
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2.6 Supplementary Analysis of Nominated Data  
A section at the bottom of each recording form investigates aspects of patient health or health care 
delivery in general practice not covered by the consultation-based data. These additional substudies 
are referred to as SAND, Supplementary Analysis of Nominated Data. 
• Each year the 12-month data period is divided into 10 blocks, each of 5 weeks, with three 
substudies per block. The research team aims to include data from about 100 GPs in each block. 
• Each GP’s pack of 100 forms includes 40 forms that ask for the start and finish times of the 
encounter, and include questions about patient risk factors: patient height and weight (used to 
calculate body mass index, BMI), alcohol intake and smoking status (patient self-report). The 
methods and results of topics in the SAND substudies for alcohol consumption, smoking status 
and BMI are reported in Chapter 13. The start and finish times collected for these encounters are 
used to calculate length of consultation. The length of consultation for Medicare-claimable 
encounters is reported in Section 5.3. 
• The remaining 60 forms in each pack are divided into two blocks of 30, so each of these other 
SAND studies includes about 3,000 records (30 x 100 GPs). Different questions are asked of the 
patient in each block and these vary throughout the year. Some topics are repeated to increase 
sample size. 
• The order of SAND sections is rotated in the GP recording pack, so that 40 patient risk factor 
forms may appear first, second or third in the pad. Rotation of ordering ensures there was no 
order effect on the quality of the information collected. 
Abstracts of results and the research tools used in all SAND substudies from April 1998 to March 
2015 have been published. Those: 
• from April 1998 to March 1999 were published in Measures of health and health care delivery in 
general practice in Australia24 
• from April 1999 to July 2006 were published in Patient-based substudies from BEACH: abstracts 
and research tools 1999–200625 
• conducted between August 2006 and March 2014 have been published in each of the general 
practice activity annual reports26-33 
• conducted in the 2014–15 BEACH year are provided in Chapter 14 of this publication. 
Abstracts of results for all SAND substudies are also available on the FMRC’s website 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
2.7 Statistical methods 
The analysis of the 2014–15 BEACH data was conducted with Statistical Analysis System (SAS) 
version 9.3,34 and the encounter is the primary unit of inference. Proportions are used only when 
describing the distribution of an event that can arise only once at a consultation (for example, patient 
or GP age and sex), or to describe the distribution of events within a class of events (for example, 
problem A as a percentage of total problems). Due to rounding, proportions may not always add to 
exactly 100%. 
Calculations are made in SAS using the precise data with multiple decimal points. Therefore, if a 
reader recalculates the result from the reported rounded numbers presented in tables, their result may 
differ from that presented by 0.1.  
Rates per 100 encounters are used when an event can occur more than once at the consultation (for 
example, RFEs, problems managed or medications). 
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Rates per 100 problems are also used when a management event can occur more than once per 
problem managed. In general, the results present the number of observations (n), the rate per 100 
encounters, and (in the case of management actions) the rate per 100 problems managed, and the 
95% confidence interval. 
BEACH is a single stage cluster sample study design, each 100 encounters forming a cluster around 
each GP participant. In cluster samples, variance needs to be adjusted to account for the correlation 
between observations within clusters. Procedures in SAS version 9.3 were used to calculate 
intracluster correlation, and adjust the confidence intervals accordingly.34  
Post-stratification weighting of encounter data adjusts for: any difference in the age–sex distribution of 
the participating GPs and those GPs in the sample frame from which the samples were drawn; and 
for the varying activity level of each GP (measured by the number of claims each has made in the 
previous 12 months from Medicare Australia) (see Chapter 3). 
Statistical significance is tested by chi-square statistic for GP characteristics. However, where 
changes over time are investigated in the companion report, the significance of differences in rates is 
judged by non-overlapping confidence intervals (CIs) of the results being compared. The magnitude 
of this difference can be described as at least p < 0.05. Assessment using non-overlapping 
confidence intervals is a conservative measure of significance,35-37 particularly when differences are 
assessed by comparing results from independent random samples, as is the case when changes over 
time are investigated using BEACH data. Due to the number of comparisons made, we believe this 
conservative approach is warranted. 
2.8 Classification of data 
The following data elements are classified according to the International Classification of Primary 
Care – Version 2 (ICPC-2), of the World Organization of Family Doctors (Wonca):8 
• patient reasons for encounter (RFEs) 
• problems managed 
• clinical treatments (for example, counselling, advice) 
• procedural treatments 
• referrals 
• investigations ordered (including pathology, imaging and other investigations). 
The ICPC-2 is used in more than 45 countries as the standard for data classification in primary care. 
It is accepted by the WHO in the WHO Family of International Classifications,38 and is the declared 
national standard in Australia for reporting of health data from general practice and patient 
self-reported health information.39  
The ICPC-2 has a biaxial structure, with 17 chapters on one axis (each with an alphabetic code) and 
seven components on the other (numeric codes) (Figure 2.2). Chapters are based on body systems, 
with additional chapters for psychological and social problems. Component 1 includes symptoms and 
complaints. Component 7 covers diagnoses – it can also be expanded to provide data about 
infections, injuries, neoplasms, congenital anomalies and ‘other’ diagnoses. 
Component 2 (diagnostic, screening and prevention) is often applied in describing the problem 
managed (for example, check-up, immunisation). Components 3 to 6 cover other processes of care, 
including referrals, other (non-pharmacological) treatments and orders for pathology and imaging. The 
components are standard and independent throughout all chapters. The updated component 
groupings of ICPC-2 codes, released by the Wonca International Classification Committee in 200440 
have been used in this report. 
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The ICPC-2 is an excellent epidemiological tool. The diagnostic and symptom rubrics have been 
selected for inclusion on the basis of their relative frequency in primary care settings, or because of 
their relative importance in describing the health of the community. ICPC has about 1,370 rubrics and 
these are sufficient for meaningful analyses. However, reliability of data entry, using ICPC-2 alone, 
requires a thorough knowledge of the classification for correct classification of a concept to be 
ensured. 
In 1995, recognising a need for a coding and classification system for general practice electronic 
health records, the FMRC (then the Family Medicine Research Unit, FMRU) developed an extended 
clinical terminology classified according to the ICPC, now called ICPC-2 PLUS.41 This is an interface 
terminology, developed from all the terms used by GPs in studies such as The Australian Morbidity 
and Treatment Survey 1990–91 (113,468 encounters),42 A comparison of country and metropolitan 
general practice 1990–91 (51,277 encounters),43 The Morbidity and Therapeutic Index 1992–1998 (a 
clinical audit tool that was available to GPs; approximately 400,000 encounters), and BEACH  
1998–2015 (about 1.7 million encounters). Together, these make up about 2.3 million encounter 
records, involving about 3.4 million free text descriptions of problems managed and a further 
3.4 million for patient reasons for encounter. These terms are classified according to ICPC-2 to 
ensure data can be compared internationally. Readers interested in seeing how coding works can 
download the ICPC-2 PLUS Demonstrator at 
<sydney.edu.au/medicine/fmrc/icpc-2-plus/demonstrator>. 
When the free-text data are received from the GPs, trained secondary coders (who are 
undergraduate students), code the data in specific terms using ICPC-2 PLUS. This ensures high 
coder reliability and automatic classification of the concept, and allows us to ‘ungroup’ such ICPC-2 
rubrics as ‘other diseases of the circulatory system’ and select a specific disease from the terms 
within it. 
 
                    
 Components A B D F H K L N P R S T U W X Y Z  
 1. Symptoms, complaints                    
 2. Diagnostic, screening, prevention                   
 3. Treatment, procedures, medication                   
 4. Test results                   
 5. Administrative                   
 6. Other                   
 7. Diagnoses, disease                   
 A General and unspecified L Musculoskeletal U Urinary 
 B Blood & blood-forming organs N Neurological W Pregnancy, family planning 
 D Digestive P Psychological X Female genital  
 F Eye R Respiratory Y Male genital  
 H Ear S Skin Z Social  
 K Circulatory T Endocrine, nutritional & metabolic   
 
Figure 2.2: The structure of the International Classification of Primary Care – Version 2 (ICPC-2) 
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Presentation of data classified in ICPC-2 
Statistical reporting is usually at the level of the ICPC-2 classification (for example, acute otitis 
media/myringitis is ICPC-2 code H71). However, there are some exceptions where data are grouped 
either above the ICPC-2 level or across the ICPC-2 level. These grouped morbidity, pathology and 
imaging codes are defined in Appendix 4 available at: <hdl.handle.net/2123/13765>. 
Reporting morbidity with groups of ICPC-2 codes 
When recording problems managed, GPs may not always be very specific. For example, in recording 
the management of hypertension, they may simply record the problem as ‘hypertension’. In ICPC-2, 
‘hypertension, unspecified’ is classified as ‘uncomplicated hypertension’ (code K86). There is another 
code for ‘complicated hypertension’ (K87). In some cases the GP may simply have failed to specify 
that the patient had hypertension with complications. The research team therefore feels that for 
national data reporting, it is more reliable to group the codes K86 and K87 and label this 
‘Hypertension*’ – the asterisk indicating that multiple ICPC-2 codes (as in this example), or 
ICPC-2 PLUS codes (see below), are included. Appendix 4, Table A4.1 lists the codes included in 
these groups. 
Reporting morbidity with groups of ICPC-2 PLUS codes 
In other cases, a concept can be classified within (but be only part of) multiple ICPC-2 codes. For 
example, osteoarthritis is classified in ICPC-2 in multiple broader codes according to site, such as 
L92 – shoulder syndrome (includes bursitis, frozen shoulder, osteoarthritis of shoulder, rotator cuff 
syndrome). When reporting osteoarthritis in this publication, all the more specific osteoarthritis ICPC-2 
PLUS terms classified within all the appropriate ICPC-2 codes are grouped. This group is labelled 
‘Osteoarthritis*’ – the asterisk again indicating multiple codes, but in this case they are PLUS codes 
rather than ICPC-2 codes. Appendix 4, Table A4.1 lists the codes included in these groups. 
Reporting chronic morbidity 
Chronic conditions are medical conditions characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last 6 months or more, a pattern of 
recurrence or deterioration, a poor prognosis, and consequences or sequelae that affect an 
individual’s quality of life. 
To identify chronic conditions, a chronic condition list44 classified according to ICPC-2 was applied to 
the BEACH data set. Chronic and non-chronic conditions (for example, diabetes and gestational 
diabetes) are often grouped together when reporting (for example, diabetes – all*). When reporting 
chronic morbidity, only problems regarded as chronic have been included in the analysis. Where the 
group used for the chronic analysis differs from that used in other analyses in this report, they are 
marked with a double asterisk. Codes included in the chronic groups are provided in Appendix 4, 
Table A4.2. 
Reporting pathology and imaging test orders 
All the pathology and imaging tests are coded very specifically in ICPC-2 PLUS, but ICPC-2 classifies 
pathology and imaging tests very broadly (for example, a test of cardiac enzymes is classified in  
K34 – Blood test associated with the circulatory system; a CT scan of the lumbar spine is classified as 
L41 – Diagnostic radiology/imaging of the musculoskeletal system). In Australia, the MBS classifies 
pathology and imaging tests in groups that are relatively well recognised. The team therefore 
regrouped all pathology and imaging ICPC-2 PLUS codes into MBS standard groups. This allows 
comparison of data between data sources. 
The groups are marked with an asterisk, and inclusions are provided in Appendix 4, Tables A4.8 and 
A4.9. 
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Classification of pharmaceuticals 
Pharmaceuticals that are prescribed, provided by the GP or advised for over-the-counter purchase 
are coded and classified according to an in-house classification, the Coding Atlas for Pharmaceutical 
Substances (CAPS). 
This is a hierarchical structure that facilitates analysis of data at a variety of levels, such as 
medication class, medication group, generic name/composition, and brand name. 
The generic name of a medication is its non-proprietary name, which describes the pharmaceutical 
substance(s) or active pharmaceutical ingredient(s). 
When strength and regimen are combined with the CAPS code, we can derive the prescribed daily 
dose for any prescribed medication or group of medications. 
CAPS is mapped to the Anatomical Therapeutic Chemical (ATC)45 classification, which is the 
Australian standard for classifying medications at the generic level.39 The ATC has a hierarchical 
structure with five levels. For example: 
• Level 1: C – Cardiovascular system 
• Level 2: C10 – Serum lipid reducing agents 
• Level 3: C10A – Cholesterol and triglyceride reducers 
• Level 4: C10AA – HMG CoA reductase inhibitors 
• Level 5: C10AA01 – Simvastatin (the generic drug). 
Use of the pharmaceutical classifications in reporting 
For pharmaceutical data, there is the choice of reporting in terms of the CAPS coding scheme or the 
ATC. They each have advantages in different circumstances. 
In the CAPS system, a new drug enters at the product and generic level, and is immediately allocated 
a generic code. Therefore, the CAPS classification uses a bottom-up approach. 
In the ATC, a new generic may initially enter the classification at any level (1 to 5), not always at the 
generic level. Reclassification to lower ATC levels may occur later. Therefore, the ATC uses a 
top-down approach. 
When analysing medications across time, a generic medication that is initially classified to a higher 
ATC level will not be identifiable in that data period and may result in under-enumeration of that drug 
during earlier data collection periods. 
There are some differences in the labels applied to generic medications in the two classifications. For 
example, the medication combination of paracetamol and codeine is labelled as 
‘Paracetamol/codeine’ in CAPS and as ‘Codeine combinations excluding psycholeptics’ in the ATC. 
• When reporting annual results for pharmaceutical data, the CAPS database is used in tables of 
the ‘most frequent medications’ (Tables 9.2 to 9.4). 
• When reporting the annual results for pharmaceuticals in terms of the ATC hierarchy (Table 9.1), 
ATC levels 1, 3, and 5 are used. The reader should be aware that the results reported at the 
generic level (Level 5) may differ slightly from those reported in the ‘most frequent medication’ 
tables for the reasons described above. 
Practice nurse and Aboriginal health worker activities associated 
with the encounter 
The BEACH form was changed in 2005–06 to capture ‘other treatments’ performed by practice nurses 
(PNs) following the introduction of MBS item numbers for defined PN activities. GPs were asked to 
tick the ‘practice nurse’ box if a treatment was provided by the PN. If not ticked, it was assumed that 
the GP provided the ‘other treatment’. 
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Over the years, new PN item numbers were added to the MBS and some items were broadened to 
include work done by Aboriginal health workers (AHWs). From 2005–06 to 2010–11, we reported the 
results referring to PNs alone. As some GPs indicated (of their own accord) that the recorded action 
was done by an AHW rather than a PN, this information is now included. In this report we refer to 
work undertaken at encounters by PNs and AHWs in conjunction with the GPs, though the vast 
majority will have been done by PNs. There is a limitation to this approach. Few GPs specifically 
indicated that the work was done by an AHW. Others may have considered the question referred 
specifically to PNs, and therefore did not record work done by AHWs. These results therefore have 
the potential to be an underestimate of the work undertaken at GP–patient encounters by AHWs. 
2.9 Quality assurance 
All morbidity and therapeutic data elements were secondarily coded by staff entering key words or 
word fragments, and selecting the required term or label from a pick list. This was then automatically 
coded and classified by the computer. To ensure reliability of data entry we use computer-aided error 
checks (‘locks’) at the data entry stage, and a physical check of samples of data entered versus those 
on the original recording form. Further logical data checks are conducted through SAS regularly. 
2.10 Validity and reliability 
A discussion of the reliability and validity of the BEACH program has been published elsewhere.46 
This section touches on some aspects of reliability and validity of active data collection from general 
practice that should be considered by the reader. 
In the development of a database such as BEACH, data gathering moves through specific stages: GP 
sample selection, cluster sampling around each GP, GP data recording, secondary coding and data 
entry. At each stage the data can be invalidated by the application of inappropriate methods. The 
methods adopted to ensure maximum reliability of coding and data entry have been described above. 
The statistical techniques adopted to ensure valid analysis and reporting of recorded data are described 
in Section 2.7. Previous work has demonstrated the extent to which a random sample of GPs recording 
information about a cluster of patients represents all GPs and all patients attending GPs,47 the degree to 
which GP-reported patient RFEs and problems managed accurately reflect those recalled by the 
patient,48 and reliability of secondary coding of RFEs49 and problems managed.42 The validity of ICPC as 
a tool with which to classify the data has also been investigated in earlier work.50 
2.11 Extrapolated national estimates 
A section at the end of each chapter highlights changes that have occurred over the decade 2005–06 
to 2014–15. These sections summarise results published in the companion publication, A decade of 
Australian general practice activity 2005–06 to 2014–15.1 Where the results demonstrate a significant 
change over time, the estimated national change across total GP Medicare services from 2005–06 to 
2014–15 can be calculated using the method detailed below. 
Note that extrapolations are always based on rate per 100 encounters rather than rate per 100 
problems because there is no independent measure of the total number of problems managed in 
Australian general practice. In contrast, the number of national encounters can be drawn from 
Medicare claims data. 
In this report, we also occasionally extrapolate data for the single year 2014–15 to give the reader 
some feeling of the real size of the issue across Australian general practice. 
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When extrapolating from a single time point we: 
• divide the ‘rate per 100 encounters’ of the selected event by 100, and then multiply by the total 
number of GP service items claimed through Medicare in that year, (137.3 million in 2014–15, 
rounded to the nearest 100,000, see Table 2.1), to give the estimated number of the selected 
event across Australia in 2014–15. 
When extrapolating measured change over the decade to national estimates, we: 
• divide the ‘rate per 100 encounters’ of the selected event for 2005–06 by 100, and then multiply 
by the total number of GP service items claimed through Medicare in that year, (101.1 million, 
rounded to the nearest 100,000, see Table 2.1), to give the estimated national number of events 
in 2005–06 
• repeat the process using data for 2014–15. 
The difference between the two estimates gives the estimated national change in the frequency of 
that event over the decade. Estimates are rounded to the nearest 100,000 if more than a million, and 
to the nearest 10,000 if below a million. 
Change is expressed as the estimated increase or decrease over the study period (from 2005–06 to 
2014–15), in the number of general practice contacts for that event (for example, an increase or 
decrease in the number of GP management contacts with a certain problem), or an increase or 
decrease in the number of times a particular medication type was prescribed in Australia. 
Table 2.1 provides the rounded number of GP service items claimed from Medicare in each 
financial year from 2005–06 to 2014–15. 
Table 2.1: Rounded number of general practice professional services claimed from Medicare Australia 
each financial year, 2005–06 to 2014–15 (million) 
 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 2013–14 2014–15(a) 
Rounded number of 
Medicare GP items 
of service claimed 
101.1 103.4 109.5 113.0 116.6 119.2 123.9 126.8 134.2 137.3 
(a) Medicare data for the 2014–15 year included data from the April 2014 to March 2015 quarters because the 2014–15 financial year data 
were not available at the time of preparation of this report. 
Source: Medicare Statistics.2 
Examples of extrapolation 
Example 1: Number of GP encounters at which depression was managed nationally in 
2014–15 
Depression was managed at a rate of 4.5 per 100 GP encounters (95% CI: 4.2–4.7) in 2014–15 
(shown in Table 7.4). How many times does this suggest that depression was managed in GP 
encounters across Australia in 2014–15?  
Our best estimate is: 
6.2 million times [(4.5/100) x 137.3 million], but we are 95% confident that the true number 
lies between 5.8 million [(4.2/100) x 137.3 million] and 6.5 million [(4.7/100) x 137.3 million]. 
Using the management rate per 100 encounters as the basis for extrapolation works very well 
when estimating total national GP encounters at which a single concept (symptom/complaint, or 
diagnosis/disease) is managed. However, if you wish to estimate how many GP–patient 
encounters involve management of any psychological problem, you need to use a different 
approach (see example 2 below). 
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Example 2: Number of GP encounters which involve management of psychological 
problems 
The concept ‘psychological problems’ includes many different individual concepts (for example, 
depression, dementia, anorexia nervosa, etc). In BEACH, GPs record at least one and up to four 
problems managed, per encounter. It is therefore possible that at a single encounter a GP can 
manage more than one of the many problems classified as ‘psychological problems’ in the 
International Classification of Primary Care. 
If you use the management rate per 100 encounters to estimate the national number of 
encounters at which at least one psychological problem was managed in 2014–15, you will 
overestimate the true number of encounters, because more than one of these problems can be 
managed at a single encounter. 
To overcome this problem we have a column on the right hand side of Table 6.4 (Patient reasons 
for encounter by ICPC-2 chapter and most frequent individual reasons for encounter within 
chapter) and Table 7.3 (Problems managed by ICPC-2 chapter and frequent individual problems 
within chapter), which gives you the proportion of all BEACH encounters at which at least one 
problem of each chapter type was managed. 
In the examples provided, we use this column to answer the question: At how many encounters 
across Australia, did GPs manage at least one psychological problem in 2014–15? 
Using the far right column of Table 7.3, our best estimate is: 
17.4 million times (12.7% of 137.3 million), but we are 95% confident that the true number 
lies between 16.6 million (12.1% of 137.3 million) and 18.1 million (13.2% of 137.3 million). 
 
Example 3: National increase in the number of problems managed from 2005–06 to  
2014–15 
There was a statistically significant increase in the number of problems managed at GP–patient 
encounters, from 146.2 per 100 encounters in 2005–06 to 155.1 in 2014–15 (see Table 7.2 in 
A decade of Australian general practice activity 2005–06 to 2014–15).1 The calculation used to 
extrapolate the effect of this change across Australia is:  
(146.2/100) x 101.1 million = 147.8 million problems managed nationally in 2005–06, and 
(155.1/100) x 137.3 million = 213.0 million problems managed nationally in 2014–15. 
This suggests there were 65 million (213.0 million minus 147.8 million) more problems managed 
at GP–patient encounters in Australia in 2014–15 than in 2005–06. This is the result of the 
compound effect of the increase in the number of problems managed by GPs at encounters plus 
the far higher number of number of visits across Australia in 2014–15 than in 2005–06. 
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Considerations and limitations in extrapolations 
The extrapolations to the total events occurring nationally in any one year are only estimates. They 
may provide: 
• an underestimate of the true ‘GP workload’ of a condition/treatment because the extrapolations 
are made to GP Medicare items claimed, not to the total number of GP encounters per year – an 
additional 5% or so of BEACH encounters annually include encounters paid by sources other 
than Medicare, such as DVA, state governments, workers compensation insurance, and 
employers, or not charged to anyone. 
• an underestimate of activities of relatively low frequency with a skewed distribution across 
individual GPs. Where activity is so skewed across the practising population, a national random 
sample will provide an underestimate of activity because the sample reflects the population rather 
than the minority. 
Further, the base numbers used in the extrapolations are rounded to the nearest 100,000, and 
extrapolation estimates are rounded to the nearest 100,000 if more than a million, and to the nearest 
10,000 if below a million, so can only be regarded as approximations. However, the rounding has 
been applied to all years, so the effect on measures of change will be very small. Therefore, the 
extrapolation still provides an indication of the size of the effect of measured change nationally. 
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 3 The sample 
This chapter describes the GP sample and sampling methods used in the BEACH program. The 
sampling and recruitment methods are only summarised in this chapter. A more detailed explanation 
of the BEACH methods is provided in Chapter 2. 
A summary of the BEACH data sets is reported for each year from 2005–06 to 2014–15 in the 
companion report, A decade of Australian general practice activity 2005–06 to 2014–15.1 
3.1 Response rate 
A random sample of GPs who claimed at least 375 general practice Medicare items of service in the 
previous 3 months is regularly drawn from Medicare claims data by the Australian Government 
Department of Health (see Chapter 2). 
Contact was attempted with 4,437 GPs, but 23.1% could not be contacted. A quarter of these had 
moved (and were untraceable), or had retired or died (Table 3.1), but more than half (60.9%) were 
those with whom contact could not be established after five calls. Younger GPs were harder to 
contact. In previous years these have largely been registrars moving through practices during training, 
who were no longer at the nominated practice and could not be traced. We were not able to measure 
the proportion of ‘no contact’ GPs who were registrars as, owing to changes in the privacy 
requirements in 2013 for data provided by DoH, information relating to any GPs who do not 
participate in BEACH must be destroyed quarterly, so is not available for comparison. 
The fact that one-in-four GPs were not contactable may be a reflection of the uptake of electronic 
communication between GPs and DoH. Updating practice location may be overlooked, and may 
result in the contact details being out-of-date at the time the samples are provided. 
The final participating sample consisted of 995 practitioners, representing 29.2% of those who were 
contacted and available, and 22.4% of those with whom contact was attempted (Table 3.1). 
Table 3.1: Recruitment and participation rates 
Type of contact Number 
Per cent of  
approached  
(n = 4,437) 
Per cent of contacts 
established  
(n = 3,411) 
Letter sent and phone contact attempted 4,437 100.0 — 
No contact  1,026 23.1 — 
 No phone number could be established 20 0.5 — 
 Moved & untraceable/retired/deceased 293 6.6 — 
 Unavailable (overseas, maternity leave, etc.) 88 1.2 — 
 No contact after five calls 625 14.0 — 
Telephone contact established 3,411 76.9 100.0 
 Declined to participate 2,162 48.7 63.4 
 Agreed but withdrew 254 5.7 7.4 
 Agreed and completed 995 22.4 29.2 
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3.2 Representativeness of the GP sample 
Whenever possible, the study group of GPs should be compared with the population from which the 
GPs were drawn (the sample frame) to identify and, if necessary, adjust for any sample bias that may 
affect the findings of the study. Comparisons between characteristics of the final GP sample and 
those of the GPs in the sample frame are provided below. The method by which weightings are 
generated as a result of these comparisons and applied to the data are described in Section 3.3. 
Statistical comparisons, using the chi-square statistic (2) (significant at the 5% level), were made 
between BEACH participants and all recognised GPs in the sample frame during the study period 
(Table 3.2). The GP characteristics data for BEACH participants were drawn from their GP profile 
questionnaire. DoH provided the grouped data for all GPs in the sample frame, drawn from Medicare 
claims data. 
Table 3.2 demonstrates there were no significant differences in characteristics of GPs in the final 
sample of BEACH participants and those of all GPs in the sample frame, in terms of sex, 
State/Territory and practice location as classified by the Australian Standard Geographical 
Classification (ASGC). In the final BEACH GP sample, there was a slight under-representation of GPs 
in the <35 year and 35–44 year age groups, and a slight over-representation in the 55+ years age 
group, compared with GPs in the sample frame. The proportion of GPs who had graduated from their 
primary medical degree in Australia (place of graduation) was also higher than that in the sample 
frame. 
Table 3.2: Comparison of BEACH participants and all active recognised GPs in Australia who satisfied 
the selection criteria (the sample frame) 
Variable 
BEACH(a)(b)  Australia(a)(c) 
Number 
Per cent of GPs 
(n = 995)  Number 
Per cent of GPs 
(n = 23,818)  
Sex (2 = 0.2, p = 0.68)      
 Males 570 57.3  13,803  58.0 
 Females 425 42.7  10,015 42.0 
Age (2 = 16.3, p < 0.001)      
 < 35 years 73 7.4  2,269  9.5 
 35–44 years 188 19.0  5,411  22.7 
 45–54 years 279 28.2  6,517  27.4 
 55+ years 448 45.3  9,621  40.4 
 Missing  7 —  — — 
Place of graduation (2 = 26.0, p < 0.001)      
 Australia 663 67.0  14,014 58.8 
 Overseas 327 33.0  9,804 41.2 
 Missing 5 —  — — 
State (2 = 9.9, p = 0.19)      
 New South Wales 341 34.3  7,558 31.7 
 Victoria 237 23.8  5,899  24.8 
 Queensland 204 20.5  4,930  20.7 
 South Australia 74 7.4  1,937  8.1 
 Western Australia 97 9.8  2,317  9.7 
 Tasmania 15 1.5  631  2.6 
(continued) 
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Table 3.2 (continued): Comparison of BEACH participants and all active recognised GPs in Australia who 
satisfied the selection criteria (the sample frame) 
Variable 
BEACH(a)(b)  Australia(a)(c) 
Number 
Per cent of GPs 
(n = 995)  Number 
Per cent of GPs 
(n = 23,818)  
 Australian Capital Territory 20 2.0  354  1.5 
 Northern Territory 6 0.6  192 0.8 
 Missing 1 —  — — 
ASGC (2 = 4.1, p = 0.4)      
 Major Cities of Australia 708 71.2  16,625  69.8 
 Inner Regional Australia 191 19.2  4,634  19.5 
 Outer Regional Australia 82 8.2  2,090  8.8 
 Remote Australia 11 1.1  304  1.3 
 Very Remote Australia 2 0.2  160  0.7 
 Missing 1 —  — — 
(a) Missing data removed. 
(b) Data drawn from the BEACH GP profile completed by each participating GP. 
(c) All GPs who satisfied the sample selection criteria of at least 375 MBS-claimed GP consultation service items during the most recent  
3-month Medicare Australia data period prior to their being sampled. Data provided by the Australian Government Department of Health. 
Note: ASGC – Australian Standard Geographical Classification.51 
GP activity in the previous year 
Data on the number of MBS general practice service items claimed in the previous year were also 
provided by DoH for each GP in the drawn samples, and for all GPs (as a group) in the sample frame. 
These data were used to determine the ‘activity level’ of each participating GP, and to compare the 
activity level of the final participants with that of GPs in the sample frame. 
When comparing GP activity level in the previous 12 months, the proportion of GPs in the final 
participant sample who had claimed fewer than 1,500 services in the previous year was half that of 
GPs in the sample frame. A slightly larger proportion of participants had claimed 1,501–3,000 
services, and 3001–4,500 services, and there was only a very small difference (<2%) in the two most 
active service claim groups. Comparison of the mean number of claims made by the participating GPs 
was slightly lower than that of the GP sample frame. Participants conducted on average 143.1 fewer 
services per year, or 2.8 consultations per week (on a 52-week year, or 3 per week on a 48-week 
year, assuming 4 weeks leave) (Table 3.3). As the mean number of claims for the sample frame sat 
within the 95% CIs around the mean for BEACH participants, there was no statistically significant 
difference in activity levels of the two groups. 
This result differs from year to year (the previous report showed small differences in terms of sex, 
place of graduation, state, and a slight variation in some categories of GP age33). The effect of 
random sampling may also influence this measure as, occasionally, the randomly selected 
recruitment sample can differ slightly from the sample frame in one or more variables, which can 
affect the ultimate representativeness of the final participant group. 
The 2013 changes to privacy requirements regarding data provided by DoH mean that we can no 
longer examine this possibility. 
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Table 3.3: Activity level in the previous 12 months of participating GPs and GPs in the sample frame 
(measured by the number of GP service items claimed) 
Variable 
Participants  
(n = 995)  
Australia(a) 
(n = 23,848) 
Number of GPs Per cent  Number of GPs Per cent 
Activity (2 = 38.2, p < 0.0001)      
 1–1,500 services in previous year 42 4.2  1,991 8.7 
 1,501–3,000 services in previous year 223 22.4  4,410 19.3 
 3,001–4,500 services in previous year 263 26.4  5,279 23.1 
 4,501–6,000 services in previous year 190 19.1  3,959 17.3 
 6,001–10,000 services in previous year 213 21.4  5,406 23.7 
 > 10,000 services in previous year 64 6.4  1,803 7.9 
 Number of claims 95% CI  Number of claims  
Mean activity level  4,909.4 4,736.6–5,082.3  5,052.5 — 
Standard deviation 2,779.2 —  — — 
Median activity level 4,358.0 —  — — 
(a) Number of GPs in the sample frame for whom these data were provided. 
Note: The ‘n’ for Australia reported above differs from that of Table 3.2 because activity level is only provided for GPs who were in the sample 
frame for the entire year. GPs coming into or leaving the sample frame part-way through the year do not have an ‘activity level’ for the 
previous year; CI – confidence interval. 
3.3 Weighting the data 
Age–sex weights  
As described in Section 3.2, comparisons are made annually to test how representative BEACH 
participants are of the GPs in the original Australian sample frame. Where participants in a particular 
age or sex group are over-represented or under-represented, GP age–sex weights need to be applied 
to the data sets in post-stratification weighting to achieve comparable estimates and precision. 
Because there are always slight (even if not statistically significant) differences, even in years where 
the BEACH participants are representative in all age and sex categories, post-stratification weighting 
for GP age and sex is applied for consistency over recording years. 
Activity weights  
In BEACH, each GP provides details of 100 encounters. There is considerable variation among GPs 
in the number of services each provides in a given year. Encounters were therefore assigned an 
additional weight directly proportional to the activity level of the recording GP. Please note – GP 
activity level was measured as the number of MBS general practice service items claimed for services 
by the GP in the previous 12 months (data supplied by DoH). Because the measure is based on 
annual activity, estimates could only be provided for GPs who had claimed service items during the 
whole year. Those entering or leaving the sample frame part way through the year will have met the 
eligibility criteria for inclusion in the BEACH sample (that is, claiming a minimum of 375 MBS GP 
consultation services during the most recent 3-month Medicare Australia data period at sampling 
date) but would not have an annual activity level. 
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Total weights  
The final weighted estimates were calculated by multiplying raw rates by the GP age–sex weight and 
the GP sampling fraction of services (‘activity’) in the previous 12 months. Table 3.4 shows the 
precision ratio calculated before and after weighting the encounter data. 
3.4 Representativeness of the encounter sample 
In the BEACH program, we aim to gain a representative sample of GP–patient encounters each year. 
To assess the representativeness of the final weighted sample of encounters, the age–sex distribution 
of patients at weighted BEACH encounters with GP consultation service items claimed (excluding 
those with Department of Veterans’ Affairs [DVA] patients) was compared with that of patients at all 
encounters claimed as GP consultation service items through Medicare in the 2014–15 study period 
(data provided by DoH). 
As shown in Table 3.4, there is an excellent fit of the age–sex distribution of patients at the weighted 
MBS-claimed BEACH encounters with that of the MBS claims distribution, with all precision ratios 
within the 0.88–1.10 range. This indicates that the BEACH sample is a good representation of 
Australian GP–patient encounters, as no age–sex category varied by more than 12% from the 
population distribution, and only one by 12%. 
The age–sex distribution of patients at BEACH encounters and for MBS GP consultation service item 
claims is shown graphically for all patients in Figure 3.1, for males in Figure 3.2, and for females in 
Figure 3.3. 
26
  
Table 3.4: Age–sex distribution of patients at BEACH and MBS GP consultation service items 
 
BEACH–raw(a)  BEACH–weighted(b)  Australia(c)  
Precision ratios 
(Australia = 1.00) 
Sex/age 
Number 
Per cent  
(n = 82,865)  Number 
Per cent 
(n = 82,353)  
Per cent 
(n = 116,073,886)  Raw(a) Weighted(c) 
All           
 < 1 year 1,741 2.1  1,640 2.0  1.9  1.11 1.05 
 1–4 years 3,869 4.7  3,933 4.8  5.1  0.92 0.94 
 5–14 years 4,511 5.4  4,521 5.5  6.2  0.87 0.89 
 15–24 years 6,875 8.3  6,866 8.3  8.6  0.97 0.97 
 25–44 years 18,225 22.0  18,058 21.9  23.0  0.96 0.95 
 45–64 years 22,562 27.2  22,426 27.2  26.2  1.04 1.04 
 65–74 years 11,979 14.5  11,866 14.4  13.2  1.10 1.09 
 75+ years 13,103 15.8  13,044 15.8  15.8  1.00 1.00 
Male           
 < 1 year 901 1.1  858.4 1.0  1.0  1.07 0.97 
 1–4 years 2,049 2.5  2,122.6 2.6  2.7  0.93 0.96 
 5–14 years 2,249 2.7  2,321.4 2.8  3.2  0.84 0.88 
 15–24 years 2,335 2.8  2,496.6 3.0  3.1  0.89 0.96 
 25–44 years 6,324 7.6  6,730.3 8.2  8.7  0.88 0.95 
 45–64 years 9,123 11.0  9,610.7 11.7  11.2  0.98 1.04 
 65–74 years 5,090 6.1  5,326.0 6.5  6.1  1.00 1.07 
 75+ years 5,342 6.4  5,588.9 6.8  6.7  0.96 1.02 
Female           
 < 1 year 840 1.0  781.2 0.9  0.9  1.12 1.01 
 1–4 years 1,820 2.2  1,810.3 2.2  2.4  0.93 0.93 
 5–14 years 2,262 2.7  2,199.3 2.7  3.0  0.89 0.89 
 15–24 years 4,540 5.5  4,369.7 5.3  5.4  1.01 0.97 
 25–44 years 11,901 14.4  11,327.0 13.8  14.3  1.00 0.96 
 45–64 years 13,439 16.2  12,815.0 15.6  14.9  1.08 1.04 
 65–74 years 6,889 8.3  6,539.7 7.9  7.2  1.16 1.10 
 75+ years 7,761 9.4  7,455.3 9.1  9.1  1.03 1.00 
(a) Unweighted Medicare-claimed GP consultation service items only, excluding encounters with patients who hold a DVA Repatriation Health 
Card. 
(b) Calculated from BEACH weighted data, excluding encounters with patients who hold a DVA Repatriation Health Card. 
(c) Age–sex distribution of patients at MBS-claimed GP consultation services; data provided by the Australian Government Department of 
Health. 
Note: GP consultation services – see ‘Glossary’. Only encounters with valid patient age and sex recorded are included in the comparison. 
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 Figure 3.1: Age distribution of all patients at BEACH and MBS GP consultation services, 2014–15 
 
 
 
 
 
 Figure 3.2: Age distribution of male patients at BEACH and MBS GP consultation services, 2014–15 
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 Figure 3.3: Age distribution of female patients at BEACH and MBS GP consultation services, 2014–15 
3.5 The weighted data set 
The final unweighted data set from the 17th year of collection contained encounters, reasons for 
encounters, problems and management/treatments. All variables decreased after weighting. Raw and 
weighted totals for each data element are shown in Table 3.5. The weighted data set is used for all 
analyses in the remainder of this report. 
Table 3.5: The BEACH data set, 2014–15 
Variable Raw Weighted 
General practitioners 995 995 
Encounters 99,500 98,728 
Reasons for encounter 153,539 151,636 
Problems managed 158,263 153,133 
Medications 101,917 101,776 
Other treatments(a) 53,085 50,204 
Referrals and admissions 16,530 15,697 
Pathology 50,465 46,435 
Imaging 11,405 11,314 
Other investigations 819 732 
(a) Other treatments excludes injections for immunisations/vaccinations (raw n = 2,815, weighted n = 2,573) (see Chapter 10). 
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 4 The participating GPs 
This chapter reports data collected between April 2014 and March 2015 (the 17th year of the BEACH 
program) about the participating GPs and their practices. Details of GP and practice characteristics 
are reported for each year from 2005–06 to 2014–15 in the 10-year summary report, A decade of 
Australian general practice activity 2005–06 to 2014–15.1  
4.1 Characteristics of the GP participants 
All participants returned a GP profile questionnaire, although some were incomplete. The results are 
provided in Tables 4.1 and 4.2 (median results not tabled). Of the 995 participants: 
• 57.3% were male, and 45.3% were aged 55 years and over (mean age 52.4 years; median age 
53 years) 
• 59.3% had been in general practice for more than 20 years 
• 67.0% had graduated in Australia and 13.3% in Asia 
• 58.0% spent 21–40 hours on average per week on direct patient care services (mean hours 
worked was 36.6; median was 36.0 hours) 
• 63.8% were Fellows of the RACGP, and 5.9% were Fellows of the ACRRM 
• 48.4% had provided care in a residential aged care facility in the previous month 
• 90.4% worked in an accredited practice 
• 71.2% practised in Major cities (using Australian Standard Geographical Classification51) 
• 76.0% worked at only one practice location in a regular week, and 19.9% worked in two. 
At their major practice address: 
• 30.8% were in practices of fewer than five individual GPs, and 29.1% were in practices of 10 or 
more individual GPs. On average, there were 7.5 individual GPs per practice, with a median of 
7 per practice 
• 48.2% were in practices of fewer than five full-time-equivalent (FTE) GPs. On average, there 
were 5.4 FTE GPs per practice, with a median of 5 FTE GPs per practice 
• 84.0% of the GPs worked in a practice that employed practice nursing staff. Of these practices, 
more than one-third (36.1%) employed fewer than two FTEs (35–45 hours per week). On 
average, there were 0.3 FTE practice nurses per FTE GP 
• more than three-quarters (78.4%) had a co-located pathology laboratory or collection centre in, or 
within 50 metres of the practice, and more than half (57.0%) had a co-located psychologist  
• 41.4% worked in a practice that provided their own or cooperative after-hours care, and 56.9% in 
a practice that used a deputising service for after-hours patient care (multiple responses allowed). 
Those interested in the clinical activity of overseas trained doctors will find more information in 
Bayram et al. (2007) Clinical activity of overseas trained doctors practising in general practice in 
Australia.52 Readers interested in the effects of GP age on clinical practice will find more information 
in Charles et al. (2006) The independent effect of age of general practitioner on clinical practice.53 For 
more information about the effect of the sex of the GP on clinical practice see Harrison et al. (2011) 
Sex of the GP.54   
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Table 4.1: Characteristics of participating GPs and their practices 
GP characteristic Number(a) 
Per cent of GPs(a) 
(n = 995) 
Sex (missing n = 0)   
 Male 570 57.3 
 Female 425 42.7 
Age (missing n = 7)   
 < 35 years 73 7.4 
 35–44 years 188 19.0 
 45–54 years 279 28.2 
 55+ years 448 45.3 
Years in general practice (missing n = 13)   
 < 2 years 9 0.9 
 2–5 years 116 11.8 
 6–10 years 109 11.1 
 11–19 years 166 16.9 
 20+ years 582 59.3 
Place of graduation (missing n = 5)   
 Australia 663 67.0 
 Overseas 327 33.0 
  Asia 132 13.3 
  United Kingdom/Ireland 83 8.4 
  Africa and Middle East 59 6.0 
  Europe 31 3.1 
  New Zealand 13 1.3 
  Other 9 0.9 
Direct patient care hours (worked) per week (missing n = 23)   
 ≤ 10 hours 12 1.2 
 11–20 hours 104 10.7 
 21–40 hours 564 58.0 
 41–60 hours 276 28.4 
 61+ hours 16 1.7 
GP Registrar (in training) 37 3.8 
Fellow of RACGP (missing n = 6) 631 63.8 
Fellow of ACRRM (missing n = 38) 56 5.9 
Patient care provided in previous month(b)    
 In a residential aged care facility (missing n = 6) 479 48.4 
 As a salaried/sessional hospital medical officer (missing n = 6) 113 11.4 
(continued) 
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Table 4.1 (continued): Characteristics of participating GPs and their practices 
GP characteristic Number(a) 
Per cent of GPs(a) 
 (n = 995) 
Accredited practice (missing n = 10) 890 90.4 
Practice location by ASGC remoteness structure (missing n = 1)   
 Major cities 708 71.2 
 Inner regional 191 19.2 
 Outer regional 82 8.3 
 Remote 11 1.1 
 Very remote 2 0.2 
Number of practice locations worked at in a regular week (missing n = 19)   
 1 742 76.0 
 2 194 19.9 
 3 32 3.3 
 4+ 8 0.8 
Size of practice – number of individual GPs (missing n = 25)   
 Solo 93 9.6 
 2–4  206 21.2 
 5–9  389 40.1 
 10–14 193 19.9 
 15+  89 9.2 
Size of practice – full-time equivalent GPs (missing n = 150)   
 < 1 3 0.4 
 1.0– <2 91 10.8 
 2.0– <3 98 11.6 
 3.0– <4 100 11.8 
 4.0– <5 115 13.6 
 5.0– <10 345 40.8 
 10.0– <15 68 8.1 
 15+ 25 3.0 
Practice nurse at major practice address (missing n = 7) 830 84.0 
Number of individual practice nurses (missing n = 25)   
 0 158 16.3 
 1 150 15.5 
 2  206 21.2 
 3 171 17.6 
 4–5  186 19.2 
 6+ 99 10.2 
(continued) 
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Table 4.1 (continued): Characteristics of participating GPs and their practices 
GP characteristic Number(a) 
Per cent of GPs(a) 
 (n = 995) 
Number of full-time equivalent practice nurses (missing n = 163)   
 0 158 19.0 
 < 1 63 7.6 
 1.0– <2 237 28.5 
 2.0– <3 191 23.0 
 3.0– <4 104 12.5 
 4.0+ 79 9.5 
Co-located services(c) (missing n = 27)   
 Pathology laboratory/collection centre 759 78.4 
 Psychologist 552 57.0 
 Physiotherapist 484 50.0 
 Medical specialist 270 27.9 
 Imaging/radiology services 260 26.9 
 Dietitian 453 46.8 
 Podiatrist 411 42.5 
 Other service 169 17.5 
 None 92 9.5 
After-hours arrangements(b) (missing n = 5)   
 Practice does own and/or cooperative with other practices 410 41.4 
  Practice does its own 313 31.6 
  Cooperative with other practices 115 11.6 
 Deputising service 563 56.9 
 Other arrangement 82 8.3 
 None 39 3.9 
(a) Missing data removed. 
(b) Multiple responses allowed. 
(c) Services located/available in the practice, in the same building or within 50 metres, available on a daily or regular basis. 
Note: ASGC – Australian Standard Geographical Classification; RACGP – Royal Australian College of General Practitioners;  
ACRRM – Australian College of Rural and Remote Medicine. 
 
Table 4.2: Means of selected characteristics of participating GPs and their practices 
Characteristic 
Mean 
(n = 955) 95% LCL 95% UCL 
Mean age of participating GPs (missing n = 7) 52.4 51.7 53.1 
Mean hours worked per week on direct patient care (missing n = 23) 36.6 35.8 37.4 
Mean number of individual GPs at major practice address (missing n = 25) 7.5 7.2 7.9 
Mean number of FTE GPs at major practice address (missing n = 150) 5.4 5.2 5.7 
FTE practice nurse: FTE GP (missing n = 214) 0.3 0.3 0.3 
Note: LCL – lower confidence limit; UCL – upper confidence limit; FTE – full-time equivalent. 
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4.2 Computer use at GP practices 
As computers are now increasingly used by GPs in their clinical activity, the GP profile questionnaire 
was redesigned in 2014–15 to gain more comprehensive information about the uses to which 
computers are put in a general practice clinical environment (see Appendix 2). In particular, more 
specific information was collected about electronic and other prescribing, and whether the medical 
records used were paper only, a mix of paper and electronic medical records, or whether the records 
were completely paperless. 
Table 4.3 shows the proportion of individual participating GPs who used computers for each of the 
listed activities. 
• Only 3.6% of GPs did not use a computer at all for clinical purposes. 
• 97.8% of GPs were producing prescriptions electronically (either ePrescribing or printing scripts). 
• More than two-thirds (70.7%) reported they used electronic medical records exclusively (that is, 
were paperless). 
• One-quarter (25.5%) reported maintaining a hybrid record where some patient information is kept 
electronically and some on paper records. 
Table 4.3: Computer applications available/used at major practice address 
Computer use Number 
Per cent of GPs  
(n = 995)(a) 
Computer not used for any clinical purposes (missing n = 3) 36 3.6 
 Not used at all 23 2.3 
 Internet/email only 13 1.3 
Clinical use 956 96.4 
Prescribing(b) (missing n = 41)   
 Electronic (ePrescribing online) 305 32.0 
  (*Electronic + print scripts) 92 9.6 
 Print scripts only 628 65.8 
 Paper only (handwritten) 19 2.0 
 Both print scripts and handwritten 2 0.2 
Internet (missing n = 3) 739 74.5 
Email (missing n = 3) 557 56.1 
Medical records (missing n = 12)   
 Complete (paperless) 695 70.7 
 Partial/hybrid records 251 25.5 
 Paper records only 37 3.8 
(a) Missing data removed. 
(b) Multiple responses allowed. 
* Subset of ePrescribing. 
 
Those interested in the effect of computerisation on quality of care in general practice will find more 
detailed information in Henderson (2007) The effect of computerisation on the quality of care in 
Australian general practice.55  
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4.3 Changes in characteristics of the GPs over the 
 decade 2005–06 to 2014–15 
Changes over the decade 2005–06 to 2014–15 are described in detail in Chapter 4 of the 
accompanying report, A decade of Australian general practice activity 2005–06 to 2014–15.1 Briefly, 
the major changes in the characteristics of the participating GPs were: 
• the proportion of participants who were female increased over time 
• the proportion who were younger than 45 years did not change significantly, whereas the 
proportion aged 55 years or more increased over the decade 
• the proportion of GPs working 21–40 hours per week on direct patient care significantly 
increased, and the proportion working 41–60 hours, and the proportion working more than 
60 hours, significantly decreased 
• the mean number of hours spent on direct patient care significantly decreased 
• the proportion of participants holding the Fellowship of the RACGP increased over the decade 
• the proportion of GPs in solo practice decreased over time, and the proportion in practices with 
10 or more individual GPs more than doubled 
• fewer practices are providing after-hours care on their own, or in cooperation with other practices, 
but more practices are using deputising services for after-hours care than a decade ago. 
  
35
  
 5 The encounters 
This chapter describes the content and types of encounters recorded in the 2014–15 BEACH year. 
Data about the encounters are reported for each year from 2005–06 to 2014–15 in the 10-year report, 
A decade of Australian general practice activity 2005–06 to 2014–15.1 
5.1 Content of the encounters 
In 2014–15, details of 98,728 encounters (weighted data) were available from 995 GPs. A summary 
of these encounters is provided in Table 5.1. Reasons for encounter (RFEs) and problems managed 
are expressed as rates per 100 encounters. Each management action is presented in terms of both a 
rate per 100 encounters and a rate per 100 problems managed, with 95% confidence limits. 
• On average, patients gave 154 RFEs, and GPs managed about 155 problems per 
100 encounters. 
• Chronic problems accounted for 35.5% of all problems managed, and an average of 55.0 chronic 
problems were managed per 100 encounters. 
• New problems accounted for 38.2% of all problems, and on average 59.2 new problems were 
managed per 100 encounters. 
• Medications were the most common treatment choice (103.1 per 100 encounters). Most 
medications were prescribed (85.5 per 100) rather than supplied by the GP (8.0 per 100) or 
advised for over-the-counter purchase (9.5 per 100). 
• For an ‘average’ 100 GP–patient encounters, GPs provided 103 medications and 34 clinical 
treatments (such as advice and counselling), undertook 17 procedures, made 10 referrals to 
medical specialists and 5 to allied health services, and placed 47 pathology test orders and 
12 imaging test orders (Table 5.1). 
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Table 5.1: Summary of morbidity and management at GP–patient encounters 
Variable Number 
Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems  
(n = 153,133) 
95% 
LCL 
95% 
UCL 
General practitioners 995 — — — — — — 
Encounters 98,728 — — — — — — 
Reasons for encounter 151,636 153.6 151.8 155.4 — — — 
Problems managed 153,133 155.1 153.0 157.2 — — — 
 New problems 58,428 59.2 57.8 60.6 38.2 37.2 39.1 
 Chronic problems 54,298 55.0 53.0 57.0 35.5 34.5 36.4 
Medications 101,776 103.1 100.6 105.6 66.5 65.1 67.8 
 Prescribed 84,455 85.5 83.1 88.0 55.2 53.8 56.5 
 GP-supplied 7,923 8.0 7.4 8.6 5.2 4.8 5.5 
 Advised OTC 9,398 9.5 8.8 10.2 6.1 5.7 6.6 
Other treatments(a) 50,204 50.9 48.4 53.3 32.8 31.3 34.2 
 Clinical 33,443 33.9 31.8 36.0 21.8 20.6 23.1 
 Procedural 16,761 17.0 16.2 17.8 10.9 10.5 11.4 
Referrals 15,697 15.9 15.3 16.5 10.3 9.9 10.6 
 Medical specialist* 9,464 9.6 9.2 10.0 6.2 5.9 6.4 
 Allied health services* 5,107 5.2 4.9 5.5 3.3 3.1 3.5 
 Hospital* 355 0.4 0.3 0.4 0.2 0.2 0.3 
 Emergency department* 305 0.3 0.3 0.4 0.2 0.2 0.2 
 Other referrals* 466 0.5 0.4 0.5 0.3 0.3 0.4 
Pathology 46,435 47.0 45.2 48.9 30.3 29.3 31.4 
Imaging 11,314 11.5 11.0 11.9 7.4 7.1 7.7 
Other investigations(b) 732 0.7 0.7 0.8 0.5 0.4 0.5 
(a) Other treatments includes treatment given by practice nurses or Aboriginal health workers in the context of the GP–patient encounter and 
treatment given by GPs. 
(b) Other investigations reported here include only those ordered by the GP. Other investigations in Chapter 12 include those ordered by the 
GP and those done by the GP or practice staff. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; OTC – over-the-counter. 
5.2 Encounter type 
Of the 89,969 encounters where a payment source was recorded, 95.8% related to MBS/DVA 
GP items of service. Items with other health professionals, for example, practice nurse item numbers 
not accompanied by a GP item of service were recorded infrequently. 
Table 5.2 reports the breakdown of encounter type by payment source, counting a single Medicare 
item number per encounter (where applicable). 
• Indirect encounters (where the patient was not seen by the GP) accounted for 1.5%, and direct 
encounters (where the patient was seen by the GP) for 98.5% of encounters at which a payment 
source was recorded. 
• The vast majority of all direct encounters (97.3%) were claimable through Medicare or the DVA. 
• Twelve indirect encounters were claimed as chronic disease management or care conference 
items. 
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• Direct encounters where the GP indicated that no charge was made were rare, accounting for 
0.3% of encounters. 
• Encounters claimable through workers compensation accounted for 1.7%. 
• Encounters claimable through other sources (for example, hospital-paid encounters) accounted 
for 0.7%. 
Table 5.2: Type of encounter and a source of payment recorded for the encounter  
Type of encounter Number 
Per cent of 
encounters(a) 
(n = 89,969) 
95% 
LCL 
95% 
UCL 
Per cent of direct 
encounters 
(n = 88,579) 
Indirect encounters(b) (patient not seen by GP) 1,390  1.5 1.3 1.8   
Direct encounters (patient seen by GP)  88,578  98.5 98.2 98.7  100.0  
 MBS/DVA items of service (direct encounters only)(c)  86,188  95.8 95.5 96.1  97.3  
 Workers compensation  1,487  1.7 1.5 1.8  1.7  
 Other paid (hospital, state, etc) 595  0.7 0.5 0.8  0.7  
 No charge 309  0.3 0.3 0.4 0.3  
Total 89,969 100.0 — — — 
(a) Missing data (no payment source specified) removed from analysis (n = 8,760). 
(b) Twelve encounters involving chronic disease management or case conference items were recorded as indirect encounters. 
(c) Includes direct encounters at which either a GP item or an item with an other health professional (or both) was recorded. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule; DVA – Australian Government 
Department of Veterans’ Affairs. 
 
Table 5.3 provides an overview of the MBS/DVA item numbers recorded in BEACH in 2014–15. 
At least one MBS/DVA item number was recorded at 86,202 encounters. A single item number was 
recorded at 95.8% of BEACH encounters said to be claimable from the MBS/DVA. 
Table 5.3: Number of MBS/DVA items recorded 
Variable Number 
Per cent of MBS/DVA encounters 
(n = 86,202)(a) 
Encounters at which one MBS/DVA item was recorded 82,608  95.8 
Encounters at which two MBS/DVA items were recorded 3,173  3.7 
Encounters at which three MBS/DVA items were recorded 422  0.5 
Total encounters at which at least one item was recorded 86,202  100.0 
(a) Total includes 86,188 direct encounters and 14 indirect, including 12 for chronic disease items and 2 practice nurse only items. 
Note: MBS – Medicare Benefits Schedule; DVA – Department of Veterans’ Affairs. 
 
GPs could record up to three MBS/DVA item numbers per encounter. For comparability with 
earlier years, in Table 5.4 only one item number per MBS/DVA-claimable encounter has been 
counted. Selection of one item number was undertaken on a priority basis: consultation item numbers 
overrode incentive item numbers, which overrode procedural item numbers, which overrode other 
Medicare item numbers. 
• Standard surgery consultations accounted for 78.8% of MBS/DVA-claimable GP consultations, 
and for 75.5% of all encounters for which a payment source was recorded. 
• 11.4% of MBS/DVA-claimable encounters were claimable as long or prolonged surgery 
consultations. 
• Home or institution visits, and visits at residential aged care facilities were all relatively rare, 
together accounting for 2.6% of MBS/DVA-claimable encounters. 
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• About 1.5% of encounters were claimable as GP mental health care items, 1.7% as chronic 
disease management items, and 0.4% as health assessments. 
• There was a decrease in home visits in the decade to 201056 and this has important implications 
for ageing patients wishing to be managed at home rather than in institutional care. The changes 
to the Medicare schedule in May 2010 mean that it is no longer possible to separate home visits 
from institutional visits using Medicare item numbers. The BEACH collection form was altered 
from the 2012–13 BEACH data year onwards to include a tick box to identify home visits. In 
2014–15, there were 530 encounters identified as home visits at a rate of 0.6 per 100 encounters 
(95% CI: 0.4–0.8) (results not tabled). An MBS/DVA GP item was recorded at 525 home visit 
encounters, or 0.6% (95% CI: 0.4–0.8) of encounters at which an MBS/DVA item was recorded 
(results not tabled). 
Table 5.4: Summary of GP only MBS/DVA items recorded (counting one item per encounter) 
MBS/DVA item Number 
Rate per 100 
encounters(a) 
(n = 89,969) 
95% 
LCL 
95% 
UCL 
Per cent of 
MBS/DVA  
GP items  
(n = 86,198) 
Short surgery consultations 1,450 1.6 1.4 1.8 1.7 
Standard surgery consultations 67,937 75.5 74.4 76.6 78.8 
Long surgery consultations 9,249 10.3 9.6 11.0 10.7 
Prolonged surgery consultations 603 0.7 0.5 0.8 0.7 
Residential aged care facility (RACF) visits 1,372 1.5 1.0 2.0 1.6 
Home or institution visits (excluding RACF) 861 1.0 0.7 1.2 1.0 
GP mental health care 1,330 1.5 1.3 1.6 1.5 
Chronic disease management items 1,545 1.7 1.5 2.0 1.8 
Health assessments 403 0.4 0.4 0.5 0.5 
Case conferences 7 0.0Ŧ 0.0Ŧ 0.0Ŧ 0.0Ŧ 
Attendances associated with Practice 
Incentives Program payments 
148 0.2 0.1 0.2 0.2 
Other items 1,292 1.4 1.2 1.7 1.5 
 Therapeutic procedures 545 0.6 0.5 0.7 0.6 
 Surgical operations 326 0.4 0.3 0.4 0.4 
 Acupuncture 236 0.3 0.1 0.4 0.3 
 Other items 185 0.2 0.1 0.3 0.2 
Total MBS/DVA items of service (GPs only) 86,198 95.8 95.5 96.1 100.0 
(a) Encounters with missing payment source were removed from analysis (n = 8,760). Denominator used for analysis n = 89,969. 
Ŧ Rates are reported to one decimal place. This indicates that the rate is less than 0.05 per 100 encounters. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule; DVA – Australian Government 
Department of Veterans’ Affairs; GP – general practitioner; RACF – residential aged care facility. 
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Table 5.5 provides the distribution of all MBS/DVA item numbers recorded across Medicare item 
number groups and the number of encounters at which at least one of each type of item number was 
recorded. Overall, there were 90,217 item numbers recorded at 86,202 MBS/DVA-claimable 
encounters in 2014–15, an average of 1.0 item per encounter claimable through MBS/DVA. 
Surgery consultations (including short, standard, long and prolonged) were the most commonly 
recorded type of item number, accounting for 87.8% of all MBS items, and at least one of these items 
was recorded at 91.9% of MBS/DVA claimable encounters. 
Items for hospital, residential aged care and home visits together accounted for 2.5% of all MBS 
items. Items for other practice nurse, Aboriginal health worker and allied health services accounted for 
0.3% of all MBS items, and were recorded at 0.3% of claimable encounters at which at least one MBS 
item was recorded. 
Table 5.5: Distribution of MBS/DVA service item numbers recorded, across item number groups and 
encounters 
Items/encounters 
All MBS/ 
DVA items(a) 
(n = 90,217)  
Encounters with at least 
one item recorded(b) 
(n = 86,202) 
Number Per cent  Number Per cent  
95% 
LCL 
95% 
UCL 
Surgery consultations 79,240 87.8  79,240 91.9 91.2 92.7 
Home, institution and residential aged care visits 2,251 2.5  2,251 2.6 2.0 3.2 
Chronic disease management items (including 
case conferences) 
2,842 3.2 
 
2,043 2.4 2.0 2.7 
Other practice nurse/Aboriginal health 
worker/allied health worker services 
270 0.3 
 
270 0.3 0.2 0.4 
GP mental health care items 1,707 1.9  1,707 2.0 1.8 2.2 
Surgical operations 1,272 1.4  1,224 1.4 1.2 1.6 
Diagnostic procedures and investigations 598 0.7  584 0.7 0.6 0.8 
Health assessments 559 0.6  558 0.6 0.5 0.7 
Therapeutic procedures 666 0.7  658 0.8 0.6 0.9 
Acupuncture 239 0.3  239 0.3 0.1 0.5 
Pathology services 128 0.1  124 0.1 0.1 0.2 
Diagnostic imaging services 28 0.0Ŧ  27 0.0Ŧ 0.0Ŧ 0.1 
Attendances associated with Practice Incentives 
Program payments 
211 0.2 
 
211 0.2 0.2 0.3 
Other items 206 0.2  206 0.2 0.1 0.4 
Total items 90,217 100.0   — — — — 
(a) Up to three MBS/DVA items could be recorded at each encounter. 
(b) Identifies encounters where at least one item from the MBS group was recorded. 
Ŧ Rates are reported to one decimal place. This indicates that the rate is less than 0.05 per 100 encounters. 
Note: MBS – Medicare Benefits Schedule; DVA – Australian Government Department of Veterans’ Affairs; LCL – lower confidence limit; UCL –
upper confidence limit. 
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5.3 Consultation length 
In a subsample of 33,392 BEACH MBS/DVA-claimable encounters at which start and finish times 
were recorded by the GP, the mean length of consultation in 2014–15 was 14.7 minutes  
(95% CI: 14.4–15.0). The median length was 13.0 minutes (results not tabled). 
For A1 MBS/DVA-claimable encounters, the mean length of consultation in 2014–15 was 
14.4 minutes (95% CI: 14.1–14.6), and the median length was 13.0 minutes (results not tabled). 
Methods describing the substudy from which data on consultation length are collected are described 
in Section 2.6. 
The determinants of consultation length were investigated by Britt et al. (2004) in Determinants of GP 
billing in Australia: content and time57 and Britt et al. (2005) in Determinants of consultation length in 
Australian general practice.58 Length of GP consultations is also discussed in a ‘Byte from BEACH’ 
published on the FMRC website (2014): Britt H, Valenti L, Miller G. Debunking the myth of general 
practice as ‘6 minute medicine’.59 
5.4 Changes in the encounters over the decade 
 2005–06 to 2014–15 
Chapter 5 of the companion report, A decade of Australian general practice activity 2005–06 to 
2014–15,1 provides an overview of changes in general practice encounters over the past decade. 
The major changes between 2005–06 and 2014–15 are summarised below. 
• There was an increase in the average number of problems managed at encounter, from 146 per 
100 encounters in 2005–06 to 155 in 2014–15. 
• The number of clinical treatments provided in general practice increased significantly from 29 per 
100 encounters in 2005–06 to 34 per 100 encounters in 2014–15. 
• The number of procedures undertaken per 100 encounters rose significantly from 14.4 to 17.0 
per 100 encounters. 
• There was an increased rate of referrals, which was reflected in referrals to allied health services 
and to medical specialists. 
• Pathology test/battery order rates increased by 22%. Orders for imaging tests also increased. 
Of the encounters claimable from MBS/DVA: 
• short surgery consultations as a proportion of all MBS/DVA-claimed consultations increased over 
the study period and standard surgery consultations decreased significantly 
• the proportion claimable as chronic disease management items, health assessments and GP 
mental health care all increased significantly 
• the mean length of A1 MBS/DVA-claimable GP–patient encounters in 2014–15 was significantly 
longer than in 2005–06, increasing from 13.8 to 14.4 minutes. The mean length of all 
MBS/DVA-claimable encounters increased significantly over the decade from 13.9 minutes to 
14.7 minutes. The median length of both groups of MBS/DVA-claimable encounters increased 
from 12 to 13 minutes from 2012–13 to 2014–15. 
The changes in management actions are expressed in terms of rates per 100 encounters. As there 
was a significant increase in the number of problems managed at encounters, it may be more 
informative to consider changes in management actions in terms of rates per 100 problems managed. 
Rates per 100 problems are reported in the individual chapters dealing with these items in the 10-year 
report. 
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 6 The patients 
This chapter reports data collected between April 2014 and March 2015 about the characteristics of 
patients at GP encounters and their reasons for encounter from the 17th year of the BEACH program. 
Data on patient characteristics and reasons for encounter are reported for each year from 2005–06 to 
2014–15 in the 10-year report, A decade of Australian general practice activity 2005–06 to 2014–15.1 
6.1 Age–sex distribution of patients at encounter 
The age–sex distribution of patients at encounters is shown in Figure 6.1. Females accounted for the 
greater proportion (57.1%) of encounters (Table 6.1). This was reflected across all age groups except 
among children aged less than 15 years (Figure 6.1). 
Patients aged less than 25 years accounted for 19.7% of encounters; those aged 25–44 years for 
22.3%; those aged 45–64 years accounted for 27.3% and those aged 65 years and over accounted 
for 30.7% of encounters (Table 6.1). Readers interested in changes in the care of older people in 
general practice should see Chapter 14. 
 
  
 
Note: Missing data removed. The distributions will not agree perfectly with those in Table 6.1 because of missing data in either age or  
sex fields. 
 Figure 6.1: Age–sex distribution of patients at encounter, 2014–15 
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6.2 Other patient characteristics 
Table 6.1 presents other characteristics of the patients at GP encounters. In summary: 
• the patient was new to the practice at 6.3% of encounters 
• nearly half of the encounters were with patients who held a Commonwealth concession card 
(46.2%) and/or a Repatriation Health Card (2.1%) 
• at 1 in 10 encounters (10.2%) the patient was from a non-English-speaking background 
• at 1.7% of encounters the patient identified themselves as an Aboriginal and/or Torres Strait 
Islander person. 
Table 6.1: Characteristics of the patients at encounters 
Patient characteristics Number 
Per cent of encounters 
(n = 98,728) 
95% 
LCL 
95%  
UCL 
Sex (missing)(a) (880)    
 Males 41,960 42.9 42.0 43.7 
 Females 55,888 57.1 56.3 58.0 
Age group (missing)(a) (855)    
 < 1 year 1,847 1.9 1.7 2.0 
 1–4 years 4,362 4.5 4.2 4.7 
 5–14 years 5,097 5.2 4.9 5.5 
 15–24 years 8,014 8.2 7.8 8.6 
 25–44 years 21,797 22.3 21.4 23.1 
 45–64 years 26,672 27.3 26.7 27.8 
 65–74 years 13,941 14.2 13.7 14.8 
 75+ years 16,144 16.5 15.6 17.4 
New patient to practice (missing)(a) (1,192)    
 New patient to practice 6,184 6.3 5.8 6.9 
 Patient seen previously 91,353 93.7 93.1 94.2 
Commonwealth concession card status (missing)(a) (6,100)    
 Has a Commonwealth concession card 42,826 46.2 44.6 47.9 
 No Commonwealth concession card 49,803 53.8 52.1 55.4 
Repatriation Health Card status (missing)(a) (7,645)    
 Has a Repatriation Health Card 1,951 2.1 2.0 2.3 
 No Repatriation Health Card 89,132 97.9 97.7 98.0 
Language status (missing)(a) (7,579)    
 Non-English-speaking background(b) 9,305 10.2 8.6 11.9 
 English-speaking background 81,844 89.8 88.1 91.4 
Indigenous status (missing)(a) (7,589)    
 Aboriginal and/or Torres Strait Islander(c) 1,536 1.7 1.3 2.1 
 Non-Indigenous 89,604 98.3 97.9 98.7 
(a) Missing data removed. 
(b) Speaks a language other than English as their primary language at home. 
(c) Self-identified. 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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6.3 Patient reasons for encounter 
Patient reasons for encounter (RFEs) reflect the patient’s demand for care and can provide an 
indication of service use patterns. Patient demand for care can be influenced by interventions aimed 
at the general population (for example, health awareness campaigns in popular media and print). 
RFEs are those concerns and expectations that patients bring to the GP. Participating GPs were 
asked to record at least one, and up to three, patient RFEs in words as close as possible to those 
used by the patient, before the diagnostic or management process had begun. These reflect the 
patient’s view of their reasons for consulting the GP. RFEs can be expressed in terms of one or more 
symptoms (for example, ‘itchy eyes’, ‘chest pain’), in diagnostic terms (for example, ‘about my 
diabetes’, ‘for my hypertension’), a request for a service (‘I need more scripts’, ‘I want a referral’), an 
expressed fear of disease or a need for a check-up. 
The patient may describe a single RFE that relates to a single problem managed at the encounter, a 
single RFE that relates to multiple problems, multiple RFEs that relate to a single problem managed, 
or multiple RFEs that relate to multiple problems managed at the encounter. GPs may also manage a 
problem that is unrelated to the patient’s RFE (for example, a patient presents about her diabetes but 
while she is there the GP also provides a vaccination and performs a Pap smear). 
Number of reasons for encounter 
There were 151,636 RFEs recorded at 98,728 encounters in 2014–15 (Table 6.3). At 58.5% of 
encounters only one RFE was recorded, at 29.4% two RFEs were recorded and at 12.1% of 
encounters three RFEs were recorded (Table 6.2). On average, patients presented with 153.6 RFEs 
per 100 encounters, or about one-and-a-half RFEs per encounter (Table 6.3). 
Table 6.2: Number of patient reasons for encounter  
Number of RFEs at encounter 
Number of encounters 
(n = 98,728) 
Per cent of 
encounters 
95% 
LCL 
95% 
UCL 
One RFE 57,770 58.5 57.3 59.7 
Two RFEs 29,009 29.4 28.6 30.1 
Three RFEs 11,949 12.1 11.4 12.8 
Total 98,728 100.0 — — 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit. 
Reasons for encounter by ICPC-2 component 
The distribution of patient RFEs by ICPC-2 component is presented in Table 6.3, expressed as a 
percentage of all RFEs and as a rate per 100 encounters with 95% confidence limits. In the 
‘diagnosis, diseases’ group we provide data about infections, injuries, neoplasms, congenital 
anomalies and ‘other’ diagnoses. 
Approximately 4 out of 10 (42.7%) patient RFEs were expressed in terms of a symptom or complaint 
(for example, ‘tired’, ‘fever’). RFEs described in diagnostic terms (for example, ‘about my diabetes’, 
‘for my depression’) accounted for 18.7% of RFEs. The remaining 38.7% of RFEs were described in 
terms of processes of care, such as requests for a health check, prescriptions, referrals, test results or 
medical certificates. 
On average at 100 encounters, patients described 65.6 ‘symptom or complaint’ RFEs, 28.7 diagnosis/ 
disease RFEs, 23.0 procedural RFEs and made 16.1 requests for treatment. 
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Table 6.3: Patient reasons for encounter by ICPC-2 component 
ICPC-2 component Number 
Per cent of  
total RFEs 
(n = 151,636) 
Rate per 100 
encounters 
(n = 98,728) 
95%  
LCL 
95%  
UCL 
Symptoms and complaints 64,726 42.7 65.6 63.7 67.4 
Diagnosis, diseases 28,288 18.7 28.7 27.3 30 
 Infections 6,897 4.5 7.0 6.6 7.4 
 Injuries 4,309 2.8 4.4 4.1 4.6 
 Neoplasms 987 0.7 1.0 0.9 1.1 
 Congenital anomalies 212 0.1 0.2 0.2 0.3 
 Other diagnoses, diseases 15,883 10.5 16.1 15.1 17.1 
Diagnostic and preventive procedures 22,716 15.0 23.0 22.2 23.8 
Medications, treatments and therapeutics 15,897 10.5 16.1 15.3 16.9 
Results 9,342 6.2 9.5 9.0 9.9 
Referrals and other RFEs 7,414 4.9 7.5 7.1 7.9 
Administrative 3,252 2.1 3.3 3.1 3.5 
Total RFEs 151,636 100.0 153.6 151.8 155.4 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit. 
Reasons for encounter by ICPC-2 chapter  
The distribution of patient RFEs by ICPC-2 chapter and the most common RFEs within each chapter 
are presented in Table 6.4. Each chapter and individual RFE is expressed as a percentage of all 
RFEs and as a rate per 100 encounters with 95% confidence limits. 
RFEs of a general and unspecified nature were presented at a rate of 44.9 per 100 encounters, with 
requests for prescriptions, general check-ups and test results the most frequently recorded of these. 
RFEs related to the respiratory system occurred at a rate of 19.3 per 100 encounters, those related to 
the musculoskeletal system at a rate of 15.9 per 100, and those relating to skin at a rate of 15.2 per 
100 encounters (Table 6.4). 
The far right column of Table 6.4 shows the proportion of patient encounters where there was at least 
one RFE within an ICPC-2 chapter (representing body systems). Patients may describe multiple RFEs 
that are classified within the same ICPC-2 chapter (for example, depression and anxiety; or 
rheumatoid arthritis and osteoporosis), however this column reports only one instance per chapter. 
RFEs classified as ‘General and unspecified’ were described at least once at 39.0% of encounters in 
2014–15, equating to approximately 53.5 million out of 137.3 million MBS-claimed GP encounters 
nationally in 2014–15. At least one respiratory RFE was recorded at 16.2% of encounters, while one 
or more RFEs related to the musculoskeletal system were recorded at 14.7% of encounters. 
It is possible to extrapolate the ‘rate per 100 encounters’ and the ‘per cent of encounters’ results to 
the 137.3 million MBS-claimed GP encounters in 2014–15. This allows calculation of the estimated 
number of times an RFE was used at GP encounters as well as the number of encounters where an 
RFE was used. Using respiratory-related RFEs as an example, we estimate that nationally in  
2014–15, patients described 26.4 million RFEs related to the respiratory system at 22.2 million 
GP–patient encounters. 
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Table 6.4: Patient reasons for encounter by ICPC-2 chapter and most frequent individual reasons for 
encounter within chapter  
Reasons for encounter Number 
Per cent of 
total RFEs(a) 
(n = 151,636) 
Rate per 100 
encounters 
 (n = 98,728) 
95%  
LCL 
95%  
UCL 
Per cent of 
encounters(b)  
(n = 98,728) 
(95% CI) 
General and unspecified 44,283 29.2  44.9 43.7 46.0 
39.0 
(38.1–39.9) 
 Prescription NOS 9,858 6.5 10.0 9.4 10.6 — 
 General check-up* 4,539 3.0 4.6 4.3 4.9 — 
 Results tests/procedures NOS 7,959 5.2 8.1 7.6 8.5 — 
 Administrative procedure NOS 2,851 1.9 2.9 2.7 3.1 — 
 Immunisation/vaccination NOS 2,016 1.3 2.0 1.9 2.2 — 
 Fever 1,826 1.2 1.8 1.7 2.0 — 
 Weakness/tiredness 1,464 1.0 1.5 1.4 1.6 — 
 Other referrals NEC 1,458 1.0 1.5 1.4 1.6 — 
 Blood test NOS 973 0.6 1.0 0.8 1.1 — 
 Observation/health education/advice/ 
diet NOS 
925 0.6 0.9 0.8 1.0 
— 
 Follow-up encounter unspecified 906 0.6 0.9 0.8 1.0 — 
 Chest pain NOS 859 0.6 0.9 0.8 0.9 — 
 Trauma/injury NOS 780 0.5 0.8 0.7 0.9 — 
 Clarify or discuss patient’s RFE 777 0.5 0.8 0.7 0.9 — 
 Other reason for encounter NEC 724 0.5 0.7 0.6 0.9 — 
Respiratory 19,007 12.5 19.3 18.4 20.1 
16.2 
(15.6–16.8) 
 Cough 6,187 4.1 6.3 5.8 6.7 — 
 Throat symptom/complaint 2,836 1.9 2.9 2.6 3.1 — 
 Upper respiratory tract infection 2,077 1.4 2.1 1.8 2.4 — 
 Sneezing/nasal congestion 1,281 0.8 1.3 1.1 1.5 — 
 Immunisation/vaccination – respiratory 1,175 0.8 1.2 1.0 1.4 — 
 Shortness of breath/dyspnoea 843 0.6 0.9 0.8 0.9 — 
Musculoskeletal 15,747 10.4 15.9 15.5 16.4 
14.7 
(14.3–15.1) 
 Back complaint* 3,347 2.2 3.4 3.2 3.6 — 
 Knee symptom/complaint 1,505 1.0 1.5 1.4 1.6 — 
 Shoulder symptom/complaint 1,259 0.8 1.3 1.2 1.4 — 
 Foot/toe symptom/complaint 1,058 0.7 1.1 1.0 1.2 — 
 Leg/thigh symptom/complaint 951 0.6 1.0 0.9 1.0 — 
 Neck symptom/complaint 811 0.5 0.8 0.7 0.9 — 
 Musculoskeletal injury NOS 712 0.5 0.7 0.6 0.8 — 
(continued) 
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Table 6.4 (continued): Patient reasons for encounter by ICPC-2 chapter and most frequent individual 
reasons for encounter within chapter  
Reasons for encounter Number 
Per cent of 
total RFEs(a) 
(n = 151,636) 
Rate per 100 
encounters 
 (n = 98,728) 
95%  
LCL 
95%  
UCL 
Per cent of 
encounters(b)  
(n = 98,728) 
(95% CI) 
Skin 15,050 9.9 15.2 14.7 15.8 
14.4 
(13.9–14.9) 
 Rash* 2,678 1.8 2.7 2.5 2.9 — 
 Skin symptom/complaint, other 1,577 1.0 1.6 1.5 1.7 — 
 Skin check-up* 1,376 0.9 1.4 1.2 1.6 — 
 Swelling (skin)* 994 0.7 1.0 0.9 1.1 — 
 Laceration/cut 786 0.5 0.8 0.7 0.9 — 
Digestive 9,703 6.4 9.8 9.5 10.2 
8.7 
(8.4–9.0) 
 Abdominal pain* 2,101 1.4 2.1 2.0 2.3 — 
 Diarrhoea 1,238 0.8 1.3 1.2 1.4 — 
 Vomiting 730 0.5 0.7 0.7 0.8 — 
Psychological 9,366 6.2 9.5 9.0 10.0 
8.4 
(8.0–8.8) 
 Depression* 2,224 1.5 2.3 2.1 2.4 — 
 Anxiety* 1,465 1.0 1.5 1.3 1.6 — 
 Sleep disturbance 1,162 0.8 1.2 1.1 1.3 — 
Circulatory 8,644 5.7 8.8 8.3 9.2 
8.4 
(7.9–8.8) 
 Cardiovascular check-up* 3,493 2.3 3.5 3.3 3.8 — 
 Hypertension/high blood pressure* 1,505 1.0 1.5 1.3 1.7 — 
Endocrine and metabolic 5,734 3.8 5.8 5.5 6.1 
5.5 
(5.2–5.8) 
 Diabetes (non-gestational)* 1,239 0.8 1.3 1.1 1.4 — 
 Prescription – endocrine/metabolic 854 0.6 0.9 0.8 1.0 — 
Female genital system 4,549 3.0 4.6 4.2 5.0 
4.2 
(3.9–4.5) 
 Female genital check-up/Pap smear* 1,611 1.1 1.6 1.5 1.8 — 
Neurological 4,452 2.9 4.5 4.3 4.7 
4.3 
(4.1–4.5) 
 Headache* 1,635 1.1 1.7 1.5 1.8 — 
 Vertigo/dizziness 1,086 0.7 1.1 1.0 1.2 — 
Pregnancy and family planning 3,421 2.3 3.5 3.2 3.8 
3.4 
(3.1–3.7) 
 Prenatal/postnatal check-up* 932 0.6 0.9 0.8 1.1  
Ear 3,333 2.2 3.4 3.2 3.5 
3.3 
(3.1–3.4) 
 Ear pain/earache 1,220 0.8 1.2 1.1 1.3 — 
(continued)  
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Table 6.4 (continued): Patient reasons for encounter by ICPC-2 chapter and most frequent individual 
reasons for encounter within chapter  
Reasons for encounter Number 
Per cent of 
total RFEs(a) 
(n = 151,636) 
Rate per 100 
encounters 
 (n = 98,728) 
95%  
LCL 
95%  
UCL 
Per cent of 
encounters(b)  
(n = 98,728) 
(95% CI) 
Urology 2,618 1.7 2.7 2.5 2.8 
2.5 
(2.4–2.6) 
Eye 2,077 1.4 2.1 2.0 2.2 
2.0 
(1.9–2.1) 
Blood and blood-forming organs 1,486 1.0 1.5 1.3 1.7 
1.5 
(1.3–1.7) 
 Blood test – blood and blood 
 forming organs 
909 0.6 0.9 0.8 1.1 — 
Male genital system 1,135 0.7 1.1 1.0 1.3 
1.1 
(1.0–1.2) 
Social 1,028 0.7 1.0 0.9 1.1 
1.0 
(0.9–1.1) 
Total RFEs 151,636 100.0 153.6 151.8 155.4 — 
(a) Only individual RFEs accounting for  0.5% of total RFEs are included. 
(b) The proportion of all encounters at which the patient described at least one reason for encounter that was classified in the chapter. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <hdl.handle.net/2123/13765>). 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit; CI – confidence interval; NEC – not elsewhere 
classified; NOS – not otherwise specified. 
Most frequent patient reasons for encounter 
The 30 most commonly recorded RFEs (Table 6.5), accounted for more than half (58.9%) of all RFEs. 
In this analysis, the specific ICPC-2 chapter to which an across-chapter concept belongs is 
disregarded, so that, for example, ‘check-up – all’ includes all check-ups from all ICPC-2 chapters, 
irrespective of whether or not the body system was specified. 
Of the top 30 RFEs (Table 6.5), most were either symptom or disease descriptions such as cough, 
back complaint, throat complaint or rash. However, the top three RFEs reflected requests for a 
process of care (that is, requests for prescription, check-up and test results), and together accounted 
for nearly one-quarter of all RFEs (23.4%). 
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 Table 6.5: Thirty most frequent patient reasons for encounter 
Patient reason for encounter Number 
Per cent of 
total RFEs(a) 
(n = 151,636) 
Rate per 100 
encounters 
 (n = 98,728) 
95%  
LCL 
95%  
UCL 
Prescription – all* 13,131 8.7 13.3 12.6 14.0 
Check-up – all* 13,015 8.6 13.2 12.6 13.8 
Test results* 9,342 6.2 9.5 9.0 9.9 
Cough 6,187 4.1 6.3 5.8 6.7 
Back complaint* 3,347 2.2 3.4 3.2 3.6 
Immunisation/vaccination – all* 3,324 2.2 3.4 3.1 3.6 
Administrative procedure – all* 3,252 2.1 3.3 3.1 3.5 
Throat symptom/complaint 2,836 1.9 2.9 2.6 3.1 
Rash* 2,678 1.8 2.7 2.5 2.9 
Blood test – all* 2,283 1.5 2.3 2.1 2.5 
Depression* 2,224 1.5 2.3 2.1 2.4 
Abdominal pain* 2,101 1.4 2.1 2.0 2.3 
Upper respiratory tract infection 2,077 1.4 2.1 1.8 2.4 
Fever 1,826 1.2 1.8 1.7 2.0 
Headache* 1,635 1.1 1.7 1.5 1.8 
Skin symptom/complaint, other 1,577 1.0 1.6 1.5 1.7 
Hypertension/high blood pressure* 1,505 1.0 1.5 1.3 1.7 
Knee symptom/complaint 1,505 1.0 1.5 1.4 1.6 
Observation/health education/advice/diet – all* 1,499 1.0 1.5 1.4 1.7 
Anxiety* 1,465 1.0 1.5 1.3 1.6 
Weakness/tiredness 1,464 1.0 1.5 1.4 1.6 
Other referrals NEC 1,458 1.0 1.5 1.4 1.6 
Sneezing/nasal congestion 1,281 0.8 1.3 1.1 1.5 
Shoulder symptom/complaint 1,259 0.8 1.3 1.2 1.4 
Diabetes – all* 1,251 0.8 1.3 1.1 1.4 
Diarrhoea 1,238 0.8 1.3 1.2 1.4 
Ear pain/earache 1,220 0.8 1.2 1.1 1.3 
Sleep disturbance 1,162 0.8 1.2 1.1 1.3 
Vertigo/dizziness 1,086 0.7 1.1 1.0 1.2 
Foot/toe symptom/complaint 1,058 0.7 1.1 1.0 1.2 
Subtotal 89,287 58.9 — — — 
Total RFEs 151,636 100.0 153.6 151.8 155.4 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <hdl.handle.net/2123/13765>). 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified. 
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6.4 Changes in patients and their reasons for 
 encounter over the decade 2005–06 to 2014–15 
An overview of changes in the characteristics of patients at encounters and their reasons for 
encounter over the decade 2005–06 to 2014–15, can be found in Chapter 6 of the companion report, 
A decade of Australian general practice activity 2005–06 to 2014–15.1 Major changes are 
summarised below. 
With the ageing of the Australian population, the proportion of the population that was aged 65 years 
and over increased from 12.9% in 2005 to 14.7% in 2014.60 Over the same period, the proportion of 
BEACH encounters with patients aged 65 years and over increased from 26.7% to 30.7%. When 
extrapolated, this change (in combination with the increased number of encounters nationally) means 
that in 2014–15 there were 15.2 million more encounters with older patients nationally than a decade 
earlier. 
The increase in the proportion of encounters with older patients was greater than the population 
increase in this age group, because older patients attend general practice more often than do younger 
patients.61 This change in the age distribution of patients at GP encounters will affect all aspects of 
general practice as older patients are more likely to have more problems managed at encounters, 
more chronic conditions managed and are more likely to have multimorbidity.23 
There was a significant decrease in the proportion of encounters with patients who were new to the 
practice (from 9.1% in 2005–06 to 6.3% in 2014–15). This may be due to the need for continuity of 
care for chronic conditions. The proportion of patients holding a Repatriation Health Card decreased 
by one-third, from 3.4% in 2005–06 to 2.1% in 2014–15. This is probably due to a decline in the 
number of World War 2 veterans and their partners. 
Over the decade, there was no significant change in the number of reasons for encounter recorded 
per 100 encounters, from 150.3 in 2005–06 to 153.6 in 2014–15. However, there was a marginal 
decrease in the proportion of patients providing a single RFE and a significant increase in the 
proportion providing two RFEs. There was a significant increase in the rate of RFEs describing 
processes of care, particularly requests for ‘medications, treatments and therapeutics’ and for test 
results. 
There was a large increase in requests for administrative procedures such as sickness certificates. 
This is probably due to an increasing number of policies forcing workers to provide such 
documentation to claim sick days and children to stay at home from school. 
The rate of RFEs describing an infection decreased across the decade. This continues a trend that 
has been seen particularly among children at GP encounters.62 Psychological RFEs increased 
significantly over the decade. This may be due to the introduction of both the Better Outcomes and 
Better Access general practice mental health care initiatives.63 
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 7 Problems managed 
A ‘problem managed’ is a formal statement of the provider’s understanding of a health problem 
presented by the patient, family or community, and can be described in terms of a disease, symptom 
or complaint, social problem or ill-defined condition managed at the encounter. GPs were instructed to 
record each problem at the most specific level possible from the information available. As a result, the 
problem managed may at times be limited to the level of a presenting symptom. 
At each patient encounter, up to four problems could be recorded by the GP. A minimum of one 
problem was compulsory. The status of each problem to the patient – new (first presentation to a 
medical practitioner) or old (follow-up of previous problem) – was also indicated. The concept of a 
principal diagnosis, which is often used in hospital statistics, is not adopted in studies of general 
practice where multiple problem management is the norm rather than the exception. Further, the 
range of problems managed at the encounter often crosses multiple body systems and may include 
undiagnosed symptoms, psychosocial problems or chronic disease, which makes the designation of a 
principal diagnosis difficult. Thus, the order in which the problems were recorded by the GP is not 
significant. All problems managed include those that involved some management by a practice nurse 
at the recorded encounter, which are also reported separately in Section 10.4. 
There are two ways to describe the frequency of problems managed: as a percentage of all problems 
managed in the study or as a rate at which problems are managed per 100 encounters. Where 
groups of problems are reported (for example, circulatory problems) it must be remembered that more 
than one of that type of problem (such as hypertension and heart failure) may have been managed at 
a single encounter. We therefore report these data in a variety of ways to aid interpretation and 
reporting. 
For a single ungrouped problem that can only be managed once per encounter, the rate per 100 
encounters can also be regarded as equivalent to the percentage of encounters at which that problem 
was managed. For example, ‘asthma was managed at 2.1 per 100 encounters’, can also be regarded 
as ‘asthma was managed at 2.1% of encounters’. The reader must be mindful that such a statement 
cannot be made for grouped concepts (ICPC-2 chapters and those marked with asterisks in the 
tables), as more than problem within that group could have been managed at a single encounter. 
The last column in Table 7.3 describes the proportion of encounters during which at least one 
problem within each ICPC-2 chapter was managed. This allows users to make the following types of 
statements: ‘at least one psychological problem was managed at 12.8% of encounters’; or (using the 
extrapolation methods described in Chapter 2) ‘at least one digestive problem was managed at 
14.3 million general practice encounters in 2014–15.’ 
Changes in the problems managed in Australian general practice from the BEACH study are reported 
for each year from 2005–06 to 2014–15 in the 10-year report, A decade of Australian general practice 
activity 2005–06 to 2014–15.1  
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7.1 Number of problems managed at encounter 
In 2014–15, there were 153,133 problems managed, at a rate of 155.1 per 100 encounters 
(Table 7.2). Table 7.1 shows that one problem was managed at 61.0% of encounters and two 
problems were managed at 26.2% of encounters. Approximately 10% of encounters involved the 
management of three problems (9.6%), and four problems were managed at 3.2% of encounters. 
Table 7.1: Number of problems managed at an encounter 
Number of problems managed at encounter Number of encounters Per cent 95% LCL 95% UCL 
One problem 60,192 61.0 59.7 62.2 
Two problems 25,851 26.2 25.5 26.9 
Three problems 9,503 9.6 9.1 10.1 
Four problems 3,183 3.2 2.9 3.5 
Total 98,728 100.0 — — 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
 
Figure 7.1 shows the age–sex-specific rates of problems managed. The number of problems 
managed at encounter increased steadily with the age of the patient from young adulthood up to 
those aged 65–74 years. 
Significantly more problems were managed overall at encounters with female patients (157.3 per 100 
encounters, 95% CI: 155.0–159.5) than at those with male patients (152.4 per 100 encounters,  
95% CI: 150.2–154.7) (results not tabled). Figure 7.1 demonstrates that this difference was evident in 
the 15–24, 25–44 and 45–64 year age groups. There was no difference in the average number of 
problems managed between males and females for those aged 65–74 and 75 years and over. For 
both sexes, the number of problems managed at encounters significantly increased with each step in 
adult age up to those aged 45–64. 
 
 
Note: Missing data removed. 
Figure 7.1: Age–sex-specific rates of problems managed per 100 encounters, 2014–15 
(95% confidence intervals) 
<1 1–4 5–14 15–24 25–44 45–64 65–74 75+
Male 124.9 115.7 118.3 125.8 138.7 160.2 174.7 175.4
Female 120.5 114.2 118.8 138.2 145.2 165.7 178.3 178.3
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7.2 Problems managed by ICPC-2 component 
A broad view of the types of problems managed in general practice can be seen by examining 
problems managed from the perspective of the component structure of the ICPC-2 classification (as 
described in Section 2.8). Table 7.2 lists the distribution of problems managed by ICPC-2 component. 
Nearly two-thirds (65.7%) of problems were described as diagnoses or diseases. Of these, the 
majority were ‘other diagnoses’ (accounting for 42.8% of all problems managed), followed by 
infections (14.9%), injuries (4.6%) and neoplasms (3.0%). 
Nearly 1 in 5 problems (19.7%) were expressed as a symptom or complaint. In some situations, 
rather than providing clinical descriptions of the problem under management, processes of care were 
recorded. The processes recorded most often were diagnostic and preventive procedures (for 
example, check-ups), accounting for 8.7% of problems managed. 
At an ‘average’ 100 encounters GPs managed 102 diagnoses/diseases: 23 infections; 7 injuries; and 
5 neoplasms. They also managed an average 31 symptoms and complaints, and 13 problems 
described as a diagnostic and preventive procedure. 
Table 7.2: Problems managed by ICPC-2 component 
ICPC-2 component Number 
Per cent of 
total problems 
(n = 153,133) 
Rate per 100 
encounters 
(n = 98,728) 
95% 
 LCL 
95% 
 UCL 
Diagnosis, diseases 100,577 65.7 101.9 99.9 103.8 
 Infections 22,807 14.9 23.1 22.4 23.8 
 Injuries 7,007 4.6 7.1 6.8 7.4 
 Neoplasms 4,585 3.0 4.6 4.3 5.0 
 Congenital anomalies 614 0.4 0.6 0.6 0.7 
 Other diagnoses 65,563 42.8 66.4 64.4 68.4 
Symptoms and complaints 30,166 19.7 30.6 29.7 31.4 
Diagnostic and preventive procedures 13,252 8.7 13.4 12.8 14.0 
Medications, treatments and therapeutics 4,200 2.7 4.3 3.9 4.6 
Results 2,154 1.4 2.2 2.0 2.4 
Administrative 1,455 1.0 1.5 1.3 1.6 
Referrals and other RFEs 1,329 0.9 1.3 1.2 1.5 
Total problems  153,133 100.0 155.1 153.0 157.2 
Note: LCL – lower confidence limit; UCL – upper confidence limit; RFE – reason for encounter. 
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7.3 Problems managed by ICPC-2 chapter 
The frequency and the distribution of problems managed are presented in Table 7.3 by ICPC-2 
chapter (equivalent to body systems, as described in Chapter 2). Rates per 100 encounters and the 
proportion of total problems are provided at the ICPC-2 chapter level, and for frequent individual 
problems within each chapter. Individual problems accounting for at least 0.5% of all problems 
managed are listed in the table, in decreasing order of frequency within chapter. 
The most common problems managed were: 
• problems of a general and unspecified nature (19.9 per 100 encounters and 12.8% of all 
problems), particularly general check-ups, prescriptions and general immunisations (usually 
multisystem childhood immunisations) 
• those classified to the musculoskeletal system (18.5 per 100 encounters), such as arthritis and 
back complaints 
• respiratory problems (18.5 per 100 encounters), in particular upper respiratory tract infections, 
acute bronchitis/bronchiolitis, asthma and respiratory immunisations 
• skin problems (17.1 per 100 encounters), with contact dermatitis and solar keratosis/sunburn the 
most common 
• circulatory problems (15.9 per 100), led by hypertension and atrial fibrillation/flutter 
• psychological problems (13.6 per 100), with depression and anxiety the most common. 
The last column in Table 7.3 describes the proportion of encounters at which at least one problem 
within an ICPC-2 chapter was managed. GPs may manage more than one problem within an ICPC-2 
chapter (for example, depression and anxiety; rheumatoid arthritis and osteoporosis), but this column 
reports only one instance per chapter. 
At least one general and unspecified problem was managed at 18.4% of encounters in 2014–15, 
equating to approximately 27.3 million encounters at which at least one general and unspecified 
problem was managed in 2014–15. At least one musculoskeletal problem was managed at 17.5% of 
encounters, which extrapolates to 24.0 million encounters at which at least one musculoskeletal 
problem was managed nationally in 2014–15 (Table 7.3). 
Table 7.3: Problems managed by ICPC-2 chapter and most frequent individual problems within chapter  
Problem managed  Number 
Per cent total 
problems(a)  
(n = 153,133) 
Rate per 100 
encounters 
(n = 98,728) 
95%  
LCL 
95%  
UCL 
Per cent of 
encounters(b)  
(n = 98,728) 
(95% CI) 
General and unspecified 19,642 12.8 19.9 19.1 20.7 
18.4 
(17.7–19.0) 
 General check-up* 2,987 2.0 3.0 2.8 3.2 — 
 Prescription NOS 1,983 1.3 2.0 1.7 2.3 — 
 Immunisation/vaccination NOS 1,931 1.3 2.0 1.8 2.1 — 
 Results tests/procedures NOS 1,584 1.0 1.6 1.4 1.8 — 
 Administrative procedure NOS 1,293 0.8 1.3 1.2 1.5 — 
 Viral disease, other/NOS 1,054 0.7 1.1 0.9 1.2 — 
 Abnormal result/investigation NOS 1,000 0.7 1.0 0.9 1.1 — 
 Weakness/tiredness, general 785 0.5 0.8 0.7 0.9 — 
Musculoskeletal 18,278 11.9 18.5 18.0 19.0 
17.5 
(17.0–17.9) 
 Arthritis – all* 3,709 2.4 3.8 3.5 4.0 — 
(continued)  
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Table 7.3 (continued): Problems managed by ICPC-2 chapter and frequent individual problems within 
chapter 
Problem managed  Number 
Per cent total 
problems(a)  
(n = 153,133) 
Rate per 100 
encounters 
(n = 98,728) 
95%  
LCL 
95%  
UCL 
Per cent of 
encounters(b)  
(n = 98,728) 
(95% CI) 
 Osteoarthritis* 2,855 1.9 2.9 2.7 3.1 — 
 Back complaint* 3,297 2.2 3.3 3.2 3.5 — 
 Sprain/strain* 1,149 0.8 1.2 1.1 1.3 — 
 Bursitis/tendonitis/synovitis NOS 1,159 0.8 1.2 1.1 1.3 — 
 Fracture* 942 0.6 1.0 0.9 1.0 — 
 Injury musculoskeletal NOS 917 0.6 0.9 0.8 1.0 — 
 Osteoporosis 846 0.6 0.9 0.8 1.0 — 
Respiratory 18,226 11.9 18.5 17.8 19.1 
17.8 
(17.2–18.4) 
 Upper respiratory tract infection 5,726 3.7 5.8 5.4 6.2 — 
 Acute bronchitis/bronchiolitis 2,146 1.4 2.2 2.0 2.4 — 
 Asthma 2,061 1.3 2.1 1.9 2.2 — 
 Immunisation/vaccination – 
 respiratory 
1,361 0.9 1.4 1.2 1.6 — 
 Sinusitis acute/chronic  1,157 0.8 1.2 1.1 1.3 — 
 Chronic obstructive pulmonary 
 disease 
927 0.6 0.9 0.8 1.0 — 
 Tonsillitis* 797 0.5 0.8 0.7 0.9 — 
Skin 16,931 11.1 17.1 16.6 17.7 
16.2 
(15.7–16.7) 
 Contact dermatitis 1,775 1.2 1.8 1.7 1.9 — 
 Solar keratosis/sunburn 1,227 0.8 1.2 1.1 1.4 — 
 Malignant neoplasm, skin 1,200 0.8 1.2 1.1 1.4 — 
 Laceration/cut 1,019 0.7 1.0 0.9 1.1 — 
 Skin disease, other 1,002 0.7 1.0 0.9 1.1 — 
 Skin symptom/complaint, other 709 0.5 0.7 0.6 0.8 — 
Circulatory 15,666 10.2 15.9 15.1 16.6 
14.6 
(14.0–15.3) 
 Hypertension* 7,778 5.1 7.9 7.4 8.3 — 
 Atrial fibrillation/flutter 1,272 0.8 1.3 1.2 1.4 — 
 Ischaemic heart disease* 1,124 0.7 1.1 1.0 1.3 — 
 Cardiovascular check-up* 915 0.6 0.9 0.8 1.1 — 
Psychological 13,432 8.8 13.6 12.9 14.3 
12.7 
(12.1–13.2) 
 Depression* 4,410 2.9 4.5 4.2 4.7 — 
 Anxiety* 2,220 1.4 2.2 2.1 2.4 — 
 Sleep disturbance 1,632 1.1 1.7 1.5 1.8 — 
 Acute stress reaction 692 0.5 0.7 0.6 0.8 — 
(continued) 
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Table 7.3 (continued): Problems managed by ICPC-2 chapter and frequent individual problems within 
chapter 
Problem managed  Number 
Per cent total 
problems(a)  
(n = 153,133) 
Rate per 100 
encounters 
(n = 98,728) 
95%  
LCL 
95%  
UCL 
Per cent of 
encounters(b)  
(n = 98,728) 
(95% CI) 
Endocrine and metabolic 12,850 8.4 13.0 12.5 13.6 
11.8 
(11.3–12.2) 
 Diabetes (non-gestational)* 3,919 2.6 4.0 3.7 4.2 — 
 Lipid disorder 2,952 1.9 3.0 2.8 3.2 — 
 Vitamin/nutritional deficiency 1,337 0.9 1.4 1.2 1.5 — 
 Hypothyroidism/myxoedema  799 0.5 0.8 0.7 0.9 — 
Digestive 11,201 7.3 11.3 11.0 11.7 
10.9 
(10.6–11.2) 
 Gastro-oesophageal reflux disease* 2,762 1.8 2.8 2.6 3.0 — 
 Gastroenteritis* 1,285 0.8 1.3 1.2 1.4 — 
 Abdominal pain* 767 0.5 0.8 0.7 0.9 — 
Female genital system 5,308 3.5 5.4 5.0 5.7 
5.0 
(4.7–5.3) 
 Female genital check-up/Pap 
 smear* 
1,528 1.0 1.5 1.4 1.7 — 
Neurological 4,063 2.7 4.1 3.9 4.3 
4.0 
(3.9–4.2) 
 Headache* 1,137 0.7 1.2 1.1 1.2 — 
Pregnancy and family planning 3,932 2.6 4.0 3.7 4.3 
3.9 
(3.6–4.2) 
 Pregnancy* 1,206 0.8 1.2 1.0 1.4 — 
 Oral contraception* 999 0.7 1.0 0.9 1.1 — 
Ear 3,583 2.3 3.6 3.5 3.8 
3.6 
(3.4–3.7) 
 Acute otitis media/myringitis 919 0.6 0.9 0.8 1.0 — 
 Excessive ear wax 817 0.5 0.8 0.8 0.9 — 
Urology 3,429 2.2 3.5 3.3 3.6 
3.4 
(3.3–3.6) 
 Urinary tract infection* 1,688 1.1 1.7 1.6 1.8 — 
Eye 2,299 1.5 2.3 2.2 2.5 
2.3 
(2.2–2.4) 
Male genital system 1,815 1.2 1.8 1.7 2.0 
1.8 
(1.7–1.9) 
Blood and blood-forming organs 1,611 1.1 1.6 1.5 1.8 
1.6 
(1.5–1.8) 
Social 864 0.6 0.9 0.8 1.0 
0.9 
(0.8–1.0) 
Total problems 153,133 100.0 155.1 153.0 157.2 — 
(a) Only those individual problems accounting for ≥ 0.5% of total problems are included in the table. 
(b) The proportion of all encounters at which at least one problem classified in this chapter was managed. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; CI – confidence interval; NOS – not otherwise specified. 
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7.4 Most frequently managed problems 
Table 7.4 shows the most frequently managed individual problems in general practice, in decreasing 
order of frequency. These 35 problems accounted for 53.5% of all problems managed, and the top 10 
problems accounted for 29.4%. 
In this analysis, the specific chapter to which ‘across chapter concepts’ (for example, check-ups, 
immunisation/vaccination and prescriptions) apply is ignored, and the concept is grouped with all 
similar concepts regardless of body system. For example, immunisation/vaccination includes 
vaccinations for influenza, childhood diseases, hepatitis and many others. 
Hypertension was the most common problem managed (7.9 per 100 encounters), followed by 
check-ups (6.9 per 100), upper respiratory tract infection (URTI) (5.8 per 100), depression (4.5 per 
100) and diabetes (4.0 per 100) (Table 7.4). 
The percentage of each problem that was ‘new’ is listed in the far right column in Table 7.4. If a 
problem was a new chronic problem to the patient, or a new episode of a recurrent problem and the 
patient had not been treated for that problem or episode by any medical practitioner before the 
encounter, it was considered a new problem. This can provide a measure of general practice 
incidence. For example, only 5.5% of all contacts with hypertension were new diagnoses. In contrast, 
76.4% of URTI problems were new to the patient, suggesting that the majority of people with URTIs 
who attend the GP, do so only once per episode. 
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Table 7.4: Most frequently managed problems 
Problem managed Number 
Per cent of 
total problems 
(n = 153,133) 
Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
New as per 
cent of all 
problems(a) 
Hypertension* 7,778 5.1 7.9 7.4 8.3 5.5 
Check-up – all* 6,778 4.4 6.9 6.5 7.2 44.7 
Upper respiratory tract infection 5,726 3.7 5.8 5.4 6.2 76.4 
Depression* 4,410 2.9 4.5 4.2 4.7 13.0 
Diabetes – all* 3,960 2.6 4.0 3.8 4.3 4.8 
Arthritis – all* 3,755 2.5 3.8 3.6 4.0 16.9 
Immunisation/vaccination – all* 3,531 2.3 3.6 3.3 3.9 65.9 
Back complaint* 3,297 2.2 3.3 3.2 3.5 24.6 
Lipid disorder 2,952 1.9 3.0 2.8 3.2 10.9 
Prescription – all* 2,865 1.9 2.9 2.6 3.3 6.6 
Gastro-oesophageal reflux 
disease* 
2,762 1.8 2.8 2.6 3.0 14.8 
Anxiety* 2,220 1.4 2.2 2.1 2.4 16.7 
Test results* 2,154 1.4 2.2 2.0 2.4 37.4 
Acute bronchitis/bronchiolitis 2,146 1.4 2.2 2.0 2.4 75.9 
Asthma 2,061 1.3 2.1 1.9 2.2 22.0 
Contact dermatitis 1,775 1.2 1.8 1.7 1.9 45.5 
Urinary tract infection* 1,688 1.1 1.7 1.6 1.8 63.9 
Sleep disturbance 1,632 1.1 1.7 1.5 1.8 20.1 
Administrative procedure – all* 1,455 1.0 1.5 1.3 1.6 37.6 
Vitamin/nutritional deficiency 1,337 0.9 1.4 1.2 1.5 32.8 
Gastroenteritis* 1,285 0.8 1.3 1.2 1.4 78.7 
Atrial fibrillation/flutter 1,272 0.8 1.3 1.2 1.4 5.6 
Abnormal test results* 1,235 0.8 1.3 1.1 1.4 47.3 
Solar keratosis/sunburn 1,227 0.8 1.2 1.1 1.4 50.1 
Pregnancy* 1,206 0.8 1.2 1.0 1.4 35.4 
Malignant neoplasm, skin 1,200 0.8 1.2 1.1 1.4 58.6 
Bursitis/tendonitis/synovitis NOS 1,159 0.8 1.2 1.1 1.3 56.7 
Sinusitis acute/chronic 1,157 0.8 1.2 1.1 1.3 68.7 
Sprain/strain* 1,149 0.8 1.2 1.1 1.3 60.9 
Headache* 1,137 0.7 1.2 1.1 1.2 36.2 
Ischaemic heart disease* 1,124 0.7 1.1 1.0 1.3 9.8 
Viral disease, other/NOS  1,054 0.7 1.1 0.9 1.2 74.6 
Laceration/cut 1,019 0.7 1.0 0.9 1.1 45.0 
Skin disease, other 1,002 0.7 1.0 0.9 1.1 59.7 
Oral contraception* 999 0.7 1.0 0.9 1.1 19.0 
Subtotal  81,507 53.5 — — — — 
Total problems 153,133 100.0 155.1 153.0 157.2 38.2 
(a) The proportion of total contacts with this problem that were accounted for by new problems. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified.  
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7.5 Most common new problems 
For each problem managed, participating GPs are asked to indicate whether the problem under 
management was a new problem for the patient (see definition in Section 7.4). Table 7.5 lists the 
most common new problems managed in general practice, in decreasing order of frequency. Overall, 
58,428 problems (38.2% of all problems) were specified as new, and were managed at a rate of 59.2 
per 100 encounters. 
New problems were often acute in nature, such as URTI (4.4 per 100 encounters), acute 
bronchitis/bronchiolitis (1.6 per 100) and urinary tract infection (1.1 per 100). Preventive activities 
were also frequently recorded, including check-ups (3.1 per 100) and immunisation/vaccination 
(2.4 per 100 encounters) (Table 7.5). 
The far right column of this table shows the new cases of this problem as a proportion of total 
contacts with this problem. This provides an indication of the incidence of each problem. For example, 
the 635 new cases of arthritis represented only 17% of all GP contacts with diagnosed arthritis, 
suggesting that by far the majority of contacts for arthritis were for ongoing management. In contrast, 
76% of acute bronchitis/bronchiolitis contacts were first consultations with a medical practitioner for 
this episode, indicating that the balance (24%) were follow-up consultations for this episode. This 
indicates that most patients only require one visit to a GP for the management of an episode of acute 
bronchitis/bronchiolitis. 
Table 7.5: Most frequently managed new problems 
New problem managed Number 
Per cent of total 
 new problems 
(n = 58,428) 
Rate per 100 
 encounters 
(n = 98,728) 
95% 
 LCL 
95% 
UCL 
New as per 
cent of all 
problems(a) 
Upper respiratory tract infection 4,374 7.5 4.4 4.1 4.8 76.4 
Check-up – all* 3,033 5.2 3.1 2.9 3.3 44.7 
Immunisation/vaccination – all* 2,327 4.0 2.4 2.1 2.6 65.9 
Acute bronchitis/bronchiolitis 1,628 2.8 1.6 1.5 1.8 75.9 
Urinary tract infection* 1,079 1.8 1.1 1.0 1.2 63.9 
Gastroenteritis* 1,011 1.7 1.0 0.9 1.1 78.7 
Back complaint* 810 1.4 0.8 0.7 0.9 24.6 
Contact dermatitis  807 1.4 0.8 0.7 0.9 45.5 
Test results* 806 1.4 0.8 0.7 0.9 37.4 
Sinusitis acute/chronic  795 1.4 0.8 0.7 0.9 68.7 
Viral disease, other/NOS 786 1.3 0.8 0.6 1.0 74.6 
Malignant neoplasm, skin 703 1.2 0.7 0.6 0.8 58.6 
Acute otitis media/myringitis 702 1.2 0.7 0.6 0.8 76.4 
Sprain/strain* 700 1.2 0.7 0.6 0.8 60.9 
Bursitis/tendonitis/synovitis NOS 657 1.1 0.7 0.6 0.7 56.7 
Arthritis – all* 635 1.1 0.6 0.6 0.7 16.9 
Solar keratosis/sunburn 615 1.1 0.6 0.5 0.7 50.1 
Skin disease, other 599 1.0 0.6 0.5 0.7 59.7 
Tonsillitis* 587 1.0 0.6 0.5 0.7 73.6 
Abnormal test results* 584 1.0 0.6 0.5 0.7 47.3 
Depression* 572 1.0 0.6 0.5 0.6 13.0 
(continued) 
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Table 7.5 (continued): Most frequently managed new problems 
New problem managed Number 
Per cent of total 
 new problems 
(n = 58,428) 
Rate per 100 
 encounters 
(n = 98,728) 
95% 
 LCL 
95% 
UCL 
New as per 
cent of all 
problems(a) 
Administrative procedure – all* 547 0.9 0.6 0.5 0.6 37.6 
Observation/health education/advice/ 
diet – all* 
499 0.9 0.5 0.4 0.6 58.3 
Excessive ear wax 499 0.9 0.5 0.4 0.6 61.0 
Musculoskeletal injury NOS 488 0.8 0.5 0.4 0.6 53.2 
Fracture* 465 0.8 0.5 0.4 0.5 49.4 
Laceration/cut 458 0.8 0.5 0.4 0.5 45.0 
Asthma 454 0.8 0.5 0.4 0.5 22.0 
Vitamin/nutritional deficiency 438 0.7 0.4 0.4 0.5 32.8 
Abdominal pain* 436 0.7 0.4 0.4 0.5 56.9 
Subtotal 28,094 48.1 — — — — 
Total new problems 58,428 100.0 59.2 57.8 60.6 — 
(a) The proportion of total contacts with this problem that were accounted for by new problems. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
7.6 Most frequently managed chronic problems 
To identify chronic conditions, a list classified according to ICPC-2, based on work undertaken by 
O’Halloran et al. in 200444 and regularly updated (see ‘Chronic conditions’ grouper G84 in the 
‘Analysis and reporting’ section of the ICPC-2 PLUS Demonstrator64), was applied to the BEACH data 
set. More than one-third (35.5%) of the problems managed in general practice were chronic. At least 
one chronic problem was managed at 41.0% of encounters (95% CI: 39.9–42.2) (results not tabled), 
and chronic problems were managed at an average rate of 55.0 per 100 encounters (Table 7.6). 
In other parts of this chapter, both chronic and non-chronic conditions (for example, diabetes and 
gestational diabetes) may have been grouped together when reporting (for example, diabetes – all*, 
Table 7.4). In this section, only problems regarded as chronic have been included in the analysis. For 
this reason, the condition labels and figures in this analysis may differ from those in Table 7.4. Where 
the group used for the chronic analysis differs from that used in other analyses in this report, the 
labels are marked with a double asterisk (for example, Diabetes [non-gestational]**). Codes included 
in asterisked concepts are presented in Appendix 4, Table A4.2. 
Table 7.6 shows the most frequently managed chronic problems. Together, these 30 chronic 
problems accounted for 78.9% of all chronic problems managed, and for 28.0% of all problems 
managed. Half of all chronic problems managed (50.9%) were accounted for by the top seven chronic 
problems: non-gestational hypertension (14.3% of chronic conditions), depressive disorder (8.1%), 
non-gestational diabetes (7.2%), chronic arthritis (6.9%), lipid disorder (5.4%), oesophageal disease 
(5.2%) and asthma (3.8%) (Table 7.6). 
A new column added to Table 7.6 this year shows the proportion of each chronic problem that was 
new to the patient (as defined in Section 7.4). Overall, 15.8% of chronic problems managed were new 
diagnoses, though just 4.3% of non-gestational diabetes problems were new, and 58.6% of malignant 
skin neoplasms managed were new problems. 
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Table 7.6: Most frequently managed chronic problems 
Chronic problem managed Number 
Per cent of 
total chronic 
problems 
(n = 54,298) 
Rate per 100 
encounters 
(n = 98,728) 
95% 
 LCL 
95% 
UCL 
New as per 
cent of all 
chronic 
problems 
Hypertension (non-gestational)** 7,759 14.3 7.9 7.4 8.3 5.5 
Depressive disorder** 4,374 8.1 4.4 4.2 4.7 12.9 
Diabetes (non-gestational)** 3,919 7.2 4.0 3.7 4.2 4.3 
Chronic arthritis** 3,745 6.9 3.8 3.6 4.0 16.8 
Lipid disorder 2,952 5.4 3.0 2.8 3.2 10.9 
Oesophageal disease 2,807 5.2 2.8 2.7 3.0 15.2 
Asthma 2,061 3.8 2.1 1.9 2.2 22.0 
Atrial fibrillation/flutter 1,272 2.3 1.3 1.2 1.4 5.6 
Malignant neoplasm, skin 1,200 2.2 1.2 1.1 1.4 58.6 
Ischaemic heart disease** 1,124 2.1 1.1 1.0 1.3 9.8 
Back syndrome with radiating pain** 1,011 1.9 1.0 0.9 1.1 23.9 
Chronic obstructive pulmonary 
disease 
927 1.7 0.9 0.8 1.0 14.5 
Osteoporosis 846 1.6 0.9 0.8 1.0 17.3 
Hypothyroidism/myxoedema 799 1.5 0.8 0.7 0.9 8.7 
Shoulder syndrome (excluding 
arthritis)** 
658 1.2 0.7 0.6 0.7 44.7 
Obesity (BMI > 30) 649 1.2 0.7 0.6 0.7 10.7 
Migraine 626 1.2 0.6 0.6 0.7 21.3 
Heart failure 619 1.1 0.6 0.5 0.7 11.6 
Chronic back pain** 591 1.1 0.6 0.5 0.7 2.3 
Chronic skin ulcer (including 
varicose ulcer) 
580 1.1 0.6 0.5 0.7 20.0 
Chronic pain NOS 518 1.0 0.5 0.4 0.6 0.7 
Gout 512 0.9 0.5 0.5 0.6 18.5 
Schizophrenia 496 0.9 0.5 0.4 0.6 3.1 
Anxiety disorder** 482 0.9 0.5 0.4 0.6 15.2 
Dementia (including senile, 
Alzheimer’s) 
470 0.9 0.5 0.4 0.6 9.6 
Chronic acne** 421 0.8 0.4 0.4 0.5 33.0 
Back syndrome without radiating 
pain (excluding arthritis, sprains and 
strains)** 
389 0.7 0.4 0.3 0.5 14.4 
Chronic kidney disease** 386 0.7 0.4 0.3 0.4 11.4 
Affective psychosis 330 0.6 0.3 0.3 0.4 7.3 
Vertiginous syndrome 320 0.6 0.3 0.3 0.4 54.0 
Subtotal 42,843 78.9 — — — — 
Total chronic problems 54,298 100.0 55.0 53.0 57.0 15.8 
** Includes multiple ICPC-2 or ICPC-2 PLUS codes and indicates that this group differs from that used for analysis in other sections of this 
chapter, as only chronic conditions have been included in this analysis (see Appendix 4, Table A4.2 <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; BMI – body mass index; NOS – not otherwise specified. 
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7.7 Changes in problems managed over the decade 
 2005–06 to 2014–15 
Data about the problems managed in general practice from each of the past 10 years of the BEACH 
study, 2005–06 to 2014–15 are reported in Chapter 7 of the companion report, A decade of Australian 
general practice activity 2005–06 to 2014–15.1 Major changes that occurred over the decade are 
summarised below. 
Overall, the number of problems managed at general practice encounters increased from 146.2 per 
100 encounters in 2005–06, to 155.1 per 100 encounters in 2014–15. When this result is extrapolated 
to estimate national figures, this represents 65.1 million more problems managed at general practice 
encounters in 2014–15 than in 2005–06. A rise in GP attendances over the decade also contributed 
to this increase. This was reflected in a significant increase over the decade in the management of 
new problems (56.9 to 59.2 per 100 encounters). 
Changes in some of the most common individual problems managed in general practice are 
summarised below. 
• The management rate of hypertension decreased from 9.4 per 100 encounters in 2005–06 to 
7.9 per 100 in 2014–15. Of the most frequently managed problems, hypertension was the only 
chronic problem with a decreased management rate. However, due to the overall increase in the 
number of general practice encounters nationally, there was still an additional 1.3 million 
encounters at which hypertension was managed in 2014–15 than in 2005–06. 
• General check-ups were managed more often in 2014–15 than in 2005–06, increasing from 2.1 
to 3.0 per 100 encounters. This represents 2.0 million more occasions where general check-ups 
were managed in 2014–15 than in 2005–06. 
• The management rate of depression increased from 3.6 per 100 encounters to 4.5 per 100 
between 2005–06 and 2014–15, suggesting about 2.5 million more occasions where depression 
was managed in 2014–15 than in 2005–06. 
• Immunisation/vaccination was managed at a significantly lower rate in 2014–15 than in 2005–06 
(from 5.0 per 100 encounters to 3.6 per 100). This equated to 110,000 fewer occasions at which 
immunisation/vaccination was managed in 2014–15 than in 2005–06. This is probably due to a 
delay in the supply of influenza vaccine for the 2015 flu season, which was not available until 
after this BEACH year was completed. 
The management rate of chronic conditions did not differ in 2014–15 (55.0 per 100 encounters) from 
that of 2005–06 (52.1 per 100 encounters). However, due to the increase in the number of GP visits 
nationally, we estimate that GPs managed 23 million more chronic problems in 2014–15 than they did 
a decade earlier. 
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 8 Overview of management 
The BEACH survey form allows GPs to record several aspects of patient management for each 
problem managed at each encounter. Pharmaceutical management is recorded in detail. Other 
modes of treatment, including clinical treatments (for example, counselling) and procedures, recorded 
briefly in the GP’s own words, are also related to a single problem. The form allows for referrals, 
hospital admissions, pathology and imaging test orders to be related to a single problem or to multiple 
problems (see Appendix 1). 
A summary of management at general practice encounters from 2005–06 to 2014–15 is reported for 
each year in the 10-year report, A decade of Australian general practice activity 2005–06 to 2014–15.1  
At the 98,728 encounters, GPs undertook 226,158 management activities in total. The most common 
management form was medication, either prescribed, GP-supplied, or advised for over-the-counter 
purchase. ‘Other treatments’ were the second most common management activity, with clinical 
treatments more frequent than procedural treatments (Table 8.1). 
For an ‘average’ 100 patient problems managed, GPs provided 55 prescriptions and 22 clinical 
treatments, undertook 11 procedures, made 6 referrals to medical specialists and 3 to allied health 
services, and placed 30 pathology test/battery orders and 7 imaging test orders. 
Table 8.1: Summary of management 
Management type Number 
Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems  
(n = 153,133) 
95% 
LCL 
95% 
UCL 
Medications 101,776 103.1 100.6 105.6 66.5 65.1 67.8 
 Prescribed 84,455 85.5 83.1 88.0 55.2 53.8 56.5 
 GP-supplied 7,923 8.0 7.4 8.6 5.2 4.8 5.5 
 Advised OTC 9,398 9.5 8.8 10.2 6.1 5.7 6.6 
Other treatments 50,204 50.9 48.4 53.3 32.8 31.3 34.2 
 Clinical 33,443 33.9 31.8 36.0 21.8 20.6 23.1 
 Procedural 16,761 17.0 16.2 17.8 10.9 10.5 11.4 
Referrals and admissions 15,697 15.9 15.3 16.5 10.3 9.9 10.6 
 Medical specialist* 9,464 9.6 9.2 10.0 6.2 5.9 6.4 
 Allied health services* 5,107 5.2 4.9 5.5 3.3 3.1 3.5 
 Hospital* 355 0.4 0.3 0.4 0.2 0.2 0.3 
 Emergency department* 305 0.3 0.3 0.4 0.2 0.2 0.2 
 Other referrals* 466 0.5 0.4 0.5 0.3 0.3 0.4 
Pathology 46,435 47.0 45.2 48.9 30.3 29.3 31.4 
Imaging 11,314 11.5 11.0 11.9 7.4 7.1 7.7 
Other investigations(a) 732 0.7 0.7 0.8 0.5 0.4 0.5 
Total management activities 226,158 229.1 — — 147.8 — — 
(a) Other investigations reported here include only those ordered by the GP. Other investigations in Chapter 12 include those ordered by the 
GP and those done by the GP or practice staff. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; OTC – over-the-counter. 
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The number of encounters or problems for which at least one form of management was recorded by 
the GPs gives us another perspective (Table 8.2). At least one management action was recorded at 
90.8% of encounters, for 85.0% of problems managed. 
• At least one medication or other treatment was given for 70.5% of the problems managed. 
• At least one medication (most commonly prescribed) was prescribed, supplied or advised for 
more than half (51.8%) of the problems managed. 
• At least one other treatment (most commonly clinical) was provided for nearly one-third (29.4%) 
of problems managed. 
• At least one referral (most commonly to a medical specialist) was made for 10.2% of problems 
managed. 
• At least one investigation (most commonly pathology) was requested for 19.0% of problems 
managed (Table 8.2). 
When extrapolated nationally based on the total number of MBS claims for GP consultation items of 
service (see Section 2.11), which in 2014–15 was 137.3 million: 
• at least one medication was prescribed, advised for over-the-counter purchase, or supplied by 
the GP at approximately 85.5 million (95% CI: 84.3–86.9 million) GP–patient encounters across 
the country in 2014–15 
• at least one procedure was undertaken at 21.1 million (95% CI: 20.2–22.0 million) encounters 
nationally 
• at least one referral to a specialist, allied health professional, hospital or emergency department 
was provided by GPs at 19.9 million (95% CI: 19.2–20.7 million) encounters nationally 
• at least one pathology, imaging or other investigation was ordered at 34.9 million (95% CI:  
33.9–35.8 million) encounters across Australia in 2014–15. 
 
64
  
Ta
bl
e 
8.
2:
 E
nc
ou
nt
er
s 
an
d 
pr
ob
le
m
s 
fo
r 
w
hi
ch
 m
an
ag
em
en
t w
as
 r
ec
or
de
d
 
M
an
ag
em
en
t t
yp
e 
N
um
be
r 
of
 
en
co
un
te
rs
 
P
er
 c
en
t o
f a
ll 
en
co
un
te
rs
 
(n
 =
 9
8,
72
8)
 
95
%
 L
C
L
 
95
%
 U
C
L
 
N
um
be
r 
of
 
pr
ob
le
m
s 
P
er
 c
en
t o
f a
ll 
pr
ob
le
m
s 
(n
 =
 1
53
,1
33
) 
95
%
 L
C
L
 
95
%
 U
C
L
 
A
t 
le
as
t o
ne
 m
an
ag
em
en
t t
yp
e 
 8
9,
64
8 
 
90
.8
 
90
.2
 
91
.4
 
13
0,
22
4 
 
85
.0
 
84
.4
 
85
.7
 
 
A
t 
le
as
t o
ne
 m
ed
ic
at
io
n 
or
 o
th
er
 tr
ea
tm
en
t 
78
,7
86
  
79
.8
 
78
.9
 
80
.7
 
10
7,
93
5 
 
70
.5
 
69
.6
 
71
.4
 
 
A
t 
le
as
t o
ne
 m
ed
ic
at
io
n 
 
61
,5
55
  
62
.3
 
61
.4
 
63
.3
 
79
,3
83
  
51
.8
 
50
.9
 
52
.8
 
 
 
A
t l
ea
st
 o
ne
 p
re
sc
rip
tio
n 
52
,4
05
  
53
.1
 
52
.1
 
54
.0
 
67
,0
82
  
43
.8
 
42
.8
 
44
.8
 
 
 
A
t l
ea
st
 o
ne
 G
P
-s
up
pl
ie
d 
6,
06
5 
 
6.
1 
5.
7 
6.
6 
6,
23
4 
 
4.
1 
3.
8 
4.
4 
 
 
A
t l
ea
st
 o
ne
 O
TC
 a
dv
is
ed
 
8,
21
2 
 
8.
3 
7.
7 
8.
9 
8,
43
4 
 
5.
5 
5.
1 
5.
9 
 
A
t 
le
as
t o
ne
 o
th
er
 tr
ea
tm
en
t 
38
,9
08
  
39
.4
 
37
.8
 
41
.0
 
45
,0
89
  
29
.4
 
28
.2
 
30
.6
 
 
 
A
t l
ea
st
 o
ne
 c
lin
ic
al
 tr
ea
tm
en
t 
26
,5
43
  
26
.9
 
25
.4
 
28
.3
 
30
,4
84
  
19
.9
 
18
.8
 
21
.0
 
 
 
A
t l
ea
st
 o
ne
 p
ro
ce
du
ra
l t
re
at
m
en
t 
15
,1
70
  
15
.4
 
14
.7
 
16
.0
 
15
,8
40
  
10
.3
 
9.
9 
10
.8
 
 
A
t 
le
as
t o
ne
 r
ef
er
ra
l o
r 
ad
m
is
si
on
 
14
,3
60
  
14
.5
 
14
.0
 
15
.1
 
15
,5
53
  
10
.2
 
9.
8 
10
.5
 
 
 
A
t l
ea
st
 o
ne
 re
fe
rr
al
 to
 a
 m
ed
ic
al
 s
pe
ci
al
is
t 
8,
99
6 
 
9.
1 
8.
7 
9.
5 
9,
57
4 
 
6.
3 
6.
0 
6.
5 
 
 
A
t l
ea
st
 o
ne
 re
fe
rr
al
 to
 a
lli
ed
 h
ea
lth
 s
er
vi
ce
s 
4,
77
7 
 
4.
8 
4.
5 
5.
1 
5,
06
0 
 
3.
3 
3.
1 
3.
5 
 
 
A
t l
ea
st
 o
ne
 re
fe
rr
al
 to
 h
os
pi
ta
l 
 3
55
  
0.
4 
0.
3 
0.
4 
 3
77
  
0.
2 
0.
2 
0.
3 
 
 
A
t l
ea
st
 o
ne
 re
fe
rr
al
 to
 e
m
er
ge
nc
y 
de
pa
rtm
en
t 
 3
05
  
0.
3 
0.
3 
0.
4 
 3
16
  
0.
2 
0.
2 
0.
2 
 
 
A
t l
ea
st
 o
ne
 o
th
er
 re
fe
rr
al
 
 4
66
  
0.
5 
0.
4 
0.
5 
 4
88
  
0.
3 
0.
3 
0.
4 
 
A
t 
le
as
t o
ne
 in
ve
st
ig
at
io
n
 
25
,1
14
  
25
.4
 
24
.7
 
26
.1
 
29
,0
40
  
19
.0
 
18
.5
 
19
.5
 
 
 
A
t l
ea
st
 o
ne
 p
at
ho
lo
gy
 o
rd
er
 
17
,8
75
  
18
.1
 
17
.5
 
18
.7
 
20
,5
44
  
13
.4
 
13
.0
 
13
.8
 
 
 
A
t l
ea
st
 o
ne
 im
ag
in
g 
or
de
r 
9,
64
1 
 
9.
8 
9.
4 
10
.1
 
10
,0
58
  
6.
6 
6.
3 
6.
8 
 
 
A
t l
ea
st
 o
ne
 o
th
er
 in
ve
st
ig
at
io
n(
a
)  
 6
99
  
0.
7 
0.
6 
0.
8 
 7
13
  
0.
5 
0.
4 
0.
5 
(a
) 
O
th
er
 in
ve
st
ig
at
io
ns
 re
po
rte
d 
he
re
 o
nl
y 
in
cl
ud
e 
th
os
e 
or
de
re
d 
by
 th
e 
G
P
. O
th
er
 in
ve
st
ig
at
io
ns
 in
 C
ha
pt
er
 1
2 
in
cl
ud
e 
th
os
e 
or
de
re
d 
by
 th
e 
G
P
 a
nd
 th
os
e 
do
ne
 b
y 
th
e 
G
P
 o
r p
ra
ct
ic
e 
st
af
f. 
N
ot
e:
 L
C
L 
– 
lo
w
er
 c
on
fid
en
ce
 li
m
it;
 U
C
L 
– 
up
pe
r c
on
fid
en
ce
 li
m
it;
 O
TC
 –
 o
ve
r-
th
e-
co
un
te
r. 
 
65
  
The combinations of management types related to each problem were investigated. The majority of 
treatments occurred as a single component, or in combination with one other component. 
Management was provided: 
• as a single component for almost two-thirds (61.3%) of the problems managed (Table 8.3) 
• as a double component for 19.1% of problems managed 
• less often (3.6%) with more than two components (results not tabled). 
Table 8.3 lists the most common management combinations, where management action(s) was 
recorded. Medication alone was the most common management, followed by a clinical treatment 
alone, and the combination of a medication and a clinical treatment. When a problem was referred it 
was most likely that no other treatments were given for that problem at the encounter. 
Table 8.3: Most common management combinations 
1+ 
medication 
1+ clinical 
treatment 
1+ procedural  
treatment 
1+  
referral 
1+ imaging 
order 
1+ pathology 
order 
Per cent of 
total 
problems  
(n = 153,133) 
Per cent  
of total 
encounters 
 (n = 98,728) 
No recorded management 15.0 9.2 
1+ management recorded   
      34.6 28.5 
      9.4 6.8 
      5.9 9.5 
      5.2 3.9 
      5.1 3.0 
      4.3 3.7 
      3.0 4.5 
      2.7 2.0 
      2.6 4.2 
      1.5 3.2 
      1.3 1.4 
      1.2 2.2 
      1.1 1.2 
      1.0 1.3 
      0.6 0.8 
      0.5 0.5 
      0.4 1.3 
      0.3 0.5 
      0.3 0.4 
      0.3 0.6 
Note: 1+ – at least one specified management type. 
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8.1 Changes in management over the decade 
 2005–06 to 2014–15 
Changes in management over the decade 2005–06 to 2014–15 are described in detail in Chapter 8 of 
the accompanying report, A decade of Australian general practice activity 2005–06 to 2014–15.1 In 
that publication, changes over time are largely reported in terms of changes in management actions 
as a rate per 100 problems. This reflects change in how GPs are managing problems after accounting 
for the significant increase in the number of problems managed per encounter over the decade. 
The major changes over the 10 years to 2014–15 are summarised below. 
• There was a significant decrease in the rate of medications prescribed, supplied by the GP or 
advised for over-the-counter purchase, from 71.4 per 100 problems managed in 2005–06 to 
66.5 per 100 problems managed in 2014–15. 
• The major contributor to the above change was a significant decrease in the rate of prescribed 
medications over the time period, from 58.7 to 55.2 per 100 problems, and in GP-supplied 
medications, from 6.0 to 5.2 per 100 problems. 
• The rate of other treatments increased significantly, from 29.9 to 32.8 per 100 problems, 
influenced by the significant increase in procedural treatments, from 9.9 to 10.9 per 100 problems 
over the decade. 
• The rate of referrals to other health providers significantly increased, from 8.2 to 10.3 per 100 
problems managed between 2005–06 and 2014–15, influenced by an 11% increase in referrals 
to medical specialists (from 5.6 to 6.2 per 100 problems managed) and a 65% increase in 
referrals to allied health services over the period (from 2.0 to 3.3 per 100 problems managed). It 
was further influenced by a marginal increase in referrals to emergency departments (from 0.1 to 
0.2 per 100 problems managed). 
• The rate at which pathology tests/batteries were ordered significantly increased by 15%, from 
26.4 tests/batteries per 100 problems managed in 2005–06 to 30.3 in 2014–15. 
• The rate at which imaging was ordered increased significantly, from 6.0 imaging orders per 
100 problems managed in 2005–06 to 7.4 per 100 in 2014–15, an increase of 23%. 
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 9 Medications 
GPs could record up to four medications for each of four problems managed – a maximum of 
16 medications per encounter. Each medication could be recorded as prescribed (the default), 
supplied by the GP, or recommended for over-the-counter (OTC) purchase. The generic name of a 
medication is its non-proprietary name, which describes the pharmaceutical substance(s) or active 
pharmaceutical ingredient(s). 
• GPs were asked to: 
– record the generic or brand name, the strength, regimen and number of repeats ordered for 
each medication 
– designate this as a new or continued medication for this patient for this problem. 
• Generic or brand names were entered into the database in the manner recorded by the GP. 
• Medications were coded using the Coding Atlas of Pharmaceutical Substances (CAPS) system 
developed by the FMRC, a hierarchical classification system which captures details of products 
down to the generic and brand level. Every medication in the CAPS coding system is mapped to 
the international Anatomical Therapeutic Chemical (ATC) classification index.45 
• The reporting of results at drug group, subgroup and generic level uses ATC levels 1, 3 and 5. 
The most frequently prescribed, supplied or advised individual medications are reported at the 
CAPS generic level (equivalent to ATC level 5) because ATC does not include many of the  
over-the-counter medications that arise in BEACH. Further, some ATC level 5 labels are not 
sufficiently specific for clarity. 
Data on medications are reported for each year from 2005–06 to 2014–15 in the 10-year summary 
report, A decade of Australian general practice activity 2005–06 to 2014–15.1 
Readers interested in adverse drug events will find more detailed information from the BEACH 
program in Drugs causing adverse events in patients aged 45 or older: a randomised survey of 
general practice patients.65 
9.1 Source of medications 
As reported in Chapter 8, a total of 101,776 medications were recorded, at rates of 103.1 per 100 
encounters and 66.5 per 100 problems managed. We can derive from Table 8.1 that: 
• approximately 4 out of 5 medications (83.0%) were prescribed 
• 7.8% of medications were supplied to the patient by the GP 
• 9.2% of medications were recommended by the GP for OTC purchase. 
When medication rates per 100 encounters are extrapolated to the 137.3 million general practice 
Medicare-claimed encounters in Australia from April 2014 to March 2015, we estimate that GPs in 
Australia: 
• prescribed, supplied or advised at least one medication at 85.5 million encounters (62.3% of 
encounters, Table 8.2) 
• wrote a prescription (with/without repeats) for more than 117.4 million medications 
• supplied 11 million medications directly to the patient 
• recommended 13 million medications for OTC purchase (Table 8.1). 
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9.2 Prescribed medications 
Prescribed medications accounted for 83.0% of all medications. There were 84,455 prescriptions 
recorded, at rates of 85.5 per 100 encounters and 55.2 per 100 problems managed (Table 8.1). 
GPs recorded 79.6% of prescribed medications by brand (proprietary) name and 20.4% by their 
generic (non-proprietary) name. Medications most likely to be recorded by generic name were 
paracetamol, amoxycillin, and prednisolone (results not tabled). 
As shown in Table 8.2, at least one prescription was given at 53.1% of encounters. Extrapolated to 
the 137.3 million general practice Medicare-claimed encounters, we estimate that GPs prescribed at 
least one medication at 72.9 million encounters. 
At least one prescription was given for 43.8% of problems managed. 
• No prescription was given for 56.2% of problems managed. 
• One prescription was given for 35.4% of problems managed. 
• Two prescriptions were given for 6.2% of problems managed. 
• Three or four prescriptions were given for 2.3% of problems managed (Figure 9.1). 
 
 
 
 Figure 9.1: Number of medications prescribed per problem, 2014–15 
Number of repeats 
For 68,128 prescriptions (80.7% of all prescriptions), the GPs recorded ‘number of repeats’. The 
distribution of the specified number of repeats (from nil to more than five) is provided in Figure 9.2. 
For 35.3% of these prescriptions, the GP specified that no repeats had been prescribed, and for 
36.6% five repeats were ordered. The latter proportion reflects the Pharmaceutical Benefits Scheme 
(PBS) provision of one month’s supply and five repeats for many medications used for chronic 
conditions such as hypertension. The ordering of one repeat was also quite common (15.3%). 
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Note: Percentages are based on the 68,128 prescriptions for which number of repeats was known. 
Figure 9.2: Number of repeats ordered per prescription, 2014–15 
Age–sex-specific rates of prescribed medications 
Age–sex-specific analysis showed similar prescription rates for male (87 per 100 encounters) and 
female patients (85 per 100), and the well-described tendency for the number of prescriptions written 
at each encounter to rise with the advancing age of the patient. 
The rate of prescribing almost doubled from 55 per 100 encounters for patients aged less than 
25 years to 108 per 100 encounters for patients aged 65 years and over (results not tabled). 
However, Figure 9.3 demonstrates that this age-based increase lessens if the prescription rate is 
considered in terms of the number of problems managed in each age group. This suggests that a 
substantial part of the higher prescription rate for older patients is due to the increased number of 
health problems they have managed at an encounter. The remaining increase in prescription rate 
associated with patient age is probably a reflection of the problems under management, as the rate of 
chronic problem management increases with patient age.66 
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 Figure 9.3: Age–sex-specific prescription rates per 100 problems managed, 2014–15 
Types of medications prescribed 
Table 9.1 shows the distribution of prescribed medications using the WHO ATC classification.45 This 
allows comparison with other data sources such as those produced from PBS data. The table lists 
medications in frequency order within ATC levels 1, 3 and 5, which are drug category (mainly 
anatomical), subgroup, and non-proprietary drug name. Prescriptions are presented as a percentage 
of total prescriptions, as a rate per 100 encounters, and as a rate per 100 problems managed, each 
with 95% confidence intervals. 
Drugs acting on the nervous system accounted for one-quarter (24.9%) of all medications. Most 
common were the opioids (7.6% of all medications), which include analgesics containing high-dose 
(30 mg) codeine. The inclusion of analgesic combinations with 30 mg of codeine aligns with the 
Poisons Regulations of the Therapeutic Goods Administration,67 which stipulates that high-dose 
codeine combinations are Schedule 4 (prescription only) medications. Oxycodone was prescribed at a 
similar rate to the codeine combinations. Antidepressants were also common nervous system 
medications, as were other analgesics, in particular, plain paracetamol. 
Cardiovascular system medications made up 18.0% of medications, and lipid-modifying agents were 
the most common of these. Anti-infectives for systemic use, a group including antibiotics and 
antivirals, accounted for 17.6% of medications. 
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Table 9.1: Prescribed medications by ATC levels 1, 3 and 5  
  
ATC Classification level 
Number 
Per cent of 
prescribed 
medications 
(n = 84,455)(a) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,728) 
Rate per 100 
problems 
 (95% CI)  
(n = 153,133) 1 3 5 
Nervous system  21,004 24.9 21.3 (20.3–22.2) 13.7 (13.1–14.3) 
  Opioids 6,397 7.6 6.5 (6.1–6.9) 4.2 (3.9–4.4) 
 Codeine, combinations excl. psycholeptics 1,794 2.1 1.8 (1.7–2.0) 1.2 (1.1–1.3) 
 Oxycodone 1,637 1.9 1.7 (1.5–1.8) 1.1 (1.0–1.2) 
  Tramadol 881 1.0 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
  Oxycodone, combinations 659 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
 Buprenorphine 618 0.7 0.6 (0.5–0.7) 0.4 (0.4–0.5) 
  Antidepressants 4,502 5.3 4.6 (4.3–4.8) 2.9 (2.8–3.1) 
  Sertraline 634 0.8 0.6 (0.6–0.7) 0.4 (0.4–0.5) 
  Escitalopram 603 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
 Amitriptyline 566 0.7 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
 Venlafaxine 513 0.6 0.5 (0.5–0.6) 0.3 (0.3–0.4) 
 Mirtazepine 428 0.5 0.4 (0.4–0.5) 0.3 (0.2–0.3) 
  Other analgesics and antipyretics 2,551 3.0 2.6 (2.3–2.8) 1.7 (1.5–1.8) 
  Paracetamol, plain 2,411 2.9 2.4 (2.2–2.7) 1.6 (1.4–1.7) 
  Anxiolytics 1,894 2.2 1.9 (1.7–2.1) 1.2 (1.1–1.4) 
  Diazepam 1,267 1.5 1.3 (1.1–1.4) 0.8 (0.7–0.9) 
 Oxazepam 454 0.5 0.5 (0.4–0.5) 0.3 (0.3–0.3) 
  Hypnotics and sedatives 1,526 1.8 1.5 (1.4–1.7) 1.0 (0.9–1.1) 
  Temazepam 947 1.1 1.0 (0.9–1.1) 0.6 (0.6–0.7) 
  Antipsychotics 1,344 1.6 1.4 (1.2–1.5) 0.9 (0.8–1.0) 
 Prochlorperazine 519 0.6 0.5 (0.5–0.6) 0.3 (0.3–0.4) 
  Antiepileptics 1,316 1.6 1.3 (1.2–1.4) 0.9 (0.8–0.9) 
 Pregabalin 729 0.9 0.7 (0.7–0.8) 0.5 (0.4–0.5) 
  Drugs used in addictive disorders 727 0.9 0.7 (0.5–0.9) 0.5 (0.4–0.6) 
Cardiovascular system 15,232 18.0 15.4 (14.6–16.2) 9.9 (9.5–10.4) 
 Lipid modifying agents, plain 3,586 4.2 3.6 (3.4–3.9) 2.3 (2.2–2.5) 
 Atorvastatin 1,352 1.6 1.4 (1.3–1.5) 0.9 (0.8–1.0) 
 Rosuvastatin 1,351 1.6 1.4 (1.2–1.5) 0.9 (0.8–1.0) 
 Simvastatin 433 0.5 0.4 (0.4–0.5) 0.3 (0.3–0.3) 
 Angiotensin II antagonists, plain 2,135 2.5 2.2 (2.0–2.3) 1.4 (1.3–1.5) 
 Irbesartan 713 0.8 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
 Telmisartan 613 0.7 0.6 (0.6–0.7) 0.4 (0.4–0.4) 
 Candesartan 589 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
 ACE inhibitors, plain 1,881 2.2 1.9 (1.8–2.1) 1.2 (1.1–1.3) 
 Perindopril 1,082 1.3 1.1 (1.0–1.2) 0.7 (0.6–0.8) 
 Ramipril 542 0.6 0.5 (0.5–0.6) 0.4 (0.3–0.4) 
 (continued)  
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Table 9.1 (continued): Prescribed medications by ATC levels 1, 3 and 5  
 
ATC Classification level 
Number 
Per cent of 
prescribed 
medications 
(n = 84,455) (a) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,728) 
Rate per 100 
problems 
 (95% CI)  
(n = 153,133) 1 3 5 
 Beta blocking agents 1,617 1.9 1.6 (1.5–1.8) 1.1 (1.0–1.1) 
 Atenolol 659 0.8 0.7 (0.6–0.7) 0.4 (0.4–0.5) 
 Metoprolol 505 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
 Angiotensin II antagonists, combinations 1,474 1.7 1.5 (1.4–1.6) 1.0 (0.9–1.0) 
 Irbesartan and diuretics 445 0.5 0.5 (0.4–0.5) 0.3 (0.3–0.3) 
 Selective calcium channel blockers with mainly 
vascular effects 
1,138 1.3 1.2 (1.0–1.3) 0.7 (0.7–0.8) 
 Amlodipine 527 0.6 0.5 (0.5–0.6) 0.3 (0.3–0.4) 
 Lercanidipine 392 0.5 0.4 (0.3–0.5) 0.3 (0.2–0.3) 
 High-ceiling diuretics 663 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
 Frusemide 654 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
 ACE inhibitors, combinations 635 0.8 0.6 (0.6–0.7) 0.4 (0.4–0.5) 
Anti-infective for systemic use 14,876 17.6 15.1 (14.5–15.6) 9.7 (9.3–10.1) 
  Beta-lactam antibacterials, penicillins 5,964 7.1 6.0 (5.7–6.4) 3.9 (3.7–4.1) 
 Amoxycillin 3,007 3.6 3.0 (2.8–3.3) 2.0 1.8–2.1) 
 Amoxycillin and enzyme inhibitor 2,052 2.4 2.1 (1.9–2.3) 1.3 (1.2–1.5) 
 Flucloxacillin 394 0.5 0.4 (0.3–0.5) 0.3 (0.2–0.3) 
 Other beta-lactam antibacterials 3,157 3.7 3.2 (3.0–3.4) 2.1 (1.9–2.2) 
 Cephalexin 2,744 3.2 2.8 (2.6–2.8) 1.8 (1.7–1.9) 
 Macrolides, lincosamides and streptogramins 1,990 2.4 2.0 (1.9–2.2) 1.3 (1.2–1.4) 
 Roxithromycin 858 1.0 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
 Clarithromycin 525 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
 Tetracyclines 804 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
 Doxycycline 732 0.9 0.7 (0.7–0.8) 0.5 (0.4–0.5) 
 Sulfonamides and trimethoprim 672 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
 Trimethoprim 462 0.5 0.5 (0.4–0.5) 0.3 (0.3–0.3) 
 Other antibacterials 491 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
 Viral vaccines 474 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
 Direct acting antivirals 431 0.5 0.4 (0.3–0.6) 0.3 (0.2–0.4) 
Alimentary tract and metabolism 8,956 10.6 9.1 (8.6–9.5) 5.8 (5.6–6.1) 
 Drugs for peptic ulcer and gastro-oesophageal 
reflux 
3,716 4.4 3.8 (3.6–4.0) 2.4 (2.3–2.5) 
 Esomeprazole 1,749 2.1 1.8 (1.7–1.9) 1.1 (1.1–1.2) 
 Pantoprazole 836 1.0 0.8 (0.8–0.9) 0.5 (0.5–0.6) 
 Rabeprazole 428 0.5 0.4 (0.4–0.5) 0.3 (0.2–0.3) 
 Blood glucose lowering drugs, excluding insulins 2,154 2.6 2.2 (2.0–2.4) 1.4 (1.3–1.5) 
 Metformin 1,269 1.5 1.3 (1.2–1.4) 0.8 (0.7–0.9) 
 Propulsives 579 0.7 0.6 (0.5–0.6) 0.4 (0.3–0.5) 
 Metoclopramide 448 0.5 0.5 (0.4–0.5) 0.3 (0.3–0.3) 
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Table 9.1 (continued): Prescribed medications by ATC levels 1, 3 and 5  
 
ATC Classification level 
Number 
Per cent of 
prescribed 
medications 
(n = 84,455) (a) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,728) 
Rate per 100 
problems 
 (95% CI)  
(n = 153,133) 1 3 5 
 Insulins and analogues 556 0.7 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
 Drugs for constipation 444 0.5 0.4 (0.4–0.5) 0.3 (0.3–0.3) 
Respiratory system 4,988 5.9 5.1 (4.7–5.4) 3.3 (3.1–3.5) 
 Adrenergics, inhalants 2,662 3.2 2.7 (2.5–2.9) 1.7 (1.6–1.9) 
 Salbutamol 1,265 1.5 1.3 (1.2–1.4) 0.8 (0.8–0.9) 
 Salmeterol and fluticasone 750 0.9 0.8 (0.7–0.8) 0.5 (0.4–0.5) 
 Formoterol and budesonide 515 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
 Decongestants and other nasal preparations 850 1.0 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
 Other drugs for obstructive airway diseases, 
inhalants 
811 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
Musculoskeletal system 4,150 4.9 4.2 (4.0–4.4) 2.7 (2.6–2.9) 
 Anti-inflammatory and antirheumatic products,  
non-steroid 
2,981 
3.5 3.0 (2.8–3.2) 1.9 (1.8–2.1) 
 Meloxicam 893 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.7) 
 Diclofenac 582 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
 Celecoxib 552 0.7 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
 Drugs affecting bone structure and mineralization 468 0.6 0.5 (0.4–0.5) 0.3 (0.3–0.3) 
 Antigout preparations 465 0.6 0.5 (0.4–0.5) 0.3 (0.3–0.3) 
Dermatologicals 3,759 4.5 3.8 (3.6–4.0) 2.5 (2.3–2.6) 
 Corticosteroids, plain 2,198 2.6 2.2 (2.1–2.4) 1.4 (1.3–1.5) 
 Betamethasone 740 0.9 0.7 (0.7–0.8) 0.5 (0.4–0.5) 
 Mometasone 604 0.7 0.6 (0.5–0.7) 0.4 (0.4–0.4) 
Genitourinary system and sex hormones 3,175 3.8 3.2 (3.0–3.4) 2.1 (2.0–2.2) 
 Hormonal contraceptives for systemic use 1,312 1.6 1.3 (1.2–1.4) 0.9 (0.8–0.9) 
 Estrogens 495 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
 Urologicals 458 0.5 0.5 (0.4–0.5) 0.3 (0.3–0.3) 
Blood and blood-forming organs 2,684 3.2 2.7 (2.5–2.9) 1.8 (1.6–1.9) 
 Antithrombotic agents 2,043 2.4 2.1 (1.9–2.3) 1.3 (1.2–1.4) 
 Warfarin 917 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.7) 
Systemic hormonal preparations, excluding sex 
hormones  
2,697 3.2 2.7 (2.6–2.9) 1.8 (1.7–1.9) 
  Corticosteroids for systemic use, plain  1,548 1.8 1.6 (1.4–1.7) 1.0 (0.9–1.1) 
  Prednisolone 1,001 1.2 1.0 (0.9–1.1) 0.7 (0.6–0.7) 
  Thyroid preparations  873 1.0 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
  Levothyroxine sodium 856 1.0 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
Sensory organs  2,125 2.5 2.2 (2.0–2.3) 1.4 (1.3–1.5) 
  Anti-infectives ophthalmological  692 0.8 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
  Chloramphenicol ophthalmological 592 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
  Corticosteroids and anti-infective in combination 
otological  
580 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
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Table 9.1 (continued): Prescribed medications by ATC levels 1, 3 and 5  
 
ATC Classification level 
Number 
Per cent of 
prescribed 
medications 
(n = 84,455) (a) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,728) 
Rate per 100 
problems 
 (95% CI)  
(n = 153,133) 1 3 5 
Antineoplastic and immunomodulating agents  430 0.5 0.4 (0.4–0.5) 0.3 (0.2–0.3) 
Antiparasitic products, insecticides and repellent 215 0.3 0.2 (0.2–0.3) 0.1 (0.1–0.2) 
Various  165 0.2 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Total prescribed medications 84,455 100.0 85.5 (83.1–88.0) 55.2 (53.8–56.5) 
(a) Only those individual medications accounting for ≥ 0.5% of total prescribed medications are included in the table. 
Note: ATC – Anatomical Therapeutic Chemical classification; CI – confidence interval; ACE – angiotensin-converting enzyme.  
 
Most frequently prescribed medications 
The most frequently prescribed individual medications are reported at the CAPS generic level (ATC 
level 5 equivalent) in Table 9.2. Together these 30 medications made up 42.9% of all prescribed 
medications. 
Table 9.2: Most frequently prescribed medications  
Generic medication Number 
Per cent of 
prescribed 
medications 
(n = 84,455) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,728) 
Rate per 100 
problems 
 (95% CI)  
(n = 153,133) 
Amoxycillin 3,007 3.6 3.0 (2.8–3.3) 2.0 (1.8–2.1) 
Cephalexin 2,744 3.2 2.8 (2.6–3.0) 1.8 (1.7–1.9) 
Paracetamol [plain] 2,411 2.9 2.4 (2.2–2.7) 1.6 (1.4–1.7) 
Amoxycillin/potassium clavulanate 2,052 2.4 2.1 (1.9–2.3) 1.3 (1.2–1.5) 
Paracetamol/codeine 1,759 2.1 1.8 (1.6–1.9) 1.1 (1.1–1.2) 
Esomeprazole 1,749 2.1 1.8 (1.7–1.9) 1.1 (1.1–1.2) 
Oxycodone 1,637 1.9 1.7 (1.5–1.8) 1.1 (1.0–1.2) 
Atorvastatin 1,352 1.6 1.4 (1.3–1.5) 0.9 (0.8–1.0) 
Rosuvastatin 1,351 1.6 1.4 (1.2–1.5) 0.9 (0.8–1.0) 
Salbutamol 1,269 1.5 1.3 (1.2–1.4) 0.8 (0.8–0.9) 
Metformin 1,269 1.5 1.3 (1.2–1.4) 0.8 (0.7–0.9) 
Diazepam 1,267 1.5 1.3 (1.1–1.4) 0.8 (0.7–0.9) 
Perindopril 1,082 1.3 1.1 (1.0–1.2) 0.7 (0.6–0.8) 
Temazepam 947 1.1 1.0 (0.9–1.1) 0.6 (0.6–0.7) 
Warfarin sodium 917 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.7) 
Meloxicam 893 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.7) 
Tramadol 881 1.0 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
Roxithromycin 858 1.0 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
Thyroxine 856 1.0 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
Pantoprazole  836 1.0 0.8 (0.8–0.9) 0.5 (0.5–0.6) 
Levonorgestrel/ethinyloestradiol 798 0.9 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
Fluticasone/salmeterol 750 0.9 0.8 (0.7–0.9) 0.5 (0.4–0.5) 
Betamethasone topical 740 0.9 0.7 (0.7–0.8) 0.5 (0.4–0.5) 
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Table 9.2 (continued): Most frequently prescribed medications 
Generic medication Number 
Per cent of 
prescribed 
medications 
(n = 84,455) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,728) 
Rate per 100 
problems 
 (95% CI)  
(n = 153,133) 
Doxycycline 732 0.9 0.7 (0.7–0.8) 0.5 (0.4–0.5) 
Pregabalin 729 0.9 0.7 (0.7–0.8) 0.5 (0.4–0.5) 
Irbesartan  713 0.8 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
Prednisolone 679 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
Oxycodone/naloxone 659 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
Atenolol 659 0.8 0.7 (0.6–0.7) 0.4 (0.4–0.5) 
Frusemide 654 0.8 0.7 (0.6–0.7) 0.4 (0.4–0.5) 
Subtotal 36,250 42.9 — — 
Total prescribed medications 84,455 100.0 85.5 (83.1–88.0) 55.2 (53.8–56.5) 
Note: CI – confidence interval. 
9.3 Medications supplied by GPs 
GPs supplied 7,923 medications in 2014–15, at a rate of 8.0 medications per 100 encounters, and 
5.2 per 100 problems managed. At least one medication was supplied for 4.1% of all problems 
managed, and at 6.1% of encounters, an estimated 8.4 million encounters nationally. The most 
frequently supplied medications are listed in Table 9.3. 
Table 9.3: Medications most frequently supplied by GPs  
Generic medication Number 
Per cent of 
supplied 
medications 
(n = 7,923) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,728) 
Rate per 100 
problems 
 (95% CI)  
(n = 153,133) 
Influenza virus vaccine 1,232 15.5 1.2 (1.0–1.5) 0.8 (0.7–0.9) 
Pneumococcal vaccine 622 7.8 0.6 (0.5–0.7) 0.4 (0.4–0.5) 
Vitamin B12 (cobalamin) 492 6.2 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
Diphtheria/pertussis/tetanus/hepatitis B/polio/ 
Haemophilus influenzae B vaccine 
441 5.6 0.4 (0.4–0.5) 0.3 (0.3–0.3) 
Rotavirus vaccine 379 4.8 0.4 (0.3–0.4) 0.2 (0.2–0.3) 
Measles/mumps/rubella vaccine 336 4.2 0.3 (0.3–0.4) 0.2 (0.2–0.3) 
Triple antigen (diphtheria/pertussis/tetanus) 191 2.4 0.2 (0.2–0.2) 0.1 (0.1–0.1) 
Diphtheria/tetanus vaccine 144 1.8 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Haemophilus B/Meningococcus C vaccine 141 1.8 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Measles/mumps/rubella/varicella zoster vaccine 125 1.6 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Hepatitis B vaccine 117 1.5 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Denosumab 117 1.5 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Diphtheria/pertussis/tetanus/polio vaccine 114 1.4 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Hepatitis A vaccine 106 1.3 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Allergen treatment 104 1.3 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Typhoid vaccine (Salmonella typhi) 103 1.3 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Hepatitis A/typhoid (Salmonella typhi) vaccine 102 1.3 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
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Table 9.3 (continued): Medications most frequently supplied by GPs 
Generic medication Number 
Per cent of 
supplied 
medications 
(n = 7,923) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,728) 
Rate per 100 
problems 
 (95% CI)  
(n = 153,133) 
Medroxyprogesterone 85 1.1 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Celecoxib 72 0.9 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Salbutamol 61 0.8 0.1 (0.1–0.1) 0.0 (0.0–0.1) 
Etonogestrel 60 0.8 0.1 (0.1–0.1) 0.0 (0.0–0.1) 
Metoclopramide 57 0.7 0.1 (0.1–0.1) 0.0 (0.0–0.0) 
Immunisation NEC 55 0.7 0.1 (0.1–0.1) 0.0 (0.0–0.0) 
Testosterone 54 0.7 0.1 (0.1–0.1) 0.0 (0.0–0.0) 
Meloxicam 52 0.7 0.1 (0.1–0.1) 0.0 (0.0–0.0) 
Mometasone nasal 51 0.6 0.1 (0.1–0.1) 0.0 (0.0–0.0) 
Steroid injection NEC 48 0.6 0.0 (0.0–0.1) 0.0 (0.0–0.0) 
Betamethasone systemic 45 0.6 0.0 (0.0–0.1) 0.0 (0.0–0.0) 
Meningitis vaccine 45 0.6 0.0 (0.0–0.1) 0.0 (0.0–0.0) 
Pregabalin 43 0.5 0.0 (0.0–0.1) 0.0 (0.0–0.0) 
Subtotal 5,594 70.6 — — 
Total supplied medications 7,923 100.0 8.0 (7.4–8.6) 5.2 (4.8–5.5) 
Note: CI – confidence interval; NEC – not elsewhere classified. 
9.4 Medications advised for over-the-counter 
 purchase 
The GPs recorded 9,398 medications as recommended for OTC purchase, at rates of 9.5 per 100 
encounters and 6.1 per 100 problems managed. At least one OTC medication was advised at 8.3% of 
encounters, equivalent to an estimated 11.4 million encounters nationally where GPs recommended 
at least one OTC medication. At least one OTC medication was advised for 5.5% of problems 
(Table 8.2). Table 9.4 shows the top 30 advised medications at the CAPS generic level (ATC level 5 
equivalent). Advised medications covered a wide range, and the most common was paracetamol, 
which accounted for 26.2% of these medications. 
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Table 9.4: Most frequently advised over-the-counter medications  
Generic medication Number 
Per cent of 
OTC 
medications 
(n = 9,398) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,728) 
Rate per 100 
problems 
 (95% CI)  
(n = 153,133) 
Paracetamol [plain] 2,465 26.2 2.5 (2.2–2.8) 1.6 (1.4–1.8) 
Ibuprofen 683 7.3 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
Sodium chloride topical nasal 226 2.4 0.2 (0.1–0.3) 0.1 (0.1–0.2) 
Vitamin D3 (cholecalciferol) 205 2.2 0.2 (0.1–0.2) 0.1 (0.1–0.2) 
Sodium/potassium/citric acid/glucose 184 2.0 0.2 (0.1–0.2) 0.1 (0.1–0.2) 
Loratadine 176 1.9 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Diclofenac topical 158 1.7 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Fexofenadine 150 1.6 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Cetirizine 147 1.6 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Simple analgesics 144 1.5 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Saline bath/solution/gargle 134 1.4 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Hydrocortisone/clotrimazole 115 1.2 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Paracetamol/codeine 108 1.2 0.1 (0.1–0.2) 0.1 (0.0–0.1) 
Cream/ointment/lotion NEC 96 1.0 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Clotrimazole vaginal 91 1.0 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Clotrimazole topical 89 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Hyoscine butylbromide 87 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Multivitamins with minerals 87 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Docusate otic 84 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Ferrous sulfate/sodium ascorbate 82 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Vitamin D NEC 81 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Bromhexine 77 0.8 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Sodium chloride/potassium chloride/sodium 
bicarbonate 
77 0.8 0.1 (0.1–0.1) 0.0 (0.0–0.1) 
Hydrocortisone topical 72 0.8 0.1 (0.1–0.1) 0.0 (0.0–0.1) 
Mometasone nasal 66 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Loperamide 63 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Aspirin cardiovascular 62 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Cold and flu medication NEC 62 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Fish oil 60 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Cinchocaine/hydrocortisone topical rectal 56 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.0) 
Subtotal 6,186 65.8 — — 
Total advised medications 9,398 100.0 9.5 (8.8–10.2) 6.1 (5.7–6.6) 
Note: OTC – over-the-counter; CI – confidence interval; NEC – not elsewhere classified. 
  
78
  
9.5 Changes in medications over the decade 
 2005–06 to 2014–15  
Data on medications are reported for each year from 2005–06 to 2014–15 in Chapter 9 of the 
companion report, A decade of Australian general practice activity 2005–06 to 2014–15.1 In that 
report, changes over time are measured as change in the management of problems (that is, as a rate 
per 100 problems). This reflects change in how GPs are managing problems, and takes into account 
the significant increase in the number of problems managed per encounter over the decade to  
2014–15. 
The rate at which medications were prescribed decreased significantly from 2005–06 (58.7 per 100 
problems, 95% CI: 57.2–60.3) to 2014–15 (55.2 per 100 problems, 95% CI: 53.8–56.5). Among the 
prescribed drug groups that decreased significantly were antibacterials for systemic use, systemic 
anti-inflammatory medications and sex hormones. At the same time, prescribing rates of several drug 
groups increased significantly, including psychoanaleptics, digestive drugs for acid-related disorders 
and antiepileptic drugs. 
At the individual generic level, significant increases were found in the prescribing rates of a number of 
medications. Among them were esomeprazole, oxycodone, rosuvastatin, pantoprazole, and 
pregabalin. On the other hand, amoxycillin, plain paracetamol and paracetamol/codeine combination 
products, atorvastatin and roxithromycin were among the medications for which significant decreases 
in prescribing rates occurred over time. 
Other changes that occurred over the 10-year period were a significant decrease in GP-supplied 
medications, in particular the influenza virus vaccine after peaks in previous years. There were 
increases in the supply of vitamin B12 and a number of combination childhood vaccines. Among 
medications advised for over-the-counter purchase, there was a significant rise in vitamin D3 but 
overall the rate of OTC medications did not change. There was a steady rise in the proportion of 
prescriptions for which five repeats were recorded, and a corresponding decrease in those for which 
one repeat was recorded. 
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 10 Other treatments 
The BEACH survey form allows GPs to record up to two other (non-pharmacological) treatments for 
each problem managed at the encounter, and to indicate if each of these was done by a practice 
nurse (PN) or Aboriginal health worker (AHW). Other treatments include all clinical and procedural 
treatments provided. These groups are defined in Appendix 4, Tables A4.4 and A4.5. 
Routine clinical measurements or observations, such as measurements of blood pressure and 
physical examinations, were not recorded if they were undertaken by the GP. However GPs were 
instructed to record clinical measurements or observations if these were undertaken by a PN or AHW 
in conjunction with the GP at the encounter. 
In Sections 10.1–10.3 inclusive, ‘other treatments’ have been counted irrespective of whether they 
were done by the GP or by the PN/AHW. That is, the non-pharmacological management provided at 
general practice patient encounters is described, rather than management provided specifically by the 
GP. In the analysis of procedural treatments, injections given in the provision of vaccines were 
removed, as this action has already been counted and reported in Section 9.3. 
In Section 10.4, treatments provided by the PN/AHW (including injections given for vaccination) are 
reported separately to provide a picture of the work they undertake in association with GP–patient 
encounters. 
Data on other treatments are reported for each year from 2005–06 to 2014–15 in the 10-year report,  
A decade of Australian general practice activity 2005–06 to 2014–15.1  
10.1 Number of other treatments 
In 2014–15, 50,204 other treatments were recorded, at a rate of 50.9 per 100 encounters. Two-thirds 
(66.6%) of these were clinical treatments. At least one other treatment was provided at 39.4% of all 
encounters, and for 29.4% of all problems managed. For every 100 problems managed, 22 clinical 
treatments and 11 procedures were performed by a GP or PN/AHW (Table 10.1). 
Table 10.1: Summary of other treatments 
Variable Number 
Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 153,133) 
95% 
LCL 
95% 
UCL 
At least one other treatment 38,908 39.4 37.8 41.0 — — — 
Other treatments 50,204 50.9 48.4 53.3 32.8 31.3 34.2 
 Clinical treatments 33,443 33.9 31.8 36.0 21.8 20.6 23.1 
 Procedural treatments(a) 16,761 17.0 16.2 17.8 10.9 10.5 11.4 
(a) Excludes all local injection/infiltrations performed for immunisations/vaccinations (n = 2,573). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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Table 10.2 shows the relationship between other treatments and pharmacological treatments given 
for problems managed. 
• For 63.3% of the problems that were managed with an ‘other treatment’, no medication was 
prescribed, supplied or advised for that problem at that encounter. 
• Around 1 in 5 problems (19.9%) were managed with at least one clinical treatment. For 62.6% of 
these problems, no concurrent pharmacological treatment was provided. 
• About 1 in 10 problems (10.3%) were managed with at least one procedural treatment, with no 
pharmacological management given for 64.0% of these problems. 
Table 10.2: Relationship between other treatments and pharmacological treatments 
Co-management of problems with other treatments 
Number of 
problems  
Per cent  
within class 
Per cent of  
problems 
(n = 153,133) 
95%  
LCL 
95%  
UCL 
At least one other treatment  45,089 100.0 29.4 28.2 30.6 
 Without pharmacological treatment 28,551 63.3 18.6 17.9 19.4 
At least one clinical treatment  30,484 100.0 19.9 18.8 21.0 
 Without pharmacological treatment 19,072 62.6 12.5 11.8 13.1 
At least one procedural treatment 15,840 100.0 10.3 9.9 10.8 
 Without pharmacological treatment  10,137 64.0 6.6 6.3 6.9 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
 
10.2 Clinical treatments 
Clinical treatments include general and specific advice, counselling or education, and administrative 
processes. During 2014–15, there were 33,443 clinical treatments recorded, at a rate of 33.9 per 100 
encounters, and 21.8 per 100 problems managed (Table 10.1). 
Most frequent clinical treatments 
Table 10.3 lists the 20 most common clinical treatments provided. Each clinical treatment is 
expressed as a percentage of all clinical treatments, as a rate per 100 encounters and as a rate per 
100 problems managed, with 95% confidence limits. 
The top 10 most frequently provided clinical treatments accounted for 84.8% of all clinical treatments. 
General advice and education was the most frequently recorded (6.1 per 100 encounters), accounting 
for 18.1% of all clinical treatments, followed by counselling about the problem under management 
(4.2 per 100 encounters). 
Several groups of clinical treatments related to preventive activities. The most common was 
counselling and advice about nutrition and weight (3.0 per 100 encounters), followed by counselling 
and advice for lifestyle, exercise, smoking, alcohol and prevention. Together, these preventive 
treatments accounted for 17.9% of clinical treatments, provided at a rate of 6.1 per 100 encounters. 
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Table 10.3: Most frequent clinical treatments 
Clinical treatment Number 
Per cent of 
clinical 
treatments 
(n = 33,443) 
Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 153,133) 
95% 
LCL 
95% 
UCL 
Advice/education NEC* 6,037 18.1 6.1 5.3 6.9 3.9 3.4 4.5 
Counselling – problem* 4,127 12.3 4.2 3.6 4.8 2.7 2.3 3.1 
Advice/education – treatment* 3,284 9.8 3.3 2.9 3.7 2.1 1.9 2.4 
Counselling – psychological* 3,020 9.0 3.1 2.8 3.3 2.0 1.8 2.1 
Counselling/advice – nutrition/weight* 2,977 8.9 3.0 2.7 3.4 1.9 1.7 2.2 
Advice/education – medication* 2,801 8.4 2.8 2.6 3.1 1.8 1.7 2.0 
Other administrative procedure/ 
document (excluding sickness 
certificate)* 
2,260 6.8 2.3 2.1 2.5 1.5 1.4 1.6 
Sickness certificate* 1,549 4.6 1.6 1.3 1.8 1.0 0.9 1.2 
Reassurance, support*  1,428 4.3 1.4 1.2 1.7 0.9 0.8 1.1 
Counselling/advice – lifestyle* 862 2.6 0.9 0.7 1.0 0.6 0.5 0.7 
Counselling/advice – exercise* 830 2.5 0.8 0.7 1.0 0.5 0.5 0.6 
Counselling/advice – smoking* 610 1.8 0.6 0.5 0.7 0.4 0.3 0.5 
Counselling/advice – alcohol* 374 1.1 0.4 0.3 0.4 0.2 0.2 0.3 
Counselling/advice – health/body* 355 1.1 0.4 0.3 0.4 0.2 0.2 0.3 
Observe/wait* 353 1.1 0.4 0.3 0.4 0.2 0.2 0.3 
Counselling/advice – prevention* 344 1.0 0.3 0.3 0.4 0.2 0.2 0.3 
Counselling/advice – other* 289 0.9 0.3 0.2 0.4 0.2 0.1 0.2 
Family planning* 283 0.8 0.3 0.2 0.3 0.2 0.2 0.2 
Consultation with primary care 
provider* 
269 0.8 0.3 0.2 0.3 0.2 0.1 0.2 
Counselling/advice – pregnancy* 243 0.7 0.2 0.2 0.3 0.2 0.1 0.2 
Subtotal  32,296 96.6 — — — — — — 
Total clinical treatments 33,443 100.0 33.9 31.8 36.0 21.8 20.6 23.1 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.4 <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified. 
Problems managed with a clinical treatment 
Table 10.4 lists the top 10 problems managed with a clinical treatment. It also shows the extent to 
which clinical treatments were used for each problem, and the relationship between the use of a 
clinical treatment and the provision of medication for that problem at that encounter. 
• A total of 30,484 problems (19.9% of all problems) involved one or more clinical treatments in 
their management (Table 10.2). 
• There was a very broad range of problems managed with clinical treatments. However, the 
10 most common accounted for 30% of all problems for which clinical treatments were provided. 
• Upper respiratory tract infection (URTI) represented the largest proportion of problems managed 
with a clinical treatment (5.9%), followed by depression (5.4%). 
• URTI was managed with a clinical treatment at a rate of 1.8 per 100 encounters. This means that 
for every 100 GP–patient encounters in 2014–15, URTI was managed with at least one clinical 
treatment on about two occasions. Extrapolation of this result suggests that across Australia in 
2014–15, there were 2.5 million occasions where URTI was managed with a clinical treatment. 
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• A clinical treatment was provided at 31.5% of contacts with URTI, with no concurrent 
pharmacological treatment provided for 60.8% of these contacts where a clinical treatment was 
provided. 
• Of the top 10 problems, acute stress reaction was the problem most likely to be managed with a 
clinical treatment (at 68.8% of contacts). Of the contacts with acute stress reaction where a 
clinical treatment was provided, 88.8% did not result in concurrent medication prescribed, 
supplied or advised for that problem. 
Table 10.4: The 10 most common problems managed with a clinical treatment 
Problem managed Number(a) 
Per cent of 
problems with 
clinical treatment  
(n = 30,484) 
Rate per 100 
encounters(b) 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Per cent 
 of this 
problem(c) 
Per cent of 
treated 
 problems no 
medications(d) 
Upper respiratory tract infection  1,804 5.9 1.8 1.6 2.1 31.5 60.8 
Depression* 1,653 5.4 1.7 1.5 1.8 37.5 47.5 
Diabetes – all* 998 3.3 1.0 0.9 1.1 25.2 65.3 
Anxiety* 901 3.0 0.9 0.8 1.0 40.6 65.7 
Hypertension* 861 2.8 0.9 0.7 1.0 11.1 46.3 
Lipid disorder 694 2.3 0.7 0.6 0.8 23.5 67.0 
Gastroenteritis* 602 2.0 0.6 0.5 0.7 46.9 55.8 
Back complaint* 584 1.9 0.6 0.5 0.7 17.7 51.8 
Acute stress reaction 476 1.6 0.5 0.4 0.5 68.8 88.8 
Test results* 472 1.5 0.5 0.4 0.6 21.9 94.4 
Subtotal  9,045 29.7 — — — — — 
Total problems with clinical 
treatments 
30,484 100.0 30.9 29 32.7 — — 
(a) Number of contacts with this problem that generated at least one clinical treatment. 
(b) Rate at which a selected problem was managed with one or more clinical treatments, per 100 encounters. 
(c) Percentage of contacts with this problem that generated at least one clinical treatment. 
(d) The numerator is the number of contacts with this problem that generated at least one clinical treatment but generated no medications.  
The denominator is the total number of contacts for this problem that generated at least one clinical treatment (with or without medications). 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
 
10.3 Procedural treatments 
Procedural treatments include therapeutic actions and diagnostic procedures undertaken at the 
encounter. Injections for immunisations/vaccinations (n = 2,573) are not counted here as these were 
already counted as a GP-supplied medication in Section 9.3. There were 16,761 procedures recorded 
at a rate of 17.0 per 100 encounters, and 10.9 per 100 problems managed (Table 10.1). 
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Most frequent procedures 
Table 10.5 lists the most common procedural treatments recorded. Each procedural treatment is 
expressed as a percentage of all procedures, as a rate per 100 encounters and as a rate per 100 
problems, with 95% confidence limits. Some of the procedures (for example, international normalised 
ratio [INR] tests, electrical tracings, physical function tests) are investigations undertaken at the 
encounter. Results presented in Table 10.5 do not include investigations that were ordered by the GP 
to be performed by an external provider. A summary of all investigations (both undertaken and 
ordered) is provided in Chapter 12 (Table 12.6). 
The top 10 most frequently performed procedural treatments accounted for 82.5% of all procedures. 
The most frequent group of procedures was excision/removal tissue/biopsy/destruction/debridement/ 
cauterisation (3.0 per 100 encounters), accounting for 17.6% of procedural treatments recorded. 
Table 10.5: Most frequent procedural treatments 
Procedural treatment Number 
Per cent of 
procedural 
treatments 
(n = 16,761) 
Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 153,133) 
95% 
LCL 
95% 
UCL 
Excision/removal tissue/biopsy/ 
destruction/debridement/cauterisation* 
2,942 17.6 3.0 2.7 3.2 1.9 1.7 2.1 
Dressing/pressure/compression/ 
tamponade* 
2,421 14.4 2.5 2.3 2.6 1.6 1.5 1.7 
Local injection/infiltration*(a) 2,320 13.8 2.3 2.2 2.5 1.5 1.4 1.6 
Physical medicine/rehabilitation – all* 1,215 7.3 1.2 1.1 1.4 0.8 0.7 0.9 
Incision/drainage/flushing/aspiration/ 
removal body fluid* 
1,072 6.4 1.1 1.0 1.2 0.7 0.6 0.8 
Pap smear*  848 5.1 0.9 0.8 1.0 0.6 0.5 0.6 
Repair/fixation – suture/cast/prosthetic 
device (apply/remove)* 
818 4.9 0.8 0.7 0.9 0.5 0.5 0.6 
Other therapeutic procedures/minor 
surgery*  
818 4.9 0.8 0.6 1.0 0.5 0.4 0.7 
INR test* 722 4.3 0.7 0.6 0.9 0.5 0.4 0.5 
Check-up – PN/AHW* 656 3.9 0.7 0.5 0.8 0.4 0.3 0.5 
Electrical tracings* 651 3.9 0.7 0.6 0.7 0.4 0.4 0.5 
Other preventive procedures/high-risk 
medication* 
646 3.9 0.7 0.6 0.7 0.4 0.4 0.5 
Physical function test* 479 2.9 0.5 0.4 0.6 0.3 0.3 0.4 
Other diagnostic procedures* 308 1.8 0.3 0.2 0.4 0.2 0.2 0.2 
Urine test* 208 1.2 0.2 0.2 0.3 0.1 0.1 0.2 
Hormone implant* 162 1.0 0.2 0.1 0.2 0.1 0.1 0.1 
Glucose test* 156 0.9 0.2 0.1 0.2 0.1 0.1 0.1 
Pregnancy test* 129 0.8 0.1 0.1 0.2 0.1 0.1 0.1 
Subtotal  16,572 98.9 — — — — — — 
Total procedural treatments  16,761 100.0 17.0 16.2 17.8 10.9 10.5 11.4 
(a) Excludes all local injection/infiltrations performed for immunisations/vaccinations (n = 2,573). 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Tables A4.5 and A4.6, <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; INR – international normalised ratio; PN – practice nurse; AHW – Aboriginal 
health worker.  
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Problems managed with a procedural treatment 
Table 10.6 lists the top 10 problems managed with a procedural treatment. It also shows the 
proportion of contacts with each problem that were managed with a procedure, and the proportion of 
these contacts where medication was not given concurrently. 
• One or more procedural treatments were provided in the management of 15,840 problems 
(10.3% of all problems) (Table 10.2). 
• The top 10 problems accounted for more than one-third (35.4%) of all problems managed with a 
procedural treatment. 
• Solar keratosis/sunburn accounted for the largest proportion of problems managed with a 
procedure (5.3%), followed by laceration/cut (5.1%). 
• Solar keratosis/sunburn was managed with a procedure at 68.1% of contacts with this problem, 
at a rate of 0.8 per 100 encounters. Extrapolation of this result suggests that across Australia in 
2014–15, there were about 1.1 million occasions where solar keratosis/sunburn was managed 
with a procedure. 
• Of the top 10 problems, laceration/cut was the problem most likely to be managed with a 
procedure, undertaken at 4 out of 5 (79.7%) contacts with this problem. Of those contacts where 
laceration/cut was managed with a procedural treatment, no medication was prescribed, supplied 
or advised for that problem at 80.4% of contacts. 
Table 10.6: The 10 most common problems managed with a procedural treatment 
Problem managed Number(a) 
Per cent of 
problems with 
procedure 
(n = 15,840)  
Rate per 100 
encounters(b) 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Per cent 
of this 
problem(c) 
Per cent of 
treated problems 
no medications(d) 
Solar keratosis/sunburn  835 5.3 0.8 0.7 1.0 68.1 96.9 
Laceration/cut 812 5.1 0.8 0.7 0.9 79.7 80.4 
Female genital check-up/ 
Pap smear* 
709 4.5 0.7 0.6 0.8 46.4 97.0 
Excessive ear wax  577 3.6 0.6 0.5 0.6 70.6 92.8 
Malignant neoplasm, skin 565 3.6 0.6 0.5 0.7 47.1 96.0 
General check-up*  503 3.2 0.5 0.4 0.6 16.8 73.6 
Warts 438 2.8 0.4 0.4 0.5 77.9 94.3 
Chronic ulcer skin 
(including varicose ulcer) 
415 2.6 0.4 0.4 0.5 71.5 76.5 
Atrial fibrillation/flutter 403 2.5 0.4 0.3 0.5 31.7 64.9 
Vitamin/nutritional deficiency 349 2.2 0.4 0.3 0.4 26.1 0.2 
Subtotal  5,607 35.4 — — — — — 
Total problems with 
procedural treatments 
15,840 100.0 16.0 15.3 16.8 — — 
(a) Number of contacts with this problem that generated at least one procedural treatment. 
(b) Rate at which a selected problem was managed with one or more procedural treatments, per 100 encounters. 
(c) Percentage of contacts with this problem that generated at least one procedural treatment. 
(d) The numerator is the number of contacts with this problem that generated at least one procedural treatment but generated no medications. 
The denominator is the total number of contacts for this problem that generated at least one procedural treatment (with or without 
medications). 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit.  
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10.4 Practice nurse/Aboriginal health worker activity 
This section describes the activities of practice nurses (PNs) and Aboriginal health workers (AHWs) 
recorded in association with the GP–patient encounters detailed by the BEACH GP participants. 
The survey form allows GPs to record up to two other treatments for each problem managed at the 
encounter (up to eight per encounter). Other treatments include all clinical and procedural treatments 
provided at the encounters. These groups are defined in Appendix 4, Tables A4.4 and A4.5. 
As a result of the introduction of new item numbers in the MBS that allowed GPs to claim for specific 
PN clinical activities68, the BEACH recording form was amended in 2005–06 to allow GPs to record 
information about the actions PNs undertook in association with the GP–patient encounter. In the 
‘other treatments’ section for each problem managed, GPs were asked to tick the ‘practice nurse’ box 
if the treatment recorded was provided by the PN rather than by the GP. If the box was not ticked it 
was assumed the GP gave the treatment. 
Over time, new PN item numbers were added to the MBS, and some items were broadened, to cover 
work done by AHWs. In January 2012, the Australian Government significantly altered the payment 
structure for PN and AHW activities in general practice, such that the range of claimable MBS item 
numbers was reduced and the Practice Nurse Incentive Program (PNIP) introduced. 
The following section investigates: the proportion of encounters involving PNs/AHWs; the proportion 
of these claimable with a Medicare item number; treatments provided by PNs/AHWs in association 
with the GP–patient encounters; and the problems for which these treatments were provided. 
Remember that these results will not include PN/AHW activities undertaken during the GP’s BEACH 
recording period that were not associated with the recorded encounter. Such activities could include 
Medicare-claimable activities (for example, chronic disease management) provided under instruction 
from the GP but not at the time of the encounter recorded in BEACH, or provision of other services 
not claimable from Medicare. 
Practice nurse/Aboriginal health worker Medicare claims 
There were 7,075 GP–patient encounters (7.2% of all encounters) at which at least one PN/AHW 
activity was recorded. However, for 58 of these, their activity was not described. At the remaining 
encounters, a PN/AHW was involved in the management of 7,324 problems (4.8% of all problems 
managed at all encounters) (Table 10.7). Extrapolation of these results suggests that during 2014–15 
practice nurses were involved in about 9.9 million GP–patient consultations across Australia. 
A PN/AHW Medicare item was recorded at only 270 encounters, or 3.8% of the 7,075 encounters 
involving a PN/AHW (Table 10.7). 
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Table 10.7: Summary of PN or AHW involvement at encounters 
Variable Number 
Total encounters  98,728 
Encounters involving PN/AHW 7,075 
 Encounters at which PN/AHW activity described 7,018 
 Encounters with PN/AHW item number(s) recorded but activity not described  58 
Encounters at which one or more MBS PN/AHW item numbers were recorded as claimable  270 
Total problems managed 153,133 
Problems managed with PN/AHW-involvement 7,324 
 
Per cent  
(95% CI) 
Encounters involving the PN/AHW as a proportion of total encounters  
7.2 
(6.6–7.7) 
PN/AHW-claimable encounters as a proportion of total encounters  
0.3 
(0.2–0.4) 
Proportion of PN/AHW-involved encounters for which one or more PN/AHW item numbers were 
claimed from Medicare  
3.8 
(2.7–5.0) 
Problems involving the PN/AHW as a proportion of total problems (95% CI) 
4.8 
(4.4–5.2) 
Note: PN/AHW – practice nurse/Aboriginal health worker; MBS – Medicare Benefits Schedule; CI – confidence interval. 
Treatments provided by practice nurses or Aboriginal health 
workers at GP–patient encounters  
As shown in Section 10.1, GPs reported 50,204 other treatments. A further 1,289 local injections in 
administration of vaccine were given by a PN/AHW and 1,283 by the recording GP (these were not 
reported in Section 10.2). Of the 52,776 other treatments recorded, PNs/AHWs accounted for 7,797 
of these, representing 14.8% of all other treatments recorded (Table 10.8), at a rate of 7.9 per 100 
recorded encounters (result not tabled). 
The vast majority (87.6%) of the PN/AHW recorded activity was procedural, and these procedures 
represented 35.3% of all procedures recorded. In contrast, clinical treatments accounted for 12.4% of 
PN/AHW recorded activity at encounters, but PNs/AHWs provided only 2.9% of all recorded clinical 
treatments. PNs/AHWs did 50.1% of the recorded immunisation injections at GP–patient encounters 
(Table 10.8). 
Table 10.8: Summary of treatments given by GPs, and by PN or AHW at GP–patient encounters 
Treatment 
Performed/assisted by PN/AHW  Performed by the GP 
Total number 
recorded(a) Number 
Row per cent  
of total 
 
Number 
Row per cent  
of total 
Procedures(a) 6,829 35.3  12,505 64.7 19,333 
(Immunisation injections) (1,289) (50.1)  (1,283) (49.9) (2,573) 
Clinical treatments 968 2.9  32,475 97.1 33,443 
All other treatments 7,797 14.8  44,979 85.2 52,776 
(a)  Procedural treatments here include all injections given by a PN/AHW or the GP for immunisations/vaccinations (n = 2,573).  
These are not included in the summary of the content of encounter in Table 5.1, summary of management in Table 8.1 or in the analyses of 
other treatments in Chapter 10, because the immunisation/vaccination is already counted as a prescription or GP-supplied medication. 
Note: PN/AHW – practice nurse/Aboriginal health worker; columns and rows may not add to total due to rounding. 
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Of the 6,829 procedures performed by a PN/AHW, 2,170 (31.8%) were injections (Table 10.9), of 
which 1,289 (59.4%) were for immunisations (Table 10.8). A further 20.3% of the recorded 
procedures were dressing/pressure/compression/tamponade. Together, these accounted for more 
than half (52.1%) of all procedures undertaken by PNs/AHWs. Check-ups made up 9.6%, followed by 
INR tests (7.4%) (Table 10.9). 
Other administrative procedure (including administrative/documentation work but excluding provision 
of sickness certificates) was the most frequently recorded clinical activity, accounting for 33.8% of the 
968 clinical treatments provided by PNs/AHWs, followed by advice/education (not elsewhere 
classified) (9.6%), advice/education about treatment (9.4%), counselling about a health problem 
(7.9%), counselling/advice about nutrition/weight (7.5%), and advice/education about medication 
(5.4%) (Table 10.9). 
Table 10.9: Most frequent activities done by a PN or AHW at GP encounters 
Activity Number 
Per cent 
of group(a) 
Rate per 100 encs 
where PN/AHW 
activity described(a) 
 (n = 7,018) 
95% 
 LCL 
95% 
UCL 
Procedural treatments 6,829 100.0 97.3 95.2 99.5 
 Local injection/infiltration* 2,170  31.8 30.9 28.4 33.4 
 Dressing/pressure/compression/tamponade* 1,385  20.3 19.7 17.9 21.6 
 Check-up – PN/AHW* 653 9.6 9.3 7.0 11.6 
 INR test* 508 7.4 7.2 6.1 8.4 
 Incision/drainage/flushing/aspiration/removal body fluid* 412 6.0 5.9 4.9 6.8 
 Electrical tracings* 364 5.3 5.2 4.4 6.0 
 Excision/removal tissue/biopsy/destruction/
 debridement/cauterisation* 
335 4.9 4.8 3.7 5.8 
 Repair/fixation – suture/cast/prosthetic device(apply/
 remove)* 
327 4.8 4.7 4.0 5.3 
 Physical function test* 209 3.1 3.0 2.2 3.7 
 Other therapeutic procedures/minor surgery* 92 1.4 1.3 0.9 1.7 
 Urine test* 87 1.3 1.2 0.9 1.6 
 Other diagnostic procedures* 73 1.1 1.0 0.7 1.4 
 Glucose test* 57 0.8 0.8 0.5 1.2 
 Pap smear* 39 0.6 0.6 0.3 0.8 
Clinical treatments 968 100.0 13.8 11.8 15.8 
 Other administrative procedure/document 
 (excluding sickness certificate)* 
327 33.8 4.7 3.7 5.6 
 Advice/education NEC* 93 9.6 1.3 0.8 1.9 
 Advice/education – treatment* 91 9.4 1.3 0.9 1.7 
 Counselling – problem* 76 7.9 1.1 0.6 1.6 
 Counselling/advice – nutrition/weight* 73 7.5 1.0 0.4 1.7 
 Advice/education – medication* 52 5.4 0.7 0.4 1.0 
 Consultation with primary care provider* 46 4.8 0.7 0.4 0.9 
(a) Only the most common individual treatments provided by practice nurses/Aboriginal health workers are included in this table. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Tables A4.4–A4.6 <hdl.handle.net/2123/13765>). 
Note: Encs – encounters; PN/AHW – practice nurse/Aboriginal health worker; LCL – lower confidence limit; UCL – upper confidence limit;  
INR – international normalised ratio; NEC – not elsewhere classified. 
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Problems managed with practice nurse or Aboriginal health 
workers involvement at encounter 
PNs and AHWs were involved in the management of a wide range of problems in association with 
GP–patient encounters. The problems they managed most often were immunisation/vaccination 
(18.1% of all problems managed with the involvement of a PN or AHW), check-ups (6.9%), 
laceration/cut (6.7%), diabetes (4.4%), chronic skin ulcer (4.2%), and atrial fibrillation (3.7%). Other 
common problems for which PNs/AHWs were involved are listed in Table 10.10. These top 20 
problems accounted for two-thirds (65.9%) of all encounters which involved a PN/AHW. 
Table 10.10: The 20 most common problems managed with involvement of PNs or AHWs at 
GP–patient encounters 
Problem managed Number 
Per cent  
of problems 
involving  
PN/AHW 
(n = 7,324) 
Rate per 100 
encounters with 
recorded PN/AHW 
activity(a) 
(n = 7,018) 
95% 
LCL 
95% 
UCL 
Immunisation/vaccination – all* 1,322 18.1 18.8 16.8 20.9 
Check-up – all* 508 6.9 7.2 6.3 8.2 
Laceration/cut 494 6.7 7.0 6.1 8.0 
Diabetes – all* 320 4.4 4.6 3.7 5.4 
Chronic ulcer skin (including varicose ulcer) 309 4.2 4.4 3.7 5.1 
Atrial fibrillation/flutter  268 3.7 3.8 3.0 4.6 
Excessive ear wax  236 3.2 3.4 2.8 3.9 
Malignant neoplasm, skin 199 2.7 2.8 2.1 3.5 
Vitamin/nutritional deficiency 156 2.1 2.2 1.7 2.7 
Administrative procedure – all* 118 1.6 1.7 1.1 2.3 
Asthma 110 1.5 1.6 1.2 1.9 
Repair/fixation – suture/cast/prosthetic device 
(apply/remove)* 
109 1.5 1.6 1.2 1.9 
Hypertension* 108 1.5 1.5 1.1 2.0 
Skin infection, other 100 1.4 1.4 1.0 1.8 
Blood test – all* 94 1.3 1.3 0.8 1.9 
Prescription – all* 84 1.2 1.2 0.7 1.7 
Skin symptom/complaint, other 79 1.1 1.1 0.8 1.5 
Other preventive procedures/high risk medication* 73 1.0 1.0 0.7 1.4 
Excision/removal tissue/biopsy/destruction/ 
debridement/cauterisation* 
72 1.0 1.0 0.6 1.4 
Contraception female, other 71 1.0 1.0 0.7 1.3 
Subtotal  4,830  65.9 — — — 
Total problems involving practice nurse  7,324  100.0 104.4 103.6 105.1 
(a) Rate at which a PN/AHW provided a treatment in the management of the selected problem (as a rate per 100 PN/AHW encounters). 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, A4.3 <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; PN/AHW – practice nurse/Aboriginal health worker.  
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10.5 Changes in other treatments over the decade 
2005–06 to 2014–15 
An overview of changes in other treatments provided in general practice over the decade can be 
found in Chapter 10 of the companion report, A decade of Australian general practice activity  
2005–06 to 2014–15.1 A summary of the results is provided below. 
Clinical treatments 
Between 2006–07 and 2007–08, there was a significant increase in the rate at which clinical 
treatments were provided by the GP or the PN/AHW at GP–patient encounters, from 19.9 to 22.9 per 
100 problems managed. The rate then remained relatively steady, but in 2014–15 clinical treatments 
were provided at a rate that did not significantly differ from that of 10 years earlier, at a rate of 21.8 
clinical treatments per 100 problems. 
Although there was no significant change over the decade in the rate at which clinical treatments were 
provided per 100 problems, there was a significant increase in the rate per 100 encounters, from 
29.3 per 100 encounters in 2005–06 to 33.9 per 100 in 2014–15. This was due to the increased 
number of problems managed per encounter over the decade. There was also a massive increase in 
the number of encounters claimed through Medicare due to the increased visit rate. The combination 
of increased number of problems managed at encounters and the increased attendance rate over the 
study period affects the number of clinical treatments provided nationally. We estimate that as a 
result, 16.9 million more clinical treatments were provided at GP–patient encounters nationally in 
2014–15 than in 2005–06. 
There was a significant increase in the likelihood that one or more clinical treatments were provided in 
the management of an individual problem, from 26.7 problems for every 100 GP–patient encounters 
in 2005–06 to 30.9 per 100 in 2014–15. 
Procedural treatments 
There was a significant increase in the rate at which procedures were performed from 9.8 per 
100 problems in 2005–06 to 10.9 per 100 in 2014–15. The extrapolated effect of this change, from 
14.4 procedures per 100 encounters in 2005–06 to 17.0 per 100 in 2014–15, is that nationally in 
2014–15, there were an estimated 8.8 million more procedures undertaken at GP–patient encounters 
than a decade earlier. 
For every 100 GP–patient encounters in 2005–06, one or more procedures were used in the 
management of 13.5 problems. The rate significantly increased over time, reaching 16.0 problems per 
100 encounters in 2014–15. This increase was reflected in significant increases in the rate at which 
one or more procedures were undertaken for the management of general check-up and atrial 
fibrillation/flutter. 
Practice nurse/Aboriginal health worker activity  
Section 10.5 of the companion report, A decade of Australian general practice activity 2005–06 to 
2014–15,1 provides an overview of changes in general practice encounters over the past decade. The 
major changes between 2005–06 and 2014–15 are summarised below. 
Encounters involving a PN/AHW as a proportion of all encounters more than doubled from 4.2% in 
2005–06 to peak at 9.0% in 2009–10. Since then, PN/AHW involvement in GP–patient encounters 
has significantly decreased, with only 7.2% of encounters in 2014–15 involving a PN/AHW. 
Similarly, the proportion of problems managed with PN/AHW involvement at GP–patient encounters 
increased significantly from 2.8% in 2005–06 to 6.1% in 2009–10, and then gradually decreased to 
reach a significant change by 2014–15 at 4.8%. 
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In 2005–06, GPs recorded one or more PN/AHW MBS item numbers at 39.2% of encounters with 
recorded PN/AHW activity. By 2009–10, this proportion had risen to 45.5%. In 2011–12, which 
included 3 months of the new 2012 PNIP, GPs recorded a PN/AHW item at only 27.4% of encounters 
involving a PN/AHW. 
In 2014–15, PN/AHW activities were claimable from Medicare at only 3.8% of encounters with which 
they were associated. When this result is considered in terms of the total GP–patient encounters 
recorded in BEACH, a PN/AHW Medicare item number was claimable at 4.1% of all GP encounters in 
2009–10 but only 0.3% in 2014–15. 
Clearly, PN/AHW involvement with patient care in association with GP–patient consultations is 
decreasing. While it is likely that PNs/AHWs are increasingly working with patients independent of 
GP–patient encounters, this is not measured in the BEACH program. 
The rate at which procedures (including injections and tests) were undertaken by PNs/AHWs in 
association with the recorded GP–patient encounters more than doubled from 4.0 per 100 encounters 
in 2005–06 to 9.2 per 100 in 2009–10. The rate then decreased in 2011–12 to 7.2 per 100 
encounters, with no further significant change in the ensuing years. 
While their provision of clinical treatments (such as advice and health education) remained infrequent 
at GP–patient encounters, there was a steady increase over the study period, from 0.2 clinical 
treatments per 100 encounters in 2005–06 to 1.1 per 100 in 2012–13 and then remaining steady 
through to 2014–15. 
Changes in the problems for which PNs/AHWs were involved in management largely reflect the 
changes in the activities undertaken. Their assistance in management of immunisation/vaccination at 
GP encounters significantly decreased from 30.9 per 100 PN/AHW involved encounters in 2005–06 to 
18.8 per 100 in 2014–15. This parallels the overall decrease in the management rate of 
immunisations/vaccinations in the total data set in 2014–15, perhaps reflecting the delay in availability 
of influenza vaccines in 2015. There were significant increases in the rate at which PNs/AHWs were 
involved in the management of check-ups, diabetes, atrial fibrillation/flutter, and vitamin/nutritional 
deficiency. 
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 11 Referrals and admissions 
A referral is defined as the process by which the responsibility for part, or all, of the care of a patient is 
temporarily transferred to another health care provider. GPs were instructed only to record new 
referrals at the encounter (that is, to not record continuations). For each encounter, GPs could record 
up to two referrals, and each referral was linked by the GP to the problem(s) for which the patient was 
referred. Referrals included those to medical specialists, allied health services, hospitals for 
admission, emergency departments, and those to other services (including outpatient clinics and to 
other GPs). 
Data on referrals and admissions are reported for each of the most recent BEACH years from  
2005–06 to 2014–15, in the 10-year report, A decade of Australian general practice activity 2005–06 
to 2014–15.1  
11.1 Number of referrals and admissions 
Table 11.1 provides a summary of referrals and admissions, and the rates per 100 encounters and 
per 100 problems managed. The patient was given at least one referral at 14.5% of all encounters, for 
10.2% of all problems managed. 
There were 15,697 referrals made at a rate of 15.9 per 100 encounters, most often to medical 
specialists (9.6 per 100 encounters, 6.2 per 100 problems managed), followed by referrals to allied 
health services (5.2 per 100 encounters, 3.3 per 100 problems). Relatively few patients were 
referred/admitted to hospital, or referred to the emergency department. 
Table 11.1: Summary of referrals and admissions 
Variable Number 
Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 153,133) 
95% 
LCL 
95% 
UCL 
At least one referral(a) 14,360 14.5 14.0 15.1 10.2 9.8 10.5 
Referrals 15,697 15.9 15.3 16.5 10.3 9.9 10.6 
 Medical specialist* 9,464 9.6 9.2 10.0 6.2 5.9 6.4 
 Allied health services* 5,107 5.2 4.9 5.5 3.3 3.1 3.5 
 Hospital* 355 0.4 0.3 0.4 0.2 0.2 0.3 
 Emergency department* 305 0.3 0.3 0.4 0.2 0.2 0.2 
 Other referrals* 466 0.5 0.4 0.5 0.3 0.3 0.4 
(a) At least one referral was given in the management of 15,553 problems at the 14,360 encounters. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.7, <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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11.2 Most frequent referrals 
Table 11.2 shows the medical specialists and allied health service groups to whom GPs most often 
referred patients. Referrals to medical specialists were most often to surgeons (8.8% of specialist 
referrals), orthopaedic surgeons (8.5%), and cardiologists (8.0%). The top 10 specialists accounted 
for 63.7% of specialist referrals and for 41.3% of the 14,571 referrals to specialists and allied health 
services combined. 
Referrals to allied health services were most often to physiotherapists (27.8% of allied health services 
referrals), psychologists (24.3%), podiatrists/chiropodists (12.6%), dietitians/nutritionists (7.2%) and 
dentists (2.9%). The top 10 allied health services accounted for 84.1% of allied health referrals and 
29.5% of the 14,571 referrals to specialists and allied health services combined. 
Table 11.2: Most frequent referrals to medical specialists and allied health services 
Professional/organisation Number 
Per cent of 
referrals to 
spec/AHS  
Per cent 
of referral 
group 
Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 153,133) 
95% 
LCL 
95% 
UCL 
Medical specialist* 9,464 65.0 100.0 9.6 9.2 10.0 6.2 5.9 6.4 
 Surgeon 835 5.7 8.8 0.8 0.8 0.9 0.5 0.5 0.6 
 Orthopaedic surgeon 808 5.5 8.5 0.8 0.7 0.9 0.5 0.5 0.6 
 Cardiologist 760 5.2 8.0 0.8 0.7 0.9 0.5 0.4 0.6 
 Dermatologist 654 4.5 6.9 0.7 0.6 0.7 0.4 0.4 0.5 
 Gastroenterologist 652 4.5 6.9 0.7 0.6 0.7 0.4 0.4 0.5 
 Ophthalmologist 639 4.4 6.7 0.6 0.6 0.7 0.4 0.4 0.5 
 Gynaecologist  545 3.7 5.8 0.6 0.5 0.6 0.4 0.3 0.4 
 Ear, nose and throat 489 3.4 5.2 0.5 0.4 0.5 0.3 0.3 0.4 
 Urologist  343 2.4 3.6 0.3 0.3 0.4 0.2 0.2 0.3 
 Neurologist  300 2.1 3.2 0.3 0.3 0.4 0.2 0.2 0.2 
 Subtotal: top 10 medical  
 specialist referrals 
6,025 41.3 63.7 — — — — — — 
Allied health services* 5,107 35.0 100.0 5.2 4.9 5.5 3.3 3.1 3.5 
 Physiotherapist 1,418 9.7 27.8 1.4 1.3 1.6 0.9 0.8 1.0 
 Psychologist 1,243 8.5 24.3 1.3 1.1 1.4 0.8 0.7 0.9 
 Podiatrist/chiropodist 641 4.4 12.6 0.6 0.6 0.7 0.4 0.4 0.5 
 Dietitian/nutritionist 369 2.5 7.2 0.4 0.3 0.4 0.2 0.2 0.3 
 Dentist 149 1.0 2.9 0.2 0.1 0.2 0.1 0.1 0.1 
 Optometrist 124 0.8 2.4 0.1 0.1 0.1 0.1 0.1 0.1 
 Exercise physiologist 106 0.7 2.1 0.1 0.1 0.1 0.1 0.1 0.1 
 Audiologist 88 0.6 1.7 0.1 0.1 0.1 0.1 0.0 0.1 
 Chiropractor 81 0.6 1.6 0.1 0.1 0.1 0.1 0.0 0.1 
 Diabetes educator 74 0.5 1.4 0.1 0.1 0.1 0.0Ŧ 0.0 0.1 
 Subtotal: top 10 allied  
 health referrals 
4,293 29.5 84.1 — — — — — — 
Total allied health and 
medical specialist referrals 14,571 100.0 — 14.8 14.1 15.4 9.5 9.1 9.9 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.7, <hdl.handle.net/2123/13765>). 
Ŧ Rates are reported to one decimal place. This indicates that the rate is less than 0.05 per 100 encounters. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; spec/AHS – specialists and allied health services combined. 
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11.3 Problems most frequently referred to a 
 specialist 
The GP could link a single referral to multiple problems that were managed at the encounter. 
Therefore, there are more problem–referral links than referrals. Table 11.3 shows the most common 
problems referred to a medical specialist, in decreasing frequency order of problem-referral links. 
The 9,464 referrals to a medical specialist were provided in the management of 9,710 problems. The 
10 problems most often referred to a specialist accounted for only 18.1% of all problem–referral links, 
reflecting the breadth of problems referred to specialists. Malignant skin neoplasm accounted for 
2.5% of problem-referral links, followed by osteoarthritis (2.3%), diabetes (1.9%) and back complaint 
(1.9%) (Table 11.3). The ranking of problems most often referred reflects not only the need for referral 
but how frequently that problem is managed at GP encounters. For example, osteoarthritis, commonly 
managed at GP encounters, is ranked highly, even though referrals were made (far right column) at 
only 7.9% of GP contacts with this problem. Malignant skin neoplasm resulted in a specialist referral 
at 1 in 5 (20.1%) GP contacts with this problem. This was followed by ischaemic heart disease 
(15.7%) and pregnancy (11.8%). The likelihood of referral depends not only on the need for referral, 
but on other factors such as the acuity/chronicity of the condition. For example, at only 3.2% of GP 
contacts at which depression is managed is this problem referred, partly due to the relatively high 
number of GP encounters that may be required in any recurrent or chronic condition. 
Table 11.3: The 10 problems most frequently referred to a medical specialist 
Problem managed 
Problem–referral links Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Per cent of 
contacts with this 
problem(a) Number Per cent  
Malignant neoplasm, skin 242 2.5 0.2 0.2 0.3 20.1 
Osteoarthritis* 226 2.3 0.2 0.2 0.3 7.9 
Diabetes – all* 187 1.9 0.2 0.2 0.2 4.7 
Back complaint* 186 1.9 0.2 0.2 0.2 5.6 
Ischaemic heart disease* 177 1.8 0.2 0.1 0.2 15.7 
Sleep disturbance 165 1.7 0.2 0.1 0.2 10.1 
Gastro-oesophageal reflux disease* 149 1.5 0.2 0.1 0.2 5.4 
Pregnancy* 142 1.5 0.1 0.1 0.2 11.8 
Abnormal test results* 142 1.5 0.1 0.1 0.2 11.5 
Depression* 139 1.4 0.1 0.1 0.2 3.2 
Subtotal: top 10 problems referred to a 
medical specialist 
1,755 18.1 — — — — 
Total problems referred to medical 
specialist  9,710 100.0 9.8 9.4 10.3 — 
(a) The proportion of GP contacts with this problem that was referred to a medical specialist. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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Table 11.4 shows the five problems accounting for the greatest proportion of referrals to each of the 
10 most common medical specialty types. The top five problems may represent a small or large 
proportion of all problems referred to a particular specialty. For example, the top five problems 
accounted for 30.4% of all referrals to ear, nose and throat (ENT) specialists (indicative of the broad 
range of conditions referred to them), but for 55.7% of all referrals to orthopaedic surgeons, consistent 
with a more defined range of clinical work. 
Surgeon: The two problems accounting for the most referrals were inguinal hernia (6.1% of 
general/unspecified surgeon referrals) and malignant neoplasm of skin (5.4% of referrals). Of the five 
problems most frequently referred to a general/unspecified surgeon, those most likely to be referred 
at each GP contact with that problem were inguinal hernia (referred at 39.0% of contacts) and other 
(not inguinal or diaphragmatic) abdominal hernia (32.3%). 
Orthopaedic surgeon: The two problems accounting for the most referrals were osteoarthritis 
(21.7% of referrals) and acute internal knee damage (13.0%). Of the five problems most frequently 
referred, those most likely to be referred were acute internal knee damage (referred at 28.1% of GP 
contacts) and musculoskeletal injury (not otherwise specified) (7.2%). 
Cardiologist: The two problems accounting for the most referrals were ischaemic heart disease 
(20.8% of referrals) and atrial fibrillation/flutter (9.0%). Of the five problems most frequently referred, 
those most likely to be referred were ischaemic heart disease (referred at 14.8% of GP contacts) and 
chest pain (not otherwise specified) (14.6%). 
Dermatologist: The two problems accounting for the most referrals were malignant neoplasm of skin 
(12.6% of referrals) and other skin disease (9.4%). Of the five problems most frequently referred to a 
dermatologist, those most likely to be referred were skin check-up (referred at 9.5% of GP contacts) 
and other skin symptom/complaint (8.1%). 
Gastroenterologist: The two problems accounting for the most referrals were gastro-oesophageal 
reflux disease (11.4% of referrals) and digestive neoplasm (benign or uncertain) (7.9%). Of the five 
problems most frequently referred to a gastroenterologist, those most likely to be referred were 
benign/uncertain digestive neoplasm (referred at 26.3% of GP contacts) and rectal bleeding (26.1%). 
Ophthalmologist: The two problems accounting for the most referrals were cataract (12.8%) and 
diabetes (10.5%). Of the five problems most frequently referred to an ophthalmologist, those most 
likely to be referred were other visual disturbance (referred at 60.2% of GP contacts) and cataract 
(59.7%). 
Gynaecologist: The two problems accounting for the most referrals were menstrual problems (14.0% 
of referrals) and other female genital disease (13.7%). Of the five problems most frequently referred 
to a gynaecologist, those most likely to be referred were uterovaginal prolapse (referred at 45.6% of 
GP contacts) and other female genital disease (31.3%). 
Ear, nose and throat: The two problems accounting for the most referrals were acute/chronic 
sinusitis (11.4% of referrals to an ENT specialist) and tonsillitis (6.1%). Of the five problems most 
frequently referred to an ENT specialist, those most likely to be referred were throat 
symptom/complaint (referred at 12.1% of GP contacts) and other respiratory disease (9.0%). 
Urologist: The two problems accounting for the most referrals were benign prostatic hypertrophy 
(16.1% of referrals) and abnormal test results (7.8%). Of the five problems most frequently referred, 
those most likely to be referred were benign prostatic hypertrophy (referred at 19.9% of GP contacts) 
and urinary calculus (16.5%). 
Neurologist: The two problems accounting for the most referrals were headache (11.4% of referrals) 
and epilepsy (11.2%). Of the five problems most frequently referred to a neurologist, those most likely 
to be referred at each GP contact with that problem were Parkinsonism (referred at 12.9% of GP 
contacts) and epilepsy (12.2%) (Table 11.4). 
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Table 11.4: The top problems most frequently referred, by type of medical specialist 
Specialist Problem managed Number 
Per cent of 
problems referred 
to each specialist 
Per cent of contacts with  
this problem(a) 
Surgeon Total 856 100.0 — 
 Inguinal hernia 52 6.1 39.0 
 Malignant neoplasm, skin 46 5.4 3.9 
 Abdominal hernia, other 45 5.2 32.3 
 Cholecystitis/cholelithiasis 42 4.9 26.6 
 Haemorrhoids 32 3.8 12.1 
 Subtotal: top five problems 217 25.4  — 
Orthopaedic surgeon Total 826 100.0 — 
 Osteoarthritis* 179 21.7 6.3 
 Acute internal knee damage 107 13.0 28.1 
 Injury musculoskeletal NOS 66 8.0 7.2 
 Bursitis/tendonitis/synovitis NOS 58 7.0 5.0 
 Fracture* 50 6.0 5.3 
 Subtotal: top five problems 460 55.7  — 
Cardiologist Total 801 100.0 — 
 Ischaemic heart disease* 167 20.8 14.8 
 Atrial fibrillation/flutter 72 9.0 5.7 
 Hypertension* 69 8.6 0.9 
 Heart failure 49 6.1 7.8 
 Chest pain NOS 48 6.0 14.6 
 Subtotal: top five problems 405 50.5  — 
Dermatologist Total 661 100.0 — 
 Malignant neoplasm, skin 83 12.6 6.9 
 Skin disease, other 62 9.4 6.2 
 Skin symptom/complaint, other 58 8.7 8.1 
 Skin check-up* 57 8.7 9.5 
 Solar keratosis/sunburn 57 8.7 4.7 
 Subtotal: top five problems 318 48.1  — 
Gastroenterologist Total 672 100.0 — 
 Gastro-oesophageal reflux disease* 76 11.4 2.8 
 Benign/uncertain neoplasm digestive 53 7.9 26.3 
 Abdominal pain* 50 7.5 6.6 
 Rectal bleeding 39 5.9 26.1 
 Disease digestive system, other 29 4.3 9.3 
 Subtotal: top five problems 248 36.9  — 
(continued) 
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Table 11.4 (continued): The top problems most frequently referred, by type of medical specialist 
Specialist Problem managed Number 
Per cent of 
problems referred 
to each specialist 
Per cent of 
contacts with this 
problem(a) 
Ophthalmologist  Total 653 100.0 — 
 Cataract 84 12.8 59.7 
 Diabetes – all* 69 10.5 1.7 
 Glaucoma 67 10.2 32.1 
 Eye/adnexa disease, other 60 9.1 28.7 
 Visual disturbance, other 34 5.2 60.2 
 Subtotal: top five problems 312 47.9  — 
Gynaecologist  Total 558 100.0 — 
 Menstrual problems* 78 14.0 11.4 
 Genital disease, other (female) 76 13.7 31.3 
 Abnormal test results* 38 6.8 3.1 
 Uterovaginal prolapse 36 6.4 45.6 
 Contraception, intrauterine 26 4.6 17.6 
 Subtotal: top five problems 254 45.6  — 
Ear, nose and throat Total 494 100.0 — 
 Sinusitis acute/chronic 56 11.4 4.9 
 Tonsillitis* 30 6.1 3.8 
 Acute otitis media/myringitis 22 4.5 2.4 
 Throat symptom/complaint 21 4.3 12.1 
 Respiratory disease, other 20 4.0 9.0 
 Subtotal: top five problems 150 30.4  — 
Urologist  Total 353 100.0 — 
 Benign prostatic hypertrophy 57 16.1 19.9 
 Abnormal test results* 27 7.8 2.2 
 Malignant neoplasm, prostate 27 7.8 8.9 
 Haematuria 20 5.6 12.1 
 Urinary calculus 17 4.9 16.5 
 Subtotal: top five problems 149 42.2  — 
Neurologist Total 305 100.0 — 
 Headache* 35 11.4 3.0 
 Epilepsy 34 11.2 12.2 
 Parkinsonism 24 8.0 12.9 
 Neurological disease, other 16 5.4 3.1 
 Carpal tunnel syndrome 16 5.4 8.6 
 Subtotal: top five problems 126 41.4  — 
(a) The proportion of GP contacts with this problem that was referred to each type of medical specialist. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <hdl.handle.net/2123/13765>). 
Note: NOS – not otherwise specified. 
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11.4 Problems most frequently referred to allied 
 health services and hospitals  
The 5,107 referrals to an allied health service were provided in the management of 5,325 problems. 
The 10 most commonly referred problems accounted for 47.9% of all problem–referral links. 
Depression was the problem accounting for the largest proportion of allied health referrals (12.2%), 
followed by diabetes (7.4%), back complaints (7.2%) and anxiety (6.0%). However, of the 10 most 
commonly referred problems, the most likely to be referred to an allied health service was acute 
stress reaction, referred at 16.7% of all GP contacts with this problem (Table 11.5). 
Table 11.5: The 10 problems most frequently referred to allied health services 
Problem managed 
Problem–referral links Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Per cent of 
contacts with 
this problem(a) Number Per cent 
Depression* 647 12.2 0.7 0.6 0.7 14.7 
Diabetes – all* 394 7.4 0.4 0.3 0.5 10.0 
Back complaint* 386 7.2 0.4 0.3 0.5 11.7 
Anxiety* 317 6.0 0.3 0.3 0.4 14.3 
Osteoarthritis* 189 3.5 0.2 0.2 0.2 6.6 
Sprain/strain* 152 2.9 0.2 0.1 0.2 13.2 
Administrative procedure NOS 143 2.7 0.1 0.1 0.2 11.0 
Bursitis/tendonitis/synovitis NOS 116 2.2 0.1 0.1 0.1 10.0 
Acute stress reaction 116 2.2 0.1 0.1 0.1 16.7 
Obesity (BMI > 30) 93 1.7 0.1 0.1 0.1 14.3 
Subtotal: top 10 problems referred to AHS 2,552 47.9 — — — — 
Total problems referred to AHS 5,325 100.0 5.4 5.1 5.7 — 
(a) The proportion of GP contacts with this problem that was referred to allied health services. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified; BMI – body mass index; AHS – allied health 
service. 
 
The 355 referrals to a hospital were provided in the management of 377 problems. The 10 problems 
most frequently referred to a hospital are shown in Table 11.6. Pregnancy accounted for the highest 
proportion (5.8%) of these referrals, but pneumonia was the problem most likely to be referred 
(4.2% of GP contacts). 
The 305 referrals to an emergency department were associated with the management of 
316 problems. The 10 problems most frequently referred to an emergency department are shown in 
Table 11.7. Appendicitis accounted for the highest proportion (7.0%) of these referrals, and was the 
most likely to be referred (62.3% of GP contacts). 
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Table 11.6: The 10 problems most frequently referred to hospital 
Problem managed 
Problem–referral links Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Per cent of 
contacts with 
this problem(a) Number Per cent 
Pregnancy* 22 5.8 0.02 0.01 0.03 1.8 
Fracture* 20 5.2 0.02 0.01 0.03 2.1 
Pneumonia 13 3.5 0.01 0.01 0.02 4.2 
Anaemia* 10 2.7 0.01 0.00 0.02 1.8 
Heart failure 10 2.6 0.01 0.00 0.02 1.6 
Chest pain NOS 9 2.3 0.01 0.00 0.02 2.6 
Chronic obstructive pulmonary disease 8 2.2 0.01 0.00 0.02 0.9 
Urinary tract infection* 8 2.1 0.01 0.00 0.02 0.5 
Skin infection, other 7 1.9 0.01 0.00 0.01 1.3 
Ischaemic heart disease* 7 1.8 0.01 0.00 0.01 0.6 
Subtotal: top 10 problems referred for 
admission 
113 30.0 — — — — 
Total problems referred to hospital 377 100.0 0.38 0.31 0.45 — 
(a) The proportion of GP contacts with this problem that was referred to hospital. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
 
Table 11.7: The 10 problems most frequently referred to an emergency department 
Problem managed 
Problem–referral links Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Per cent of 
contacts with 
this problem(a) Number Per cent 
Appendicitis 22 7.0 0.02 0.01 0.04 62.3 
Abdominal pain* 16 5.1 0.02 0.00 0.03 2.1 
Chest pain NOS 14 4.4 0.01 0.01 0.02 4.2 
Fracture* 14 4.3 0.01 0.01 0.02 1.4 
Pneumonia 12 3.8 0.01 0.00 0.02 3.9 
Skin infection, other 11 3.4 0.01 0.00 0.02 2.0 
Injury musculoskeletal NOS 6 2.0 0.01 0.00 0.01 0.7 
Ischaemic heart disease* 6 2.0 0.01 0.00 0.01 0.6 
Urinary tract infection* 6 2.0 0.01 0.00 0.01 0.4 
Pleurisy/pleural effusion 6 1.9 0.01 0.00 0.01 10.7 
Subtotal: top 10 problems referred to 
emergency department 
114 36.0 — — — — 
Total problems referred to emergency 
department 316 100.0 0.32 0.27 0.38 — 
(a) The proportion of GP contacts with this problem that was referred to an emergency department. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
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11.5 Changes in referrals over the decade 2005–06 
 to 2014–15 
An overview of changes in referrals over the decade can be found in Chapter 11 of the companion 
report, A decade of Australian general practice activity 2005–06 to 2014–15.1 In that report, changes 
over time are discussed in terms of change in the management of problems (that is, as a rate per 100 
problems managed). This reflects change in how GPs are managing problems, and accounts for the 
significant increase in the number of problems managed per encounter over the decade. 
In summary, over the 10 years there was a significant increase in the proportion of problems that 
were referred: in 2005–06 at least one referral was made in the management of 8.2% of problems 
and this increased to 10.2% of problems managed in 2014–15. 
The overall rate of referral per 100 problems managed increased from 8.2 in 2005–06 to 10.3 in  
2014–15, and per 100 encounters from 12.0 to 15.9. This suggests that there were 9.7 million more 
referrals made by GPs nationally in 2014–15 than a decade earlier. 
Referrals to medical specialists increased from 5.6 per 100 problems managed in 2005–06, to 6.2 in 
2014–15. There were no changes in the rate of referrals to the most frequent medical specialists, 
except for a marginally significant decrease in referrals to ophthalmologists. 
Referrals to allied health services increased from 2.0 per 100 problems managed in 2005–06 to 3.3 in 
2014–15. This was reflected in significant increases in referral rates per 100 problems to 
psychologists and podiatrists/chiropodists. 
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 12 Investigations 
The GP participants were asked to record (in free text) any pathology, imaging or other tests ordered 
or undertaken at the encounter, and to nominate the patient problem(s) associated with each test 
order placed. This allows the linkage of a test order to a single problem or multiple problems. Up to 
five orders for pathology, and two for imaging and other tests could be recorded at each encounter. A 
single test may have been ordered for the management of multiple problems, and multiple tests may 
have been used in the management of a single problem. 
A pathology test order may be for a single test (for example, Pap smear, HbA1c) or for a battery of 
tests (for example, lipids, full blood count). Where a battery of tests was ordered, the battery name 
was recorded rather than each individual test within the battery. GPs also recorded the body site for 
any imaging ordered (for example, x-ray chest, CT head). 
Data on investigations are reported for each year from 2005–06 to 2014–15 in the 10-year report,  
A decade of Australian general practice activity 2005–06 to 2014–15.1 
12.1 Number of investigations 
Table 12.1 shows the number of encounters and problems at which a pathology or imaging test was 
ordered. There were no pathology or imaging tests recorded at three-quarters (74.9%) of encounters. 
At least one pathology test order was recorded at 18.1% of encounters (and for 13.4% of problems 
managed), and at least one imaging test was ordered at 9.8% of encounters (and for 6.6% of 
problems managed). 
Table 12.1: Number of encounters and problems for which pathology or imaging was ordered 
Pathology/imaging test 
ordered 
Number of 
encounters  
Per cent of 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Number of 
problems 
Per cent of 
problems 
(n = 153,133) 
95% 
LCL 
95% 
UCL 
Pathology and imaging ordered 2,730 2.8 2.6 2.9 1,984 1.3 1.2 1.4 
Pathology only ordered 15,146 15.3 14.8 15.8 18,560 12.1 11.7 12.5 
Imaging only ordered 6,911 7.0 6.7 7.3 8,074 5.3 5.1 5.5 
No pathology or imaging tests 
ordered 
73,942 74.9 74.2 75.6 124,515 81.3 80.8 81.8 
At least one pathology ordered 17,875 18.1 17.5 18.7 20,544 13.4 13.0 13.8 
At least one imaging ordered 9,641 9.8 9.4 10.1 10,058 6.6 6.3 6.8 
At least one other investigation 
ordered 
699 0.7 0.6 0.8 713 0.5 0.4 0.5 
At least one other investigation 
performed in the practice 
1,380 1.4 1.3 1.5 1,391 0.9 0.8 1.0 
At least one other investigation 
ordered or performed 
2,019 2.0 1.9 2.2 2,048 1.3 1.2 1.4 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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12.2 Pathology ordering 
A report on changes in pathology ordering by GPs from 1998 to 2001 was produced in 2003.69 A 
review of GP pathology orders in the National Health Priority Areas and other selected problems 
between 2000 and 2008 was reported in General practice in Australia, health priorities and policies 
1998 to 2008.13 A report Evidence-practice gap in pathology test ordering: a comparison of BEACH 
pathology data and recommended testing was produced by the FMRC for the Australian Government 
Quality Use of Pathology Program in June 2009.16 A PhD thesis Evaluation of pathology ordering by 
general practitioners in Australia was completed in 2013.14 Readers may wish to consider those 
publications in conjunction with the information presented below. 
Nature of pathology orders at encounter 
The GPs recorded 46,435 orders for pathology tests (or batteries of tests), at a rate of 47.0 per 
100 encounters or 30.3 per 100 problems managed (Table 12.2). The pathology tests recorded were 
grouped according to the categories set out in Appendix 4, Table A4.8. The main pathology groups 
reflect those used in the Medicare Benefits Schedule (MBS).70 
The distribution of pathology tests by MBS group, and the most common tests within each group are 
presented in Table 12.2. Each group and individual test is expressed as a proportion of all pathology 
tests, as a proportion of the group, as a rate per 100 encounters and as a rate per 100 problems 
managed with 95% confidence limits. 
Tests classed as chemistry accounted for more than half (58.1%) of the pathology test orders, the 
most common being: lipid tests, for which there were 3.8 orders per 100 encounters and 2.4 per 100 
problems; multi-biochemical analysis (3.4; 2.2); thyroid function tests (3.1; 2.0); and electrolytes, urea 
and creatinine (2.8; 1.8). Haematology tests accounted for 17.8% of all pathology including the most 
frequently ordered individual pathology test, full blood count (FBC). FBC tests accounted for 14.3% of 
all pathology, there being 6.7 FBC orders per 100 encounters and 4.3 per 100 problems managed. 
Microbiology accounted for 13.5% of pathology orders, with urine microscopy, culture and sensitivity 
being the most frequent test type in the group at 2.0 orders per 100 encounters and 1.3 per 100 
problems managed. 
Table 12.2: Most frequent pathology tests ordered within each MBS pathology group  
Pathology test ordered Number 
Per cent  
of all 
pathology  
Per cent  
of group 
Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 153,133) 
95% 
LCL 
95% 
UCL 
Chemistry*  26,977 58.1 100.0 27.3 26.1 28.6 17.6 16.9 18.4 
 Lipids* 3,734 8.0 13.8 3.8 3.5 4.0 2.4 2.3 2.6 
 Multi-biochemical analysis* 3,372 7.3 12.5 3.4 3.1 3.7 2.2 2.0 2.4 
 Thyroid function* 3,012 6.5 11.2 3.1 2.9 3.2 2.0 1.8 2.1 
 Electrolytes, urea and creatinine* 2,793 6.0 10.4 2.8 2.6 3.1 1.8 1.7 2.0 
 Glucose/glucose tolerance* 2,294 4.9 8.5 2.3 2.1 2.5 1.5 1.4 1.6 
 Liver function* 2,235 4.8 8.3 2.3 2.1 2.5 1.5 1.3 1.6 
 Ferritin* 1,717 3.7 6.4 1.7 1.6 1.9 1.1 1.0 1.2 
 HbA1c* 1,279 2.8 4.7 1.3 1.2 1.4 0.8 0.8 0.9 
 Chemistry; other*  1,131 2.4 4.2 1.1 1.0 1.3 0.7 0.7 0.8 
 C reactive protein 1,029 2.2 3.8 1.0 0.9 1.2 0.7 0.6 0.7 
 Hormone assay* 815 1.8 3.0 0.8 0.7 0.9 0.5 0.5 0.6 
(continued) 
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Table 12.2 (continued): Most frequent pathology tests ordered within each MBS pathology group  
Pathology test ordered Number 
Per cent  
of all 
pathology  
Per cent  
of group 
Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 153,133) 
95% 
LCL 
95% 
UCL 
 Prostate specific antigen*  779 1.7 2.9 0.8 0.7 0.9 0.5 0.5 0.6 
 Vitamin B12 621 1.3 2.3 0.6 0.5 0.7 0.4 0.4 0.5 
 Vitamin D 559 1.2 2.1 0.6 0.5 0.6 0.4 0.3 0.4 
 Albumin/creatinine, urine* 524 1.1 1.9 0.5 0.4 0.6 0.3 0.3 0.4 
 Calcium/phosphate/magnesium* 323 0.7 1.2 0.3 0.3 0.4 0.2 0.2 0.2 
Haematology*  8,257 17.8 100.0 8.4 7.9 8.8 5.4 5.1 5.6 
 Full blood count 6,653 14.3 80.6 6.7 6.4 7.1 4.3 4.1 4.6 
 ESR 869 1.9 10.5 0.9 0.8 1.0 0.6 0.5 0.6 
 Coagulation*  548 1.2 6.6 0.6 0.5 0.6 0.4 0.3 0.4 
Microbiology*  6,273 13.5 100.0 6.4 6.0 6.7 4.1 3.9 4.3 
 Urine M,C&S* 1,930 4.2 30.8 2.0 1.8 2.1 1.3 1.2 1.3 
 Microbiology; other* 922 2.0 14.7 0.9 0.8 1.0 0.6 0.5 0.7 
 Faeces M,C&S* 517 1.1 8.2 0.5 0.5 0.6 0.3 0.3 0.4 
 Hepatitis serology* 438 0.9 7.0 0.4 0.4 0.5 0.3 0.2 0.3 
 Venereal disease* 380 0.8 6.1 0.4 0.3 0.5 0.2 0.2 0.3 
 Vaginal swab M,C&S* 339 0.7 5.4 0.3 0.3 0.4 0.2 0.2 0.3 
 Chlamydia* 322 0.7 5.1 0.3 0.3 0.4 0.2 0.2 0.2 
 Skin swab M,C&S* 223 0.5 3.6 0.2 0.2 0.3 0.1 0.1 0.2 
Cytopathology*  1,507 3.2 100.0 1.5 1.4 1.7 1.0 0.9 1.1 
 Pap smear*  1,455 3.1 96.5 1.5 1.3 1.6 1.0 0.9 1.0 
Immunology*  1,061 2.3 100.0 1.1 1.0 1.2 0.7 0.6 0.8 
 Immunology, other* 602 1.3 56.7 0.6 0.5 0.7 0.4 0.3 0.4 
Tissue pathology*  951 2.0 100.0 1.0 0.8 1.1 0.6 0.5 0.7 
 Histology; skin 874 1.9 91.9 0.9 0.8 1.0 0.6 0.5 0.7 
Other NEC*  955 2.1 100.0 1.0 0.8 1.1 0.6 0.5 0.7 
 Blood test  515 1.1 53.9 0.5 0.4 0.7 0.3 0.3 0.4 
 Other test NEC* 251 0.5 26.3 0.3 0.2 0.3 0.2 0.1 0.2 
Simple tests*  232 0.5 100.0 0.2 0.2 0.3 0.2 0.1 0.2 
Infertility/pregnancy* 222 0.5 100.0 0.2 0.2 0.3 0.1 0.1 0.2 
Total pathology tests  46,435 100.0 — 47.0 45.2 48.9 30.3 29.3 31.4 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.8, <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; ESR – erythrocyte sedimentation rate; M,C&S – microscopy, culture and 
sensitivity; NEC – not elsewhere classified. 
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Problems for which pathology tests were ordered 
Table 12.3 describes the problems for which pathology was commonly ordered, in decreasing 
frequency order of problem–pathology combinations. Diabetes (accounting for 7.0% of all  
problem–pathology combinations), hypertension, general check-up, and weakness/tiredness were the 
most common problems for which pathology tests were ordered. 
The two columns on the far right show the proportion of each problem that resulted in a pathology 
order, and the rate of pathology tests/batteries of tests per 100 specified problems when at least one 
test was ordered. For example, 68.1% of contacts with weakness/tiredness resulted in pathology 
orders, and when pathology was ordered for weakness/tiredness, the GPs ordered an average of 
394 tests/batteries of tests per 100 ‘tested’ weakness/tiredness contacts. In contrast, only 12.0% of 
contacts with hypertension problems resulted in a pathology test, but the resulting test orders 
accounted for more tests (5.8%) than those ordered for weakness/tiredness (4.4%). This is because 
in general practice, hypertension is managed far more frequently (7.9 per 100 encounters) than 
weakness/tiredness (0.8 per 100 encounters) (see Section 7.3). 
Table 12.3: The 10 problems for which pathology was most frequently ordered 
Problem managed 
Number of 
problems 
Number of 
problem–
pathology 
combinations(a) 
Per cent of 
problem–
pathology 
combinations(a) 
Per cent of 
problems with 
test(b) 
Rate of pathology 
orders per 100 
problems with 
pathology(c) 
Diabetes – all* 3,960 3,376 7.0 30.8 276.8 
Hypertension* 7,778 2,789 5.8 12.0 298.3 
General check-up* 2,987 2,720 5.6 26.6 342.6 
Weakness/tiredness 785 2,105 4.4 68.1 394.1 
Lipid disorder 2,952 1,713 3.5 25.0 232.5 
Female genital check-up/ 
Pap smear*  
1,528 1,400 2.9 75.6 121.1 
Blood test NOS 366 1,188 2.5 88.1 368.6 
Abnormal test results* 1,235 1,107 2.3 50.9 176.2 
Urinary tract infection* 1,688 1,079 2.2 55.1 116.1 
Pregnancy* 1,206 876 1.8 35.6 203.8 
Subtotal 24,485 18,352 38.0 — — 
Total problems 153,133 48,250 100.0 13.4 234.9 
(a) A test was counted more than once if it was ordered for the management of more than one problem at an encounter. There were 46,435 
pathology test orders and 48,250 problem–pathology combinations. 
(b) The percentage of total contacts with the problem that generated at least one order for pathology. 
(c) The rate of pathology orders placed per 100 problem contacts with at least one order for pathology. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <hdl.handle.net/2123/13765>). 
Note: NOS – not otherwise specified. 
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12.3 Imaging ordering 
Readers wanting a more detailed study of imaging orders should consult the comprehensive report on 
imaging orders by GPs in Australia in 1999–00, by the FMRC using BEACH data, and published by 
the Australian Institute of Health and Welfare and the University of Sydney in 2001.71 A 2014 report, 
Evaluation of imaging ordering by general practitioners in Australia 2002–03 to 2011–12, described 
changes in GPs’ imaging ordering over time and evaluated the alignment between guidelines and GP 
test ordering for selected problems.17 This recent report was funded by a grant from the Diagnostic 
Imaging Quality Program, through the Australian Government Department of Health. Readers may 
wish to consider those reports in conjunction with the information presented below. 
Nature of imaging orders at encounter 
There were 11,314 imaging test orders recorded, at a rate of 11.5 per 100 encounters and 7.4 per 
100 problems managed. The distribution of imaging tests by MBS group and the most common tests 
within each group are presented in Table 12.4. Each group and individual test is expressed as a 
percentage of all imaging tests, as a percentage of the group, as a rate per 100 encounters, and as a 
rate per 100 problems with 95% confidence limits. Ultrasound accounted for 42.5% of all imaging test 
orders, and diagnostic radiology accounted for 39.5%. This is the first time that ultrasound orders 
have outnumbered diagnostic radiology orders since BEACH began in April 1998. 
Table 12.4: Most frequent imaging tests ordered within each MBS imaging group 
Imaging test ordered Number 
Per cent of 
all imaging  
 Per cent 
of group 
Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 153,133) 
95% 
LCL 
95% 
UCL 
Ultrasound* 4,811 42.5 100.0 4.9 4.6 5.1 3.1 3.0 3.3 
 Ultrasound; pelvis 701 6.2 14.6 0.7 0.6 0.8 0.5 0.4 0.5 
 Ultrasound; shoulder  562 5.0 11.7 0.6 0.5 0.6 0.4 0.3 0.4 
 Ultrasound; abdomen 476 4.2 9.9 0.5 0.4 0.5 0.3 0.3 0.3 
 Ultrasound; breast; female 348 3.1 7.2 0.4 0.3 0.4 0.2 0.2 0.3 
 Ultrasound; obstetric 319 2.8 6.6 0.3 0.3 0.4 0.2 0.2 0.2 
 Echocardiography 181 1.6 3.8 0.2 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; hip  172 1.5 3.6 0.2 0.1 0.2 0.1 0.1 0.1 
 Test; Doppler 149 1.3 3.1 0.2 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; foot/toe(s)  141 1.2 2.9 0.1 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; kidney 139 1.2 2.9 0.1 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; kidney/ureter/bladder 133 1.2 2.8 0.1 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; thyroid 123 1.1 2.6 0.1 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; leg  114 1.0 2.4 0.1 0.1 0.1 0.1 0.1 0.1 
 Ultrasound; knee 98 0.9 2.0 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; scrotum 94 0.8 2.0 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; groin 89 0.8 1.8 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; wrist 85 0.8 1.8 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; hand/finger(s) 83 0.7 1.7 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; elbow 79 0.7 1.6 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; neck 72 0.6 1.5 0.1 0.1 0.1 0.0 0.0 0.1 
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Table 12.4 (continued): Most frequent imaging tests ordered within each MBS imaging group 
Imaging test ordered Number 
Per cent of 
all imaging  
 Per cent 
of group 
Rate per 100 
encounters 
(n = 98,728) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 153,133) 
95% 
LCL 
95% 
UCL 
 Ultrasound; abdomen upper 63 0.6 1.3 0.1 0.0 0.1 0.0 0.0 0.1 
 Ultrasound; liver 55 0.5 1.1 0.1 0.0 0.1 0.0 0.0 0.0 
 Test; doppler carotid 51 0.5 1.1 0.1 0.0 0.1 0.0 0.0 0.0 
Diagnostic radiology* 4,465 39.5 100.0 4.5 4.3 4.8 2.9 2.8 3.1 
 X-ray; chest 986 8.7 22.1 1.0 0.9 1.1 0.6 0.6 0.7 
 X-ray; knee 485 4.3 10.9 0.5 0.4 0.6 0.3 0.3 0.4 
 Test; densitometry  292 2.6 6.5 0.3 0.2 0.3 0.2 0.2 0.2 
 Mammography; female 287 2.5 6.4 0.3 0.2 0.3 0.2 0.2 0.2 
 X-ray; foot/feet 281 2.5 6.3 0.3 0.2 0.3 0.2 0.2 0.2 
 X-ray; hip  255 2.3 5.7 0.3 0.2 0.3 0.2 0.1 0.2 
 X-ray; shoulder 254 2.2 5.7 0.3 0.2 0.3 0.2 0.1 0.2 
 X-ray; hand 187 1.7 4.2 0.2 0.2 0.2 0.1 0.1 0.1 
 X-ray; ankle 159 1.4 3.6 0.2 0.1 0.2 0.1 0.1 0.1 
 X-ray; wrist  140 1.2 3.1 0.1 0.1 0.2 0.1 0.1 0.1 
 X-ray; spine; lumbar  114 1.0 2.6 0.1 0.1 0.1 0.1 0.1 0.1 
 X-ray; abdomen  109 1.0 2.4 0.1 0.1 0.1 0.1 0.1 0.1 
 X-ray; finger(s)/thumb 95 0.8 2.1 0.1 0.1 0.1 0.1 0.0 0.1 
 X-ray; spine; lumbosacral 78 0.7 1.7 0.1 0.1 0.1 0.1 0.0 0.1 
 X-ray; spine; cervical 71 0.6 1.6 0.1 0.1 0.1 0.0 0.0 0.1 
 X-ray; spine; thoracic 59 0.5 1.3 0.1 0.0 0.1 0.0 0.0 0.1 
 X-ray; ribs  52 0.5 1.2 0.1 0.0 0.1 0.0 0.0 0.0 
Computerised tomography* 1,441 12.7 100.0 1.5 1.3 1.6 0.9 0.9 1.0 
 CT scan; spine; lumbar 215 1.9 14.9 0.2 0.2 0.3 0.1 0.1 0.2 
 CT scan; abdomen  211 1.9 14.6 0.2 0.2 0.2 0.1 0.1 0.2 
 CT scan; brain 162 1.4 11.2 0.2 0.1 0.2 0.1 0.1 0.1 
 CT scan; head  113 1.0 7.8 0.1 0.1 0.1 0.1 0.1 0.1 
 CT scan; chest  103 0.9 7.1 0.1 0.1 0.1 0.1 0.1 0.1 
 CT scan; sinus  85 0.7 5.9 0.1 0.1 0.1 0.1 0.0 0.1 
 CT scan; spine; lumbosacral  83 0.7 5.8 0.1 0.1 0.1 0.1 0.0 0.1 
 CT scan; pelvis 62 0.6 4.3 0.1 0.0 0.1 0.0 0.0 0.1 
 CT scan; neck 59 0.5 4.1 0.1 0.0 0.1 0.0 0.0 0.1 
 CT scan; spine; cervical 55 0.5 3.8 0.1 0.0 0.1 0.0 0.0 0.0 
Magnetic resonance imaging* 503 4.4 100.0 0.5 0.4 0.6 0.3 0.3 0.4 
 MRI; knee 190 1.7 37.8 0.2 0.2 0.2 0.1 0.1 0.1 
 MRI; brain 77 0.7 15.3 0.1 0.1 0.1 0.1 0.0 0.1 
Nuclear medicine* 93 0.8 100.0 0.1 0.1 0.1 0.1 0.0 0.1 
Total imaging tests 11,314 100.0 — 11.5 11.0 11.9 7.4 7.1 7.7 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.9 <hdl.handle.net/2123/13765>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; CT – computerised tomography; MRI – magnetic resonance imaging. 
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Problems for which imaging tests were ordered 
Table 12.5 lists the problems for which imaging was commonly ordered, in decreasing frequency 
order of problem–imaging combinations. Back complaints accounted for 5.1% of all orders, followed 
by osteoarthritis (4.6%), bursitis/tendonitis/synovitis (3.8%) and shoulder syndrome (3.3%). 
The two columns on the far right show the proportion of each problem that resulted in an imaging test, 
and the rate of imaging tests per 100 specified problems when at least one test was ordered. For 
example, 15.7% of contacts with back complaints resulted in an imaging test, and 113.4 tests were 
ordered per 100 ‘tested’ back complaint contacts. Note that shoulder syndrome and knee 
symptom/complaint were the problems most likely to be tested (46.0% and 44.4% respectively). 
Table 12.5: The 10 problems for which an imaging test was most frequently ordered 
Problem managed 
Number of 
problems 
Number of  
problem–imaging 
 combinations(a) 
Per cent of 
problem–imaging 
combinations(a) 
Per cent  
of problems 
with test(b) 
Rate of imaging 
orders per 100 
problems with 
imaging(c) 
Back complaint* 3,297 588 5.1 15.7 113.4 
Osteoarthritis* 2,855 521 4.6 15.6 117.2 
Bursitis/tendonitis/synovitis NOS 1,159 438 3.8 31.5 119.7 
Shoulder syndrome 658 378 3.3 46.0 124.8 
Fracture* 942 369 3.2 36.5 107.2 
Injury musculoskeletal NOS  917 366 3.2 33.9 117.8 
Pregnancy* 1,206 354 3.1 29.0 101.3 
Sprain/strain* 1,149 322 2.8 22.9 122.1 
Abdominal pain* 767 316 2.8 36.1 114.0 
Knee symptom/complaint 384 196 1.7 44.4 115.1 
Subtotal 13,334 3,847 33.7 — — 
Total problems 153,133 11,433 100.0 6.6 113.7 
(a) A test was counted more than once if it was ordered for the management of more than one problem at an encounter. There were 11,314 
imaging test orders and 11,433 problem–imaging combinations. 
(b) The percentage of total contacts with the problem that generated at least one order for imaging. 
(c) The rate of imaging orders placed per 100 tested problem contacts with at least one order for imaging. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <hdl.handle.net/2123/13765>). 
Note: NOS – not otherwise specified. 
12.4 Other investigations 
Other investigations include diagnostic procedures ordered by the GP, or undertaken by the GP or 
practice staff at the encounter. GPs ordered 732 other investigations during the study year, and GPs 
or practice staff undertook a further 1,439. There were, in total, 2,171 other investigations either 
ordered or undertaken (Table 12.6). 
The first section of Table 12.6 lists the other investigations ordered by GPs. The second lists the other 
investigations undertaken in the practice by GPs or practice staff. The third section lists the total other 
investigations (either ordered or undertaken in the practice). Each investigation is expressed as a 
percentage of total other investigations ordered or undertaken, as a rate per 100 encounters, and as a 
rate per 100 problems, each with 95% confidence limits. Electrical tracings were the most common 
group of other investigations ordered or undertaken, making up 48.4% of other investigations, 
followed by physical function test (29.0%). 
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The results also demonstrate the majority of electrical tracings were undertaken in the practice 
(62.0%). In contrast, the majority (92.7%) of diagnostic endoscopies were ordered to be done by 
external providers (Table 12.6). 
Table 12.6: Other investigations ordered by GPs or performed in the practice 
 Investigations ordered by the GP 
Investigation  Number Per cent 
Rate per 100 
encounters (95% CI) 
(n = 98,728) 
Rate per 100 
problems (95% CI) 
(n = 153,133) 
Investigations ordered by the GP 732 100.0 0.7 (0.7–0.8) 0.5 (0.4–0.5) 
 Electrical tracings* 399 54.5 0.4 (0.4–0.5) 0.3 (0.2–0.3) 
 Diagnostic endoscopy* 179 24.5 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
 Physical function test*  150 20.5 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
 Other diagnostic procedures* 4 0.5 0.0 (0.0–0.0) 0.0 (0.0–0.0) 
Investigations undertaken in the practice 1,439 100.0 1.5 (1.3–1.6) 0.9 (0.8–1.0) 
 Electrical tracings* 651 45.3 0.7 (0.6–0.7) 0.4 (0.4–0.5) 
 Diagnostic endoscopy* 13 0.9 0.0 (0.0–0.0) 0.0 (0.0–0.0) 
 Physical function test* 479 33.3 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
 Other diagnostic procedures* 295 20.5 0.3 (0.2–0.4) 0.2 (0.1–0.2) 
All investigations (ordered or undertaken) 2,171 100.0 2.2 (2.0–2.4) 1.4 (1.3–1.5) 
 Electrical tracings* 1,050 48.4 1.1 (1.0–1.2) 0.7 (0.6–0.8) 
 Diagnostic endoscopy* 193 8.9 0.2 (0.2–0.2) 0.1 (0.1–0.2) 
 Physical function test* 630 29.0 0.6 (0.6–0.7) 0.4 (0.4–0.5) 
 Other diagnostic procedures* 298 13.7 0.3 (0.2–0.4) 0.2 (0.2–0.2) 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.6 <hdl.handle.net/2123/13765>). 
Note: CI – confidence interval. 
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12.5 Changes in investigations over the decade 
 2005–06 to 2014–15 
Data on investigations are reported for each year from 2005–06 to 2014–15 in Chapter 12 of the 
companion report, A decade of Australian general practice activity 2005–06 to 2014–15.1 In that 
report, changes over time are measured as change in the management of problems (that is, as a rate 
per 100 problems). This reflects change in how GPs are managing problems, and adjusts for the 
significant increase in the number of problems managed per encounter over the decade. The major 
changes are highlighted below. 
• There was no change in the proportion of problems where at least one pathology test was 
ordered (12.7% of problems managed in 2005–06 and 13.4% in 2014–15). However, the number 
of pathology tests ordered increased over the decade from 26.4 tests (or batteries of tests) per 
100 problems managed in 2005–06 to 30.3 in 2014–15. This increased rate of ordering (per 100 
problems) was due to GPs ordering more tests per problem once the decision to order pathology 
had been made, not to any change in the likelihood of pathology being ordered in the 
management of problems. The largest increase was in orders for chemical pathology, which 
increased from 14.8 per 100 problems managed in 2005–06 to 17.6 per 100 in 2014–15. 
• There was an increase in the proportion of encounters involving at least one pathology test from 
16.4% of encounters in 2005–06 to 18.1% in 2014–15, equating to approximately 8.3 million 
more encounters at which pathology was ordered nationally in 2014–15 than 10 years earlier. 
This national increase was driven by a rise in the number of problems managed at encounter 
(increasing from 146.2 to 155.1 per 100 encounters over the decade, see Chapter 5) and the 
increased GP attendance rate in Australia.2 
• The rate of pathology tests ordered per 100 encounters increased from 38.6 per 100 encounters 
in 2005–06 to 47.0 in 2014–15, which extrapolates to approximately 25.5 million more tests (or 
batteries of tests) ordered nationally in 2014–15 than a decade earlier. The largest increase was 
in the order rate of ultrasound imaging, which increased by 55.0% over the decade, from 2.0 tests 
per 100 problems in 2005–06 to 3.1 per 100 in 2014–15. 
• At least one imaging test was ordered for 5.5% of all problems managed in 2005–06, rising to 
6.6% of all problems in 2014–15. The proportion of encounters generating imaging orders 
increased from 7.8% in 2005–06 to 9.8% in 2014–15. This resulted in an estimated 5.6 million 
more encounters nationally at which imaging was ordered by GPs in 2014–15 than in 2005–06. 
• The number of imaging tests ordered increased from 6.0 tests per 100 problems managed in 
2005–06 to 7.4 per 100 problems in 2014–15. Total imaging orders per 100 encounters increased 
significantly from 8.8 per 100 encounters in 2005–06 to 11.5 in 2014–15, suggesting that 
nationally there were 6.9 million more imaging tests ordered by GPs in 2014–15 than in 2005–06. 
• There were changes in the types of imaging tests ordered, with a move away from diagnostic 
radiology toward ultrasound imaging. Ultrasounds were the most commonly ordered imaging test, 
and GPs’ ordering increased from 2.9 to 4.9 per 100 encounters, a national increase of about 
3.8 million ultrasound orders over the decade period. The rates of computerised tomography and 
magnetic resonance imaging, while accounting for a smaller proportion of orders, also increased 
over the decade. 
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 13 Patient risk factors 
General practice is a useful intervention point for health promotion because the majority of the 
population visit a GP at least once per year. In 2014–15, 85.8% of Australians visited a GP at least 
once (personal communication, DoH, June 2015). GPs have substantial knowledge of population 
health, screening programs and other interventions. They are therefore in an ideal position to advise 
patients about the benefits of health screening, and to counsel individuals about their lifestyle choices. 
Since the beginning of the BEACH program (1998), a section at the bottom of each encounter form 
has been used to investigate aspects of patient health or healthcare delivery not covered by general 
practice consultation-based information. These additional substudies are referred to as SAND 
(Supplementary Analysis of Nominated Data). The SAND methods are described in Section 2.6. 
The patient risk factors collected in BEACH include body mass index (BMI) (calculated using 
self-reported height and weight), self-reported alcohol consumption and self-reported smoking status. 
These patient risk factors are recorded for a subsample of 40 of the 100 patient encounters recorded 
by each GP. An example of the encounter form with the patient risk factor SAND questions is included 
as Appendix 1. The methods used in the risk factor substudies reported in this chapter are described 
in each section below. 
Unweighted (sample) data on patient risk factors measured in SAND are reported for each of the 
10 most recent years, and risk factor prevalence after adjustment for general practice attendance 
patterns by age–sex for each of the eight most recent years are reported in the companion report,  
A decade of Australian general practice activity 2005–06 to 2014–15.1 
Abstracts of results and the research tools used in other SAND substudies from April 1998 to March 
2014 have been published. Those conducted: 
• from April 1998 to March 1999 were published in Measures of health and health care delivery in 
general practice in Australia24 
• from April 1999 to July 2006 were published in Patient-based substudies from BEACH: abstracts 
and research tools 1999–200625 
• since August 2006 have been published in each of the general practice annual reports26-33 
• in the 2014–15 BEACH year are provided in Chapter 14 of this publication. 
13.1 Body mass index 
From the most recent publicly available Australian data, high body mass (BMI) was the third highest 
contributor to the total burden of disease in Australia in 2003, accounting for 7.5% of the total 
burden,72 an increase from 4.3% of the total burden and sixth rank in 1996.73 The Global Burden of 
Disease 2010 study compared burden of disease and injury attributable to 67 risk factors in 21 
regions. In Australasia (which includes Australia) ‘high body mass index’ was the leading risk factor 
for disease burden. This Australasian ranking compares unfavourably with the global risk factor 
ranking, in which ‘high body mass index’ ranks sixth.74 
In 2015, the Organisation for Economic Co-operation and Development (OECD) reported that 
Australia’s adult obesity rates (based on measured data) in 1989, 1995, 2007 and 2011 were among 
the highest in the world (10.8%, 19.8%, 24.6% and 28.3% of adults respectively), with Australia’s 
adult obesity rate fifth globally, behind the United States, Mexico and New Zealand and on par with 
Hungary (28.5%).75  
In 2007 (or nearest year), Australia was fourth, with obesity rates two percentage points below that of 
New Zealand, and in 2013 (or nearest year), Australia was fifth with obesity rates still around two 
percentage points below New Zealand. The obesity rates of both nations increased by about four 
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percentage points (from 24.6% to 28.3% and 26.5% to 30.6% respectively). In a similar 6-year period, 
obesity rates in the United States increased by about one percentage point to 35.3%, and those in 
Mexico increased by two percentage points to 32.4%.75 
Australia’s obesity rate of 28.3% in 2011 is much higher than the average for the 16 OECD countries 
with recent measured data (22.9%). It has been suggested that the growing prevalence of obesity in 
Australia foreshadows increases in related health problems (such as diabetes and cardiovascular 
diseases) and escalating health care costs in future.76 
The Australian Health Survey (2011–12), using trained interviewer measured data, estimated that 
35% of Australians aged 18 years and over were overweight (BMI 25–<30) and 28% were obese (BMI 
30 or more). Men were more likely to be overweight (42%) than women (28%), but obesity rates did 
not differ between the sexes (28% among both men and women).77  
The Australian Health Survey also reported that 25% of children aged 2–17 years were classified as 
overweight or obese (18% overweight, 7% obese).77  
The Australian government has recognised the epidemic of overweight and obesity, and the likely 
impact on future health costs and negative health outcomes. New guidelines about the clinical 
management of overweight and obesity were released by the National Health and Medical Research 
Council (NHMRC) in May 2013.78 
Method 
Patient BMI was investigated for a subsample of 40 of each GP’s 100 patient encounters. Each GP 
was instructed to ask the patient (or their carer in the case of children): 
• What is your height in centimetres (without shoes)? 
• What is your weight in kilograms (unclothed)? 
Metric conversion tables (from feet and inches; from stones and pounds) were provided to the GP. 
The BMI for an individual was calculated by dividing weight (kilograms) by height (metres) squared. 
The WHO recommendations79 for BMI groups were used. They specify that an adult (18 years and 
over) with a BMI: 
• less than 18.5 is underweight 
• greater than or equal to 18.5 and less than 25 is normal weight 
• greater than or equal to 25 and less than 30 is overweight 
• of 30 or more is obese. 
The reported height for adult patients was checked against sex-appropriate upper and lower height 
limits from the ABS.80 Adults whose self-reported height was outside the sex-appropriate limits were 
excluded from the analysis. 
The standard BMI cut-offs described above are not appropriate in the case of children. Cole et al. 
(2000 & 2007) developed a method to calculate the age–sex-specific BMI cut-off levels for 
underweight, overweight and obesity specific to children aged 2–17 years.81,82 There are four 
categories defined for childhood BMI: underweight, normal weight, overweight and obese. This 
method, based on international data from developed Western cultures, is applicable in the Australian 
setting. 
The reported height of children was checked against age–sex-appropriate upper and lower height 
limits from the ABS and Centres for Disease Control.80,83 Children whose self-reported height was 
outside the age–sex-appropriate limits were excluded from the analysis. 
The BEACH data on BMI are presented separately for adults (aged 18 years and over) and children 
(aged 2–17 years). 
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Results 
Body mass index of adults 
The sample size was 32,956 patients aged 18 years and over at encounters with 992 GPs. 
• Over half (62.1%) of these adults were overweight (34.1%) or obese (28.0%) (Table 13.1). 
• Just over one-third (35.5%) of adult patients had a BMI in the normal range, and 2.4% of were 
underweight. Underweight was more prevalent among females than males. 
• Males were more likely to be overweight or obese (69.5%, 95% CI: 68.5–70.5) than females 
(57.3%, 95% CI: 56.2–58.3) (results not tabled). 
• Overweight/obesity was most prevalent among male patients aged 45–64 years (77.0%) and  
65–74 years (76.0%) (Figure 13.1). 
• In female patients overweight/obesity was most prevalent in those aged 65–74 years (69.5%) and 
45–64 years (63.8%) (Figure 13.1). 
• Underweight was most prevalent among patients aged 18–24 years (6.9%, 95% CI: 5.8–8.0) 
(results not tabled). 
• Of young adults (aged 18–24 years), 8.6% of females and 3.3% of males were underweight, and 
among those aged 75 years and over, 4.2% of females and 1.5% of males were underweight 
(Figure 13.2). 
Our overall and sex-specific prevalence estimates of overweight/obesity among patients at general 
practice encounters (62% of adults, 70% of males and 57% of females are remarkably consistent with 
the ABS 2011–12 figures from the Australian Health Survey (based on measured BMI data), which 
reported that 63% of adults aged 18 years and over (70% of males and 56% of females) were 
overweight or obese.18  
Readers interested in the prevalence of the three WHO-defined levels of obesity will find more 
information and discussion in Chapter 7 of General practice in Australia, health priorities and policies 
1998 to 2008.84  
Estimation of body mass index for the adult general practice patient 
population 
The BEACH study provides data about patient BMI from a sample of the patients attending general 
practice. As older people attend a GP more often than young adults, and females attend more often 
than males, they have a greater chance of being selected in the subsample. This leads to a greater 
proportion of older and female patients in the BEACH sample than in the total population who attend a 
GP at least once in a year. The 2014–15 BEACH sample was weighted to estimate the BMI of the 
GP–patient attending population (that is, the 15.8 million adult patients who attended a GP at least 
once in 2014–15 (personal communication, DoH, June 2015), using the method described by Knox 
et al. (2008).20 This statistical adjustment had little effect on the resulting proportions. 
The estimates for the adult population who attended general practice at least once (after adjusting for 
age–sex general practice attendance patterns) suggest that 27.2% of the adult patient population 
were obese, 33.9% were overweight, 36.6% were normal weight and 2.3% were underweight 
(Table 13.1). 
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Table 13.1: Patient body mass index (aged 18 years and over) 
 Male(a)  Female(a)  Total respondents 
BMI class 
Per cent in 
BEACH sample 
(95% CI) 
(n = 12,947) 
Per cent  
in patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 19,765) 
Per cent  
in patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 32,956) 
Per cent  
in patient 
population 
(95% CI)(b) 
Obese 28.1 
(27.1–29.0) 
27.1 
(26.0–28.1)  
27.9 
(27.0–28.8) 
27.4 
(26.4–28.3)  
28.0 
(27.3–28.8) 
27.2 
(26.4–28.0) 
Overweight 41.4 
(40.5–42.4) 
40.2 
(39.2–41.3)  
29.3 
(28.6–30.1) 
28.5 
(27.7–29.2)  
34.1 
(33.5–34.7) 
33.9 
(33.3–34.6) 
Normal 29.6 
(28.5–30.6) 
31.7 
(30.5–32.9)  
39.5 
(38.4–40.5) 
40.8 
(39.7–41.9)  
35.5 
(34.7–36.3) 
36.6 
(35.7–37.5) 
Underweight 0.9 
(0.8–1.1) 
1.0 
(0.8–1.2)  
3.3 
(3.0–3.6) 
3.4 
(3.1–3.6)  
2.4 
(2.2–2.6) 
2.3 
(2.1–2.5) 
(a) Patient sex was not recorded for 244 respondents. 
(b) Estimation of BMI among the total adult general practice patient population (that is, patients aged 18 years and over who attended a GP at 
least once in 2014–15). 
Note: BMI – body mass index; CI – confidence interval. 
 
 
 
 Figure 13.1: Age–sex-specific rates of overweight/obesity among sampled adults, 2014–15 (95%  
confidence intervals) 
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 Figure 13.2: Age–sex-specific rates of underweight among sampled adults, 2014–15 (95%  
confidence intervals) 
 
Body mass index of children 
BMI was calculated for 3,112 patients aged 2–17 years at encounters with 901 GPs. 
• Just over one-quarter of children (27.0%, 95% CI: 25.2–28.8) were classed as overweight or 
obese, including 8.6% (95% CI: 7.5–9.7) obese and 18.4% (95% CI: 17.0–19.9) overweight 
(results not tabled). 
• There was no difference in the prevalence of overweight/obesity among male (26.6%, 95% CI: 
24.2–28.9) and female children (27.5%, 95% CI: 25.1–29.8) (results not tabled). 
• The age-specific rates of obesity followed similar patterns for both sexes (Figures 13.3 and 13.4). 
Readers interested in further detail and discussion about overweight and obesity in children attending 
general practice will find more information in Cretikos et al. (2008) General practice management of 
overweight and obesity in children and adolescents in Australia.85 
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Figure 13.3: Age-specific rates of obesity, overweight, normal weight and underweight among  
sampled male children, 2014–15 
 
 
 
 
 Figure 13.4: Age-specific rates of obesity, overweight, normal weight and underweight among  
sampled female children, 2014–15 
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13.2 Smoking (patients aged 18 years and over) 
Tobacco smoking is the leading cause of ill health, drug-related death and hospital separations in 
Australia.86 It is a major risk factor for coronary heart disease, stroke, peripheral vascular disease, 
several cancers, respiratory disorders and other diseases.87 The most recent publicly available 
Australian data identified smoking as the risk factor associated with the greatest disease burden, 
accounting for 7.8% of the total burden of disease in Australia in 2003,72 a decrease from 9.7% of 
total burden in 1996.73  
The Global Burden of Disease 2010 study has compared burden of disease and injury attributable to 
67 risk factors in 21 regions. In Australasia (which includes Australia), ‘tobacco smoking, including 
second-hand smoke’ was ranked as the second most important risk factor for disease burden. These 
Australasian rankings are on par with the global risk factor rankings, with ‘tobacco smoking, including 
second-hand smoke’ also second globally.74  
In 2015, the OECD reported that Australia has been remarkably successful in reducing tobacco 
consumption by more than half, from 30.6% of adults in 1986 to 12.8% in 2013, now one of the lowest 
smoking rates in OECD countries.75 The 2014 summary suggested “much of this decline can be 
attributed to policies aimed at reducing tobacco consumption through public awareness campaigns, 
advertising bans and increased taxation”. In December 2012, Australia became the first (and currently 
only) country to require tobacco products to be sold in plain packaging.76 In March 2015, Britain’s 
parliament approved legislation to ban branding on cigarette packs. The plain packaging legislation is 
expected to come into force in May 2016.88 
According to the 2010 National Drug Strategy Household Survey (NDSHS), 15.1% of Australians 
aged 14 years and over smoked daily: 16.4% of males and 13.9% of females.89 The 2011–12 
Australian Health Survey reported that 16.1% of Australians aged 18 years and over were daily 
smokers: 18.1% of males and 14.1% of females.77 
Method 
GPs were instructed to ask adult patients (18 years and over): 
• What best describes your smoking status?   Smoke daily 
       Smoke occasionally 
       Previous smoker 
       Never smoked 
Results 
The smoking status of 33,685 adult patients was established at encounters with 993 GPs. Table 13.2 
shows that: 
• 14.1% of sampled adult patients were daily smokers 
• significantly more male (17.4%) than female patients (11.9%) were daily smokers (Table 13.2) 
• only 2.2% of sampled adult patients were occasional smokers 
• more than one-quarter of sampled adults (27.8%) were previous smokers. 
Estimation of smoking in the adult general practice patient population 
The BEACH study provides data about patient smoking habits from a sample of the patients attending 
general practice. As older people attend a GP more often than young adults, and females attend more 
often than males, they have a greater chance of being selected in the subsample. This leads to a 
greater proportion of older and female patients in the BEACH sample than in the total population who 
attend a GP at least once in a year. The 2014–15 BEACH sample was weighted to estimate the 
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smoking status of the GP–patient attending population (that is, the 15.8 million adult patients who 
attended a GP at least once in 2014–15 [personal communication, DoH, June 2015]), using the 
method described by Knox et al. (2008).20  
After adjusting for age–sex general practice attendance patterns, we estimated that 16.5% of the 
patient population aged 18 or more were daily smokers, 2.8% were occasional smokers, 25.1% were 
previous smokers and 55.5% had never smoked. Male patients in the total general practice population 
were significantly more likely to be daily (20.5%), occasional (3.5%) and previous smokers (29.5%), 
than female patients (13.1%, 2.3% and 21.3%, respectively) (Table 13.2). 
Table 13.2: Patient smoking status (aged 18 years and over) 
 Male(a)  Female(a)  Total respondents 
Smoking 
status 
Per cent in 
BEACH sample 
(95% CI) 
(n = 13,180) 
Per cent in 
patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 20,252) 
Per cent in 
patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 33,685) 
Per cent in 
patient 
population 
(95% CI)(b) 
Daily 17.4 
(16.5–18.4) 
20.5 
(19.4–21.7)  
11.9 
(11.3–12.6) 
13.1 
(12.4–13.8)  
14.1 
(13.4–14.7) 
16.5 
(15.7–17.3) 
Occasional 2.6 
(2.3–2.9) 
3.5 
(3.1–3.9)  
2.0 
(1.7–2.2) 
2.3 
(2.0–2.6)  
2.2 
(2.0–2.4) 
2.8 
(2.6–3.1) 
Previous 36.0 
(34.8–37.2) 
29.5 
(28.3–30.6)  
22.4 
(21.6–23.3) 
21.3 
(20.5–22.1)  
27.8 
(27.0–28.6) 
25.1 
(24.3–25.9) 
Never 44.0 
(42.8–45.2) 
46.5 
(45.2–47.8)  
63.7 
(62.6–64.8) 
63.3 
(62.2–64.5)  
55.9 
(54.9–56.9) 
55.5 
(54.5–56.6) 
(a) Patient sex was not recorded for 253 respondents. 
(b) Estimation of smoking status among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2014–15). 
Note: CI – confidence interval. 
 
Daily smoking was least prevalent among older adults aged 65–74 and 75 years or more (9.1% and 
4.4% respectively), and most prevalent among adult patients aged 25–44 years (18.8%) (results not 
tabled). Over half (55.1%) of the male and 24.2% of the female patients aged 75 years and over were 
previous smokers, but only 4.7% of males and 4.3% of females in this age group were daily smokers 
(Figures 13.5 and 13.6). 
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 Figure 13.5: Smoking status – male age-specific rates among sampled patients, 2014–15  
 
 
 
 Figure 13.6: Smoking status – female age-specific rates among sampled patients, 2014–15 
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13.3 Alcohol consumption (patients aged 18 years 
 and over) 
Among people aged 65 years and over, low to moderate consumption of alcohol has been found to 
have a preventive effect against selected causes of morbidity.90 Following a review of the evidence, 
the NHMRC stated that at low levels of consumption, alcohol has some cardiovascular health benefits 
in certain age groups (middle-aged and older males, and women after menopause). Low levels of 
alcohol consumption raise high-density lipoprotein cholesterol and reduce plaque accumulations in 
arteries. Alcohol can also have a mild anti-coagulating effect. However, the authors of the review 
noted that the extent of cardiovascular risk reduction is uncertain, and the potential cardiovascular 
benefits can be gained from other means, such as exercise or diet modification.91 From the most 
recent publicly available Australian data, in 2003, alcohol consumption accounted for 3.3% of the total 
burden of disease in Australia; however, after taking into account the benefit derived from low to 
moderate alcohol consumption, this fell to 2.3%.72 
The Global Burden of Disease 2010 study compared burden of disease and injury attributable to 
67 risk factors in 21 regions. In Australasia (which includes Australia) ‘alcohol use’ was ranked as the 
ninth risk factor for disease burden, a lower ranking than in the global risk factor rankings, where 
‘alcohol use’ ranked fifth.74 
The Australian Health Survey classified alcohol use for those aged 18 years or more based on the 
estimated average daily consumption of alcohol during the previous week. The results indicated that 
11.7% drank at levels considered to be risky (13.4% of males and 10.1% of females), based on the 
2001 NHMRC guidelines.18 Based on the NHMRC 2009 guidelines, 19.5% of adults drank at levels 
exceeding the guidelines (29.1% of males and 10.1% of females).18 
The 2010 NDSHS found that 20.1% of people aged 14 years and over (29.0% of males and 11.3% of 
females) drank at levels considered to put them at risk of harm from alcohol-related disease or injury 
over their lifetime. The NDSHS also found that 28.4% of people aged 14 years or more (38.2% of 
males and 18.9% of females) drank (at least once in the previous month) in a pattern that placed 
them at risk of an alcohol-related injury from a single drinking occasion.89 These alcohol consumption 
risk levels were based on the NHMRC 2009 guidelines.91 
For consistency over time, this report uses the definitions of alcohol-related risk developed by WHO 
(see ‘Method’ below).92 This differs from the definition in the NHMRC guidelines. 
Method 
To measure alcohol consumption, BEACH uses AUDIT-C,93 which is the first three items from the 
WHO Alcohol Use Disorders Identification Test (AUDIT),92 with scoring for an Australian setting.94 The 
AUDIT-C tool has demonstrated validity and internal consistency and performs as well as the full 
AUDIT tool.95 The three AUDIT-C questions are practical and valid in a primary care setting to assess 
‘at-risk’ alcohol consumption (heavy drinking and/or active alcohol dependence).93 The scores for 
each question range from zero to four. A total (sum of all three questions) score of five or more for 
males, or four or more for females, suggests that the person’s drinking level is placing him or her at 
risk.94 
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GPs were instructed to ask adult patients (18 years and over): 
• How often do you have a drink containing alcohol?  Never 
        Monthly or less 
        Once a week/fortnight 
        2–3 times a week 
        4 times a week or more 
• How many standard drinks do you have on a typical day when you are drinking?   
 
        _______________ 
• How often do you have six or more standard drinks on one occasion?  
        Never 
        Less than monthly 
        Monthly 
        Weekly 
        Daily or almost daily 
A standard drinks chart was provided to each GP to help the patient identify the number of standard 
drinks consumed. 
Results 
Patient self-reported alcohol consumption was recorded for 32,835 adult patients (18 years and over) 
at encounters with 993 GPs. 
• Just under one-quarter of sampled adults reported drinking alcohol at at-risk levels (23.3%) 
(Table 13.3). 
• At-risk drinking was more prevalent among male (28.2%) than female patients (20.1%) 
(Table 13.3). 
• At-risk drinking was most prevalent in those aged 18–24 years, particularly among males. In this 
age group over a third of males (37.9%) and over a quarter of females (28.8%) reported at-risk 
alcohol consumption (Figure 13.7). 
• The proportion of patients who were at-risk drinkers decreased with age among both males and 
females (Figure 13.7). 
Estimation of alcohol consumption levels in the adult general practice patient 
population 
The BEACH study provides data about patient alcohol consumption from a sample of the patients 
attending general practice. As older people attend a GP more often than young adults, and females 
attend more often than males, they have a greater chance of being selected in the subsample. This 
leads to a greater proportion of older and female patients in the BEACH sample than in the total 
population who attend a GP at least once in a year. The 2014–15 BEACH sample was weighted to 
estimate the prevalence of at-risk alcohol consumption among the GP–patient attending population 
(that is, the 15.8 million adult patients who attended a GP at least once in 2014–15 (personal 
communication, DoH, June 2015), using the method described by Knox et al. (2008).20  
After adjusting for age–sex general practice attendance patterns, we estimated that 26.1% of the 
patient population were at-risk drinkers, 43.0% were responsible drinkers and 30.8% were 
non-drinkers. Males in the general practice attending population were significantly more likely to be 
at-risk drinkers (31.7%) than females (21.3%) (Table 13.3). 
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Table 13.3: Patient alcohol consumption (aged 18 years and over) 
 Male  Female  Total respondents 
Alcohol 
consumption 
Per cent in 
BEACH sample 
(95% CI) 
(n = 12,969) 
Per cent in 
patient 
population 
(95% CI)(a)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 19,866) 
Per cent in 
patient 
population 
(95% CI)(a)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 32,835) 
Per cent in 
patient 
population 
(95% CI)(a) 
At-risk drinker 28.2 
(27.1–29.4) 
31.7 
(30.3–33.0)  
20.1 
(19.2–21.0) 
21.3 
(20.3–22.3)  
23.3 
(22.5–24.2) 
26.1 
(25.2–27.1) 
Responsible 
drinker 
47.0 
(45.9–48.2) 
45.3 
(44.2–46.5)  
40.2 
(39.2–41.3) 
41.0 
(40.0–42.1)  
42.9 
(42.0–43.8) 
43.0 
(42.1–43.9) 
Non-drinker 24.7 
(23.5–25.9) 
23.0 
(21.8–24.2)  
39.7 
(38.3–41.0) 
37.6 
(36.3–39.0)  
33.8 
(32.7–34.9) 
30.8 
(29.7–31.9) 
(a) Estimation of alcohol consumption among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2014–15). 
Note: CI – confidence interval. 
 
These estimates are not directly comparable with the results from the 2011–12 Australian Health 
Survey18 or the 2010 NDSHS.89 They all use different definitions for risky levels of alcohol 
consumption, and different adult populations (patients aged 18 years or more for BEACH, persons 
aged 15 or 18 years or more for the Australian Health Survey, and persons aged 14 years or more for 
the NDSHS). 
Readers interested in the relationship between morbidities managed and alcohol consumption will find 
more information in Proude et al. (2006) The relationship between self-reported alcohol intake and the 
morbidities managed by GPs in Australia.96 
 
 
 
 Figure 13.7: Age–sex-specific rates of at-risk alcohol consumption in sampled patients, 2014–15  
  
18–24 25–44 45–64 65–74 75+
Male at-risk 37.9 35.5 33.9 24.0 11.3
Female at-risk 28.8 21.8 22.2 18.2 11.8
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13.4 Risk factor profile of adult patients 
All patient risk factor questions (BMI, smoking and alcohol consumption) were asked of the same 
subsample of patients. This allows us to build a risk profile of this sample. For the purposes of this 
analysis, being overweight or obese, a daily smoker or an at-risk drinker was considered a risk factor. 
A risk factor profile was prepared for the 31,952 adult patients from 992 GPs, for whom data were 
available in all three elements (Table 13.4). 
• About half (52.2%) the sampled adult respondents had one risk factor. The most common was 
overweight (23.1% of adults) followed by obesity (19.2%). 
• Almost 1 in 5 patients (19.0%) had two risk factors. The most common combinations were: 
– overweight and at-risk alcohol consumption – 6.5% of patients 
– obesity and at-risk alcohol consumption – 4.8% of patients 
– overweight and daily smoking – 2.7% of patients. 
• A small group of patients (3.2%) had all three risk factors. 
Table 13.5 shows the number of risk factors by patient sex. 
• Females were significantly more likely to have no risk factors (29.8%) than males (19.2%). 
• Females were significantly less likely to have two or three risk factors (14.9% and 2.2% 
respectively) than males (25.1% and 4.7%). 
Estimation of the risk profile of the adult general practice patient population 
The 2014–15 BEACH sample was weighted to estimate the risk profile of the GP–patient attending 
population; that is, the 15.8 million adult patients who attended a GP at least once in 2014–15. 
After adjusting for age–sex general practice attendance patterns we estimated that:  
• one-quarter of all attending adult patients had no risk factors (24.9%) 
• half of the adult patients had one risk factor (50.1%), with the most common being overweight 
(21.4% of adults) followed by obesity (17.7%) 
• 1 in 5 patients had two risk factors (21.0%), with the most common combinations being 
overweight and at-risk alcohol consumption (7.1%), followed by obesity and at-risk alcohol 
consumption (5.1%)  
• 3.9% of patients who attend general practice had three risk factors (Table 13.4) 
• significantly more female than male patients had no risk factors (30.1% and 18.8% respectively). 
Male patients were also more likely to have two and three risk factors (27.4% and 5.6%) than 
females (15.5% and 2.5%) (Table 13.5). 
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Table 13.4: Risk factor profile of patients (aged 18 years and over) 
Number of risk factors  Number 
Per cent in 
BEACH sample  
(n = 31,952) 
95% 
LCL 
95% 
UCL 
Per cent in 
patient 
population(a) 
95% 
LCL 
95% 
UCL 
No risk factors 8,180 25.6 24.8 26.4 24.9 24.1 25.8 
One risk factor 16,690 52.2 51.5 53.0 50.1 49.4 50.9 
 Overweight only 7,366 23.1 22.5 23.6 21.4 20.8 22.0 
 Obese only 6,133 19.2 18.6 19.8 17.7 17.0 18.3 
 At-risk alcohol level only 2,134 6.7 6.3 7.1 7.3 6.8 7.8 
 Current daily smoker only 1,057 3.3 3.1 3.6 3.7 3.4 4.0 
Two risk factors 6,059 19.0 18.3 19.6 21.0 20.3 21.7 
 Overweight and at-risk alcohol level 2,089 6.5 6.2 6.9 7.1 6.7 7.5 
 Obese and at-risk alcohol level 1,544 4.8 4.5 5.1 5.1 4.8 5.4 
 Overweight and current daily smoker 876 2.7 2.5 3.0 3.1 2.9 3.4 
 Obese and current daily smoker 833 2.6 2.4 2.8 2.8 2.6 3.1 
 Daily smoker and at-risk alcohol level 717 2.2 2.0 2.5 2.9 2.6 3.2 
Three risk factors 1,023 3.2 3.0 3.4 3.9 3.6 4.2 
Overweight and current daily smoker 
and at-risk alcohol level 
588 
1.8 1.7 2.0 2.3 2.1 2.5 
Obese and current daily smoker and 
at-risk alcohol level 
435 
1.4 1.2 1.5 1.6 1.5 1.8 
(a) Estimation of risk factor profile among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2014–15). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
 
Table 13.5: Number of risk factors by patient sex 
 Male  Female 
Number of risk factors 
Per cent in BEACH 
sample (95% CI) 
(n = 12,665) 
Per cent in patient 
population 
(95% CI)(a)  
Per cent in BEACH 
sample (95% CI) 
(n = 19,287) 
Per cent in patient 
population 
(95% CI)(a) 
No risk factors 19.2 
(18.3–20.1) 
18.8 
(17.8–19.8)  
29.8 
(28.8–30.8) 
30.1 
(29.1–31.2) 
One risk factor 51.0 
(49.9–52.0) 
48.1 
(47.0–49.3)  
53.1 
(52.2–53.9) 
51.8 
(50.9–52.7) 
Two risk factors 25.1 
(24.2–26.1) 
27.4 
(26.4–28.5)  
14.9 
(14.3–15.6) 
15.5 
(14.9–16.2) 
Three risk factors 4.7 
(4.3–5.1) 
5.6 
(5.1–6.1)  
2.2 
(2.0–2.4) 
2.5 
(2.2–2.8) 
(a) Estimation of risk factor profile among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2014–15).  
Note: CI – confidence interval. 
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13.5 Changes in patient risk factors over the 
 decade 2005–06 to 2014–15 
To investigate changes over time in prevalence of these patient risk factors (overweight and obesity, 
smoking, at-risk alcohol consumption), results are reported from the BEACH sample data for 
each year from 2005–06 to 2014–15 in Chapter 13 of the companion report, A decade of Australian 
general practice activity 2005–06 to 2014–15.1 
The major changes between 2005–06 and 2014–15 are summarised below. 
• The prevalence of obesity in adults attending general practice increased significantly, from 22.2% 
to 28.0%, an increase apparent in both male and female patients. In parallel, the prevalence of 
normal weight in adults attending general practice decreased significantly, from 40.5% to 35.5%. 
• The prevalence of overweight and obesity among sampled children aged 2–17 years remained 
static for 7 years from 2005–06 to 2011–12 (around 18% and 10% respectively), but then obesity 
dropped to around 9% in 2012–13 to 2014–15, however the drop in obesity was only marginally 
significant compared with 2005–06. Similar patterns were noted for both male and female 
children, however there were no significant differences over the decade. 
• There was a significant decrease in the prevalence of current daily smoking and occasional 
smoking among sampled adults aged 18 years and over, from 17.1% and 3.6% respectively in 
2005–06, to 14.1% and 2.2% in 2014–15. These decreases were apparent among both male and 
female patients. 
• Prevalence of at-risk levels of alcohol consumption among sampled adults declined from about 
26% in 2005–06 to 23% in 2014–15. A corresponding increase in non-drinkers from about 29% in 
2005–06 to 34% in 2014–15 was apparent. The significant decrease in at-risk levels of alcohol 
consumption and increase in non-drinkers was apparent among both male and female patients. 
• There was a significant increase in the proportion of sampled adults with one risk factor from 
49.2% in 2005–06, to 52.2% in 2014–15, and the increase applied to both male and female 
patients. About 1 in 5 adults had two risk factors in all reported years. There was a significant 
decrease in the proportion of patients with three risk factors, from 3.9% to 3.2%. 
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 14 Care of older people in general 
practice 
14.1 Background 
Like other OECD countries, Australia’s population is ageing. The proportion aged 65 years or older 
(65+) increased from 12.4% in June 2000 to 14.7% in June 2014,60 and the Australian Bureau of 
Statistics (ABS) expects the proportion to reach 18.6% by 2030.97 
The two main drivers for this increase are lower fertility rates and increased life expectancy. 
Lower fertility rates 
Since the mid 1970s, Australia’s fertility rate has been lower than that required to replace both the 
mother and her partner in the population (2.1 children per woman is considered to be the replacement 
rate).98 In 2013, the total fertility rate was approximately 1.88 children per woman,98 so the proportion 
of the population who are children is decreasing, and the proportion who are older is increasing. 
Increasing life expectancy 
People are living longer than they did in previous generations. Since 1947, life expectancy in Australia 
has increased by approximately 12 years and is currently one of the highest in the world.99 
Importantly, it is not only the total number of years that has increased, but also the years without 
disability from illness.100 The increase in life expectancy has increased the number of older 
Australians, which in turn increases the average age of the population.  
While Australians enjoy one of the longest life expectancies in the world, what we pay for health care 
is comparable to countries with lower life expectancies. Box 14.1 shows World Health Organization 
(WHO) data from 2013 for five selected developed countries. Of the group, Australia had the highest 
life expectancy (4 years more than the average American). In terms of total (public and private) health 
expenditure as a proportion of gross domestic product, Australia and the United Kingdom spent the 
least at 9%, while the United States spent 17%. In terms of total health expenditure per person in US 
dollars, the UK spent the least at $3,311 per person, the United States spent the most at $9,146 per 
person, and Australia was mid-range at $4,191 per person. 
 
Box 14.1: Life expectancy at birth and total health expenditure for selected countries (2013) 
 
 Australia New Zealand United Kingdom Canada United States of America 
Life expectancy 83 years 82 years 81 years 82 years 79 years 
Total health expenditure 
(GDP) 9% 10% 9% 11% 17% 
Total health expenditure 
(PPP USD$ per capita) $4,191 $3,405 $3,311 $4,759 $9,146 
 
Note: PPP – Purchasing Power Parity; GDP – Gross Domestic Product; USD – United States Dollars. 
Sources: WHO Global Health Expenditure Database101; WHO Global Health Observatory Data Repository, Life expectancy data by 
country.102 
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However Indigenous Australians do not enjoy the same level of life expectancy. It is estimated male 
Indigenous Australians born in 2010–12 will live 10.6 fewer years on average, and Indigenous 
females 9.5 fewer years than the average for the non-Indigenous Australian population.103 
The ageing of the population places additional demands on health and other resources because 
increased age is associated with increased prevalence of diagnosed chronic conditions. While the 
proportion of the population made up by people aged 65+ increased by 18% from June 2000 to June 
2014,60 Medicare data show that the proportion of GP encounters that were with patients aged 65+ 
increased by 22% over the same period. Nearly all people aged 65+ (98.5%) had at least one 
Medicare-claimed GP visit in 2014–15, and some of the remaining 1.5% may have also visited, with 
the visits being covered by the Department of Veterans’ Affairs. The average number of GP visits per 
person aged 65+ in a given year increased from 9.6 in 2000–01 to 10.4 in 2014–15. 
This chapter explores the care of people aged 65+ in general practice over the 15 years, from April 
2000 to March 2015, using data from the BEACH study and several of its substudies. We examine 
GP services provided, the content of the encounters, continuity of care, and the prevalence of chronic 
problems and multimorbidity. Finally, we look at risk factors which affect the health of patients in older 
age groups.  
We investigated: 
• chronic pain, which is associated with many chronic problems, as pain management adds to the 
increasing number of medications being taken by older patients 
• adverse drug events, a growing risk because of the increasing number of medications required to 
manage the multiple chronic conditions often prevalent in older patients 
• smoking, alcohol consumption and overweight in patients aged 65+, as these are modifiable risk 
factors that exacerbate many chronic respiratory, circulatory, metabolic and musculoskeletal 
conditions experienced by older patients. 
These results will provide valuable information for health policy makers and service providers, to help 
structure a response to the challenges of caring for an ageing population. 
14.2 Results 
The increase in people aged 65+ and the flow on increases in 
general practice use 
Over the period 2000–01 to 2014–15, the proportion of: 
• GP–patient encounters accounted for by people aged 65+ increased from 22.8% to 27.8%, a 
22% relative increase 
• GP face-to-face clinical consulting time that was spent managing patients aged 65+ increased 
from 23.9% to 28.7%, a 20% relative increase 
• problems managed in general practice that were with patients aged 65+ increased from 26.9% to 
35.0%, a 30% relative increase 
• all medications prescribed, supplied or advised for over-the-counter purchase in general practice 
that were for patients aged 65+ increased from 28.2% to 35.8%, a 27% relative increase 
• all pathology and imaging tests ordered that were for patients aged 65+ increased from 24.9% to 
30.8%, a 24% relative increase 
• referrals made in general practice that were for patients aged 65+ increased from 24.2% to 
32.2%, a 33% relative increase. 
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All the relative increases were far larger than the 18% relative increase in the proportion of the 
population aged 65+. This is because patients aged 65+ attended more often than average, and more 
problems were managed at these encounters. This results in more clinical actions per encounter with 
people in this age group than at encounters with younger people.  
Figure 14.1 facilitates relative comparisons between the proportion of management actions accounted 
for by patients aged 65+ and the proportion they account for in the population. For example, in  
2014–15, patients aged 65+ accounted for 35.8% of all medication emanating from general practice 
while they only accounted for 14.7% of the population. By dividing the 35.8% by 14.7%, we find that 
people aged 65+ on average use 2.4 times as many medications as the average Australian. Applying 
the same approach, in 2014–15, compared with the average Australian, people aged 65+ had: 
• 1.9 times more GP encounters 
• 2.0 times more clinical face-to-face time with GPs 
• 2.4 times more problems managed 
• 2.1 times more tests ordered 
• 2.2 times more referrals made. 
There was no significant change in the average length of consultations with this age group, ranging 
from 14.1 to 15.1 minutes across the study (results not tabled). 
Figure 14.2 gives an idea of the content of GP encounters with patients aged 65+ from 2000–01 to 
2014–15. Over this period, on average for every 100 encounters with patients aged 65+: 
• the number of problems managed increased by 5% (from 169.2 per 100 encounters to 176.9) 
• the number of tests ordered increased from 40.5 to 58.7, a 45% increase 
• the number of referrals to specialists or allied health professionals, emergency departments or 
hospitals rose from 11.0 to 16.7, a 52% increase 
• the number of medications prescribed, supplied to the patient or advised for over-the counter 
purchase decreased from 132.6 to 120.3, a decrease of 9%. This decrease may be due to the 
increasing number of combination medication products available (which now require a single 
prescription, when previously GPs had to prescribe the two products separately) and due to the 
increasing numbers of medications that used to be prescription-only, but are now available for 
over-the-counter purchase (so that patients can now acquire them without seeing a GP). 
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Age distribution of patients aged 65+ at encounters 
Over the study period, the average age of patients aged 65+ increased from 75.7 (95% CI: 75.5–75.9) 
in 2000–01 to 76.7 (95% CI: 76.4–76.9) in 2014–15. Figure 14.3 shows the age distribution of patients 
aged 65+ at BEACH encounters in 2000–01 and 2014–15. It is apparent that in 2014–15, older 
patients at GP encounters were less likely to be aged 65–84 years and more likely to be aged 
85 years or more than in 2000–01. This means that proportionally, GP encounters with patients of 
85 years or more have increased. This may explain some of the increase in use of services by 
patients aged 65+ years (reported earlier), above and beyond their increase as a proportion of the 
population. 
 
  
 
Figure 14.3: Age distribution of patients aged 65+ at BEACH encounters, 2000–01 and 2014–15  
Number of chronic conditions in people aged 65+ 
Between December 2012 and February 2015, we conducted a series of SAND substudies (see 
Section 2.6 for SAND methods) that examined the prevalence of diagnosed chronic conditions and 
multimorbidity among patients at general practice encounters. In total, information was collected from 
35,162 patients, making it one of the largest, nationally representative, multimorbidity studies in the 
world. There were 11,181 patients in the sample aged 65+. The tools used in this study are described 
in more detail in SAND abstract 231 (Chapter 15). 
Figure 14.4 shows that among those aged 65+: 
• nearly all had one or more chronic conditions (96.0% of patients at encounters and 89.7% of 
people in the population). This means that only 4.0% of patients at encounters and 10.3% of 
people in the population aged 65+ had no diagnosed chronic conditions  
• the majority had three or more diagnosed chronic conditions (72.0% of patients at encounters 
and 57.2% of people in the population) 
• about a quarter of patients at encounters and 16.2% of people in the population had six or more 
diagnosed chronic conditions 
65–74 75–84 85–94 95+
2000–01 50.8 38.2 10.3 0.8
2014–15 46.3 36.1 16.4 1.2
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10
20
30
40
50
60
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• 4.2 % of patients at encounters and 2.0% of older people in the population had 10 or more 
diagnosed chronic conditions. Although this appears to be a small proportion it does suggest 
about 70,000 older people have 10 or more diagnosed chronic conditions.  
Three or more diagnosed chronic conditions is often used as the definition of multimorbidity.23 
Multimorbidity is an important health indicator as it is associated with increased health care resource 
use,104 complexity of care,105 severity of illness,105 polypharmacy106 and adverse events.106 Of the 
11,181 patients aged 65+ in our sample, the average number of diagnosed chronic conditions among 
them was 4.2 (median = 4) and ranged from 0 to 21. 
 
  
 
Figure 14.4 Proportion of people aged 65+ with a minimum number of chronic conditions, 2000–01 
and 2014–15 
Prevalence and management of chronic conditions 
Table 14.1 shows the prevalence and management rates of common chronic conditions among 
patients aged 65+. The pattern differs markedly for individual chronic conditions. 
Example 1: diagnosed hypertension 
• was present in 55.8% of patients aged 65+ at GP–patient encounters 
• was managed at 15.5% of encounters with patients aged 65+, therefore was managed at 27.8% 
of encounters with patients with diagnosed hypertension. 
Patients aged 65+ with diagnosed hypertension visited an average 8.7 times a year. Therefore we 
can conclude that among patients with diagnosed hypertension, this condition was managed at 2.4 of 
their 8.7 visits a year on average. 
The prevalence of diagnosed hypertension among people aged 65+ in the population was 48.3%. Of 
those people with hypertension, 78.5% had two or more other chronic conditions (that is, they had 
three or more diagnosed chronic conditions in total). 
Example 2: diagnosed type 2 diabetes 
• was present in 19.4% of patients aged 65+ at encounters 
• was managed at only 6.9% of encounters with patients aged 65+ 
• was managed at about 35.8% of GP encounters with a patient with diagnosed type 2 diabetes. 
1+ 2+ 3+ 4+ 5+ 6+ 7+ 8+ 9+ 10+
Patients at encounters 96.0 86.2 72.0 55.2 39.5 26.9 17.0 11.3 7.0 4.2
People in population 89.7 75.1 57.2 40.0 26.1 16.2 9.4 5.8 3.4 2.0
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Patients aged 65+ with diagnosed type 2 diabetes visited 9.3 times a year on average (a little more 
often than patients with hypertension). This means that for these patients, their type 2 diabetes was 
managed 3.3 times a year on average. 
The prevalence of type 2 diabetes among people aged 65+ in the population was 16.0%, and 83.8% 
of these people had two or more other diagnosed chronic conditions. 
Example 3: diagnosed congestive heart failure (CHF) 
• was managed at only 1.9% of encounters with patients aged 65+ 
• was present in 7.2% of patients aged 65+ at encounters 
• was therefore managed at 26.0% of GP visits made by a patient with diagnosed CHF. 
Patients aged 65+ with CHF visited 12.6 times a year on average (nearly 50% more often than 
patients with hypertension). We conclude that in these patients, CHF was managed 3.3 times a year 
on average (35% more often than hypertension). 
The prevalence of CHF among people aged 65+ in the population was 4.2% and nearly all of these 
people (95.4%) had two or more other chronic conditions. 
Example 4: diagnosed dementia (including Alzheimers) 
• was managed at only 1.5% of encounters with patients aged 65+ 
• was present in 6.7% of patients aged 65+ at encounters 
• was therefore managed at about 22.6% of GP visits by patients with diagnosed dementia. 
Patients aged 65+ with dementia visited 10.3 times a year on average. This means that in these 
patients, dementia was managed 2.3 times a year on average. 
The prevalence of dementia among people aged 65+ in the population was 4.7% and nearly all of 
these people (84.0%) had two or more other chronic conditions. 
Patterns of multimorbidity 
We examined the specific patterns of multimorbidity, and found the most common ‘pair’ of chronic 
conditions diagnosed among patients aged 65+ was hypertension and osteoarthritis: 
• 32.4% (95% CI: 31.1–33.7) of patients surveyed at encounter having both  
• 24.1% (22.8–25.5) of people in the population having both.  
Of patients with both these conditions who were surveyed at encounter, 69.9% (95% CI: 68.4–71.4) 
had three or more other chronic conditions (i.e. five or more in total).  
Hypertension and hyperlipidaemia was the second of most prevalent pair, both being diagnosed in:  
• 24.2% (95% CI: 22.9–25.3) of patients surveyed at encounter  
• 20.0% (95% CI: 18.8–21.3) of people in the population.  
Hyperlipidaemia and osteoarthritis were the third most common pair: 
• 19.3% (95% CI: 18.1–20.5) of patients at encounters having both 
• 14.3% (95% CI: 13.2–15.4) of people in the population having both. 
It is therefore not surprising that the most prevalent “trio” of diagnosed chronic conditions was 
hypertension, hyperlipidaemia and osteoarthritis, all three conditions being diagnosed in  
• 14.7% (95% CI: 13.7–15.8) of patients at encounters  
• 10.6% (95% CI: 9.7–11.5) of people in the population  
Of those patients at encounters with these three conditions, 83.9% (95% CI: 82.1–85.7) had at least 
two or more other conditions (5 or more in diagnosed chronic conditions in total). 
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Patients aged 65+ years with chronic pain 
Our earlier research found that chronic pain affects 1 in 5 patients attending general practice.107 
(Chronic pain was defined as pain experienced every day for 3 months in the 6 months prior to this 
consultation108) A subsequent analysis of SAND substudies109-111 showed the prevalence increased 
with patient age (Figure 14.5). Of 2,217 patients aged 65 years or older, 1 in 3 (32.8%) had chronic 
pain. 
 
 
Figure 14.5: Age-specific prevalence of chronic pain (95% confidence intervals), 2000–01 and 2014–15 
 
There are many conditions that cause chronic pain, and most are musculoskeletal in nature. Patients 
and GPs were able to nominate multiple causal conditions for the pain. Among the patients aged 
65+ years with chronic pain: 
• 69.4% elected osteoarthritis as a cause 
• 21.2% nominated back problems as a cause of the chronic pain. 
The vast majority (93.4%) of patients in this age group who experienced chronic pain managed their 
pain with at least one medication. Some patients were on two or more different types of medications. 
• For 33.7%, chronic pain management included opioids (including low dose combination products) 
• For 20.7%, chronic pain management included non-steroidal anti-inflammatory drugs. 
Risk factors and chronic problems can both affect chronic pain. Collectively, two-thirds of the patients 
aged 65+ were overweight or obese (Figure 14.6). Most importantly, the proportion of patients who 
were obese increased by 55% over the 15 years between 2000–01 and 2014–15. Obesity has a 
strong influence on the cause and progression of osteoarthritis,112,113 and osteoarthritis was the 
leading cause of chronic pain in the SAND patient samples. Chronic pain can limit physical activity, 
restricting the patient’s capacity to manage their weight through exercise, which can detrimentally 
affect other chronic problems such as type 2 diabetes and cardiovascular problems. 
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Chronic pain has been found to be independently associated with multiple chronic conditions114,115 
and Figure 14.4 shows that 72.0% of patients at encounters aged 65+ have three or more co-existing 
chronic conditions. 
The fact that 93.4% of patients with chronic pain use one or more medications for pain management 
also adds to their risk of polypharmacy-related adverse events, as discussed below. 
Multiple medications and adverse drug events in patients 65+ 
The combination of increased multimorbidity, cardiovascular risk factors and secondary symptomatic 
problems such as chronic pain, described above, result in many patients aged 65+ with multiple 
medications. The occurrence of adverse drug events in this age group is directly related to this 
increased medication load. 
A series of SAND studies undertaken in 2014–15 (n = 11,477) (see Chapter 15 in this publication) 
indicate that the proportion of surveyed patients taking at least one continuing medication was: 
• 86.4% (95% CI: 83.6–89.3) of those aged 65+ 
• 84.6% (95% CI: 81.5–87.7) of those aged 65–74 
• 87.9% (95% CI: 84.7–91.1) of those aged 75+. 
The average number of medications taken by patients aged 65+ was 5.6 (95% CI: 5.3–5.9) and within 
this age group the number increased in a linear fashion with age, with: 
• patients aged 65–74 taking an average of 4.9 (95% CI: 4.6–5.2) 
• patients aged 75+ taking an average of 6.1 (95% CI: 5.7–6.5). 
The proportion of patients aged 65+ suffering an adverse drug event (ADE) in the preceding 6 months 
increased in a linear fashion with the number of continuing medications taken: 
• from 7.8% (95% CI: 4.6–11.0) of patients on one continuing medication 
• to 18.5% (95% CI: 14.9–22.1) of those on 10 or more. 
One or more ADEs were reported for 13.0% (95% CI: 11.5–14.5) of patients aged 65+ who were 
taking at least one medication. As a result of the increasing medication rate with age, one or more 
ADEs were reported for: 
• 11.1% (95% CI: 9.1–13.1) of patients aged 65–74 years taking at least one medication 
• 14.4% (95% CI: 12.3–16.6) of patients aged 75+ taking at least one medication. 
Among patients of all ages in the sample who had an ADE, hospital care (ED attendance or hospital 
admission) for the most recent ADE also increased in a linear fashion with the number of medications 
taken. Hospitalisation rate for ADEs increased from 4.7% (95% CI: 0.2–9.1) of those patients on one 
medication to 20.1% (95% CI: 12.9–27.4) of those on 10 or more. 
Our previous research demonstrated that the vast majority of ADEs are manifestations of known side 
effects of commonly prescribed medications.65 
As a result of multimorbidity and associated use of multiple medications, patients aged 65 and older 
are at a significant risk of suffering an adverse drug event and consequent hospital care. 
Lifestyle risk factors in patients aged 65+ 
While age is an important contributing factor for many chronic conditions, lifestyle risk factors are also 
important. Patient weight, smoking status and their level of alcohol consumption, are all studied in 
SAND subsamples every year. The SAND methods are described in Section 2.6. 
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Body Mass Index 
For samples from each year 2000–01 to 2014–15, the number of patients aged 65+ for whom BMI 
could be calculated ranged from 8,394 to 11,638. 
Using the WHO definitions of BMI,79 Figure 14.6 shows that between 2000–01 and 2014–15, the 
proportion of sampled patients aged 65+ who were: 
• underweight decreased significantly. This is a positive outcome as being underweight as an older 
patient is a health concern116 
• classed as ’normal’ weight decreased from 40.0% to 31.1% 
• considered ’overweight’ did not significantly change 
• classed as ‘obese’ increased by over 50% from 18.5% to 28.6% 
• classed as ‘Class III obesity’ or ‘morbidly obese’ more than doubled from 1.2% to 2.7%. 
This increase in the proportion of patients considered to be morbidly obese is a concern as it is 
expected to increase the prevalence of related health problems (such as diabetes and cardiovascular 
diseases) and escalate health care costs in future.76 Interestingly, for patients aged 65+, being 
overweight is actually a protective factor against mortality. Patients aged 65+ classified as Class I 
obesity (BMI 30–34.99) have a similar risk of mortality as those who are normal weight (BMI 20.0–
24.9).117 This means the significant increase in the proportion of patients aged 65+ considered to be 
obese is not as concerning as the rise of obesity in younger adults. 
Smoking status 
As discussed in Chapter 13, tobacco smoking is the leading cause of ill health, drug-related death and 
hospital separations in Australia.118 
We found that there was no significant change in the proportion of patients aged 65+ who had never 
smoked (range: 52.8%–56.1% over the years 2000–01 to 2014–15), were previous smokers (range: 
37.0%–38.9%), or were daily smokers (range: 6.0%–8.3%). However, we did find a decrease in the 
proportion of patients who reported they were ‘occasional’ smokers (from 1.5% in 2000–01 to 0.7% in 
2014–15). The prevalence of previous smokers was far higher than that of all adult patients and the 
prevalence of current daily smokers was lower (Chapter 13). 
Alcohol consumption 
Over the 15 years, there was no significant change in the proportion of patients aged 65+ who were 
non-drinkers (range: 39.0–43.0%), responsible drinkers (range: 41.6%–44.9%) and at-risk drinkers of 
alcohol (range: 15.1%–17.1%). Once again, while there was no change for these measures across 
the study period, the proportion of patients aged 65+ who were non-drinkers was consistently higher 
than the proportion among all surveyed adults (see Chapter 13). These older patients were 
significantly less likely to be at-risk drinkers. 
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Continuity of general practice care for patients aged 65+ 
As early as 2009, the National Primary Health Care Strategy119 suggested voluntary enrolment with a 
‘health care home’ in general practice could enhance continuity of care in Australia. The American 
Association of Family Physicians notes that: 
patient-centered medical homes integrate patients as active participants in their own health 
and well-being. Patients are cared for by a physician who leads the medical team that 
coordinates all aspects of preventive, acute and chronic needs of patients using the best 
available evidence and appropriate technology. These relationships offer patients comfort, 
convenience, and optimal health throughout their lifetimes.120 
Adoption of ‘patient-centred medical homes’ has been raised repeatedly as a possible way forward for 
Australia. The most recent have been the McKinsey Report, which provided a summary of ‘consumer 
enrolment systems’ adopted in other countries – some voluntary and some mandatory,121 and a 
subsequent discussion paper, Better outcomes for people with chronic and complex health conditions, 
recently released by the Primary Care Advisory Group. It also puts forward ‘capitated payments’ as 
one of a number of payment mechanisms that may support ‘a better primary health care system’, 
particularly for the delivery of ‘ongoing care to people with chronic and complex health conditions’.122 
Considering the very high prevalence of one or more chronic conditions among patients aged 65 
years and over described earlier in this chapter, we wondered how difficult it may be to introduce 
voluntary registration among older people in Australia. 
In a SAND substudy,123 we investigated the extent to which patients have a ‘practice they usually visit’ 
and the extent to which they used multiple practices, even when they did have a ‘regular’ practice. 
Of the 7,799 patients surveyed at encounters with 269 randomly selected GPs, 2,645 were aged 65 
years or over. Of this age group, the mean number of GP visits over the previous 12 months was 12.3, 
median 10, with a range of 1 to 110. At least one diagnosed chronic condition was present in 96.1% of 
these patients, but the proportion was significantly higher among those aged 75 years and over (98.6%, 
95% CI: 97.9–99.3) than among 65–74 year olds (93.1%, 95% CI: 91.4–94.8). Almost all the older 
patients (98.6%, 95% CI: 97.9–99.3) said that they did have a practice they usually visited and the 
proportion did not differ between the 65–74 and 75+ age groups. After adjustment for the attendance 
rate (methods described in Appendix 5), we estimated that of all patients in this age group who attended 
general practice at least once in the year, 97.8% (95% CI: 96.2–99.4) have a practice they usually visit. 
Presence of chronic condition(s) had little impact: 98.7% of those with one or more chronic conditions 
and 95.1% of the 102 without any diagnosed chronic conditions had a regular practice. 
Of the 2,603 surveyed patients with a regular practice, 367 (14.1%) had visited another practice 
during the previous 12 months, most often because (multiple responses allowed): 
• they were unable to get an appointment at their regular practice (24.1% of respondents) 
• travelling (19.9%) 
• convenience of location (16.8%) 
• emergency (13.6%) 
• they use another practice for specific health problems (9.1%). 
Visits to seek a second opinion were rare (2.1% of respondents). 
These results suggest that only 1.4% of older patients surveyed while seeing a GP did not have a 
regular practice, 82% had a regular practice and did not attend any other practice, and 17% had a 
regular practice but had, for one reason or another, visited another practice in the 12 months prior to 
being surveyed. This suggests that if voluntary registration to a practice was introduced it may well be 
taken up by the vast majority of older people. However, some means by which a visit to an ‘other’ 
practice could be covered by payment systems would be required for the 1 in 7 who visit another 
practice, for reasons such as those listed above. 
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14.3 Discussion 
Our results have highlighted some of the challenges facing general practice as a result of the ageing 
of the population. Since the beginning of the study period (2000–01) patients aged 65+ have 
consistently used a greater share of GP service resources than the proportion they accounted for in 
the population. Further, over the last 15 years this share has increased by more than their relative 
increase as a proportion of the general population. 
Patients aged 65+ use more health resources than the average Australian (ranging from 1.9 times as 
many GP encounters, to using 2.4 times as many medications). When they visit a GP now, they are 
about 50% more likely to be referred and about 45% more likely to have tests ordered than in  
2000–01. 
Nearly all patients aged 65+ at a GP consultation have one or more diagnosed chronic conditions. In 
the Australian population, 90% of this older group have at least one chronic condition, the majority 
(57%) have three or more (multimorbidity), and almost 10% have seven or more diagnosed chronic 
conditions. For example, both hypertension and osteoarthritis have already been diagnosed in more 
than 50% of older patients sitting in front of a GP. It is therefore not surprising that older people are 
more likely than younger people to have chronic pain and be taking multiple medications, and so have 
a greater chance of experiencing an adverse drug event. 
These results demonstrate the level of management complexity of these patients. When GPs manage 
a single chronic condition in an older patient, they almost always have to consider the implications of 
the presence of multiple other diagnosed chronic morbidities and the average 5.6 medications being 
taken for these conditions. 
Considered collectively, these findings suggest we have some challenges ahead of us, but most are 
merely a by-product of the success of our health system, for example, the ageing population is partly 
a product of our increased longevity. We are better able to keep people alive, with increased years 
without disability than in the past. This allows them to extend their years as productive members of 
the workforce or the community. Medical advances have changed many once life-threatening health 
events (for example, acute coronary syndrome) into ones for which intervention (for example, stents) 
can solve (but not cure) the problem, though the patient still has to have ongoing (for example, 
cardiovascular) management for the rest of their lives. 
The overall effect is that we have more people acquiring and being diagnosed with more conditions, 
and each condition is being managed for a longer period of time. The resulting exponential increase in 
chronic condition management must generate a similar growth in the number of GP visits and the 
number of management actions, such as prescriptions and test orders. The increased use of GP 
services has no doubt contributed to our increased life expectancy, and is provided at a per-person 
cost in line with, or less than, that of other countries. 
Policy changes such as the introduction to Medicare of health assessment items, chronic disease 
management items, some disease-specific service items payments (SIP) and practice incentive 
payments (PIP),70 represent efforts to improve primary and secondary health prevention, and facilitate 
early diagnosis and management of chronic disease. Early diagnosis means that over time, more and 
more chronic conditions may be managed for an individual, and these chronic conditions will be 
managed for a longer period because of Australia’s increased life expectancy. For example, a patient 
diagnosed with diabetes at 45 years of age during a 45–49 years MBS-claimed Health Assessment 
potentially has 40 more years of life in which management of that problem is required. 
Many chronic problems presenting to general practice result from modifiable risk factors. At-risk levels 
of alcohol consumption and daily tobacco smoking, though lower than adult community averages, 
may well have contributed to the health problems currently co-existing in older patients. The 
increasing prevalence of morbid obesity among older patients, more than doubling over the study 
period, is a growing problem. However the significant decrease in the prevalence of underweight in 
this age group is a positive result, as being underweight is a significant risk factor for mortality in older 
people. 
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Australia’s health system is largely structured on single diseases. The vast majority of specialists work 
within a single body system, and often sub-specialise within that system. Patients can be referred to 
multiple specialists, possibly one for each of their diagnosed diseases. Further, guidelines for care are 
based on a single/disease type; clinical trials and medical research (and its funding) are largely single 
disease/disease type focused. More broadly, a single disease/disease type focus is the basis of 
organisations such as Diabetes Australia, the Heart Foundation and Kidney Health Australia, and this 
flows through to the patient information/education material such groups distribute. Yet, we have 
shown that in this age group, 84–92% of people with one of these conditions have two or more other 
diagnosed conditions – multimorbidity is the rule, rather than the exception. 
As stated by Barbara Starfield, “Those who … (are) focusing on diseases resist understanding that 
health is a pattern. Without grasping the pattern, management is at best an approximation of 
adequate care”.124 This suggests that the patient is more than just a sum of their individual diseases 
and needs a ‘whole patient’ approach to management rather than a ‘problem’-based approach. 
As discussed earlier, the possibility of patient enrolment with a GP or practice has been raised 
repeatedly in Australia over the last 5 years. There is good evidence that continuity of care, especially 
in a ‘patient-centred medical home’ can result in improved quality of care and patient experiences, 
and decreased hospital and emergency department use. A recent review from the United States 
found some patient-centred medical home initiatives have resulted in improved quality of care and 
patient experiences and have reduced emergency department visits and hospitalisations, providing 
savings in health expenditure for the patients involved.125,126 
Our study has shown that the vast majority of patients aged 65+ have already voluntarily attached 
themselves to a single practice. Much of the ground work has already been done if Australia wanted 
to formally encourage the use of ‘patient-centred medical homes’. However, medical homes should 
not be considered in isolation, but as one key part of an integrated health care system. 
In the future, care of those with complex chronic problems will require better integration of services 
and coordination of the care given by multiple providers including hospitals, specialists, allied health 
professionals, and community services. General practices are in a prime position to act as the 
coordinators of care and help to lower the chance of ‘fragmented care’. In turn, this may help reduce 
presentations to emergency departments and primary care preventable hospitalisations. Every extra 
hospitalisation avoided reduces unnecessary testing, extra prescribing and the risk of fragmented 
care through poor communication. It is likely that any extra resources spent in primary care would be 
countered by savings though reduced use of more expensive services. 
Integration requires effective communication of core health information between different health 
sectors and different health professionals. Ideally there would be one record for one patient, a record 
all health providers could access when caring for that patient with structured standardised format for 
additions to the record made by each provider. Improvements to other forms of communication are 
also required if we are to move to a more patient-centred approach with shared decision-making 
between practitioners and the patient. 
Possible remuneration systems for the care of patients enrolled in a medical home have not been 
widely discussed. The level of multimorbidity present in a patient has been shown to be a good 
indicator of health care resource use,104 complexity of care,105 severity of illness,105 polypharmacy106 
and adverse events.106 From the BEACH data we can estimate general practice health resource 
utilisation (and its cost) for individuals with different numbers of diagnosed chronic conditions, and 
different combinations of conditions. Remuneration of the medical home for the annual care of an 
individual patient could be based on the level of their multimorbidity. 
As always, this is not as simple as it sounds, since a patient with two diagnosed conditions of 
uncomplicated hypertension and hyperlipidaemia utilises fewer services and needs less co-ordination 
of care than an individual patient with insulin-treated type 2 diabetes plus severe osteoarthritis in 
multiple sites. However, it would be a much more efficient starting point than merely paying for 
co-ordination of the care of each individual chronic condition, which must inevitably result in multiple 
payments for multiple diseases for the vast majority of older people. 
141
  
 
14.4 Conclusion 
We have demonstrated here the high chronic disease load and the resulting high service utilisation, 
(and therefore the cost to the health care budget) of people aged 65 years and over. Much more can 
be done with these data to assist in the planning of Australia’s future primary health care system. For 
example, identifying the most common multimorbidity patterns of disease among this high health care 
needs population would provide useful evidence of services that would benefit from better 
co-ordination and integration. In thinking about our future health care system, the next step is to 
repeat this study for people aged 45–64 years, many of whom already have multiple diagnosed 
chronic conditions. For many of those who do not, there is still time for further preventive activities. 
The Australian Government is aiming for a ‘strong and sustainable Medicare’.127 Perhaps what we 
should be aiming for is a system for sustainable health of the population. Clearly there will be 
challenges for quality care provision to older patients over the coming decades but with a strong 
primary care system Australia is well-placed to take up this challenge. 
 
 
 
 
 
This chapter contains unpublished methods that form part of Christopher Harrison’s thesis for his 
candidature for Doctor of Philosophy in Medicine. 
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 15 SAND abstracts and research tools 
Since BEACH began in April 1998, a section on the bottom of each encounter form has been used to 
investigate aspects of patient health or healthcare delivery not covered by general practice 
consultation-based information. These additional substudies are referred to as SAND (Supplementary 
Analysis of Nominated Data). The SAND methods are described in Section 2.6. All substudies were 
approved by the Human Ethics Committee of the University of Sydney. 
The Family Medicine Research Centre (FMRC) and most of the organisations supporting the BEACH 
program select topics for investigation in the SAND studies. In each BEACH year, up to 20 substudies 
can be conducted in addition to the study of patient risk behaviours (see Chapter 13). Topics can be 
repeated to increase the sample size and its statistical power. 
This chapter includes the abstracts and research tools for SAND substudies, most of which were 
conducted from April 2014 to March 2015. The subjects covered in the abstracts in this chapter are 
listed in Table 14.1, with the sample size for each topic. 
Table 15.1: SAND abstracts for 2014–15 and sample size for each 
Abstract 
number Subject 
Number of 
respondents  
Number  
of GPs 
223 Pneumococcal vaccination in general practice patients 2014(a) 2,718 103 
224 Cardiovascular disease risk in general practice patients 1,649 95 
225 Patients with diabetes and practice-based continuity of care 2,755 95 
226 Asthma management and asthma control in general practice patients 2014 2,870 97 
227 Care of patients with chronic heart failure 2,909 98 
228 Prevalence and management of hepatitis C virus in general practice 5,855 198 
229 Pharmacological management of type 2 diabetes among general practice patients 3,104 104 
230 Patient use of generic medication substitution 2,824 96 
231 Prevalence of chronic conditions and multimorbidity, health services utilisation 35,162 1,171 
232 Polypharmacy and adverse drug events in general practice patients 11,477 390 
233 Type 2 diabetes management and referrals among general practice patients 2,620 90 
234 Chronic musculoskeletal/nerve pain in general practice patients 2,848 97 
(a) Substudy limited to patients aged 15 years and over. 
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SAND abstract 223: Pneumococcal vaccination in general practice 
patients 2014 
Organisation collaborating for this study: bioCSL (Australia) Pty Ltd. 
Issues: The proportion of general practice patients with risk factors for pneumococcal vaccination and 
the type of risk factors they had; the proportion of patients who received a pneumococcal vaccine; 
reasons for not vaccinating against pneumococcal. 
Sample: 2,718 patients aged 15+ years from 103 GPs; data collection period: 06/05/2014 – 
09/06/2014. 
Method: Detailed in the paper entitled SAND Method 2013–14 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts/>. 
Summary of results  
The age and sex distributions of the 2,718 respondents aged 15 years and over did not differ from the 
age and sex distributions of patients at all 2013–14 BEACH encounters. 
Of 2,718 respondents, over half had at least one risk factor for pneumococcal disease (52.1%) and 
there was no significant difference between males and females in this proportion. More than one-third 
(36.1%) of all respondents were at risk due to age (65+ years), 13.8% had chronic heart disease, 
11.7% had diabetes, 9.9% had chronic lung disease, 8.5% were tobacco smokers, 3.4% had chronic 
renal failure, 2.7% had immune deficiency and 2.0% had chronic liver disease. 
Patients are eligible for a free dose of the pneumococcal vaccine under the National Immunisation 
Program (NIP) when they turn 65 years old. Recent changes to the NIP mean that patients aged 
70 years and over need an additional risk factor (other than age) to be eligible for a second free dose 
of the vaccine. In this study, 62.8% of patients aged 70 years and over had an additional risk factor. 
Of 2,673 respondents, 739 (27.6%) had been vaccinated against pneumococcal infection in the 
previous five years, 68.1% had not, and 4.3% did not know whether they had been vaccinated. Of 
1,408 respondents who had at least one risk factor for pneumococcal infection, 51.4% were currently 
vaccinated and 44.3% were not. Of the patients aged 65–69 years, 49.2% had been vaccinated, 
48.5% had not and 2.3% did not know. For patients aged 70 years or more, 70.3% were currently 
vaccinated, 26.1% were not, and 3.6% did not know. For patients aged 70 and over with at least one 
additional risk factor, 75.1% had been vaccinated, 21.1% had not, and 3.8% did not know. 
Among the 1,819 patients who had not been vaccinated against pneumococcal infection in the 
previous five years, 1,703 responded to the question on why they were not vaccinated: 72.9% were 
assessed by the GP as not at risk of pneumococcal infection, 9.2% of patients objected to the 
vaccination, 3.5% of patients cited cost as the reason, and 2.8% of patients disagreed with the risk 
assessment. There were 254 patients (14.9%) who indicated other reasons, including: patient had not 
been assessed; patient was unaware of the vaccine; patient had been vaccinated twice already; and 
some patients were to receive the vaccine at the current encounter or would soon be vaccinated. 
 
 
 
 
 
The following page contains the recording form and instructions with which the data in this substudy were 
collected.
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SAND abstract 224: Cardiovascular disease risk in general practice 
patients 
Organisation collaborating for this study: Family Medicine Research Centre. 
Issues: Cardiovascular disease risk profile of general practice patients aged 45 years and over. 
Sample: 1,649 patients from 95 GPs; data collection period: 24/09/2013 – 28/10/2013. 
Method: Detailed in the paper entitled SAND Method 2013–14 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts/>. 
Methods for this substudy: Cardiovascular disease risk assessment was based on guidelines from 
the National Vascular Disease Prevention Alliance (NVDPA) 
<www.cvdcheck.org.au/index.php?option=com_content&view=article&id=47&Itemid=27>. The Heart 
Foundation classification of blood pressure (BP) levels in adults was used to define hypertension 
<www.heartfoundation.org.au/SiteCollectionDocuments/Hypertension_slideshow.pdf>. 
Summary of results 
There were 1,649 patients aged 45 years and over who responded to the questions about 
cardiovascular disease risk. The age and sex distributions of patients in this SAND did not 
significantly differ from that of patients at all 2012–13 BEACH encounters. 
Current or previous conditions or risk factors were recorded for the 1,649 patients aged 45+ years: 
18.1% had diabetes, 50.0% had hypertension, 12.7% had ischaemic heart disease, 2.9% had left 
ventricular hypertrophy, 9.3% had familial hypercholesterolaemia, 25.1% had other dyslipidaemia, 
11.9% had an ‘other cardiovascular disease or event’, 8.6% were current smokers, 3.2% had 
microalbuminuria, 4.7% had moderate or severe chronic kidney disease, and 4.8% had a family 
history of premature heart disease. 
Cardiovascular disease risk was assessed using a three-step process. At Step 1, patients were 
assessed against a list of known high risk groups. Of all sampled patients, 618 (37.5%) had at least 
one of seven high risk conditions, placing them in the ‘Known High Risk’ category: 21.3% had known 
cardiovascular disease, 13.5% had diabetes and were aged over 60 years, 2.3% had diabetes and 
microalbuminuria, 4.7% had moderate/severe chronic kidney disease, 9.3% had familial 
hypercholesterolaemia, 1.3% had high blood pressure (systolic BP >= 180 mmHg, or diastolic 
BP >= 110 mmHg), and 1.6% had high total cholesterol (>7.5 mmol/L). 
At Step 2, the Framingham equation established absolute risk of a cardiovascular event over the 
next 5 years for 965 respondents from the 1,031 patients who were not classified as ‘Known High 
Risk’ at Step 1. There were 777 patients (80.5%) who were at low risk (<10% absolute risk of 
cardiovascular event in the next 5 years), 130 (13.5%) at moderate risk (10–15% risk) and 58 (6.0%) 
at high risk (>15% risk). 
Step 3 calculations showed that of 1,583 respondents, 528 (33.4%) had at least one of the other 
factors for cardiovascular disease risk. The three steps were combined to give a final assessment of 
cardiovascular disease risk level for 1,583 patients. There were 34.4% of patients assessed as being 
at low risk, 20.6% at moderate risk, and 45.0% at high risk. 
The proportion of patients taking at least one of the selected types of medications rose significantly 
through level of cardiovascular disease risk, from 38.2% of low risk patients to 83.7% of high risk 
patients. The average number of types of medication taken also rose significantly through level of 
cardiovascular disease risk from 0.6 medications for low risk to 2.1 for high cardiovascular disease 
risk patients. 
The following page contains the recording form and instructions with which the data in this substudy were 
collected. 
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SAND abstract 225: Patients with diabetes and practice-based 
continuity of care  
Organisation conducting this study: Family Medicine Research Centre. 
Issues: Prevalence of type 1 and type 2 diabetes in general practice patients. For patients with type 2 
diabetes: BMI; smoking status; number of GP visits in previous 12 months; proportion of patients with 
comorbidities, and types of comorbidities; proportion of patients with a regular general practice and 
number of years the regular practice has been visited; number of general practices the patient has 
visited in the previous 12 months. 
Sample: 2,755 patients from 95 GPs; data collection: 24/09/2013 – 28/10/2013. 
Method: Detailed in the paper entitled SAND Method 2013–14 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts/>.  
Summary of results  
Of the 2,755 respondents, 29 patients (1.1%, 95% CI: 0.7–1.5) had type 1 diabetes, and 307 patients 
(11.1%, 95% CI: 9.5–12.8) had type 2 diabetes, including one patient who had both types, giving a 
total of 335 patients (12.2%, 95% CI: 10.5–13.8) with diabetes. 
The age-specific rate of type 2 diabetes was 2.7% (95% CI: 1.3–4.2) for respondents aged  
25–44 years, 13.4% (95% CI: 10.7–16.1) for those aged 45–64, 24.8% (95% CI: 19.7–30.0) for 65–74 
year olds and 18.8% (95% CI: 14.6–23.1) for those 75 years and over. There was no significant 
difference between the sexes, with 13.1% of males and 9.7% of females having the condition. 
The following results refer to the 307 patients with type 2 diabetes. 
Of the 307 patients, 295 provided height and weight information, and the median body mass index 
(BMI) was 30.8 kg/m2. Of these, 87.8% were overweight or obese, including: 31.5% overweight, 
30.5% obese, and 25.8% morbidly obese. Among the 301 adult (18+) respondents, 21 (7.0%, 95% 
CI: 3.8–10.2) were current smokers, a significantly lower prevalence than among adult BEACH 
subsample respondents 2012–13 (14.4%, 95% CI: 13.7–15.1). 
At least one of the comorbidities listed on the survey form was present in 94.5% of respondents, and 
61.9% of respondents had three or more. Hypertension was the most common (75.9% of patients), 
followed by dyslipidaemia (68.7%). 
Of 281 respondents to the question on number of GP visits in the previous year, 4.3% had made 
1–3 visits, 18.9% 4–6 visits, 16.7% 7–9 visits, 29.2% 10–12 visits, 10.0% 13–15 visits, and 21.0% 16 
or more visits. There was a positive association between the number of comorbidities and number of 
GP visits. The number of comorbidities did not appear to be associated with the length of 
consultation, with most visits lasting about 15 minutes. 
Of 302 respondents with type 2 diabetes, 292 (96.7%) indicated that the current encounter was at 
their regular general practice, and eight patients (2.6%) had another regular general practice. Only 
two patients had no regular general practice. Of 282 respondents who provided length of attendance, 
the majority (77.0%) had been attending that practice for more than 5 years. Most patients (83.9%) 
had not attended any but their regular general practice in the previous year. 
 
 
 
The following page contains the recording form and instructions with which the data in this substudy were 
collected. 
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SAND abstract 226: Asthma management and asthma control in 
general practice patients 2014 
Organisation collaborating for this study: Family Medicine Research Centre. 
Issues: The proportion of patients at general practice encounters with diagnosed asthma; time since 
diagnosis; medication management; intended duration of current inhaled corticosteroid (ICS) or 
combination inhaled corticosteroid/long-acting beta agonists (ICS/LABA) management; relationship 
between level of asthma control and medication use. 
Sample: 2,870 patients from 97 GPs; data collection period: 15/07/2014 – 18/08/2014. 
Method: Detailed in the paper entitled SAND Method 2014–15 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts/>. 
Methods for this substudy: GINA guidelines (Global Initiative for Asthma, 2014) were used to 
classify asthma control: 0 symptoms = well-controlled; 1–2 = partly controlled; 3–4 = uncontrolled. 
Summary of results  
Though the sex distribution of the 2,870 respondents did not differ from that of patients at all 2013–14 
BEACH encounters, a significantly smaller proportion of patients were aged 75 years and over. 
Of the 2,870 respondents, 14.7% (95% CI: 12.8–16.7) had diagnosed asthma. There was no 
significant difference in the sex-specific rates of asthma (13.1% males; 15.9% females), however the 
age-specific rates showed some differences – diagnosed prevalence among 5–14 year-olds (23.8%) 
was significantly higher than among those aged <5 years (8.7%) and those 75+ years (13.3%), but 
not different from prevalence in other age groups. 
In the majority of patients (81.0% of 406 respondents with diagnosed asthma), asthma had been 
diagnosed more than 5 years prior to the recorded consultation. For 1 in 10 patients (9.6%) asthma 
had been diagnosed 1–3 years previously. 
Of 408 respondents with asthma, 339 (83.1%) were taking at least one medication for its 
management: 39.5% were taking one medication; 35.5% were taking two; and 6.9% were taking 
three. One patient was currently taking four asthma medications. 
A total of 555 asthma medications were recorded. Almost half (49.7%; n = 276) were short-acting 
beta agonists (SABA), and one-third (33.9%, n = 188) were ICS/LABA. ICS as single therapy 
accounted for 7.2% of asthma medications, anticholinergics for 5.8%, and oral systemic steroids for 
1.1%. Of 226 patients taking ICS or ICS/LABA, 220 responded to the question about intended 
duration of medication use. The intended duration was >6 months for 78.6% of patients on these 
medications. 
More than half (55.2%, n = 233) the patients with asthma had not experienced any symptoms in the 
previous 4 weeks (well controlled); 26.1% (n = 110) had 1–2 symptoms (partly controlled) and 18.7% 
(n = 79) had 3–4 symptoms (uncontrolled). Of 223 patients with well-controlled asthma, 38.1% were 
taking ICS or ICS/LABA. Of 108 patients with partly controlled asthma, 69.4% were taking ICS or 
ICS/LABA. Of 77 patients with uncontrolled asthma, 85.7% were taking ICS or ICS/LABA. 
 
 
 
 
The following page contains the recording form and instructions with which the data in this substudy were 
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SAND abstract 227: Care of patients with chronic heart failure  
Organisation conducting this study: Novartis Pharmaceuticals Australia Pty Ltd. 
Issues: Prevalence of chronic heart failure (CHF) in general practice patients. For those with CHF: 
current medications for CHF and initiator of medications; hospitalisation for acute heart failure; 
discharge to community-based management program; and distance to nearest hospital. 
Sample: 2,909 patients from 98 GPs; data collection: 01/04/2014 – 05/05/2014. 
Method: Detailed in the paper entitled SAND Method 2014–15 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts/>  
Summary of results  
There was a greater proportion of patients aged <5 years and a smaller proportion aged 65 years or 
more in this sample than at all BEACH encounters in 2013–14. Of the 2,909 respondents, 87 (3.0%, 
95% CI: 2.0–4.0) had CHF. There was no significant difference in CHF prevalence among males 
(4.4%, 95% CI: 2.5–6.3) and females (2.0%, 95% CI: 1.3–2.8). No patients aged <45 years had CHF. 
A significantly greater proportion of patients aged 75+ years (12.2%, 95% CI: 8.3–16.1) had CHF than 
of those aged 45–64 (1.9%, 95% CI: 0.8–3.0). CHF prevalence in those aged 65–74 was 7.1%. 
After adjusting (by age–sex) for the rates of attendance to GPs, the prevalence of CHF among 
patients who attend general practice at least once in a year was estimated to be 2.0% (95% CI:  
1.3–2.8). Extrapolation to the Australian population gave an estimated population prevalence of 1.7% 
(95% CI: 1.1–2.4). 
Medication status was known for 84 of 87 patients with CHF. Two patients (2.4%, 95% CI: 0.0–5.7) 
were taking no medication for CHF, 19 (22.6%, 95% CI: 11.4–33.8) were taking one medication, 
34 (40.5%, 95% CI: 28.0–53.0) two, and 29 (34.5%, 95% CI: 23.5–45.5) three, a total of 174 
medications. Frusemide (25.9%) was the most common individual medication, followed by ACE 
inhibitor perindopril (9.2%) and beta blocker bisoprolol (8.6%). Of the 174 medications, 33.3% were 
diuretics, and 28.2% were beta blockers. 
Initiation source was specified for 161 medications. Of those, 64.0% (95% CI: 53.3–74.7) were 
initiated by specialists, significantly more than the proportion initiated by GPs, 36.0% (95% CI:  
25.3–46.7). Specialists were significantly more likely than GPs to have initiated anti-angina 
medications, beta blockers and calcium channel blockers. 
Of 84 respondents to questions on the most recent admission, 37 (44.0%) had been hospitalised for 
an acute episode of heart failure. For the most recent admission of 36 patients, 18 (50.0%) were 
admitted through the emergency department, 15 (41.7%) from a GP referral, and four (11.1%) 
through a cardiac outpatient clinic. For the most recent admission of 35 patients, the average length 
of stay was 6.5 days (95% CI: 4.4–8.7). 
Of 37 patients hospitalised for heart failure, nine were discharged under a community-based heart 
failure management program, 20 were not, and eight did not know. Of the 37 patients, nine lived 
<5 km by road from the nearest hospital, 12 lived 5–9 km away, and a further 12 lived 10–19 km 
away. 
 
 
 
The following page contains the recording form and instructions with which the data in this substudy were 
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SAND abstract 228: Prevalence and management of hepatitis C 
virus in general practice  
Organisation collaborating for this study: AbbVie Pty Ltd. 
Issues: The prevalence of hepatitis C virus (HCV) infection in general practice patients; for those with 
HCV, the approximate duration of their HCV positive status; the proportion who have diagnosed liver 
fibrosis or cirrhosis and the stage of fibrosis; the cause of the HCV infection; specialist referral for 
HCV care; current medications for HCV; chronic comorbidities present with HCV (tick boxes and free 
text). 
Sample: 5,855 patients from 198 GPs; data collection periods: 01/04/14 – 05/05/14 and 28/10/14 – 
01/12/14. 
Method: Detailed in the paper entitled SAND Method 2014–15 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts/>. 
Methods for this substudy: The stages of fibrosis were defined using the Metavir Fibrosis Score 
Card. (Source: Poynard T, Dedossa P, Opolon P. Natural history of liver fibrosis progression in 
patients with chronic hepatitis C. Lancet 1997; Vol. 349, Issue 9055: 825–832). 
Summary of results 
The sex distributions of the 5,855 patients who gave their hepatitis C virus (HCV) status did not differ 
from all patients at 2013–14 BEACH encounters. There was a difference in the age distribution, with 
fewer patients aged 75 years and over in this sample. 
There were 61 patients (1.0%, 95% CI: 0.7–1.4) who had a diagnosed HCV infection, with a 
significantly greater likelihood among male respondents (n = 39, 1.7%, 95% CI: 1.0–2.3) than among 
female respondents (n = 21, 0.6%, 95% CI 0.3–0.9). The prevalence among patients aged 45–64 
years (2.3%, 95% CI: 1.5–3.2) was significantly higher than among patients aged 65–74 years (0.3%, 
95% CI: 0.0–0.6) or 75+ years (0.5%, 95% CI: 0.0–0.9). Of 45 patients who knew the duration of their 
HCV, 20.0% had diagnosed HCV for less than one year, 37.8% between 1 and 10 years, 33.3% had 
diagnosed HCV for 11–20 years, and 8.9% for more than 20 years. 
Of 53 patients, 10 (18.9%) had been diagnosed with liver fibrosis/cirrhosis, and of these, five had 
Stage F4 (cirrhosis), one had Stage F1 (portal fibrosis without septa), and a stage was not known for 
the remaining four. 
Thirty-three (62.3%) of 53 respondents contracted HCV through intravenous drug use, six patients 
through sexual encounter, four through body modification, three through needle stick injury, and two 
from blood/organ donation. 
Thirty-eight of 54 respondents (70.4%) had been referred to a specialist for HCV management. Of 
these, 29 (76.3%) had been referred only to a hepatologist, three had been referred to a hepatologist 
and a gastroenterologist, and one to a hepatologist and a hospital. Four patients had been referred 
only to a gastroenterologist. 
Current HCV medication status was known for 50 patients. Only four of them were on medication for 
HCV, using eight medications: all four patients were taking peginterferon/ribavarin combinations, two 
were also taking interferon, one was also taking teleprevir, and one was also taking boceprevir. 
Thirty-one (58.5%) of 53 respondents had at least one chronic comorbidity. Depressive disorder was 
the most common of the comorbidities, followed by diabetes, hypertension and chronic obstructive 
pulmonary disease. 
 
The following pages contain the recording form and instructions with which the data in this substudy were 
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SAND abstract 229: Pharmacological management of type 2 
diabetes among general practice patients  
Organisation collaborating for this study: Novartis Pharmaceuticals Australia Pty Ltd. 
Issues: Prevalence of diagnosed type 2 diabetes among patients attending general practice; use of 
metformin medication in the management of type 2 diabetes; concomitant use of selected 
glucose-lowering medications (sulfonylurea and dipeptidyl peptidase-4 [DPP-4] inhibitor [known as 
gliptin]) with the metformin. 
Sample: 3,104 patients from 104 GPs; data collection period: 10/06/2014 – 14/07/2014. 
Method: Detailed in the paper entitled SAND Method 2014–15 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts/>. 
Summary of results  
The age of the patient was recorded at 3,096 encounters. The age distribution of patients in this 
sample did not differ from those of patients at all BEACH encounters in 2013–14. Patient sex was 
known for 3,084 respondents of whom 45.3% (95% CI: 42.3–48.3) were male, a significantly larger 
proportion than among those at all BEACH encounters in 2013–14, where 40.1% (95% CI: 39.2–41.0) 
were male. 
Of the 3,104 sampled patients, 344 (11.1%, 95% CI: 9.5–12.7) had diagnosed type 2 diabetes. After 
statistical adjustment to reflect patients attending general practice at least once in the year, 
prevalence of diagnosed type 2 diabetes among the attending population was 7.1% (95% CI: 5.7–
8.4). Assuming those who did not attend did not have diagnosed type 2 diabetes, population 
prevalence was estimated as 6.1% (95% CI: 4.9–7.3). 
There was a significant step-wise increase in prevalence of diagnosed type 2 diabetes with patient 
age group, from 3.3% (95% CI: 1.9–4.7) of patients aged 25–44 years, to 21.7% (95% CI: 17.3–26.1) 
of those aged 65–74 years. The rate then remained steady among those aged 75 years or more with 
19.8% (95% CI: 16.1–23.4) having the condition. Prevalence did not significantly differ between the 
sexes, with 13.2% of males and 9.4% of females having type 2 diabetes. Of 331 respondents with 
diagnosed type 2 diabetes, 65.3% (n = 216) were currently taking metformin. The question about 
concomitant sulfonylurea and/or gliptin use was answered for 211 of these patients, most of whom 
(63.5%) did not take either medication. Metformin and sulfonylurea were being taken by 45 patients, 
metformin and gliptin were taken by 28 patients, and 4 patients took all three medications. 
Of the 45 patients taking metformin and a sulfonylurea only, reasons for taking a sulfonylurea rather 
than a gliptin were given for 43. The most common reasons were efficacy of sulfonylurea (n = 23), 
and ‘other’ (non-listed) reasons (18 patients). Most of the latter group indicated satisfactory long-term 
use of a sulfonylurea. 
Reasons for use of gliptin rather than sulfonylurea were provided for the 28 patients taking metformin 
and a gliptin only. The most common reasons given were concern about an adverse event associated 
with a sulfonylurea (n = 13), and efficacy of gliptin (n = 10). 
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SAND abstract 230: Patient use of generic medication substitution 
Organisation collaborating for this study: AstraZeneca Pty Ltd (Australia). 
Issues: The proportion of general practice patients who had been offered generic medication 
substitution when filling a prescription in the previous 12 months; patterns of purchase for those 
offered generic substitution; factors influencing the decision to purchase generic medications; medical 
conditions for which patients did not purchase generic medications. 
Sample: 2,824 patients from 96 GPs; data collection period: 15/07/2014 – 18/08/2014. 
Method: Detailed in the paper entitled SAND Method 2014–15 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts/>. 
Methods for this substudy: An information card was supplied to patients providing response options 
about factors influencing the decision to purchase or reject generic medication. 
Summary of results  
The sex distribution of this patient sample did not differ from that of patients at all 2013–14 BEACH 
encounters. However, a significantly larger proportion of the 2,806 patients in this sample for whom 
age was recorded were aged 1–4 years (5.9%, 95% CI: 4.7–7.0 compared with 4.2%, 95% CI: 
3.9–4.4), and a smaller proportion aged 75+ years (14.3%, 95% CI: 11.7–16.8 compared with 18.0%, 
95% CI: 17.2–18.9) than at all 2013–14 BEACH encounters. 
Over two-thirds of the 2,824 patients (67.3%, 95% CI: 62.7–72.0) had been offered generic 
substitution when filling a prescription in the previous 12 months, while 21.8% had not, and 10.9% of 
patients did not know whether generic substitution had been offered. 
There were 1,893 patients offered a generic substitution who responded to the question about 
whether they purchased the substitution when offered. Of these, 45.9% said they always accepted 
generic substitution when offered, 35.4% sometimes accepted, and 18.6% never accepted. Three-
quarters (75.0%) of 669 respondents who sometimes accepted substitution purchased at least one 
generic medication on the most recent occasion substitution was offered. 
Of 1,366 respondents who accepted a generic medication substitution the most recent time it was 
offered, factors influencing this decision included cost saving for self (70.6% of patients), pharmacy 
encouragement (42.2%), information provided by the pharmacy (15.3%), original brand not in stock 
(11.1%) and cost saving for government (6.7%). Multiple responses were allowed. 
Of 520 respondents who rejected a generic substitution the most recent time offered, 507 provided 
reasons for their decision, including: concerns about effectiveness of the generic (64.3%), concern 
about adverse events (22.7%), possible confusion with medications (16.6%) and substitution not 
allowed by doctor (11.2%). 
There were 448 conditions listed for which medications were prescribed for the 520 patients who 
rejected generic substitution the most recent time it was offered. One condition was recorded for 
301 patients, two conditions for 48 patients and three for 17 patients. No condition was listed for 
154 patients. Classified to ICPC-2, the most common condition listed was uncomplicated 
hypertension, followed by depressive disorder, type 2 diabetes, lipid disorder, oesophageal disease 
and asthma. 
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SAND abstract 231: Prevalence of chronic conditions and 
multimorbidity, health services utilisation  
Organisation collaborating for this study: Family Medicine Research Centre and the National 
Health Performance Authority. 
Issues: The number of visits to a GP in the previous 12 months. Prevalence of diagnosed individual 
chronic conditions, of multimorbidity (2+ chronic conditions); and of complex multimorbidity (1+ 
chronic condition in each of 3 or more body systems),(a) among the sampled patients, the population 
attending a GP in a year, and in the Australian population. In a subsample, for people with 1+ chronic 
conditions: number of different individual GPs; different specialists and different allied health 
professionals seen in the previous 12 months. 
Sample: 35,162 patients from 1,171 GPs; subsample was 14,462 patients from 482 GPs; data 
collection periods: 27/11/2012 – 14/01/2013; 19/02/2013 – 25/03/2013; 01/05/2013 – 06/06/2013; 
21/01/2014 – 31/03/2014; 06/05/2014 – 14/07/2014. 
Method: Detailed in the paper entitled SAND Method 2014–15 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. Methods for this study: Statistical 
adjustment methods for estimates among attending population and Australian population are 
described elsewhere.(b) Body systems were defined as chapters of ICPC-2.(c) 
Summary of results 
The age and sex distributions of the sampled patients and of the subsample did not significantly differ 
from those of patients at all 2013–14 BEACH encounters. 
The average number of visits to any GP in previous 12 months was 9.4, higher than the average of 
6.8 attendances of all those who see a GP, because frequent attenders have a greater chance of 
being sampled. 
Hypertension was the most prevalent chronic condition, diagnosed in 25.9% (95% CI: 25.0–26.8) of 
the sample, 15.0% (14.3–15.7) of the attending population and 11.8% (11.2–12.3) of the Australian 
population. This was followed by: osteoarthritis (22.8 [21.8–23.8]; 12.1 [11.4–12.8]; 9.3 [8.8–9.9]); 
hyperlipidaemia (16.5 [15.8–17.3], 10.0 [9.5–10.6], 8.0 [7.5–8.4]); depression; anxiety; 
gastro-oesophageal reflux disorder; and chronic back pain. 
One-third (32.1%) of patients had 1+ musculoskeletal conditions; 31.8% 1+ circulatory; 30.4% 
1+ endocrine/nutritional/metabolic; 26.4% 1+ psychological problems. Adjusted population estimates: 
1+ endocrine/nutritional/metabolic 15.4% (14.7–16.1); 1+ circulatory 14.3% (13.6–15.0); 1+ 
musculoskeletal 14.2% (13.5–14.9); 1+ psychological 13.2% (12.6–13.8). Half (51.1%) the sampled 
patients had multimorbidity and 36.9% had 3+ diagnosed chronic conditions. Adjusted population 
estimates suggested 24.9% (95% CI: 23.9–26.0) had multimorbidity, and 15.2% (14.4–16.0) had 
3+ chronic conditions. Complex multimorbidity was present in 30.1% (28.9–31.2) of the sample and 
11.5% (10.9–12.2) of the Australian population. 
Of the 14,462 patients in the subsample, 9,795 had 1+ diagnosed chronic conditions. For 8,996 of 
these, the average number of different GPs visited was 2.2 GPs (median 2). For 8,564, the average 
number of different specialists seen was 1.5 (median 1). For 7,709 patients, the average number of 
different allied health providers seen was 1.0 (median 1.0), in the previous 12 months. 
 
(a) Harrison C, Britt H, Miller G, Henderson J. Examining different measures of multimorbidity, using a large prospective cross-
sectional study in Australian general practice. BMJ Open. 2014 Jul 11;4(7):e004694. 
(b) Harrison C, Britt H, Miller G, Henderson J. Prevalence of chronic conditions in Australia. PLoS ONE 2013;8(7):e67494. 
Epub 2013 Jul 23. 
(c) Classification Committee of the World Organization of Family Doctors. ICPC-2: International Classification of Primary Care. 
2nd ed. Oxford: Oxford University Press; 1998. 
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SAND abstract 232: Polypharmacy and adverse drug events in 
general practice patients  
Organisation collaborating for this study: National Health Performance Authority. 
Issues: The proportion of general practice patients on continual medications, the number of 
medications and the number of prescribers; the proportion who had a medication review; the 
proportion who had an adverse drug event (ADE); the severity and rate of hospitalisation for adverse 
drug events. 
Sample: 11,477 patients from 390 GPs; data collection periods: 19/08/14 – 22/09/14, 23/09/14 – 
27/10/14, 20/01/15 – 23/02/15 and 24/02/15 – 30/03/15. 
Method: Detailed in the paper entitled SAND Method 2014–15 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
Summary of results  
There was no significant difference in the sex distribution of respondents in this sample and those of 
patients at all 2013–14 encounters. There were marginally more patients aged 15–24 years in this 
sample than at all BEACH encounters in 2013–14. 
Of the 11,477 patients in this sample, two-thirds (66.0%, 95% CI: 63.6–68.4) had been prescribed or 
advised at least one medication for continual use in the previous 6 months. On average, patients took 
3.1 continual medications. Polypharmacy (defined as a patient taking five or more continual 
medications) was present in 26.7% of the patients in this sample. 
Of 7,411 respondents who were taking at least one continual medication, 23.5% reported that no 
doctor had prescribed or advised any new medication in the previous 6 months, 45.3% reported that 
one doctor had prescribed or advised a new continual medication in the previous 6 months, and 
21.8% reported that two doctors had done so. For those on continual medications, on average, 
1.2 doctors had prescribed or advised new continual medications. 
Medication reviews had been performed for 74.7% of 7,010 respondents taking continual medication 
for which medication review status was known. GPs were involved (either alone or in conjunction with 
a pharmacist or nurse) in 97.0% of medication reviews. Patients with polypharmacy were more likely 
to have a medication review (81.9%, 95% CI: 78.9–84.8) than those who did not have polypharmacy 
(69.9%, 95% CI: 66.4–73.4). 
Of 7,426 respondents taking at least one continual medication, 11.3% (n = 837) had experienced an 
ADE in the previous 6 months. Significantly more patients who had polypharmacy had experienced an 
ADE in the previous 6 months (15.6%, 95% CI: 13.9–17.3) than those who were taking one to four 
continual medications (8.3%, 95% CI: 7.3–9.3). 
For 819 patients who had experienced an ADE and where information was provided about the 
severity of the most recent event, 62.4% had experienced an ADE regarded as ‘mild’ in the GP’s 
clinical opinion, 28.3% had experienced a ‘moderate’ ADE, and 9.3% had experienced a ‘severe’ 
event. 
Of 798 patients who had an ADE and information was provided about hospitalisation, 5.9% reported a 
hospital admission as a result of their most recent ADE and 4.3% reported attendance at an 
emergency department without admission to hospital. 
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SAND abstract 233: Type 2 diabetes management and referrals 
among general practice patients 
Organisation collaborating for this study: AstraZeneca Pty Ltd. 
Issues: The diagnosed prevalence of type 2 diabetes among general practice patients; for those with 
type 2 diabetes, referrals for diabetes; diabetes medication; diabetes control; test results and patient 
body mass index (BMI). 
Sample: 2,620 patients from 90 GPs; data collection period: 02/12/2014 – 19/01/2015. 
Method: Detailed in the paper entitled SAND Method 2014–15 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
Summary of results 
The sex distribution of this patient sample (46.4% male) did not differ from that of patients at all  
2013–14 BEACH encounters. However, a significantly smaller proportion of this sample were aged  
5–14 years (3.6%, 95% CI: 2.8–4.5) than at all 2013–14 BEACH encounters (4.9%, 95% CI: 4.6–5.2). 
Type 2 diabetes had been diagnosed in 262 patients (10.0%, 95% CI: 8.1–11.9). There was no 
significant difference in the prevalence among males (12.2%) and females (8.7%), and the highest 
prevalence was in patients aged 65–74 years (21.4%). 
Of the 262 patients diagnosed with type 2 diabetes, 33 (12.6%, 95% CI: 7.7–17.5) had not been 
referred to a health professional for their diabetes in the previous 12 months, 22.1% were referred to 
one, 25.2% to two and 40.1% to three or more health professionals. So 229 (87.4%, 95% CI:  
82.5–92.3) had been referred to at least one health professional. Referrals to podiatrist were the most 
common (62.6% of patients with type 2 diabetes), followed by ophthalmologist (51.5%), diabetes 
educator (31.7%), dietitian (29.0%), endocrinologist (26.7%), and other health professionals (16.4%). 
Current diabetes medication was recorded for 258 patients, and most were currently taking 
medication (n = 219, 84.9%, 95% CI: 78.0–91.8). There were 360 individual medications recorded: at 
the generic level, metformin was the most common (41.9% of medications), followed by gliclazide 
(15.8%), and insulin glargine (11.1%). In terms of medication groups, metformin (41.9%), 
sulfonamides (16.9%), and basal insulin (13.3%) were recorded most commonly. Of the 258 
respondents, 72 (27.9%) were currently taking insulin, including 26 patients on two types of insulin. 
Almost half (48.5%) of the insulins recorded were basal, 26.3% were rapid acting, and 23.2% were 
premix insulin. 
The GP's clinical opinion of the patient’s level of diabetes control was recorded for 247 patients with 
type 2 diabetes, of whom over half (n = 142, 57.5%) had well controlled, 28.3% had partly controlled, 
and 14.2% had poorly controlled type 2 diabetes. 
Most recent HbA1c level was recorded for 251 type 2 diabetes patients. The mean HbA1c level was 
55.3 mmol/mol, and the median was 50.8. The RACGP and Diabetes Australia target is HbA1c =<53 
mmol/mol for patients with diabetes. The majority (n = 148, 59.0%, 95% CI: 51.5–66.5) of patients had 
reached that target. 
Most recent eGFR (estimated glomerular filtration rate) was recorded for 246 type 2 diabetes patients: 
184 (74.8%) had an abnormal GFR (<90) and 62 (25.2%) had a normal GFR (>= 90). The most 
common category was slightly decreased GFR, with 60–89 recorded for 113 (45.9%) patients. 
Of 248 type 2 diabetes patients with recorded height and weight, 133 (53.6%) were obese, and 78 
patients (31.5%) were overweight. 
 
The following page contains the recording form and instructions with which the data in this substudy were 
collected.
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SAND abstract 234: Chronic musculoskeletal/nerve pain in general 
practice patients  
Organisation collaborating for this study: bioCSL Pty Ltd. 
Issues: The proportion of patients at general practice encounters with chronic musculoskeletal and/or 
nerve pain; causes of this chronic pain; management of pain (current and previous); pain level and 
functioning. 
Sample: 2,848 patients from 97 GPs; data collection period: 24/02/2015 – 30/03/2015. 
Method: Detailed in the paper entitled SAND Method 2014–15 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts/>. 
Methods for this substudy: ‘Live better with pain log’ (American Chronic Pain Association© 2005) 
was used to classify pain levels.  
Summary of results  
Age and sex distributions of respondents did not differ from those of patients at all 2013–14 BEACH 
encounters. 
Of the 2,848 respondents, 25.4% (95% CI: 22.1–28.6, n = 722) had chronic musculoskeletal and/or 
nerve pain: 20.2% (n = 575) had chronic musculoskeletal pain only; 1.8% (n = 50) had chronic nerve 
pain only; and 3.4% (n = 97) had both. There was no significant difference in the sex-specific rates of 
chronic musculoskeletal and/or nerve pain (21.8% males; 27.7% females). No patients under 15 
years of age had chronic musculoskeletal and/or nerve pain. The age-specific rates significantly 
increased with patient age, from 3.4% among 15–24 year-olds to 47.8% among patients aged 75+ 
years. 
Of 672 patients with chronic musculoskeletal pain, reported cause(s) (multiple responses allowed) 
were: osteoarthritis (58.9%); lower back problem (34.8%); and cancer (1.2%). Of 147 patients with 
chronic nerve pain, reported cause(s) were: lower back problem (50.3%); osteoarthritis (18.4%); and 
cancer (2.0%). 
Of 711 respondents, 60.6% managed pain with medication only, 25.6% used medication plus other 
management, 5.5% used non-medication management only, and 8.3% were using no pain 
management. Over half (51.3% of the 711 patients who responded about chronic pain management) 
were taking paracetamol, 8.2% were taking pregabalin, 7.7% were taking a paracetamol/codeine 
30mg product, and 6.6% were taking oxycodone. Of 224 patients using non-pharmacological 
treatments, 12.0% used physiotherapy, 5.3% used exercise programs and 3.1% used heat therapy. 
For three-quarters of patients (75.1%), management had not changed in the previous 6 months. Of 
166 respondents for whom a change had occurred, changes reported were: switch medication 
(31.3%); initiate medication (where none previously taken) (30.7%); add medication (16.9%); increase 
dose (6.6%); cease all pain medication (5.4%); stop (one) medication (4.8%); and decrease dose 
(4.2%). The most common reasons given for management change (136 respondents) were to 
improve musculoskeletal pain (39%) and nerve pain (16.9%), and because of side effects (13.2%) 
such as drowsiness, nausea or constipation. 
Reported pain level was significantly greater for patients with nerve pain (mean 6.3) than 
musculoskeletal pain (5.2), as was the impact of pain on activity (5.4 compared with 4.5), sleep (5.5 
compared with 4.3) and mood (5.3 compared with 4.1). 
 
 
The following page contains the recording form and instructions with which the data in this substudy were 
collected. 
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 Abbreviations 
ABS Australian Bureau of Statistics 
ACE angiotensin-converting enzyme  
ACRRM Australian College of Rural and Remote Medicine 
ADE adverse drug event 
AHS allied health service 
AHW Aboriginal health worker 
AIHW Australian Institute of Health and Welfare 
ASGC Australian Standard Geographical Classification 
ATC Anatomical Therapeutic Chemical (classification) 
BEACH Bettering the Evaluation and Care of Health 
BMI body mass index 
BP blood pressure 
CAPS Coding Atlas for Pharmaceutical Substances 
CHF chronic heart failure 
CHF congestive heart failure 
CI confidence interval (in this report 95% CI is used) 
CT computerised tomography 
DoH Australian Government Department of Health 
DVA Australian Government Department of Veterans’ Affairs 
eGFR estimated glomerular filtration rate 
ENT ear, nose and throat 
HCV hepatitis C virus 
FMRC Family Medicine Research Centre 
FTE full-time equivalent 
GDP gross domestic product 
GP general practitioner 
HbA1c haemoglobin, type A1c 
ICPC International Classification of Primary Care 
ICPC-2 International Classification of Primary Care – Version 2 
ICPC-2 PLUS a terminology classified according to ICPC-2 
ICS inhaled corticosteroid 
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INR international normalised ratio 
LABA long-acting beta agonist 
LCL lower confidence limit 
MBS Medicare Benefits Schedule 
M,C&S microscopy, culture and sensitivity 
NDSHS National Drug Strategy Household Survey 
NEC not elsewhere classified 
NESB non-English-speaking background 
NHMRC National Health and Medical Research Council 
NOS not otherwise specified 
OECD Organisation for Economic Co-operation and Development 
OTC over-the-counter (medications advised for over-the-counter purchase) 
PBS Pharmaceutical Benefits Scheme 
PIP practice incentive payments 
PN practice nurse 
PPP purchasing power parity 
RACF residential aged care facility 
RACGP Royal Australian College of General Practitioners 
RFE reason for encounter 
SABA short-acting beta agonist 
SAND Supplementary Analysis of Nominated Data 
SAS Statistical Analysis System 
SIP service incentive payments 
UCL upper confidence limit 
URTI upper respiratory tract infection 
USD United States Dollars 
WHO World Health Organization 
Wonca World Organization of Family Doctors 
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Symbols 
2 chi-square 
— not applicable 
< less than 
> more than 
n number 
Ŧ rate is less than 0.05 per 100 encounters 
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 Glossary 
A1 Medicare items: See MBS/DVA items: A1 Medicare items. 
Aboriginal: The patient identifies himself or herself as an Aboriginal person. 
Activity level: The number of general practice A1 Medicare items claimed during the previous 
3 months by a participating GP. 
Allied health services: Clinical and other specialised health services provided in the management of 
patients by allied and other health professionals including physiotherapists, occupational therapists, 
dietitians, dentists and pharmacists. 
Chapters (ICPC-2): The main divisions within ICPC-2. There are 17 chapters primarily representing 
the body systems. 
Chronic problem: See Diagnosis/problem: Chronic problem. 
Commonwealth concession card: An entitlement card provided by the Australian Government, which 
entitles the holder to reduced-cost medicines under the Pharmaceutical Benefits Scheme and some 
other concessions from state and local government authorities. 
Complaint: A symptom or disorder expressed by the patient when seeking care. 
Component (ICPC-2): In ICPC-2 there are seven components that act as a second axis across all 
chapters. 
Co-located health service: A health service (for example, physiotherapist, psychologist, etc) located in 
the practice building or within 50 metres of the practice building, available on a daily or regular basis. 
Co-operative after-hours arrangements: The normal after-hours arrangements for patient care 
provision is undertaken in co-operation with another practice(s). 
Consultation: See Encounter. 
Diagnosis/problem: A statement of the provider’s understanding of a health problem presented by a 
patient, family or community. GPs are instructed to record at the most specific level possible from the 
information available at the time. It may be limited to the level of symptoms. 
• New problem: The first presentation of a problem, including the first presentation of a recurrence 
of a previously resolved problem, but excluding the presentation of a problem first assessed by 
another provider. 
• Old problem: A previously assessed problem that requires ongoing care, including follow-up for a 
problem or an initial presentation of a problem previously assessed by another provider. 
• Chronic problem: A medical condition characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last 6 months or more, a pattern of 
recurrence or deterioration, a poor prognosis, and consequences or sequelae that impact on an 
individual’s quality of life. (Source: O’Halloran J, Miller GC, Britt H 2004. Defining chronic 
conditions for primary care with ICPC-2. Fam Pract 21(4):381–86). 
• Work-related problem: Irrespective of the source of payment for the encounter, it is likely in the 
GP’s view that the problem has resulted from work-related activity or workplace exposure, or that 
a pre-existing condition has been significantly exacerbated by work activity or workplace 
exposure. 
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Encounter (enc): Any professional interchange between a patient and a GP. 
 Indirect: Encounter where there is no face-to-face meeting between the patient and the GP but a 
service is provided (for example, prescription, referral). 
 Direct: Encounter where there is a face-to-face meeting of the patient and the GP. 
Direct encounters can be further divided into: 
– MBS/DVA-claimable: Encounters for which GPs have recorded at least one MBS item 
number as claimable, where the conditions of use of the item require that the patient be 
present at the encounter. 
– Workers compensation: Encounters paid by workers compensation insurance. 
– Other paid: Encounters paid from another source (for example, state). 
Full-time equivalent (FTE): A GP working 35–45 hours per week. 
General practitioner (GP): A medical practitioner who provides primary comprehensive and continuing 
care to patients and their families within the community (Source: Royal Australian College of General 
Practitioners). 
Generic medication: See Medication: Generic 
GP consultation service items: See MBS/DVA items: GP consultation service items. 
MBS/DVA items: MBS item numbers recorded as claimable for activities undertaken by GPs and staff 
under the supervision of GPs. In BEACH, an MBS item number may be funded by Medicare or by the 
Department of Veterans’ Affairs (DVA). 
• A1 Medicare items: Medicare item numbers 1, 2, 3, 4, 13, 19, 20, 23, 24, 25, 33, 35, 36, 37, 38, 
40, 43, 44, 47, 48, 50, 51, 601, 602. 
• GP consultation service items: Includes GP services provided under the MBS professional 
services category including MBS items classed as A1, A2, A5, A6, A7, A14, A17, A18, A19, A20, 
A22, A23, A27, A30 and selected items provided by GPs classified in A11 and A15. 
• MBS/DVA item categories: (Note: item numbers recorded in BEACH in earlier years which are no 
longer valid are mapped to the current MBS groups) 
– Surgery consultations: Identified by any of the following item numbers: short 3, 52, 5000, 
5200; standard 23, 53, 5020, 5203; long 36, 54, 2143, 5040; prolonged 44, 57, 2195, 5060, 
5208. 
– Residential aged care facility: Identified by any of the following item numbers: 20, 35, 43, 51, 
92, 93, 95, 96, 5010, 5028, 5049, 5067, 5260, 5263, 5265, 5267. 
– Home or institution visits (excluding residential aged care facilities): Identified by any of the 
following item numbers: 4, 19, 24, 33, 37, 40, 47, 50, 58, 59, 60, 65, 87, 89, 90, 91, 503, 507, 
5003, 5023, 5043, 5063, 5220, 5223, 5227, 5228. 
– GP mental health care: Identified by any of the following item numbers: 2700, 2701, 2702, 
2704, 2705, 2710, 2712, 2713, 2715, 2717, 2721, 2723, 2725. 
– Chronic disease management items: Identified by any of the following item numbers: 720, 
721, 722, 723, 724, 725, 726, 727, 729, 730, 731, 732. 
– Health assessments: Identified by any of the following item numbers: 700, 702, 703, 704, 705, 
706, 707, 708, 709, 710, 712, 713, 714, 715, 717, 718, 719. 
– Case conferences: Identified by any of the following item numbers: 139, 734, 735, 736, 738, 
739, 740, 742, 743, 744, 747, 750, 762, 765, 771, 773, 775, 778. 
– Attendances associated with Practice Incentives Program payments: Identified by any of the 
following item numbers: 2497, 2501, 2503, 2504, 2506, 2507, 2509, 2517, 2518, 2521, 2522, 
2525, 2526, 2546, 2547, 2552, 2553, 2558, 2559, 2574, 2575, 2577, 2598, 2600, 2603, 2606, 
2610, 2613, 2616, 2620, 2622, 2624, 2631, 2633, 2635, 2664, 2666, 2668, 2673, 2675, 2677, 
2704, 2705. 
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– Practice nurse/Aboriginal health worker/allied health worker services: Identified by any of the 
following item numbers: 711, 10950, 10951, 10960, 10966, 10970, 10986, 10987, 10988, 
10989, 10993, 10994, 10995, 10996, 10997, 10998, 10999, 16400, 82210. 
– Acupuncture: Identified by any of the following item numbers: 173, 193, 195, 197, 199. 
– Diagnostic procedures and investigations: Identified by item numbers: 11000–12533. 
– Therapeutic procedures: Identified by item numbers: 13206–23042 (excluding 16400). 
– Surgical operations: Identified by item numbers: 30001–52036. 
– Diagnostic imaging services: Identified by item numbers: 55037–63000. 
– Pathology services: Identified by item numbers: 65120–74991. 
Medication: Includes medication that is prescribed, provided by the GP at the encounter or advised for 
over-the-counter purchase. 
• Generic: The generic name of a medication is its non-proprietary name, which describes the 
pharmaceutical substance(s) or active pharmaceutical ingredient(s). 
• GP-supplied: The medication is provided directly to the patient by the GP at the encounter. 
• Over-the-counter (OTC): Medication that the GP advises the patient to purchase OTC (a 
prescription is not required for the patient to obtain an OTC medication). 
• Prescribed: Medications that are prescribed by the GP (that is, does not include medications that 
were GP-supplied or advised for over-the-counter purchase). 
Medication status: 
• New: The medication prescribed/provided at the encounter/advised is being used for the 
management of the problem for the first time. 
• Continued: The medication prescribed/provided at the encounter/advised is a continuation or 
repeat of previous therapy for this problem. 
• Old: See Continued. 
Morbidity: Any departure, subjective or objective, from a state of physiological wellbeing. In this sense, 
sickness, illness and morbid conditions are synonymous. 
Non-English speaking background: The patient reported that the primary language spoken at home 
was not English. 
Patient status: The status of the patient to the practice. 
• New patient: The patient has not been seen before in the practice. 
• Patient seen previously: The patient has attended the practice before. 
Problem managed: See Diagnosis/problem. 
Provider: A person to whom a patient has access when contacting the healthcare system. 
Reasons for encounter (RFEs): The subjective reasons given by the patient for seeing or contacting 
the general practitioner. These can be expressed in terms of symptoms, diagnoses or the need for a 
service. 
Recognised GP: A medical practitioner who is: 
• vocationally recognised under Section 3F of the Health Insurance Act, or 
• a holder of the Fellowship of the Royal Australian College of General Practitioners who 
participates in, and meets the requirements for, quality assurance and continuing medical 
education as defined in the Royal Australian College of General Practitioners (RACGP) Quality 
Assurance and Continuing Medical Education Program, or 
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• undertaking an approved placement in general practice as part of a training program for general 
practice leading to the award of the Fellowship of the Royal Australian College of General 
Practitioners, or undertaking an approved placement in general practice as part of some other 
training program recognised by the RACGP as being of equivalent standard. (Source: 
Commonwealth Department of Health and Aged Care 2001. Medicare Benefits Schedule book. 
Canberra: DHAC). 
Referral: The process by which the responsibility for part, or all, of the care of a patient is temporarily 
transferred to another health care provider. Only new referrals to specialists and allied health 
services, and for hospital and residential aged care facility admissions arising at a recorded 
encounter, are included. Continuation referrals are not included. Multiple referrals can be recorded at 
any one encounter. 
Repatriation Health Card: An entitlement card provided by the Department of Veterans’ Affairs that 
entitles the holder to access a range of repatriation health care benefits, including access to 
prescription and other medications under the Pharmaceutical Benefits Scheme. 
Rubric: The title of an individual code in ICPC-2. 
Significant: This term is used to refer to a statistically significant result. Statistical significance is 
measured at the 95% confidence level in this report. 
Torres Strait Islander: The patient identifies himself or herself as a Torres Strait Islander person. 
Work-related problem: See Diagnosis/problem. 
 
  
185
  
 Appendices 
Appendix 1: Example of a 2014–15 recording form
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Appendix 2: GP characteristics questionnaire, 
2014–15  
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Appendix 3: Patient information card, 2014–15 
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Appendix 4: Code groups from ICPC-2 and 
ICPC-2 PLUS 
Available at: <hdl.handle.net/2123/13765>. 
Table A4.1: Code groups from ICPC-2 and ICPC-2 PLUS – reasons for encounter and problems 
managed 
Table A4.2: Code groups from ICPC-2 and ICPC-2 PLUS – chronic problems 
Table A4.3: Code groups from ICPC-2 and ICPC-2 PLUS – problems managed by practice nurses 
Table A4.4: Code groups from ICPC-2 and ICPC-2 PLUS – clinical treatments 
Table A4.5: Code groups from ICPC-2 and ICPC-2 PLUS – procedures 
Table A4.6: Code groups from ICPC-2 and ICPC-2 PLUS – clinical measurements 
Table A4.7: Code groups from ICPC-2 and ICPC-2 PLUS – referrals 
Table A4.8: Code groups from ICPC-2 and ICPC-2 PLUS – pathology test orders (MBS groups) 
Table A4.9: Code groups from ICPC-2 and ICPC-2 PLUS – imaging test orders (MBS groups) 
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Appendix 5: Calculation methods for Table 14.1 
Attending population weight 
On the SAND recording form (see Appendix 1), there was a question asking the number of times the 
patient had seen a GP in the previous 12 months (including the current visit). An attending population 
weight was created by weighting each surveyed patient by their chance of being in our sample. The 
chance of being in our sample is based on how many times they had visited a GP in the previous 
year. A weight of X/(number of GP visits) was applied to each patient. 
Management ratios 
The management ratio was calculated by dividing the proportion of encounters at which the chronic 
condition was managed, by the prevalence of the condition among patients at general practice 
encounters. 
Number of GP visits in previous 12 months 
The average number of times patients aged 65+ with a certain chronic condition had seen a GP in the 
previous year was calculated using the attending population weight (described above). 
Number of times condition was managed in general practice 
The number of times a condition was managed in general practice was calculated by multiplying the 
management ratio by the average number of times patients with the selected chronic condition had 
visited a GP in previous 12 months. 
Population prevalence 
Population prevalence was calculated by first applying the attending population weight to the data. A 
second weight was created so that when applied to the attending population weight, the proportion of 
surveyed patients in each age–sex group matched the proportion represented by that age–sex group 
in the Australian population.  
The numerator of whether a patient had a specific chronic condition (1 = patient has chronic condition, 
0 = patient does not have condition) was weighted by the proportion of people in that age–sex group 
that saw a GP at least once in the previous year. This adjusted the data for those who did not see a 
GP, whom we assumed had not been diagnosed with that chronic condition. 
Proportion of patients with a selected condition, who had 2 or more other 
chronic conditions 
The proportion of people aged 65+ with a selected condition who had two or more other diagnosed 
chronic conditions was calculated using the attending population weight. This means that the results 
are representative of people in the population who have the selected diagnosed condition. 
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